







This is an electronic version of a PhD thesis awarded by the University of Westminster. 
© Mr George Gyamfi-brobbey, 2016.
The WestminsterResearch online digital archive at the University of Westminster aims to make the 
research output of the University available to a wider audience. Copyright and Moral Rights remain 
with the authors and/or copyright owners.
Whilst further distribution of specific materials from within this archive is forbidden, you may freely 
distribute the URL of WestminsterResearch: ((http://westminsterresearch.wmin.ac.uk/).
In case of abuse or copyright appearing without permission e-mail repository@westminster.ac.uk
AUTHOR’S DECLARATION 
I declare that the present work was carried out in accordance with the Guidelines and 
Regulations of the University of Westminster. The work is original except where indicated by 
special reference in the text. 
The submission as a whole or part is not substantially the same as any that I previously or am 
currently making, whether in published or unpublished form, for a degree, diploma or similar 
qualification at any university or similar institution. 
Until the outcome of the current application to the University of Westminster is known, the 
work will not be submitted for any such qualification at another university or similar 
institution. 
Any views expressed in this work are those of the author and in no way represent those of the 













THE MICROBIOLOGY OF DIABETIC 










 Philosophy of Doctor of degree the for Westminster of University









Diabetic foot ulcer (DFU), a major complication of both types 1 and 2 diabetes, develops in 
about 15–25% of people living with the disease. In Ghana, DFUs contribute to most hospital 
admissions (53%) among diabetics with high rates of amputation (33.3%) and death (8.8%). 
Diabetic foot ulcers are predisposed to infections from bacteria in the environment which 
normally colonise these wounds as multicellular communities called biofilms. Biofilms have 
been found to have increased resistance to antimicrobial agents probably due to the presence 
of an extracellular matrix that retards or prevents the entry of antimicrobial agents into the 
bacterial community, antibiotic resistance genes and/or the presence of persister cells that are 
unresponsive to antimicrobial agents. 
The work presented here studied the role of 2 multidrug resistant DFU isolates, Klebsiella 
pneumoniae and Proteus mirabilis in maintaining the chronicity of diabetic foot ulcers. Using 
3 in vitro biofilm models; the conventional microtitre plate and Minimum Biofilm 
Eradication Concentration (MBEC™) High-Throughput assays and the Quasi–Vivo® 
continuous flow system, K. pneumoniae and P. mirabilis were found to be positive for acyl–
homoserine lactone production, biofilm and persister cell producers and could resist and/or 
tolerate antibiotics such as ceftazidime and levofloxacin up to 1280 times their minimum 
inhibitory concentration. K. pneumoniae and P. mirabilis were also found to express the 
interspecies AI–2 quorum sensing molecules which significantly increased biofilm formation 
and fold induction of bioluminescence in a luxS mutant V. harveyi reference strain. 
Quorum sensing (QS) inhibition assays using baicalin hydrate, cinnamaldehyde and 2(5H)–
furanone showed considerable inhibition of K. pneumoniae and P. mirabilis biofilm 
formation but failed to completely inhibit their growth. The combinatorial effects of 
antibiotics and QS inhibitors/antimicrobial peptides such as polymyxin B and polymyxin B 
nonapeptide determined as fractional inhibitory concentration (FIC) index suggests that, 
additive and synergistic effects produced by the combination of two antimicrobial agents 
have the potential to eradicate biofilms. Data from the FIC indices determined from the 
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Diabetes mellitus (DM) is a chronic disease characterised by high plasma glucose 
concentrations as a result of the inability of the body to adequately produce or use insulin 
effectively (International Diabetes Federation, 2015). The disease is diagnosed when there is 
impaired glucose tolerance and characterised by high plasma glucose concentrations 
(International Diabetes Federation, 2015). DM has been categorised into three main types 
(International Diabetes Federation, 2015). Type 1 diabetes mellitus (T1DM) also known as 
juvenile–onset or insulin–dependent diabetes mellitus is an auto–immune disorder that mostly 
starts in infected persons before age 40. It is characterised by the self–destruction of insulin–
producing beta cells in the pancreas by the body’s own immune system. T1DM has been 
reported in about 10–15% of all diabetes mellitus cases (Rybka, 2010). Type 2 diabetes 
mellitus (T2DM) formerly known as non–insulin dependent diabetes mellitus is also referred 
to as late–onset diabetes. The peculiar feature of this type is the relative insulin deficiency 
and resistance leading to the build–up of plasma glucose (Landon, 2010). This accounts for 
the bulk of diabetes worldwide of about 90% of all diabetic cases. The third type is 
gestational diabetes mellitus (GDM) is characterised by intolerance to glucose which is 
evident during pregnancy after an oral glucose tolerance test (Landon, 2010). Though glucose 
intolerance can return to normal, pregnant women with family history of diabetes, increasing 
maternal age, obesity and coming from ethnic group with high risk of developing T2DM can 
develop permanent diabetes. The babies of such mothers are likely to become obese and have 
impaired tolerance to glucose (Landon, 2010).  
1.1.1 Symptoms and Complications of DM 
The major characteristic symptoms of diabetes mellitus result from the abnormal metabolism 
of glucose leading to high concentrations of glucose in the blood with its attendant 
complications. This is largely due to either the production of ineffective insulin by a defective 
pancreas or deficient insulin production. High levels of glucose in the blood otherwise known 
as hyperglycaemia are as a result of the inability of insulin to transport glucose to the cells for 
energy and storage. This leads to glycosuria and polyuria which are characterised by the 
presence of glucose in excreted urine and frequent urination from osmotic imbalance 
respectively. The body compensates for glucose loss by breaking down protein to release 
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energy in a process called gluconeogenesis. The effect of this process is weight loss as more 
proteins in the muscles are broken down (Magnusson et al., 1992). Type 2 diabetes mellitus 
has increased morbidity and mortality rates mostly due to accompanying complications such 
as neuropathy, nephropathy, retinopathy, microvascular coronary heart disease, 
cerebrovascular disease and myocardial infarction resulting in cardiovascular and peripheral 
vascular diseases and diabetic foot ulcers. About 15–25% of diabetic patients will develop a 
foot ulcer during their lifetime (Singh et al., 2005). Treatment of diabetes has spun from 
using the extracts of islets of Langerhans from special fish through putting patients on special 
diet devoid of high carbohydrate contents to transplantation of beta–cells, stem cells and 
pancreas (Johnson and Luciani, 2010). According to Garcia et al. (2001), the successful use 
of genetic engineering is highly recommended in the treatment of advanced diabetes mellitus 
in the production of naturally occurring peptides that enable the stimulation of the growth of 
insulin–producing beta–cells in the pancreas. 
1.1.2 Global picture of diabetes  
The number of people with the DM is expected to increase from 415 million (8.3% of adult 
population) to 642 million and beyond by the year 2040 (International Diabetes Federation, 
2015). Developing countries will contribute to more than 75% of this increase with a majority 
of cases among people between 40 and 59 years (International Diabetes Federation, 2015; 
King et al., 1998; Zimmet et al., 2001). Possible reasons for this increase are due to 
population growth, ageing, acculturation, obesity and physical inactivity (Wild et al., 2004). 
Urbanisation, which has been described as the population growth of urban areas due to socio–
economic movement of people from less privilege towns and villages to urban centres in 
search of jobs and good health care has also been found to be associated with lifestyle 
changes with resultant increases in the number DM cases (Cheema et al., 2014; 
Ramachandran et al., 2008). Among the 3 types of the disease, type 2 is the commonest and 
has 7.5% prevalence among the adult population (20 to 79 years). It has been estimated that 
in addition to the 415 million people living with DM, 318 million adults with impaired 
glucose tolerance are at high risk of developing the disease (International Diabetes 
Federation, 2015). This is because increase in the prevalence of the disease is directly related 
to increase in cultural and societal changes. For example, in high income countries, T2DM 
accounts for up to 91% of the adult population living with the disease (Largay, 2012). The 
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number of people with undiagnosed diabetes who risk the development of sudden 
complications has been estimated as 193 million worldwide (International Diabetes 
Federation, 2015). Figure 1.1 illustrates the current global picture of the disease. 
As a result of genetic predisposition and social deprivation diabetes tends to cluster in some 
ethnic groups such as people of South Asian and African lineage (Chen et al., 2012; Diabetes 
in the UK, 2012). Complex combinations of genetic and environmental factors as well as 
social deprivation make DM about six times more common among people of South Asia 
descent and about three times more common in people of African and African–Caribbean 
lineage (Chen et al., 2012). 
 
Figure 1 .1 Global burden of DM (Image Source: International Diabetes Federation, 2014). 
1.1.3 Diabetes in Ghana 
Diabetes prevalence in Ghana was first established as 0.4% in 1958 (Dodu, 1958). The 
current operational prevalence, 6.3% was established by Amoah et al. (2002). This 
prevalence is expected to increase to 11.0% by the year 2035 in line with predictions by the 
World Health Organisation despite increased awareness of the disease (Amoah et al., 2002; 
King et al., 1998). This implies an annual increase of 35.8% of newly diagnosed cases with 
associated complications. The predicted increase of 4.7% in the national prevalence of DM 
can also be attributed to an increase in education and awareness of the disease as well as 
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better systems of screening and recording of new cases. Studies on diabetes in most African 
countries including Ghana have mainly focused on the use of biochemical assays such as oral 
glucose tolerance test (OGTT) to determine plasma glucose concentrations, and glycated 
haemoglobin or haemoglobin A1c (HbA1C) test to estimate the amount of bound glucose to 
red blood cells in establishing the presence and severity of the disease (Amoah et al., 2002; 
Levitt, 2012; Lehman, 2009). Glycated haemoglobin has been defined as the irreversible 
glycosylation of haemoglobin A1C at either one or both N–terminals (Syed, 2011). The 
covalent bond that leads to the glycosylation of haemoglobin A1C remains throughout the 
lifespan of the bound red blood cells (Syed, 2011). Hence, the estimation of HbA1C plasma 
concentration has been used as an indicator of glucose concentration throughout the lifespan 
(120 days) of red blood cells (Kobold et al., 1997; Khaw et al., 2001; McCane et al., 1994). 
HbA1C has therefore been employed as a diagnostic tool to monitor the control of blood 
glucose in diabetic patients (Kobold et al., 1997; McCane et al., 1994). In addition, foot 
infection is confirmed by physical examination of the foot and the estimation of increased 
total white blood cell count associated with increased body temperature (Amoah et al., 2002). 
In some developing countries including Ghana, it has been found that diabetic foot ulcers 
contribute to most hospital admissions (Asumanu et al., 2010; Kengne et al., 2006; Ogbera et 
al., 2006; Singh et al., 2005). Asumanu et al. (2010) studied the impact of diabetes and foot 
ulcers on patients admitted at the 37 Military Hospital, Accra, Ghana and reported that 53% 
of people admitted with diabetes had foot ulcers, with 33.3 and 8.8% resulting in amputations 
and death respectively. However, health policies have over the years placed little emphasis on 
the effective control and prevention of diabetes. In Ghana, treatment for diabetic foot 
infections (DFI) involves the administration of broad–spectrum antibiotics before or after the 
request for a wound swab for bacterial culture and antibiogram according records 
documented at the Microbiology department, Komfo Anokye Teaching Hospital, Kumasi, 
Ghana. Most commonly used antibiotics include the quinolones such as ciprofloxacin and 
levofloxacin, and third generation cephalosporins such as cefotaxime and ceftazidime. Other 
antibiotics used include metronidazole, clindamycin and aminoglycosides such as gentamicin 
and tobramycin (Bonham, 2001; Nelson et al., 2006; O’Meara et al., 2000). Other treatment 
options include topical applications of biocides such as 0.25% hydrogen peroxide (H2O2) and 
antimicrobial agents such as honey (Ankra–Badu, 1992; Molan, 2006; Zumla and Lulat, 
1989). H2O2 at low concentrations has been found to act as a signal molecule that attracts 
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leucocytes leading to the production of cytokines and chemokines at the wound site during 
the inflammation phase of wound healing (Schreml et al., 2011). In addition, low 
concentrations (at 10 mM) of H2O2 have been reported to promote connective tissue 
formation and enhance wound closure (Loo et al., 2012). On the other hand, high 
concentrations (at 166 mM) of H2O2 have been associated with oxidative and nitrative 
damage of lipid and protein, reduced connective tissue formation and subsequently prevent 
wound closure and healing (Loo et al., 2012). The catalysis of H2O2 has been found to 
produce hydroxyl free radicals which destroy bacterial cell components such as proteins, 
lipids and DNA by attaching to exposed sulfhydryl groups and double bonds (McDonnell and 
Russell, 1999; Schreml et al., 2011). Honey has been a traditional salve for wounds for 
centuries and its antimicrobial activities include antioxidant activity, anti–inflammatory 
action, debriding action, enhanced rate of wound repair and deodorising action (Seckam and 
Cooper, 2013). As an antioxidant, topically applied honey has been reported to scavenge 
reactive oxygen species produced during tissue inflammation, enhance connective tissue 
formation and granulation, wound closure and wound healing (Henriques et al., 2006; 
Seckam and Cooper, 2013; Subrahmanyam et al., 2003). 
1.1.4 Diabetic foot ulcers (DFU) 
Diabetic foot and the associated consequences are known to have a global economic cost of 
billions of dollars with respect to treatment, lengthy hospital stay and subsequent amputation 
(Frykberg et al., 2000; Reiber et al., 1995). Complex combinations of predisposing factors 
are largely responsible for ulceration and amputation. The formation of ulcer from trauma 
and or excessive pressure on deformed foot is mostly as a result of neuropathy with sensory, 
motor and autonomic disturbances of the nervous function. Others include neuro–
osteoarthropathic deformities (Charcot disease), vascular insufficiency, hyperglycaemia and 
other metabolic derangements, patient disabilities, maladaptive patient behaviours, trauma 
and healthcare system failures (Caputo et al., 1994; Frykberg, 1998). These factors result in a 
number of mechanisms from abnormal foot anatomy and biomechanics, lack of protective 
sensation, deficient sweating through impaired immunological function and wound healing, 
reduced vision, limited mobility, poor compliance with medical care, excessive weight–
bearing to inadequate patient education and monitoring of glucose control and foot care 
eventually leading to injury or impairment (Caputo et al., 1994; Frykberg, 1998). Lipsky et 
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al. (2004) defined DFU as any inframalleolar infection in an individual with diabetes 
mellitus. Examples of inframalleolar infections are cellulitis, myositis, abscesses, necrotising 
fasciitis, septic arthritis, tendonitis, osteomyelitis and paronychia.   
1.1.5 Diabetic foot infection (DFI) 
According to Lipsky et al. (2004) the infected diabetic foot mal perforans ulceration is a 
prominent and typical lesion (Figure 1.2). The presence of an ulcer increases the 
susceptibility of the wound to infection from bacteria. An active infection progresses from 
bacterial colonisation through contiguous extension involving deeper tissues to limb–
threatening infection beyond 2 cm from the ulcer perimeter (Frykberg, 2002; Lipsky et al., 
2004). In most cases increase risk and severity of foot infections are as a result of poorly 
characterised immunologic disturbances, poor blood circulation or impaired tissue perfusion 
(Geerlings and Hoepelman, 1999). Limb–threatening infections with subsequent amputations 
are normally characterised by deep tissue abscess with severe cellulitis and osteomyelitis in 
critically ischaemic limbs (American Diabetes Association, 1999). Signs indicative of 
infection include purulence and inflammation and these should usually be followed by 
aerobic and anaerobic cultures. Purulent drainage or curetted materials from infected ulcers 





Figure 1 .2 Diabetic foot presentations with ulcerations on the; (A) the plantar and (B) the 




1.2 Biofilms in Diabetic Foot Infections 
Despite the documentation of biofilms more than a century ago by Anthony van 
Leeuwenhoek, their clinical importance became evident when they were indicated in chronic 
infections (Bispo et al., 2015; Potera, 1999). In the preface of her book titled ‘Control of 
Biofilm Infections by Signal Manipulation. Springer Series on Biofilms 2’, Balaban (2008) 
suggested that there may be more biofilm–related diseases than the total numbers affected by 
heart disease and cancer. Ever since Akiyama et al. (1993) and Serralta et al. (2001) 
demonstrated the presence and nature of biofilms in in vitro and in experimental murine and 
pig models through staining and microscopy, more researches has been conducted on 
biofilms to increase understanding of biofilms (Cooper, 2010; Lopez et al., 2010). Although 
there still remain some challenges in biofilm research such as the diagnosis of biofilm 
infection and bacterial culture, biofilm infection and colonisation, and the issue of antibiotic 
susceptibility of planktonic cultures compared to biofilm resistance to antibiotics and/or the 
presence of antibiotic tolerant persister cells, the study of biofilm is one of the most relevant 
topics in wound biology (Cooper, 2010; Hall–Stoodley and Stoodley, 2009; James et al., 
2008; Lopez et al., 2010; Mertz, 2003; Wolcott et al., 2008). It has therefore been suggested 
that the impairment of healing among people with chronic wounds including diabetic foot 
ulcers may be due to biofilm phenotype infections (James et al., 2008; Wolcott et al., 2008). 
1.2.1 The Nature of Biofilms 
Biofilms have been described as the ubiquitous and natural phenotype of bacteria (Cooper, 
2010; Lopez et al., 2010). Costerton et al. (1999) defined biofilm as ‘a structured community 
of bacterial cells enclosed in a self–produced polymeric matrix and adherent to an inert or 
living surface.’ According to Davey and O’Toole (2000) and Donlan (2002), the extracellular 
polymeric substance (EPS) can be considered as the primary matrix matter that accounts for 
about 50–90% of the biofilm. The chemical composition of the EPS may vary depending on 
the bacteria present in the biofilm but is primarily made up of polysaccharides (Donlan, 
2002). For example, in the case of Gram–negative bacteria polysaccharides present in the 
EPS are neutral or polyanionic which confers anionic properties to the EPS (Sutherland, 
2001). Some of these anionic polysaccharides include D–galacturonic, D–glucuronic, and 
mannuronic acids as well as ketal–linked pyruvates (Sutherland, 2001). Other components of 
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the EPS such as proteins and extracellular DNA, together with the various types of 
polysaccharides are known to provide structural support for the growing biofilm (Lopez et 
al., 2010). In Pseudomonas aeruginosa, 3 genes loci designated as alginate (alg), pellicle 
(pel) formation and polysaccharide synthesis locus (psl) genes have been found to produces 3 
exopolysaccharides namely; alginate, PEL and PSL (Branda et al., 2005; Colvin et al., 2012; 
Jackson et al., 2004; Matsukawa et al., 2004). In Staphylococcus aureus biofilms, biofilm–
associated proteins called Bap maintain the structural integrity. Other proteins that support 
the biofilm structure are fimbriae (Latasa et al., 2006). In addition, P. aeruginosa and S. 
aureus also produce extracellular DNA called eDNA that provides stability to the biofilms 
(Lopez et al., 2010; Rice et al., 2007). As a result of their compositions, biofilms have also 
been referred to as microbial communities containing microcolonies of bacterial cells 
enclosed in extracellular polymeric substances separated from each other by interstitial voids 
(Lewandowski, 2000). Stoodley et al. (1997) have also suggested that biofilms could be 
described as thin–based films which range from being sparse and sporadic monolayers of 
cells up to some cell layers in thickness. The amount of EPS and the total thickness of biofilm 
produced by biofilm–producing bacterial species normally vary between different bacterial 
species, shear forces experienced by the bacteria and other environmental conditions such as 
oxygen concentration, temperature, pH and availability of nutrients (Flemming and 
Wingender, 2010). It has been shown that cell–to–cell (between bacterial cells or bacteria and 
host cells) signalling play a possible role in early attachment and detachment of bacteria to 
surfaces during biofilm formation (De Kievit et al., 2001; Xie et al., 2000). Donlan and 
Costerton (2002) also added that biofilms further show evidence of altered phenotype with 
respect to growth, gene expression and protein production. The evidence of altered phenotype 
is as a result of communication among the bacteria in this sessile community referred to as 
quorum sensing. Quorum sensing will be discussed later in the literature review of this thesis 
(see section 1.4).  
Microorganisms are ubiquitous, and their distribution and dimensional movement in the 
environment are usually determined by chemical conditions like nutrient availability, the 
concentrations of inhibitory substances in addition to chemical factors such as oxygen 
tension, temperature or acidity, and biological factors such as predation and competition 
(Cooper, 2010; Mitchell and Kogure, 2006; Watnick and Kolter, 2000). The short supply of 
nutrients most often limits bacterial growth in their natural habitat. Therefore, planktonic 
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cells are attracted by complex concentration gradients created by nutrients adsorbed onto 
inert surfaces. The initial attachment of bacteria onto a surface (inert or living) prior to 
biofilm formation depends on factors that include the types of surface (substratum), 
formation of conditioning film on the surface, aqueous medium and its hydrodynamics and 
characteristics, and properties of the cell surface (Donlan, 2002). The ideal environment 
suitable for attachment and subsequent growth of bacteria is a solid–liquid interface (O’Toole 
et al., 2000). It has also been established that, rough surfaces with higher surface area have 
diminished shear forces exerted by the surrounding medium which in turn increase the rate 
and extent of bacterial attachment onto that surface (Characklis et al., 1990). 
Physicochemical properties such as hydrophobicity rather than hydrophilicity of material 
surfaces such as the wells of 96–well plates and Teflon has also been found to increase the 
rate of bacterial attachment (Bendinger et al., 1993; Fletcher and Loeb, 1979; Pringle and 
Fletcher, 1983). Hydrophobic interactions that take place between bacterial cell surfaces and 
the substratum of the material surface have been found to enable the bacterial cells to 
irreversibly attach to the surface after overcoming active repulsive forces that are present 
(Pringle and Fletcher, 1983).  
Prior to the irreversible attachment of bacterial cells onto a surface (either abiotic or 
biological) in an aqueous medium, the surface is coated by polymers from the medium called 
conditioning film in order to overcome active repulsive forces that prevent attachment (Loeb 
and Neihof, 1975). The nature of conditioning films exposed for attachment on biological (in 
vivo) and abiotic (in vitro) surfaces has been found to be differ in response to the media from 
which they are produced (Donlan, 2002). Human host conditioning film – producing media 
include tears, urine, blood, saliva, respiratory secretions and intervascular fluid (Mittelman, 
1996). They have been found to alter characteristics, such as hydrophobicity or hydrophilicity 
of the substratum (Ofek and Doyle, 1994). Conditioning films also known as microbial 
surface components recognising adhesive matrix molecules (MSCRAMMs) produced in 
human hosts which facilitate bacterial attachment to biomaterials or host surfaces comprise of 
glycoproteins, lipids, phosphoproteins, lysozymes and albumin (Clarke and Foster, 2006; 
Foster and Höök, 1998; Marsh, 1995). The effect of conditioning film on surfaces causes 
changes in the hydrodynamic interactions between the bacterial cells and the surface leading 
to decreased flow velocities and shear forces with resultant increase in the rate of microbial 
attachment (Rijnaarts et al., 1993; Zheng et al., 1994). According to O’Toole and Kolter 
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(1998), individual P. aeruginosa cells that initiate biofilm development on an abiotic surface 
adhere to these surfaces with small amounts of EPS (Stage 1, Figure 1.3). During the stage of 
reversible attachment, bacterial cells are capable of moving independently in a twitching or 
gliding manner by means of their cell surface appendages called pili (O’Toole and Kolter, 
1998; O’Toole et al., 2000). As a result of this independent movement, some bacteria may 
leave the surface to colonise new surfaces as planktonic cells while the remaining adherent 
cells may continue with the processes of biofilm formation (Stoodley et al., 2002). Prior to 
differentiation of adherent cells, the bacterial cells have been found to demonstrate some 
species–specific behaviours such as rolling, creeping, windrow–like formation and the 
subsequent formation of aggregates (Marshall et al., 1971; Korber et al., 1995). In chronic 
wounds, the initiation of irreversible attachment onto the wound bed sometimes occurs when 
planktonic bacteria sense environmental cues such as change in pH, salinity, quorum sensing 
molecules and nutrients (Wolcott et al., 2008). Consequently, cell–surface adhesins attach 
and bind to specific host cell epitopes in collagen, fibronectin, fibrinogen and vitronectin 
(Foster and Höök., 1998; Massey et al., 2002). Davies and Geesey have demonstrated that 
initial attachment of P. aeruginosa onto a surface triggers the upregulation of genes 
responsible for the production of alginate which further strengthens the bacteria–host 
attachment. In the case of P. aeruginosa, the formation of an irreversible attachment with 
host cells results in a metabolic shift that directs the expression of biofilm phenotypes 
(Harrison–Balestra et al., 2003). Once a permanent attachment has been achieved, the 
attached bacterial cells divide into biofilm phenotypes which begin to secrete the EPS (Stage 
2, Figure 1.3). As the cells continue to grow and develop into mature biofilms, they form 
microcolonies separated by water channels (Stage 3, Figure 1.3). The structure of the 
microcolonies is held together by the EPS which is primarily made up of proteins, 
polysaccharides and nucleic acid as well as organic acid that serve as building blocks to hold 
the cells together. As the biofilms mature, some individual microcolonies detach from the 
surface (with or without apparent perturbation) and disperse giving rise to planktonic cells 
that colonise new areas (Stages 4 and 5, Figure 1.3). 
Costerton et al. (1995) described the architecture of the microcolonies of mature biofilms as 
‘discrete pillar– or mushroom–shaped structures’ connected by a complex extracellular 
matrix that provides access to nutrients. Biofilms have a number of advantages over free–
living microbes. The EPS is able to capture and concentrate carbon, nitrogen and phosphate 
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as nutrients for the growing biofilm (Beveridge et al., 1997). The ability of biofilms to resist 
the action of removal agents notably antibiotics, host phagocytic clearance and host oxygen 
radical and protease defences has also been reported (O’Toole et al., 2000; Wolcott et al., 
2008). A study by Liu and Tay (2001) has demonstrated that biofilms could withstand 
detachment from varying degrees of shear stresses on abiotic surfaces by regulating their 
metabolic pathways (anabolism and catabolism) in response to substrate flux. The biofilm 
bioreactor experiments by Liu and Tay (2001) have suggested that shear stresses of flow 
velocities between 0.48 and 1.45 m/s, lead to the formation of biofilms of various thickness 
with higher flow velocity resulting in thinner and denser biofilm with a compact structure. 
Together with other reports, Liu and Tay (2001) have suggested that biofilm consortia could 
regulate their metabolic pathways in order to maintain a balance with an external detachment 
force by making use of non–growth energy that eventually decreases net negative charge, 
increases hydrophobicity and induces dehydration of the cell surface leading to increased 
cell–cell attachment and the formation of a denser biofilm consortia (Chen et al., 1998; Low 
et al., 2000; Marshall and Gruickshank 1973; Pringle and Fletcher 1983; Russell and Cook, 
1995; van Loosdrecht et al., 1987). Lastly, mature biofilms have the potential to detach from 
the growing matrix by means of dispersion as a result of mechanical shear pressure or 
through a programmed response engineered genetically (Boyd and Chakrabarty, 1994). The 
detached biofilm is capable colonising fresh surfaces and exhibit all the characteristics of the 
parent biofilm such as resistance to antimicrobials and host immune responses (Shirtliff et al., 
2002).  
Biofilms have often been associated with human conditions involving the indwelling of 
medical devices and prosthetics such as prosthetic joints, heart valves, contact lenses, 
catheters, stents and intrauterine implants (Adal and Farr, 1996; Archibald and Gaynes, 1997; 
Dickinson and Bisno, 1993; O’Toole et al., 2000).  Although mixed species biofilm has been 
found to be predominant in most environments, the presence of single–species biofilms has 
also been reported in other infections and on surfaces of medical implants such as catheters 
and prosthetics (Adal and Farr, 1996; Cooper, 2010; Dickinson and Bisno, 1993; O’Toole et 
al., 2000). Bacteria that most often cause infections in these conditions include coagulase –
negative Staphylococci, P. aeruginosa and sometimes Gram–negative bacilli and Candida. 
The cause of such infections might be as a result of the use of contaminated devices prior to 




Figure 1 .3 A model and electron micrograph illustrating the 5 stages of P. aeruginosa 
biofilm growth cycle. Stage 1; planktonic cells attach to a surface; Stage 2 – cells divide, 
secrete more EPS and form microcolonies; Stage 3 – developed microcolonies separated by 
water channels; Stages 4 and 5 – mature biofilms with “mushroom–like structures”, detach 
and disperse planktonic cells to colonise new areas (Stoodley et al., 2002).  
1.2.2 Concept of Functional Equivalent Pathogroups (FEP) 
The proposers of the concept of FEP, Dowd et al. (2008b) argued that the co–morbidities 
connected with the pathophysiology of most chronic wounds need to be defined in context of 
the host conditions. This they believe is an important step prior to the management of chronic 
wound. They further argued that the ecology of a wound comprise of both host conditions 
and host’s environment. This means that some patients may share a similar ecological wound 
as a result of similar environmental conditions and hosts’ conditions. Dowd et al. (2008b) 
studied 8 major clusters of bacterial isolated from various wounds including DFU and named 
them functional equivalent pathogroups. They hypothesised that the chronicity of infectious 
wounds cannot be maintained by some bacterial species on their own unless they co–occur in 
significant mixtures in order to symbiotically act to establish pathogenicity, develop biofilm 
and maintain the chronicity of the wounds. 
The occurrence of pathogroups in wounds especially diabetic foot infections cannot be easily 
identified using traditional culturing methods (Dowd et al., 2008b). This is because almost all 
FEPs are linked together by anaerobes which are difficult to isolate by traditional culture 
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techniques. Some studies have shown that some biofilms made up of both aerobes and 
anaerobes have the ability to withstand certain stressors by a process called coaggregation 
(Bradshaw et al., 1998). A model biofilm created by the Lewandowski laboratory has 
suggested that only bacteria found on the surface of biofilms use oxygen suggesting that 
internal regions of the biofilm are occupied by facultative and obligate anaerobes (Rasmussen 
and Lewandowski, 1998). Although the biofilm model described by Rasmussen and 
Lewandowski (1998) may not be applicable to all biofilm settings, the complex and 
polymicrobial nature of biofilms require that sensitive methods are used in their 
identification. Though the cultivability of bacterial pathogens has been the central practice in 
medical microbiology, the need to incorporate molecular technology in the attempt to deal 
with obstinate infections such as polymicrobial and complex infections has become clear 
(Dowd et al., 2008b). 
1.2.3 Detection of biofilms in wounds 
It is estimated that biofilm–infected foot ulcers make up 85% of lower limb amputations 
among diabetic patients (Adler et al., 1999). In 2005, the National Diabetes Information 
clearinghouse (USA) estimated that at least 80,000 amputations are performed each year 
among the diabetic population in United States of America. As mentioned earlier, diabetes–
related amputations are mostly preceded by wound infections, impaired wound healing and 
ischaemia in conjunction with a foot ulcer. One of the earliest discoveries of biofilms in 
wounds was observed using scanning electron microscopy of 15 sutures and 15 staples in 
healed surgical wounds (Gristina et al., 1985). Staphylococcus epidermidis was isolated from 
specimens obtained from the sutures. Surprisingly, the observed biofilms had neither 
triggered any obvious infection nor immunological host response. The formations of biofilms 
have been successfully demonstrated and examined using scanning electron microscopy 
(SEM) and confocal laser scanning microscopy (CLSM) in acute wounds using murine and 
pig models respectively (Akiyama et al., 1993; 1994, Serralta et al., 2001). Akiyama et al. 
(1996) demonstrated the formation of glycocalyx, a thick layer of extracellular polymeric 
substance by S. aureus in a biofilm.  Serralta et al. (2001) also demonstrated the production 
of a polymeric matrix encasing P. aeruginosa. 
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Apart from the use of advanced microscopy mentioned above, the presence of biofilms in 
chronic wounds has been demonstrated by molecular characterisation of the microbiota found 
in pooled biopsy specimens using ribosomal RNA gene analysis techniques.  In one such 
study, Dowd et al. (2008a) demonstrated the dominance of Staphylococcus, Pseudomonas, 
Peptoniphilus, Enterobacter, Stenotrophomonas, Finegoldia and Serratia species in chronic 
wounds using pyrosequencing and full ribosome shotgun sequencing. In another study, 
discrete biopsy samples from 40 diabetic foot ulcer patients were analysed by bacterial tag 
encoded FLX amplicon pyrosequencing (bTEFAP). Corynebacterium species was 
predominant followed by the presence of some obligate anaerobes including Bacteriodes, 
Peptoniphilus, Finegoldia, Anaerococcus and Peptostreptococcus species (Dowd et al., 
2008b).  
The biosynthesis of the EPS is a major aspect of the development of a mature biofilm. The 
presence and classes of polymeric substances in the EPS varies with every bacterial cell. 
However, the main macromolecules found in the EPS include polysaccharides, proteins, 
DNA, glycoconjugates such as glycoproteins and glycolipids, and phospholipids (Czaczyk 
and Myszka, 2007; Branda et al., 2005; Sutherland, 2001). For example, EPS components 
such as alginate produced by P. aeruginosa can be used as a marker for biofilm detection in 
cultures, or on medical devices such as catheters by means of scanning electron microscopy 
examination, staining and examination with light microscope or epifluorescence microscopy 
(Davies et al., 2007; Harrison–Balestra et al., 2003; Stickler et al, 1998). It has been 
suggested that some extracellular molecules (polysaccharides, glycoproteins and proteins) 
synthesised as part of the EPS in some bacteria have antigenic properties that can be used for 
serological classification of these bacterial cells (Branda et al., 2005; Czaczyk and Myszka, 
2007; Sutherland, 2001). Czaczyk and Myszka (2007) also mentioned that physiological 
determinants such as pH of culture medium, carbon/nitrogen availability, incubation 
temperature and growth phase influence EPS biosynthesis. 
The estimation of biofilm formation using the conventional microtitre plate method is one of 
the most widely used in vitro assays for the determination of biofilm formation. The 
microtitre plate assay provides the medium for biofilm–forming bacterial species to adhere 
and form biofilm in a batch culture which can be detected and estimated through staining 
with stains like safranin or crystal violet (Christensen et al., 1985; Merritt et al., 2011). 
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Although the morphology of the biofilm cannot be seen, the ability of organisms to form 
biofilm can easily be determined in a simple and reproducible analysis. In batch culture using 
6–well or 24–well plates or in a continues flow cultures, biofilms can be grown on slides, 
stained and examined by light, epifluorescence or confocal laser microscopy. Viable bacterial 
cell counts can also be determined after biofilm batch cultures (Sun et al., 2008).  
Further detection of biofilms in wounds known as the reporter assay was developed in rats by 
Nakagami et al. (2008). This assay involved the comparison of the levels of quorum sensing 
molecules detected in 12 pressure–induced ischaemic wounds infected with P. aeruginosa to 
12 uninfected wounds. The reporter assay test recorded change of colour in a bacterial culture 
containing acyl–homoserine lactone quorum sensing molecules. Other methods of detecting 
quorum sensing molecules by means of chemical analysis have been developed. They include 
mass spectrometry, thin layer chromatography and high performance liquid chromatography 
(HPLC). However, all these tests are limited to research laboratories and cannot be performed 
as routine tests in hospitals. 
1.2.4 Control of biofilms  
From section 1.2.3, it can be established that there is a link between wound chronicity and the 
presence of biofilms. It is also evident that the presence of antibiotic resistant strains 
contributes significantly to treatment failure (Noiby et al., 2010). There is therefore the need 
to devise strategies in controlling such wounds and reduce the need for amputations. 
Control measures required to combat biofilms can either be preventive or those that remove 
and interrupt their formation. One such strategy described by Wolcott and Rhoads, (2008) in 
the treatment of critical limb ischaemia involved sharp wound debridement and the 
administration of lactoferrin and xylitol to disrupt the formation of the extracellular 
polymeric substance by removing iron. Other remedies suggested include; biological 
debridement with maggots (van der Plas et al., 2008), enzymatic disruption of EPS (Johansen 
et al., 1997), use of antimicrobial agents such as cadexomer, iodine, hydrogen peroxide, 
chlorohexidine, octenidine, polyhexanide, and silver (Akiyama et al., 2004; Johansen et al., 
1997; Percival et al., 2007). In another study, it was shown that the sugar content in honey 
has the ability to prevent the adherence of P. aeruginosa to host cells in the development of 
infection (Lerrer et al., 2007).  Fructose and fucose carbohydrate monomers found in honey 
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have been demonstrated to block sugar – binding proteins, also called lectins, on the surface 
of P. aeruginosa preventing them from attaching to target cells and inhibiting biofilm 
formation (Merckoll et al., 2009; Tielker et al., 2005).  
1.3 Resistance of biofilm to antibiotics/antimicrobial agents 
Clinically important biofilms can normally be formed in diseased conditions such as 
endocarditis and diabetic foot ulcers in response to stresses from host defence mechanisms 
and antimicrobial treatment (Anderson and O’Toole, 2008; Mah and O’Toole, 2001; Parsek 
and Singh, 2003). According to Lewis (2007), an antibiotic is initially administered into a 
host in its benign form (pro–antibiotic) after which it is enzymatically converted into an 
active form in the cytoplasm. The active form of the antibiotic then binds to its target site and 
causes the needed conformational changes that lead to cell death (Lewis, 2007). Biofilms 
have been found to have increased resistance to antimicrobials and sustained host defence 
mechanisms than planktonic cells (Lopez et al., 2010). The ability of bacteria to resist host 
defence mechanisms has been linked to their ability to interact with each other through cell–
cell adhesion using cell–surface appendages, quorum sensing (bacterial communication) and 
the presence of antibiotic resistant and/or tolerant (persister) cells which subsequently lead to 
treatment failure (Bigger, 1944; Costerton et al., 1999; Donlan and Costerton, 2002; Dowd et 
al., 2008a; Dowd et al., 2008b; James et al., 2008, Wolcott et al., 2008; Lewis, 2005; Lewis 
2007; Lewis 2010; Conlan et al., 2013; Tielker et al., 2005; Winzer et al., 2000). Bacterial 
cell–cell interactions and quorum sensing have been further discussed in chapter 5, sections 
5.1 and 5.7, and throughout Chapter 5. In most cases, the mechanisms fundamental to 
antibiotic resistance are due to target modification by mutation; enzymatic changes leading to 
target modification; substitution of target (expression of alternative target); modification or 
destruction of antibiotic; antibiotic efflux and restricted entry of antibiotics (Lewis, 2007). 
In biofilms, the EPS acts as a physical barrier that inhibits the penetration of large 
antimicrobial proteins such a lysozyme and complement from the host immune system 
(Bjarnsholt et al., 2005; Lewis, 2001). Moreover, the negatively charged extracellular 
polymers within the matrix are able to bind to positively charged antibiotics and 
antimicrobial peptides such as the aminoglycosides (gentamicin and tobramycin) and 
defensins and prevent their subsequent permeation (Bagge et al., 2004; Brodgen, 2005; 
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Shigeta et al., 1997). Antibiotic–degrading bacterial enzymes such as N–acetyltransferases, 
O–nucleotidyltransferases and O–phosphotransferases within the EPS matrix of P. 
aeruginosa biofilm bind to aminoglycosides and covalently modify specific amino or 
hydroxyl functions which make them inactive (Mingeot–Leclercq et al., 1999).  It has also 
been found that synergy between retarded diffusion and enzymatic destruction of antibiotics 
leads to resistance of P. aeruginosa biofilm (Mah and O’Toole, 2001). As the concentration 
of the antibiotic entering the cell is restricted, P. aeruginosa expresses beta–lactamases that 
destroy incoming antibiotics. Another resistance mechanism called efflux pump located in the 
cytoplasmic membrane is expressed during antibiotic treatment with azithromycin, 
gentamicin, tobramycin and ciprofloxacin through the regulation of efflux pump genes 
(Zhang and Mah, 2008). In Escherichia coli (E. coli), the transenvelope AcrAB–TolC MDR 
pump and chloramphenicol pump (CmIA) synergistically pick up chloramphenicol 
transported into the periplasm and extrude them out of the cell (Lee et al., 2000). 
 
Figure 1 .4 The delivery of an antibiotic and target binding. Under normal conditions, a pro–
antibiotic is delivered to a cell, an enzyme converts it into a reactive form that locates and 
binds the target resulting in cell death (Lewis, 2007).  
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1.3.1 Persister cells in Biofilms  
The inability of potent antibiotics even at high concentrations to completely inhibit or 
eradicate biofilms is possibly due to the presence of persister cells (Lewis, 2007). Persister 
cells have been described as metabolically inactive cells that account for approximately 1% 
of the total biofilm population (Anderson and O’Toole, 2008; Hall–Stoodley and Stoodley, 
2009; Lewis, 2001; Lewis, 2007). It has been suggested that, these metabolically inactive 
cells are tolerant to antibiotics even at concentrations 10 to 100–fold higher than their 
minimum inhibitory concentrations and are responsible for relapse of biofilm infections 
through dispersal and colonisation of new niches (Lewis, 2001; Lewis, 2007). Though the 
mechanisms underlying the formation of persister cells remain an unknown, it has been 
shown that the highest rate of persister formation is at stationary phase of growth and 
independent of quorum sensing as spent growth media and early exponential cultures of E. 
coli or P. aeruginosa added together did not show appreciable increase in the number of 
persister cells isolated (Lewis, 2007). As they are metabolically inactive, persister cells do not 
express target sites for antibiotic activity. They are also known to express toxin–antitoxin 
systems where toxin molecules block antibiotic target sites (Lewis, 2005). Unlike resistant 
cells, persister cells do not need to undergo genetic modification to escape the effects of 
antibiotic and do not undergo genetic change (Wood et al., 2013). 
It has also been shown that translation takes place in persister cells at a very low rate (Gefen 
et al., 2009; Shad et al., 2006). However, aminoglycosides such as gentamicin that target 
ribosomes have weak activity towards persister cells. Allison et al. (2011) demonstrated that 
in metabolically–stimulated persister cells (from both Gram–negative and Gram–positive 
bacteria), aminoglycosides like gentamicin rapidly induce the killing of the cells at a greater 
rate when augmented with specific metabolites such as glucose, mannitol, fructose and 
pyruvate. When this was repeated in the presence of other antibiotics such as the quinolones 
and β–lactams, there was no significant change in killing of persister cells. They proposed 
that quinolones and β–lactams augmented with metabolic stimuli do not convert persister 
cells to an active state where DNA and cell wall synthesis take place. 
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1.3.2 Bacterial cell–cell interaction during biofilm formation 
In biofilms, bacteria attach to each other, to host cells or the extracellular matrix by means of 
their surface proteins and sugars. Cell–surface proteoglycans, glycoproteins and glycolipids 
mostly contain oligosaccharide residues that are specific to cell types. Cell–surface 
appendages such as fimbriae expressed by E. coli and P. aeruginosa have been found to 
provide structural stability during biofilm formation (Lopez et al., 2010). For example, type I 
fimbriae expressed by E. coli bind to mannose–containing receptors during biofilm 
formation. Bacterial lectins are carbohydrate–binding proteins that specifically identify and 
bind to sugar moieties to facilitate cell–cell or cell–matrix attachments during biofilm 
formation. This makes lectins useful primary diagnostic tools for the identification of 
bacterial species or cellular components (Afrough et al., 2007; Munoz et al., 1999; Munoz et 
al., 2003; Slifkin and Doyle, 1990). P. aeruginosa has been found to express two important 
lectins, LecA and LecB that bind specifically to D–galactose and L–fucose respectively 
during biofilm development (Diggle et al., 2006; Tielker et al., 2005). The production of 
LecA and LecB has been found to be directly regulated by quorum sensing genes (Winzer et 
al., 2000). Using immunoblot analysis, it was observed that quorum sensing gene rhl locus 
was directly responsible for the production of both LecA and LecB. This was confirmed 
when both lectins were lost in a mutant strain but restored after the introduction of a plasmid–
borne rhl locus.  However, in lasR mutant strains the commencement of lectin synthesis was 
found to be delayed (for about 18 hours) but not completely abolished. This is a 
demonstration that quorum sensing regulation of lectin synthesis is an essential mechanism 
for bacterial interaction during P. aeruginosa biofilm development. Therefore, the 
determination of quorum sensing genes associated with biofilms can be a useful diagnostic 
tool in differentiating between bacterial strains as either biofilm producers or non–biofilm 
producers. 
1.4 Quorum sensing in bacterial biofilms 
In a biofilm communication between bacterial cells (inter and intraspecies) is made possible 
by the production, secretion and recognition of certain chemical signals called quorum 
sensing (QS) molecules in the extracellular matrix. At a significant threshold (quorum), the 
concentration of these diffusible signalling molecules corresponds to a particular or confined 
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cell population density in the extracellular matrix. This recognition of cell population 
density–dependent signalling cascade induces a coordinated change in the gene expression 
profiles of the communicating bacteria in a process called quorum sensing (Cooper, 2010; 
Hammer and Bassler, 2003; Suga and Smith, 2003).  
Quorum sensing molecules are the signalling molecules responsible for communication 
among cells growing on a surface or in a biofilm. They are also called autoinducers (Hammer 
and Bassler, 2003; Suga and Smith, 2003). Autoinducers regulate the expression of genes in 
bacteria and extensively control their responses (Cooper, 2010; Hammer and Bassler, 2003; 
Shirtliff et al., 2002; Suga and Smith, 2003). Some of the responses that are controlled by 
quorum sensing circuits include motility, virulence, spore formation, biofilm formation, 
antibiotic resistance, conjugation, competence, pigmentation and bioluminescence (Hammer 
and Bassler, 2003: Nealson et al., 1970). Hammer and Bassler (2003) emphasised that some 
bacteria in a consortium have the ability to detect and respond to multiple autoinducers 
allowing them to differentiate between the various species thereby harmonizing behaviours 
common to their community. This peculiar characteristic enables them to undertake certain 
activities as a multicellular group other than planktonic cells.  
1.4.1 Quorum Sensing Molecules 
The first evidence of quorum sensing was reported in the marine luminescent bacterium 
Vibrio fischeri, which can exist either as free–living or in an association with their fish or 
squip (Euprymna scolopes) symbiotic hosts (Nealson et al., 1970). As free–living cells and at 
low cell densities, they do not express the luciferase–encoding genes which control light 
emission. However, when living in a specialised light organ of their symbiotic host, they 
express these genes as their cell density increases in relation to a correspondent increase in 
the production of signal molecules (Nealson et al., 1970). At a significant threshold, the 
signal molecules activate bioluminescence (Nealson et al., 1970). In a separate study by 
Eberhard et al. (1981), the autoinducers responsible for bioluminescence in V. fischeri was 
found to be 3–Oxo–C6–homoserine lactone, a member of the family of N–acyl–homoserine 
lactones. 
Two types of autoinducers have been reported in bacterial biofilms. For example, the marine 
bacterium Vibrio harveyi produces and responds to signals from acylated homoserine lactone 
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(AHLs) called HAI–1 synthesised by LuxLM and the new furanosyl borate diester 
autoinducer known as AI–2 synthesised by LuxS (Chen et al., 2002; Hammer and Bassler, 
2003; Schauder et al., 2001). 
AHLs have been reported and proposed to mediate intraspecies communication solely 
between Gram–negative bacteria (Williams, 2007). Though different forms of AHLs are 
produced by different species; all the different AHLs have a common homoserine lactone 
ring moiety with varying length, degree of saturation and specific substitutions within an 
attached acyl side–chain (Rickard et. al., 2010). The AI–2 molecules are a family of inter–
convertible molecules derived from the same precursor molecule; 4,5–dihydroxy–2,3–
pentanedione (DPD) that can be detected by over 40 species of both Gram–negative and 
Gram–positive bacteria (Semmelhack et al., 2005; Sun et al., 2004; Surette and Bassler, 
1998; Surette et al., 1999, Xavier and Bassler, 2003). AI–2 has been shown to mediate signal 
transduction between intra–species and inter–species bacteria in the formation of biofilm and 
virulence in Vibrio cholera and Streptococcus pneumoniae and bioluminescence in Vibrio 
harveyi (Bassler and Losick, 2006; Rickard et al., 2006; Schauder et al., 2001; Surette et al., 
1999; Yoshida et al., 2005).  
1.4.2 Signal Transduction in Gram–Negative Bacteria 
Different quorum sensing communication circuits exist in both Gram–negative and Gram–
positive bacteria. In Gram–negative bacteria, the main QS system comprises of a LuxI 
synthase homolog, LuxR receptor homolog and acyl–homoserine lactones signalling 
molecules (Brackman et al., 2011). The formation of cytoplasmic acyl–homoserine lactone is 
catalysed by the LuxI proteins of V. fischeri and its homologs, from the metabolic products 
S–adenosyl methionine and a suitable acyl–acyl carrier protein from the fatty acid 
biosynthetic pathway (Val and Cronan, 1998). Over 50 different bacterial species produce 
AHLs with each associated with a specific type of LuxI protein. Acylated homoserine 
lactones mediate signal transduction in Gram–negative bacteria. AHLs found in Gram–
negative bacteria include V. fischeri (3–Oxo–C6–homoserine lactone (HSL)), Pseudomonas 
aeruginosa N–3–Oxo–C8–HSL), Serratia liquefaciens (–C4–HSL), and Agrobacterium 
tumefaciens (3–Oxo–C8–HSL) (Suga and Smith, 2003). In P. aeruginosa, two AHL quorum 
sensing systems are found; las and rhl. Each system is made up of its own AHL synthase 
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designated as LasI and RhlI, and corresponding transcriptional regulator also designated as 
LasR and RhlR (Lopez et al., 2010). In P. aeruginosa, AHLs in the cytoplasm bind to DNA–
binding regulatory proteins, LasR, produced by lasR regulatory genes. The LasR–AHLs 
complexes subsequently recognise and bind to a number of genes and promoters under 
quorum sensing regulation activating the transcription of these genes in eliciting specific 
quorum sensing response (Shirtliff et al., 2002; Suga and Smith, 2003).   
1.4.3 Signal Transduction in Gram–Positive Bacteria 
Quorum sensing in Gram–positive bacteria is mediated by a two–component signal 
transduction mechanism; a histidine kinase and a response regulator domain that elicits signal 
transduction through phosphorylation.  The quorum sensing molecules are called auto–
inducing peptides which are produced either after post–translational modification or 
unmodified oligopeptides. The ATP–binding cassette exporter protein then releases the 
mature oligopeptide into the cytoplasm where they are detected by the two–component signal 
transduction system. The histidine portion of the oligopeptide is autophosphorylated by the 
sensor kinase. The phosphate is subsequently transferred onto an aspartate residue found on 
the response regulator domain or protein. The complex formed then activates the expression 
of targeted genes under quorum sensing control (Demain, 1998). An example of a modified 
autoinducing peptide that is released by Staphylococcus aureus is the cyclic thiolactone, the 
accessory gene regulator quorum sensing system (AgrD) (Bassler and Losick, 2006). 
1.4.4 Interspecies signal transduction and bioluminescence in Vibrio species 
It has been demonstrated that, the bioluminescent marine bacterium V. harveyi, is capable of 
regulating some cellular processes such as bioluminescence, type III secretion, siderophore, 
polysaccharide and metalloprotease production using 2 parallel QS systems (Bassler et al., 
1993; Bassler et al., 1994; Henke and Bassler, 2004; Lilley and Bassler, 2000; Nealson and 
Hastings, 1979). In the first system, N–(3–hydroxybutanoyl) homoserine lactone (HSL) also 
denoted as HAI–1 for V. harveyi autoinducer is produced and detected by LuxM and LuxN 
respectively (Bassler et al., 1993). The second system produces AI–2 (3A–methyl–5,6–
dihydro–furo(2,3–D) (1,3,2) dioxaborole–2,2,6,6A–tetraol), by LuxS which is detected by 
LuxP and LuxQ. The 2 QS systems which have been described in details in sections 5.2.2 and 
5.2.3 in Chapter 5 are known to synergistically regulate multiple genes in addition to the 
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luxCDABE operon, responsible for light production in V. harveyi (Miller and Bassler, 2001). 
In an E. coli – V. harveyi mixed culture, exogenous AI–2 produced by E. coli was found to 
induce bioluminescence in V. harveyi (Xavier and Bassler, 2005a). 
1.4.5 Detection of QS signalling molecule production in bacteria 
In addition to the PCR amplification of QS–associated genes, biosensor reporter systems 
have been used to detect short, medium and sometimes long acyl chains of AHLs (Steindler 
and Venturi, 2007). For example, the antibacterial purple pigment violacein produced by 
Chromobacterium violaceum is regulated by the CviI/R QS system which secretes and 
responds to both short and medium acyl chains of AHLs including C4–AHL and C8–3–oxo–
AHL (McClean et al., 1997). In order to detect the production of AHLs with long acyl chains, 
the SinI/R system of Sinorhizobium meliloti (previously called Rhizobium meliloti) was 
constructed (Llamas et al., 2004). This reporter system with a sinI–lacZ transcriptional 
fusion, incorporated a radiotracer, (normally 14C label from (14C) methionine into AHLs) and 
could produce and respond to long acyl chains of AHLs including C12–AHL, C14–3–oxo–
AHL, C16–AHL and C18–AHL (Llamas et al., 2004). Some biosensors have also been 
constructed to detect AHLs at the single–cell level (Riedel et al., 2001). An example of this is 
the QS system in Burkholderia cepacia with a cepI–gfp (green fluorescent protein) 
transcriptional fusion that enables the detection of AHLs using epifluorescence microscopy.   
The creation of a broad host range reporter plasmids (Jiwaji, 2006; Jiwaji et al., 2008; Jiwaji 
and Dorrington, 2009; Matcher et al., 2013) and the use of small molecule probes (Lowery et 
al., 2008; Lowery et al., 2013) have made it possible to explore and clarify some complex 
signalling pathways underlying molecular and cellular level behaviours of Gram–negative 
bacteria. In one of such studies, Lowery et al. (2013) introduced an AI–2 inhibitor (propyl–
4,5–dihydroxy–2,3–pentanedione) into Lrs QS system fused to a lacZ reporter gene to study 
the proteome of Salmonella enterica serovar typhimurium. They discovered that QS 
inhibitors developed in a reporter strain also had effect on wild–type strains. For example, 
some proteins belonging to the Lsr family of proteins (LsrK, LsrB, LsrF, LsrA) in the well–
characterised lsr–regulated QS system were selectively downregulated in both biosensor 
reporter and wild–type strains. However, AI–2 production by the LuxS QS system and 
associated proteins (AI–2 synthase and Pfs) in both strains were not affected.  
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In another study, Matcher et al. (2013) suggested among other reasons that the regulation of 
pyrimidine metabolism in Pseudomonas putida RU–KM3s could be through quorum sensing 
which did not require a well–characterised lux QS system. They used a gus (β–glucuronidase) 
reporter gene fused to dihydropyrimidinase (dhp) transcriptional promoter gene in the 
presence of the substrate (hydantoin) to monitor pyrimidine metabolism in P. putida RU–
KM3s. The significance of the above–mentioned studies is that biosensor reporter strains 
make it possible to detect a wide range of AHLs. 
1.4.6 Quorum sensing inhibition 
The contribution of quorum sensing molecules to enhance virulence and development of 
biofilms has promulgated the idea that the inhibition of quorum sensing might also contribute 
to the controlling of biofilms (Cooper, 2010). For example, the role of natural products such 
as garlic has been indicated in some studies to inhibit quorum sensing in P. aeruginosa 
(McLean et al., 2004). Bjarnsholt et al. (2005) have also indicated the use of garlic in treating 
bacterial infections as it was effective against P. aeruginosa isolated from cystic fibrosis 
patients. In their work, Bjarnsholt et al. (2005) observed that, garlic–treated P. aeruginosa 
biofilms grown in an in vitro continuous culture once–through flow chambers were 
susceptible to tobramycin and phagocytosis by polymorphonuclear leucocytes. Garlic extract 
has previously been reported to have antimicrobial properties and by using DNA microarray–
based transcriptomic analysis has also been found to inhibit 167 gene expressions in P. 
aeruginosa, 92 of which are quorum sensing–regulated (Ankri and Mirelman, 1999; 
Rasmussen et al., 2005).  
The theory of quorum quenching; the use of enzymes and inhibitors such as antagonists of 
autoinducers to block and disrupt quorum sensing systems thereby preventing their 
responses; has been well received as a means of controlling biofilms (Suga and Smith, 2003; 
Zhang and Dong, 2005). AHL–degrading enzymes have been identified from some 
prokaryotes and eukaryotes based on studies from the characterisation of acylated 
homoserine lactones. Some of these degrading enzymes and their sources include AHL 
lactonase–Bacillus sp.240B1 and Klebsiella pneumonia, AHL acylase–Variovorax paradoxus 
VAI–C, acylase I – porcine (kidney) and lactone–human airway epithelia (Dong et al., 2000; 
Greenberg et al., 2004; Leadbetter and Greenberg 2000; Xu et al., 2003). 
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Modifications of natural AHLs or AIs have been found to be potent antagonists. These 
include halogenated furanones produced from marine algae Delisea pulchra which interfere 
with AHL–mediated quorum sensing which affect P. aeruginosa biofilm architecture and 
subsequent bacterial detachment (Hentzer et al., 2002). Again these natural products are able 
to interfere with the SwrR–C4–HSL interaction in Serratia liquefaciens and also inhibit the 
LuxR–3–Oxo–C6–HSL interactions in V. fischeri, Erwinia carotovora, Erwinia 
chrysanthemi and Yersenia enterocolitica (Hentzer et al., 2002). 
It is highly likely that the continued search for more quorum sensing inhibitors and enzymes 
will result in the next ground–breaking success in the treatment of biofilm–infected chronic 
wounds such as diabetic foot ulcers. 
1.5 Thesis hypothesis and aims 
Quorum sensing and glycan–lectin interactions are two mechanisms in biofilm development 
that have provided important information in understanding the role of bacteria in chronic 
infections. The inhibition of quorum sensing as well as glycan–lectin interactions have been 
considered as alternative strategies to antibiotic treatment that can be useful in the treatment 
of chronic infections through the prevention and disruption of biofilm formation. Quorum 
sensing inhibitors (QSI) such as cinnamaldehyde (CA) baicalin hydrate (BH) and 2(5H)–
furanone have been found to influence matrix production and biofilm formation but do not 
stop bacterial growth in their planktonic state (Brackman et al., 2011). QSIs were found to 
increase the susceptibility P. aeruginosa and S. aureus biofilms to conventional antibiotics 
such as tobramycin, clindamycin and vancomycin, leading to increased reduction in biofilm.  
The use of lectin–inhibiting carbohydrates such as α–methyl–galactoside and α–methyl–
fucoside which specifically inhibit LecA and LecB lectins expressed by P. aeruginosa, have 
been found to reduce adhesion, lung injury and cell mortality when grown in vitro with A549 
cells and in vivo in a murine model (Chemani et al., 2009). Zinc has recently been found to 
have antibiofilm activity in inhibiting biofilm formation in both Gram–negative and Gram–
positive pathogens (Wu et al., 2013). However, the mechanism by which this takes place has 
not been characterised. 
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The hypothesis for this work was that the chronic nature of diabetic foot ulcers is maintained 
by bacterial communication and cellular interaction. The aim of the present study was to 
characterise the microbial profiles of diabetic foot ulcers and investigate their role in 
maintaining the chronicity of the wound. The development of antimicrobial combination 
strategies to effectively disrupt and/or eradicate biofilm by inhibiting quorum sensing and 
molecular interactions that underline biofilm formation was also investigated. The following 
objectives will be investigated in an attempt to achieve the aims of this study; 
 To characterise, determine the prevalence rate, and identify the causative agents of 
diabetic foot infections among the diabetic population attending the Komfo 
Anokye Teaching Hospital (KATH), Kumasi, Ghana.  
 To determine the antibiotic susceptibility patterns of DFU isolates and study their 
genetic relatedness using bioinformatics tools. 
 To investigate the existence of biofilms in DFIs through the model creation of a 
biofilm using conventional 96–well microtitre plates, MBEC™ HTP assay and the 
Quasi–Vivo® system. 
 Detect quorum sensing mechanisms during biofilm formation. 
 Perform glycan–lectin analysis to study bacterial interactions during biofilm 
formation. 
 To study the effects of the combinations of antibiotics and other antibiofilm agents 







1.5.1 Research Plan 
Throughout the period of this study the flow chart below served as a guide in achieving the 
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2.1 Sample collection and processing 
2.1.1 Study location 
This study was a collaborative work between the University of Westminster, London and the 
Komfo Anokye Teaching Hospital (KATH) Kumasi, Ghana. KATH was chosen as the 
sample collection site for three reasons; it is the second largest referral and teaching hospital 
in Ghana located close to the centre of the country and receives a lot of referral cases mostly 
from the northern part of Ghana and other surrounding regions; it is the most populated 
region in Ghana (according to the 2010 Population and housing Census) with a population of 
4.8 million representing 19.4% of the total population (24.6 million); and one–third (34.3%) 
of its residents have migrated to the region. Therefore, the location of KATH in the Ashanti 
region was perfect for the purpose of the current study as the Ashanti region provides a 
representative population for Ghana as far as the 2010 national census demographics are 
concerned. 
 
Figure 2 .1 Map of Ghana showing the location of the Komfo Anokye Teaching Hospital, 
(KATH) in Kumasi, Ashanti Region.  (Image source: Google Maps) 
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2.1.2 Ethical approval 
Ethical approval for participants’ recruitment and sample collection for this study was 
granted by the Research and Development Unit at KATH, Kumasi, Ghana (Appendix E3). 
The study was also registered and approved by the Research and Development Unit at KATH 
(Appendix E4). Ethical considerations for this study were further reviewed and approved by 
the University of Westminster Research Ethics Sub Committee, London (Appendix E1). In 
addition, facilities in the Clinical Microbiology department at KATH were permitted for 
reception, processing and storage of clinical samples throughout the sample collection period 
in Ghana.  
2.1.3 Participants’ recruitment   
Participants in this study were diabetic foot ulcer patients attending the Diabetes Centre at 
KATH, Kumasi. They included both old and new patients attending the centre. Participants 
were voluntarily recruited for the study and provided with Participant Information Sheet (PIS, 
Appendix E5) which contained thorough information about the project as well as their 
participation in the project. Recruited participants were asked to voluntarily sign consent 
forms (Appendix E5) copies of which were retained by the Diabetes Centre, KATH.   
2.1.4 Wound sampling and classification of DFUs 
Between January 2011 and December 2014, 356 wound samples were taken from diabetic 
foot ulcers (DFUs) who attended the Diabetes Centre, KATH. They included both old and 
new patients. Before the ulcers were sampled, the skin around the edges of the wound was 
first disinfected with 70% (v/v) ethanol and the surface area of the wound moistened with 
sterile water or saline. Wound sampling was performed by introducing a sterile cotton–tipped 
swab into the ulcer of the affected patient and swabbing with the cotton–tipped end to collect 
exudates that were likely to contain bacteria for further processing. In order to recover more 
bacteria from the ulcer, the wound was carefully swabbed by rotating the cotton–tipped end 
across the surface area in a zig–zag motion. All patients were sampled only once. Wound 
samples collected included swabs and pus from foot ulcers only. Swabs were also taken from 
recurrent wounds on amputated feet. All other wounds apart from foot ulcers were excluded. 
They included hand wounds, decubitus ulcers and leg ulcers. All wound samples were 
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cultured within 2 hours of collection. No sample was refrigerated overnight before culture. 
Clinical isolates recovered from these samples were subsequently employed in all 
investigations throughout the duration of this project. 
Thirty–eight of the 356 DFU samples collected between February and April, 2013 were 
classified according to Wagner’s ulcer classification grade which is based on the depth of 
penetration, the presence/absence of gangrene and the degree of tissue necrosis (Wagner, 
1987). Initial processing of all wound samples was performed at the microbiology department 
of Komfo Anokye Teaching Hospital (KATH), Kumasi. Further processing of all samples 
was done at the Molecular Biology/Microbiology laboratory, Cavendish Campus, University 
of Westminster, London 
2.2 Materials  
Materials used in this study were purchased from some selected companies including Sigma–
Aldrich (Dorset, UK), VWR Ltd (East Grinstead, UK), Qiagen (Crawley, UK), and Fisher 
Scientific Ltd (Loughborough, UK). All biofilm assays were performed using both 
conventional microtitre plates, the MBEC™ device (MBEC™ HTP and P & G, Innovotech 
Inc, Edmonton, Alberta, Canada) and Kirkstall Quasi Vivo® system (Kirkstall Ltd, 
Rotherham, UK). All PCR and DNA sequencing kits were obtained from Qiagen and Sigma–
Aldrich Ltd, UK. Solid media used for culturing bacterial strains were obtained from Sigma–
Aldrich (Dorset, UK), VWR Ltd (East Grinstead, UK), Oxoid Ltd (Basingstoke, UK) and 
Fisher Scientific Ltd (Loughborough, UK). They included Luria–Bertani (LB) agar, 
MacConkey agar (MA), chocolate agar (CA), blood agar (BA) and Kolliphor 407® gel.  
2.2.1 Bacterial strains 
2.2.1.1 Reference/control strains used in this study 
A list of control strains used in the present study is provided in Table 2.1. Vibrio harveyi 
NCIMB 1280 is a luminous strain that uses the luxCDABEGH operon to produce light 
through quorum sensing whereas V. harveyi NCIMB 1872 is the aldehyde mutant of the 
former and cannot produce light even in the presence of externally supplied autoinducer and 
aldehyde substrate (Bassler et al., 1993; Meighen, 1991; Nealson and Markovitz, 1970). 
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Control strains, E. coli NCTC 10418, P. aeruginosa PAO1 and S. aureus NCTC 6571 have 
previously been demonstrated as biofilm producers (Lopez et al., 2010). 
Table 2 –1 Reference/control strains used in this study 
Bacterial Strains* Description Purpose 





Detection of exogenous A1–2 quorum 
sensing molecules for bioluminescence 









NCIMB 14543  
pMJ258, LacZ+ Broad range host – For detection of AI–1 
quorum sensing molecules in Gram–
negative bacteria. 
Escherichia. coli  
NCTC 10418 




LasI+, RhlR+ Quorum sensing and biofilm assays. 
Staphylococcus aureus 
NCTC 6571 
Fully susceptible Antibiotic susceptibility testing and biofilm 
assay 
*– Bacterial strain: V. harveyi reference strains NCIMB 1280 and 1782 including A. 
tumefaciens NCIMB 14543 were purchased from the National Collection of Industrial and 
Marine Bacteria (NCIMB) Ltd, Aberdeen, Scotland, E. coli NCTC 10418, P. aeruginosa 
PA01 and S. aureus NCTC 6571 were obtained from Dr Patrick Kimmitt’s stock, University 
of Westminster, London. 
2.2.1.2 Identification, maintenance and growth conditions DFU isolates 
DFU samples including 38 samples collected between February and April, 2013 were directly 
cultured on freshly prepared nutrient (NA), Blood, Chocolate and MacConkey agar and 
incubated overnight 37°C under aerobic conditions. In addition, all 38 DFU samples were 
cultured on fastidious anaerobic agar (FAA) and incubated overnight at 37°C under anaerobic 
conditions. FAA cultures were incubated for up to 48 hours using anaerogen (Oxoid, 
Basingstoke, UK) and gas generators. Gram staining was performed on all isolated bacteria.  
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Pure colonies from overnight cultures were selected for biochemical identification using 
API10S and RapiD 20E kits (bioMérieux, France). All tests were carried out according to the 
manufacturer’s instructions. In all 407 bacterial strains were isolated from 356 DFU samples 
throughout the period of this study. Fifty of these strains were subsequently used as 
representative strains for further analyses.  
Positive cultures were subcultured on LB agar and in 10 mL LB broth, incubated overnight 
and processed for storage. All bacterial cultures were maintained at –80°C in LB broth 
supplemented with 50% (v/v) glycerol. Sea water broth was used for maintaining Vibrio 
harveyi strains NCIMB 1280 and NCIMB 1872. Prior to their use, V. harveyi strains NCIMB 
1280 and NCIMB 1872 were cultured on L–marine agar or sea water agar (Appendix A1) 
and incubated at 25°C and 20°C respectively for up to 48 hours under aerobic conditions. 
Agrobacterium tumefaciens strain NCIMB 14543 was cultured on LB agar or in 10 mL LB 
broth supplemented with 0.05µg/mL Kanamycin and incubated overnight at 30°C under 
aerobic conditions before each assay. All other bacterial strains were cultured on LB agar or 
in LB broth unless otherwise stated. 
2.2.2 Preparation of media, buffers and stock solutions 
2.2.2.1 Solid media 
Solid media used in this study were prepared according to manufacturer’s instructions. They 
included LB agar, L–marine (LM) agar, MacConkey agar, Chocolate agar, sea water agar and 
Kolliphor 407® gel. Briefly, the desired amounts of the powdered agar were weighed and 
dissolved in deionised water and thoroughly mixed either by heating on a hot plate or gently 
stirring and swirling till all the powdered agar is dissolved. The dissolved contents were then 
autoclaved at 121°C for 15 minutes. In the preparation of solid media supplemented with 
blood, antibiotics or sugars, the autoclaved media were left to cool down to about 50°C after 
which the supplements were added. Blood agar was normally prepared as 10% (v/v) of LB 
agar. 
2.2.2.2 Liquid media and buffers 
All liquid media were prepared according to manufacturer’s instruction. All liquid media 
were sterilised by autoclaving at 121°C for 15 minutes before use. Liquid media used in this 
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study included LB broth, LM medium for V. harveyi growth and bioluminescence assays, 
sodium thioglycolate bacterial recovery medium, trypticase soy broth (TSB), BM medium, 
AB medium. 
Buffers used in this study were prepared according to manufacturer’s instructions and 
sterilised by autoclaving. They included phosphate buffered saline (PBS), coaggregation 
buffer, 50X Tris–Acetate–Ethylene–diamine–tetra–acetic acid (TAE) buffer and TE (10 mM 
Tris–HCL, 1 mM EDTA, pH 8.0) buffer. Other solutions used in this study were, 0.9% 
physiological saline, 2.5% and 4% formaldehyde, 10 mM cetylpyridinium chloride, 10% 
(v/v) Ziehl Carbol fuchsin, 1% (w/v) Congo red, 0.1% (w/v) from (stock) Calcofluor white 
stain, 0.5mg/L ethidium bromide and 20mg/mL (w/v) 5–bromo–4–chloro–3–indolyl–β–D–
galactopyranoside (X–gal).  
2.2.2.3 Preparation of antibiotics and antimicrobials and quorum sensing inhibitors 
Antibiotics (powder form) and antimicrobials (either liquid or crystalline powder form) used 
in this study were prepared as stock solutions using their respective solvents and according 
manufacturer’s instructions (Tables 2.2 and 2.3). They included ampicillin (AMP), 
ceftazidime (CAZ), ciprofloxacin (CIP), gentamicin (GM), levofloxacin (LEV) and 
kanamycin (KAN). Stock solutions for all antibiotics used in this assay were prepared 
according to the Clinical Laboratory Standards Institute (CLSI, document M100–S24) and 
British Society for Antimicrobial Chemotherapy (BSAC) methods for antimicrobial 
susceptibility testing guidelines, filter–sterilised and stored at –80°C (British Society for 
Antimicrobial Chemotherapy, 2013; Clinical Laboratory Standards Institute, 2014). Working 
solutions of each antibiotic used for minimum inhibitory concentration (MIC) determinations 
were prepared as 10, 100 and 1000–fold concentrations using the MIC range (512, 256, 128, 
64, 32, 16, 8, 4, 2, 1, 0.5 and 0.25 µg/mL) as a guide and stored at –20°C. Working 
concentrations of each were prepared as a 5120 µg/mL. The European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used as guidelines for the 
interpretation of MIC data where BSAC and CLSI did not provide enough guidelines. The 
MIC breakpoints for ceftazidime and levofloxacin against members of the 
Enterobacteriaceae family were given as 0.125 – 4.0 mg/L, and 0.25 – 4.0 mg/L respectively 
(The European Committee on Antimicrobial Susceptibility Testing, 2015). 
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Table 2 –2 Stock solutions of some antibiotics and their concentrations 
Antibiotic Solvent/diluent Concentration (mg/mL) 
Ampicillin Water 50 
Ceftazidime Sodium Carbonate/Water 50 
Ciprofloxacin Water 50 
Gentamicin Water 50 
Levofloxacin 1:1 Water/0.1 M NaOH 100 
Kanamycin Water 25 
 
Antimicrobials and quorum sensing inhibitors (QSIs) used in the present study included, 
polymyxin B (PMB) and polymyxin B nonapeptide (PMBN), (Z–)–4–Bromo–5– 
bromomethylene)–2(5H)–furanone (2(5H)–furanone), baicalin hydrate (BH) and 
cinnamaldehyde (CIN). The above mentioned QSIs and the two antimicrobial peptides were 
purchased from Sigma Aldrich (Dorset, UK). Stock solutions of the QSIs and the 
antimicrobial peptides were prepared according to manufacturer’s instructions and stored at –
20°C (Brackman et al., 2011; Conrad, 1995). Working solutions of both QSIs and 
antimicrobial peptides were stored at 2 – 8°C for not more than 2 weeks. 






(µg/mL or µM) 
Baicalin hydrate Water 25a 
Cinnamaldehyde Ethanol/methanol 1000b 
2(5H)–Furanone Water 500 
PMB Water  500 
PMBN Water 500 
a – units for baicalin hydrate in mg/mL; b – units of cinnamaldehyde in µM (Brackman et al., 
2008; Brackman et al., 2011; Brackman and Coenye, 2015; Clinical and Laboratory 
Standards Institute, 2007). 
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2.2.2.4 Neutraliser recovery media for MBEC™ assay 
In order to accurately determine the bactericidal concentrations of the antibiotics used in the 
MBEC™ assay, the neutraliser recovery media (NRM) recommended by the manufacturer 
was used. NRM is a 2.5% (v/v) solution made up of 500 µL universal neutraliser solution and 
a 20 mL recovery media. The purpose of the universal neutraliser solution is to reduce 
toxicity of biologically active agents that are carried over from the antimicrobial challenge 
plate to the recovery media. The universal neutraliser was made up of L–histidine, L–cysteine 
and reduced glutathione dissolved in sterile distilled water and sterilised with a 0.22 µm filter 
(Merck Millipore Ltd, Watford, UK). This solution was stored at –20⁰C.  
The recovery media was prepared with Mueller–Hinton broth supplemented with saponin and 
Tween–80 (20 g/L and 10 g/L respectively) and sterilised by autoclaving. To recover 
planktonic cells after the antimicrobial challenge, the MBEC™ peg lid was transferred onto a 
96–well plate containing the neutraliser recovery media.  
Recipe for the preparation of some of the media, buffers and solutions can be found in 
Appendix A1 to A6.  
2.3 Methods 
2.3.1 Antibiotic susceptibility determination of DFU isolates 
All 407 bacterial isolates were tested for their antibiotic susceptibility patterns according to 
the British Society for Antimicrobial Chemotherapy (BSAC, 2015) and European Committee 
on Antimicrobial Susceptibility Testing (EUCAST, 2014) methods for antimicrobial 
susceptibility testing. Antibiotic susceptibility testing (AST) was performed on Iso–Sensitest 
agar (Oxoid, Basingstoke, UK). About 3 or 4 colonies were picked with a sterile 
bacteriological loop and transferred into Iso–Sensitest broth (Oxoid, Basingstoke, UK). The 
turbidity of the suspension was adjusted to 0.5 McFarland using sterile distilled water. A 
1:100 dilution of the suspension was made and evenly streaked on Iso–Sensitest agar plates 
using sterile cotton swabs in order to produce confluent growth. 
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2.3.2 Disc diffusion test 
All DFU isolates were tested against the following selection of antibiotics (Axiom® 
Laboratories, India); ampicillin (A, 10 µg), ampicillin/sulbactam (AS, 20 µg), cotrimoxazole 
(COT, 25 µg), cefotaxime (CF, 30 µg), tazobactam/piperacillin (TZP, 100/10 µg), 
chloramphenicol (CHL, 30 µg), ciprofloxacin (CIP, 5 µg), tetracycline (TE, 30), ceftazidime 
(CAZ, 30 µg), ofloxacin (OF, 5 µg), gentamicin (GM, 10 µg), amikacin (AK, 30 µg), 
levofloxacin (LEV, 5 µg) and vancomycin (VAN 5 µg). The antibiotic discs were placed on 
Iso–Sensitest agar the inoculated plates and incubated with aeration at 35 – 37°C for 18–24 
hours. Zones of inhibition (ZOI) observed after incubation was measured with rulers and 
interpreted according to BSAC and EUCAST guidelines. 
2.3.3 Growth curve of clinical strains  
Two clinical strains namely; K. pneumoniae and P. mirabilis were used as representative 
strains to study the growth patterns of clinical isolates from DFUs. section 3.6 of Chapter 3 
further outlines the reasons why K. pneumoniae and P. mirabilis were chosen as 
representative strains for the current study. E. coli NCTC 10418 was used as a control. 
Glycerol stock of each strain was cultured on LB agar (Sigma Aldrich, UK) and incubated 
overnight under aerobic conditions at 37°C. A colony from the overnight cultures was 
inoculated in 5 mL LB broth and incubated at 37°C overnight in a shaking incubator (VWR, 
UK) at 250 rpm. The optical densities (OD) of the broth cultures were read at 600 nm (OD600) 
using a spectrophotometer (Jenway 6300, Bibby Scientific Ltd, UK).  A 1:1000 dilution of 
the cultures was made in 50 mL fresh LB broth in 125 mL conical flasks. The flasks were 
then incubated with aeration at 37°C in a shaking incubator for a period of 24 hours. A 
sample was removed from each flask at designated time points (1, 2, 3, 4, 5, 12, 18 and 24 
hours) and their OD600 determined.  
To determine the growth of K. pneumoniae and P. mirabilis under the conditions cultivated, 
their total colony–forming unit per millilitre (CFU/mL), a ten–fold dilution was performed 
using 0.9% normal saline. Ten microliters (10 µL) of each diluted sample was spotted on LB 
agar (on MacConkey agar in the case of P. mirabilis) and incubated overnight at 37°C. The 
colonies were counted and the total viable count was expressed as CFU/mL of each culture 
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plate. Cultures were performed in duplicates and their mean value determined for subsequent 
analysis. 
2.3.4 Coaggregation assay 
The ability of DFU isolates to initiate biofilm formation and adhere to each other (intra– and 
inter–generically) during biofilm formation was assessed. The ability of bacterial isolates to 
adhere to each other in suspension is an important step in selecting bacterial strains for in 
vitro biofilm assays. Eight DFU isolates were selected for the coaggregation assay (Table 
2.4). Two independent standard coaggregation techniques (visual and spectrophotometric 
assays) previously described by McIntire et al. (1978), Cisar et al. (1979) and Hill et al. 
(2010) were used in this study with some modifications.  
Table 2 –4 Representative isolates for coaggregation assay 
DFU isolate ID Bacterial species 
003a Citrobacter koseri 
001 Proteus mirabilis 
015 Escherichia coli 
038 Pseudomonas aeruginosa 
025a Providencia stuartii 
021b Klebsiella pneumoniae 
005a Proteus mirabilis 
028b Klebsiella pneumoniae 
 
Firstly, bacterial strains were grown overnight in 30 mL BM medium in a shaking incubator 
at 35–37°C. BM medium was prepared according to the recipe (Appendix A3) given by Hill 
et al, (2010). All strains were grown to a stationary phase to OD600 1.8 – 2.0 and harvested by 
centrifugation at 8000 x g for 10 minutes. Cells harvested from overnight BM cultures were 
washed twice in 30 mL coaggregation buffer. Coaggregation buffer (Appendix A4) was 
prepared by making a 1 litre solution made up of 0.1 mM CaCl2, 0.1 M MgCl2, 0.15 M NaCl 
and 1 mM Tris–HCl dissolved in distilled water. The solution was sterilised by autoclaving at 
121°C for 15 minutes. Washed cells were subsequently resuspended in fresh coaggregation 
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buffer to give OD600 of 2.0. Coaggregation test was carried out in pairs by mixing equal 
volumes (500 µL) of each cell suspension in clear Eppendorf tubes. The mixture was 
vortexed for 2 minutes and left to stand 2 hours at room temperature, briefly vortexed again 
before scoring. The coaggregation of each mixture of cell suspensions was scored and 
recorded according to the visual scale developed by Cisar et al. (1979). The tubes were then 
incubated overnight at room temperature, mixed briefly the next day and then scored again 
after 24 hours. Negative controls were made of 500 µL each of each cell suspension plus 500 
µL of coaggregation buffer. Coaggregation score for each test was determined according the 
visual scale described by Cisar et al. (1979). Autoaggregation (within species) and 
coaggregation (between two different species) were visually scored on a scale of 0 – 4 and 
reported as follows; 0 – no visible aggregates; 1+ − small uniform aggregates; 2+ − definite 
visible aggregates without settling in suspension; 3+ − large aggregates settling easily 
leaving a turbid supernatant fluid; 4+ – large aggregates with clear supernatant which settles 
immediately after vortex. 
In the second quantitative assay, bacterial strains were grown in BM medium as previously 
mentioned. This assay was performed using the method described by Cisar et al. (1979) with 
some modifications. For example, overnight cultures were grown without atmospheric 
nitrogen (as all bacterial species were grown under aerobic conditions) and harvested at 
OD600 and not at OD650 (Lane et al., 2009). Overnight cultures were harvested when OD600 
was 1.5–2.0 and then centrifuged at 8000 x g for 10 minutes. The harvested cells were 
washed twice using a coaggregation buffer of pH 8 and containing 0.025 M potassium 
phosphate (KH2PO4) and 0.025 M sodium chloride (NaCl). Equal volumes (500 µL) of cell 
suspensions of a coaggregation pair were mixed together in clear (10 X 75 mm) tubes, 
allowed to stand for 10 minutes and mixed again. The cell suspension mixtures were then 
incubated at room temperature for 2 hours and centrifuged at 10 x g for 2 minutes. The 
supernatants were then collected and pipetted into 96–well plates and their absorbance 
determined at OD600 using a microtitre plate reader. Controls were made up of each bacterial 
strain plus coaggregation buffer. The absorbance of each coaggregation pair was expressed as 
a percentage according to the formula given (below) by Shen et al. (2005).  
Percentage Coaggregation =  
 
(OD600X1 + OD600 X2) – 2 x OD600(X1+X2) 
                 
 






Where; (X1) is the first coaggregation pair; (X2) is the second coaggregation pair in the cell 
suspension. Percentage coaggregation of each coaggregation pair above 5% was regarded as 
positive results for quantitative autoaggregation or coaggregation.  
2.4 Biofilm studies  
Bacterial biofilm formation and development have been studied using a variety of systems. 
These systems are mainly categorised into static and continuous flow systems. Preference for 
any of these in vitro systems depends on a number of reasons. For example, biofilm 
formation using static systems are helpful in studying early events during biofilm 
development (Merritt et al., 2011). Furthermore, static biofilm systems are quite simple to 
use and have high–throughput making them adaptable for studying biofilms under diverse 
conditions. On the other hand, flow systems are useful for studying mature biofilms where 
continuous supply of growth media and adjustments of other biofilm growth requirements 
such as oxygen, pH, nitrogen and carbon dioxide are required. 
In this study, both static and continuous flow biofilm systems were employed to determine 
the efficacy of these systems to study formation, inhibition and eradication of biofilms. The 3 
systems that were used in this study were the conventional 96–well microtitre plate assay, 
MBEC™ assay and the Kirkstall Quasi Vivo® system.  
2.4.1 Conventional microtitre plate (MTP) biofilm assay 
This technique has previously been described as suitable for growing biofilms in a wide range 
of bacteria (Merritt et al., 2011; O’Toole et al., 1999; O’Toole, 2011; Stepanovic et al., 
2001). However, some modifications were made in this study. In place of water used in the 
washing step, 1X phosphate buffered saline (PBS) was used instead and 33% (v/v) acetic acid 
was used as solubiliser. Also, unbound cells from the 24–hour old biofilm cultures grown in 
the 96 – well microtitre plates were careful aspirated before fixing with 4% formaldehyde 
followed by staining. This was done in order to recover most of the biofilm formed for 
further analysis. Culture media used to support the growth of the bacterial cells were LB (for 
aerobic cultures), brain heart infusion (BHI) and trypticase soy broth (TSB, with or without 
0.25% glucose). In this study, 9 bacterial species designated as: 003a C. koseri, 015 E. coli, 
018b K. variicola, 021a P. mirabilis, 021b K. pneumoniae, 025a P. stuartii, 028b K. 
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pneumoniae, 005 P. mirabilis and 038 P. aeruginosa in addition to 2 control species; E. coli 
NCTC 10418 and S. aureus NCTC 6571. Briefly, a 1:100 dilution of fresh broth culture was 
made and pipetted into the wells of the 96–well microtitre plate which was aerobically 
incubated overnight at 37°C. Broth suspension containing unbound cells and overlaying the 
biofilm was aspirated and the biofilm fixed with 4% formaldehyde for 10 minutes. The wells 
were washed with 1X PBS and stained with 0.1% crystal violet (CV) for 10 minutes. The 
stained biofilm was washed again with 1X PBS, allowed to air–dry and solubilised with 33% 
(v/v) acetic acid. Absorbance was measured at 570 nm with a microtitre plate reader using 
33% (v/v) acetic acid only as blank. This assay was used to study biofilm under different 
environmental conditions. All tests were done in duplicates and repeated at least three times 
to make sure the results were reproducible. E. coli NCTC 10418 was used as a control strain 
in all replicates (Branda et al., 2005). Biofilm production was defined according to the 
classification described by Pye et al. (2013). Biofilm producers were defined as; weak 
producers if OD570 was ≥ 0.05 but < 0.13, moderate producers if OD570 was ≥ 0.13 but < 0.25 
and strong producers if OD570 was ≥ 0.25. 
2.4.1.1 pH assay 
The ability of the selected clinical isolates to form biofilm in either acidic or alkaline 
environments was tested in growth media set at specific pHs. Clinical isolates were 
inoculated in LB broths of pH 4, 7 and 10 and incubated aerobically at 37°C overnight. 
However, the nutrient strengths of growth media were not altered. Biofilm growth at pH 7 
was used as a control to compare the extent of biofilm growth in normal, acidified and 
alkaline broth cultures. Residual biofilm produced by each bacterial species under the 
different pH conditions was estimated using the conventional MTP biofilm assay described in 
section 2.4.1 (above) and the results classified according to the definitions by Pye et al. 
(2013). 
2.4.1.2 Temperature Assay 
Clinical strains were also cultured in LB broth at some selected incubation temperatures to 
determine their ability to form biofilm in extreme environmental conditions. Three (3) 
incubation temperatures (26, 37 and 42°C) were selected to grow biofilms. The nutrient 
strength of growth media was unaltered. Incubation temperature at 37°C was used as a 
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control to compare the extent of biofilm growth among the selected temperatures. Residual 
biofilm produced by each bacterial species at different temperature was estimated using the 
conventional MTP biofilm assay described in section 2.4.1 and the results classified 
according to the definitions by Pye et al. (2013). 
2.4.1.3  Nutrient concentration assay 
This assay was performed to determine whether clinical strains can form biofilm in diluted 
concentrations of nutrients in the media used to support their growth. The strains were grown 
in reduced nutrient concentrations of LB broth and their ability to form biofilms was 
compared. Stock concentration (25g/L) of LB broth was diluted to 12.5g/L and 6.25g/L and 
used to grow biofilms. Residual biofilm produced by each bacterial isolate at different 
nutrient concentrations was estimated using the conventional MTP biofilm assay described in 
section 2.4.1 and the results classified according to the definitions by Pye et al. (2013). 
All biofilm assays under the environmental (pH, temperature and nutrient concentration) 
conditions described above, were performed in 3 replicates and the results statistically 
determined using GraphPad Prism statistical software (GraphPad Software, Inc., California, 
USA). 
2.4.2 Biofilm inhibition and eradication assays  
The ability of antibiotics to inhibit and/or eliminate biofilms formed by Gram–negative 
pathogens isolated from DFUs was assessed. Inhibition and eradication assays were 
performed with a focus on 2 representative facultative anaerobic Gram–negative strains 
namely; K. pneumoniae and P. mirabilis. They were selected due to their multidrug resistant 
nature and as strong biofilm producers. Antibiotics were selected with respect to their 
functionality, AST patterns and relevance to this study. The representative strains were tested 
against ampicillin, ceftazidime, ciprofloxacin, gentamicin and levofloxacin (Table 2.1) to 




2.4.2.1 Minimum inhibition concentration (MIC) determination  
The MIC test was performed to determine the lowest antibiotic concentration that inhibited 
the growth of planktonic cells and also inhibited diabetic foot isolates from forming biofilm 
after overnight incubation. Working solutions of antibiotics were prepared as 10 and 100–
fold concentrations of the MIC range as mentioned in section. A 1:100 dilution 
(corresponding to 0.5 McFarland) of overnight culture of each isolate harvested at the 
stationary growth phase was made and used for the MIC determinations. Briefly, 100 µl of 
antibiotic solution was added to 100 µl of broth culture in the 96 – well microtitre plate and 
incubated overnight at 37°C. The microtitre plates were then observed for the presence or 
absence of visible growth in the wells (i.e., turbidity of the broth supernatant). Microtitre 
plates with bacterial species showing visible growth after overnight antibiotic challenge were 
selected and the residual biofilms determined using the conventional MTP biofilm assay 
outlined in section 2.4.1. and the absorbance read at 570 nm (OD570) using the microtitre 
plate reader. A positive control was performed for each assay by adding 100 µl 1X PBS to 
the bacterial broth instead of antibiotic solution. Before reading the absorbance of stained 
residual biofilms, the microtitre plate reader was blanked using a 33% (v/v) acetic acid.  The 
extent of biofilm inhibition by an antibiotic (also known as percentage (%) inhibition or 
antibiotic efficacy) was estimated by comparing the OD570 of the residual biofilm of a 
bacterial species challenged with an antibiotic to that of the same bacterial species without 
antibiotic challenge (positive control). The formulae for calculating antibiotic efficacy and 
residual biofilm have been given in section 2.10. Percentage residual biofilms of bacterial 
species with OD570 ≤ 0.05 were considered as complete inhibition as OD570 of ≤ 0.05 after 
antibiotic challenge showed no growth on agar after 24 hours of incubation.  
2.4.2.2 Minimum bactericidal concentration (MBC) determination  
The MBC is defined as the lowest concentration of antibiotic that can prevent the growth of 
bacteria after subculture onto media free from antibiotics (Andrews, 2001). The MBCs for all 
MIC assay plates with no visible growths in the microtitre plates were diluted into 100, 10–1, 
and 10–2, subcultured on LB agar and incubated overnight at 37°C. The plates were observed 
for growth after overnight incubation. LB agar plates that showed 0.1% growth (i.e., 99.9% 
reduction in growth) after antibiotic challenge in comparison with LB agar plates without 
antibiotic challenge were considered as the MBC.  
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2.4.2.3 Minimum biofilm eradication concentration (MBEC) determination  
The minimum concentration of antibiotic that can successfully eradicate biofilm formed after 
18–24 hours was also determined. The procedure for the determination of MBEC was similar 
to the one described for MIC determination except that in MBEC determination, antibiotics 
were added after overnight incubation. The plates were then observed for the presence or 
absence of biofilm growth by comparing their measured OD570 with a positive control 
(bacteria without antibiotic) as previously outlined. Residual biofilm biomass estimation was 
determined using 0.1% CV as described earlier. 
2.4.3 The MBEC™ assay 
The MBEC™ (Minimum Biofilm Eradication Concentration) assay is a high–throughput 
assay used to study the effects of antimicrobial agents on microbial biofilms. The MBEC™ 
assay device also referred to as the MBEC™ Biofilm Inoculator consists of a plastic lid with 
96 pegs and a corresponding base; either as a trough base as shown in Figure 2.2A, for high–
throughput (HTP) assay or a 96–well base as shown in Figure 2.2B, for Physiology & 
Genetics (P&G) assay. The device which was initially called the Calgary Biofilm Device was 
first developed in 1966, by a group of microbiologists at the University of Calgary, Canada to 





Figure 2 .2 MBEC™ biofilm inoculator with (A) with a trough base used the MBEC™ HTP 
assay; (B) with a 96–well base used for the MBEC™ P&G assay. (Image source: MBEC 
assay procedural manual, version 1.0). 
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The MBEC™ device has successfully been used to study different microbial species 
including E. coli, P. aeruginosa, S. aureus, Candida species., Burkholderia species, and 
Mycobacterium species (Ceri et al., 1999; Sepandj et al., 2003; Bardouniotis et al., 2003; 
Harrison et al., 2006; Tomlin et al., 2005). 
In this study, both MBEC™ HTP and P&G assays were used to study the efficacy of 
antibiotics and antibiofilm agents on K. pneumoniae and P. mirabilis biofilms. The assays 
were performed according to the manufacturer’s instructions and the methods outlined by 
Ceri et al. (1999) and Harrison et al. (2004) with some modifications. To prepare the initial 
inoculum suspensions, K. pneumoniae and P. mirabilis stored as 50% glycerol (v/v) stocks in 
1.5 mL Eppendorf tubes at –80°C were thawed, plated out on LB agar and incubated 
aerobically at 35–37°C overnight. A second subculture was prepared from the primary 
culture by selecting and plating out two to three pure and single colonies from the overnight 
LB agar plates onto a second plate and aerobically incubated overnight at 35–37°C. Single 
colonies from the second subculture were suspended in LB broth to make a suspension which 
was adjusted to a 1.0 McFarland standard. This was further diluted 20–fold in fresh LB broth 
to yield a broth suspension containing approximately 3.0 x 108 CFU/mL of bacteria. Bacterial 
cell density of 3.0 x 108 CFU/mL was chosen as the clinically significant microbial count in 
deep and superficial wounds (Bowler, 2003; Bowler et al., 2001). Twenty–two millilitres of 
this dilution was inoculated in the MBEC™ HTP assay. The MBEC™ P&G assay plates 
were inoculated with 150 µL broth culture in each of the 96 wells. The rest of the assay was 
performed per the manufacturer’s instructions. Figure 2.3 provides a summary of the 
MBEC™ assay. The viable cell densities of the initial inocula for K. pneumoniae and P. 






Figure 2 .3 Overview of the MBEC™ HTP assay for the determination of antimicrobial 
efficacy (Adapted from Harrison et al., 2005). Steps A to L illustrate the stepwise process for 
the MBEC HTP assay from – A. culture of bacterial strains; B. inoculum preparation; C and 
D. biofilm cultivation and incubation; then through E. preparation of antimicrobial challenge 
plate; F. rinsing of pegs; to J and K. neutralisation and recovery of bacterial strains; and L. 
MIC, MBC and MBC determinations. In this study, the values for MBC, MIC, and MBEC 
were determined following absorbance reading at OD650. Details of the protocol can be found 




2.4.3.1 Biofilm Growth Check 
As part of the MBEC™ assay biofilm growth check (BGC) was performed to estimate the 
appropriate biofilm growth after overnight cultivation and before antimicrobial challenge. 
After rinsing the MBEC™ inoculator pegs in normal (sterile) saline, 3 pegs (F12, G12 and 
H12 in Figure 2.2) were carefully broken off from the lid using sterile pliers, placed in NR 
media and sonicated on high. The disrupted biofilm after sonication was serially diluted and 
spot–plated on LB agar for viable cell counting. BGC was expressed as CFU/mL. 
2.4.3.2 Antimicrobial challenge assay 
After the inoculation and overnight incubation of the MBEC™ assay plates (as outlined in 
section 2.4.3 and Figure 2.3 steps A, B, C and D), the MBEC™ assay plates were 
subsequently challenged with 2 antibiotics; ceftazidime (CAZ) and levofloxacin (LEV) to 
determine their MIC, MBC and MBEC. CAZ and LEV were prepared as two – fold dilutions 
from 5120 µg/mL working solutions. Other antimicrobials such as polymyxin B (PMB) and 
polymyxin B nonapeptide (PMBN) mentioned in section 2.2.2.3, both at working 
concentration of 500 µg/mL, were also assayed to determine their MIC and MBC against K. 
pneumoniae and P. mirabilis. In separates assays, the combined effects of antibiotics (CAZ 
and LEV) and antimicrobials (PMB, and PMBN) in inhibiting and eradicating K. pneumoniae 
and P. mirabilis biofilms. 
Mature biofilms grown on the MBEC™ peg lid were transferred onto a standard flat–bottom 
96–well plate (BD Biosciences, UK) containing serially diluted antimicrobials according to 
the layout in Figure 2.4. In this step, a two–fold serial dilution of each antimicrobial was 
prepared down the column of each plate using Mueller–Hinton (MH) broth to a final volume 







 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 100 100 100 100 100 100 100 100 100   
B 50 50 50 50 50 50 50 50 50 50   
C 25 25 25 25 25 25 25 25 25 25  SC 
D 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5  SC 
E 6.25 6.25 6.25 6.25 6.25 6.25 6.25 6.25 6.25 6.25  SC 
F 3.13 3.13 3.13 3.13 3.13 3.13 3.13 3.13 3.13 3.13 GC BGC 
G 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 1.56 GC BGC 
H 0.78 0.78 0.78 0.78 0.78 0.78 0.78 0.78 0.78 0.78 GC BGC 
 
Figure 2 .4 MBEC™ assay antimicrobial challenge plate showing a two–fold serial dilution 
for a single antimicrobial. The values in the wells represent the percentage (%) concentrations 
of the antimicrobial diluted from row A1–10 to row H1–10. 
2.4.3.3 Residual biofilm (Log10 reduction) estimation 
After antimicrobial exposure, the MBEC peg lid was transferred onto a neutraliser–recovery 
plate containing 200 µL of NR media and let to stand to equilibrate and then sonicated on 
high for 30 minutes. To determine the amount of biofilm remaining on the peg (Log10 
reduction), neutralised biofilms (in the form of dispersed planktonic cells) in the NR media 
following sonication were serially diluted (100–107) in 0.9% sterile saline and spot plated on 
LB agar for K. pneumoniae and on MacConkey agar for P. mirabilis. 
The stepwise formula for calculating the amount of biofilm remaining on pegs after 
antimicrobial challenge is given below: 
Calculate the log density for one peg as follows:  Log10 (CFU/peg) =log10 [(X/B) (D)] 
Where: X = mean CFU counted on spot plates, B = volume plated (Ex. 0.02 mL), 
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D = Dilution 
The log density per mm2 is calculated as follows: 
Log10 (CFU/mm2) =log10 [(X/B) (V/A) (D) +1] 
Where: X = mean CFU counted on spot plates, B = volume plated (Ex. 0.02 mL), V = well 
volume (0.20 mL), A = peg surface area (46.63 mm2), D = Dilution 
The Log10 reduction for each dilution is therefore given as: 
Log10 Reduction = Mean Log10 Untreated Controls – Mean Log10 Treated Pegs 
2.4.3.4 MBC determination using MBEC™ HTP assay 
To determine the minimum bactericidal concentration of each antimicrobial used against K. 
pneumoniae and P. mirabilis biofilms, 20 µL of broth suspension from each well of the 
challenge plate was removed and added to 180 µL of fresh LB broth in each well of a new 
96–well plate. The plate was covered and incubated under the conditions mentioned earlier. 
The VersaMax ELISA microplate reader (Molecular Device LLC, USA) was used to 
determine OD at 650 nm (OD650). The MBC value was determined as the lowest 
antimicrobial concentration that kills 99.9% of the population of dispersed cells shed from the 
biofilm.  
2.4.3.5 MIC determination using MBEC™ HTP assay 
Following biofilm challenge with each antimicrobial, the biofilms on the pegs shed 
planktonic cells which disperse into the antimicrobial–containing broth suspension during the 
challenge incubation period. A new non–pegged lid was placed on the 96–well challenge 
plate base and incubated overnight. Following a suitable period of incubation, the MIC of 
each antimicrobial was determined by reading the absorbance of the challenge plate at OD650. 
The MIC value was determined as the minimum antimicrobial concentration that inhibits 
growth of the dispersed cells from the biofilm. 
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2.4.3.6 MBEC determination using MBEC™ HTP assay 
Following the Log10 reduction step above, the volume of NR media used for the serial 
dilution is replaced by fresh LB broth. The plate was then covered with a sterile non–pegged 
lid and incubated overnight at 35–37°C. After the required growth period, the MBEC values 
were determined for each antimicrobial by reading the absorbance at OD650. The MBEC 
value was determined as the minimum antimicrobial concentration that eradicates the biofilm. 
2.4.3.7 Formulae for estimation of biofilm assays 
In order to ensure reproducibility and repeatability of the all biofilm assays, coefficient of 
variation (CV) was calculated for replicate assays (Feiler et al., 2014). Standard deviation, 
mean values and CV were determined for data generated from all biofilm assays to determine 
extent of dispersion between resultant OD values (replicates) using the equation;  
CV (%) = σ/µ × 100; Where σ is the standard deviation and µ is the mean value. CV % was 
subsequently set at ≤ 10%. 
Percentage efficacy of an antibiotic/antimicrobial (also known as antibiotic activity) and 
residual biofilm biomass for biofilm inhibition and eradication was determined for all 
MIC/MBEC replicate assays using the formula;  
Antibiotic/Antimicrobial efficacy (%) = [(A – B) / A] × 100 
and, 
Residual biofilm biomass (%) = 100 – Antibiotic/Antimicrobial efficacy (%) 
Where A = absorbance of control (antibiotic free culture), B = absorbance of test sample 
(bacteria with antibiotic). Percentage inhibition (PI) and percentage reduction (PR) of 
biofilms by an antibiotic/antimicrobial which can also be defined as the efficacy of that 
antibiotic/antimicrobial were calculated using the formula; 
Antibiotic/Antimicrobial efficacy (%) = [(A – B) / A] × 100, 
or 
PI/PR = 100 – Residual biofilm biomass (%) 
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2.4.3.8 Biofilm staining and microscopy 
K. pneumoniae and P. mirabilis biofilms were stained and mounted for confocal laser 
scanning microscopy (CLSM) and epifluorescence microscopy. For CLSM, appropriate pegs 
(BGC pegs and those challenged with antimicrobials) were broken off from the MBEC™ 
Biofilm Inoculator by means of sterile pliers. Pegs were placed into empty 96–well plates and 
stained with LIVE/DEAD® BacLight Bacterial Viability Kit (Molecular Probes, USA) 
according to manufacturer’s instructions. The BacLight kit comprises of a mixture of SYTO® 
9 green–fluorescent nucleic acid dye which stains live bacterial cells green and propidium 
iodide, the red–fluorescent nucleic acid dye which stains dead cells red. In this assay, the 
standard protocol was modified to stain biofilm pegs. Six microliters of the pre–mixed dyes 
(SYTO® 9 and propidium iodide) was added to 1 mL of 1X PBS and mixed. The biofilm 
pegs were placed in the wells of a 96–well plate which were filled with 150 µL of the 
combined reagent solution. The pegs were stained for 15 – 20 minutes at room temperature in 
the dark. The pegs were washed with 0.9% sterile saline after staining, transferred into empty 
wells of a 6–well plate, mounted and examined for biofilm viability using CLSM. 
For epifluorescence microscopy 6 µL of a pre–mixed combined reagent solution was added 
to 1 mL of 1X PBS. Biofilm coverslips placed in the wells of 24–well plates were covered 
with 250 µL of the combined mixture, covered with aluminium foil and incubated at room 
temperature for 15 – 20 minutes in the dark. The stained coverslips were washed twice with 
1X PBS, mounted with BacLight mounting oil and observed under epifluorescence 
microscopy. 
2.4.4 Quasi–Vivo® system 
The Quasi–Vivo® system (Kirkstall, UK) has been described as a simple, reliable, 
reproducible and effective cell culture system designed to mimic cellular interactions in 
living organisms (http://kirkstall.org/wp–content/uploads/Quasi–Vivo–User–Manual1.pdf). 
The Quasi–Vivo® system comes in a variety of chambers made to create a continuous flow 
system to study physiologically relevant biological conditions in in vitro cell culture systems.  
They include the QV500, QV600 and QV900 chamber systems. The system has been tested 
successfully on a variety of cell lines including human and rat primary hepatocytes, 
adipocytes, human liver carcinoma (HepG2) human skin and fibroblasts (Pagliari et al., 
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2014). It has an added advantage of allowing the 3D imaging of cells seeded on glass 
coverslips using fluorescence microscopy. The Quasi–Vivo® system has potential 
applications in industries such as the pharmaceutical, chemical, cosmetics, research and 
biotechnology.  
It is important to mention that; this is the first time the QV500 chamber has been adapted for 
growing bacterial biofilms. In this study, the QV500 Chamber system (Figure 2.5) was used 
to study the effect of exposure of K. pneumoniae and P. mirabilis biofilms to antimicrobials 
with time. The assay was set up according to manufacturer’s instructions (User manual for 
QV500 chamber system, Issue No. 3.0). The QV500 chamber system comprises of a silicone 
chamber with tubing and connectors, a reservoir bottle, glass coverslips (12 mm diameter), 6 
x 22 cm extension tubing with luer connectors. With the exception of extra luer connectors 
the remaining parts of the QV500 chamber system including the 0.22 µM filter were supplied 
sterile. The extra luer connectors were sterilised by autoclaving at 121°C for 15 minutes 
before use.  
 
 
Figure 2 5.  Schematic representation of the complete Quasi–Vivo® system set up with three 




2.4.4.1 Calibration of the QV500 chamber system 
Before the assay was started, the QV500 system was calibrated according to the method 
described by the manufacturer. Twenty millilitres (20 mL) of sterile 1X PBS was run through 
the set up (as illustrated in Figures 2.5 and 2.7) at 4 selected pump speed settings (2, 5, 10 
and 15 rpm). After air has been expelled from the system, liquid output from the final 
chamber was collected over 1 minute. This was repeated 3 times for each speed setting. The 
flow rate was measured for only the thicker tubing with internal diameter designated as 3/32” 
ID. This was because it was the collection tubing after the final chamber. The flow rate was 
calculated as the volume of liquid circulated through the system per minute by the increase in 
volume of the graduated collection container after 1 minute (Figure B1, Appendix B). 
2.4.4.2 Time–dependent biofilm eradication assay 
The preparation and cultivation of K. pneumoniae and P. mirabilis biofilms for the time–
dependent assay was similar to that described for cell cultures. Prior to the assay, K. 
pneumoniae and P. mirabilis planktonic cells were cultured on the glass coverslips (placed in 
a receiver vial) to produce biofilms after overnight incubation. The biofilms on the coverslips 
were aseptically transferred by means of sterile forceps to the bottom of the QV500 chamber 
(Figures 2.6) containing 1 ml of LB broth. The chambers were connected to the tubings, the 
reservoir bottle and the pump as illustrated in the set up below in Figure 2.7. The volume of 
LB broth in the reservoir bottle was 20 mL which could supply each chamber about 4 mL of 
broth suspension during the run. In separate assays, K. pneumoniae and P. mirabilis biofilms 
on coverslips were challenged individually with 20 mL of LB broths containing ceftazidime 
and levofloxacin at 512 and 5120 µg/mL of respectively. The antibiotic concentrations of 512 
and 5120 µg/mL for both ceftazidime and levofloxacin selected and used for the Quasi–
Vivo® assays were the same concentrations previously used in the biofilm inhibition and 







Figure 2 6.  QV500 Chamber with (a) visible ridges on the bottom; (b) transfer of the glass 
coverslip onto the bottom of the chamber and; c) a schematic diagram of the assembled 
chamber with the coverslip lying on the bottom of the chamber. (Diagram source: User 
manual for QV500 chamber system, Issue No. 3.0). 
The flow rate for the assay was set at 5 rpm (175 µL/min) after calibration of the system. This 
corresponds with the ‘safe range’ (25 – 1000 µL/min) established by the manufacturer and as 
previously stated by Lüdecke et al. (2014). The system was placed in an incubator with the 
peristaltic pump connected and incubated for a period of 24 hours. Samples were collected 
from the reservoir bottle every hour for the first 5 hours of incubation then at 24 hours. At 
each sample collection time point, the reservoir bottle was carefully mixed to evenly 
distribute dispersed bacteria in solution, a one–millilitre (1 mL) sample was aseptically 
pipetted into a cuvette and the OD600 measured using a spectrophotometer. To confirm 
biofilm dispersal, 10 µL of each diluted sample was also spot–plated on LB agar and 
incubated over overnight. Visible colonies after overnight incubation were counted to 
determine the CFU/mL for both K. pneumoniae and P. mirabilis planktonic cells shed from 
the biofilm on the coverslips.  A graph of absorbance (OD600) of samples collected against 
time was plotted. A control (without antibiotics) for each strain was set up and samples 
collected at the same time intervals. The assays were repeated at least 3 times and the 
averages estimated for further analysis. 
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Residual biofilm on the coverslips after 24 hours of incubation was determined using the 
LIVE/DEAD® BacLight Bacterial Viability Kit technique with some modifications (section 
2.4.3.4).   
 
Figure 2 7.  Set up of the QV500 Quasi–Vivo® system connected to a Watson–Marlow 
120U/R peristaltic pump. 
2.5 Isolation of persister cells in Gram–negative DFU isolates 
Persister cells are a small population of a biofilm that does not grow nor die in the presence 
of antibiotics (Keren et al., 2004). They have been suggested to be largely responsible for 
recurrent infections. Hence they are the other components of a biofilm that would make an 
otherwise susceptible biofilm resistant to killing by antibiotics even at high concentrations of 
the antibiotics (Brooun et al, 2000; Lewis, 2005; Spoering and Lewis, 2001).  
In this study, the ability of diabetic foot isolates K. pneumoniae and P. mirabilis to produce 
persister cells was assessed. Persister cells produced by these strains were then isolated after 
using 3 methods described by Keren et al. (2004) with some modifications. Overnight broth 
and agar cultures of K. pneumoniae and P. mirabilis were prepared by diluting thawed cells 
from –80°C glycerol stocks 1:100 in fresh LB broths and cultured aerobically for up 18–24 
hours. Antibiotic (ceftazidime and levofloxacin) concentrations for the challenge assays were 
selected after MIC determination of each antibiotic in a broth micro–dilution test (British 














dilution assay for MIC determination, two–fold dilutions of ceftazidime and levofloxacin in 
separate 96–well microtitre plates were prepared and inoculated with K. pneumoniae and P. 
mirabilis suspensions corresponding to 0.5 McFarland standard. The plates were incubated 
overnight at 35 – 37°C under aerobic conditions. MIC was defined as the lowest 
concentrations of CAZ and LEV that prevented visible growth of K. pneumoniae and P. 
mirabilis in the microtitre plates (British Society for Antibiotic Chemotherapy, 2015). 
MacConkey agar plates were used for P. mirabilis CFU confirmation. 
2.5.1 Time–dependent isolation of persister cells 
Overnight broth cultures of clinical strains were diluted 1:1000 in 20 mL of fresh LB broths 
in a 125 mL conical flask and cultured by shaking (250 rpm) at 37°C to reach exponential 
phase. Freshly prepared ceftazidime and levofloxacin were respectively added to 1 mL of 
each cell in culture tubes to a final concentration of 100 µg/mL and incubated in a shaking 
(250 rpm) incubator at 37°C for 5 hours. Samples were removed at hourly intervals, serially 
diluted (10–2, 10–3 and 10–4) in LB broth and 10 µL spot–plated on LB agar plates to 
determine their CFUs. Serially diluted antibiotic–free cells were also plated simultaneously 
for CFU determination as a control.  
2.5.2 Growth–state dependence assay of persister cells 
A 1:1000 dilution of overnight cultures of K. pneumoniae and P. mirabilis was made in 20 
mL of fresh LB broths and incubated by shaking (250 rpm) at 37°C. At selected time points 1 
mL of sample was removed from each culture. Five hundred microlitres was added to 500 µL 
each of 200 µg/mL ceftazidime and levofloxacin and incubated by shaking (250 rpm) at 37°C 
for 5 hours. The remaining 500 µL was serially diluted in LB broth and spot–plated on LB 
agar plates. This was done for 5 different time points and in 3 replicates to rule out false 
positive results.   
2.5.3 Persister heritability assay 
In this assay, overnight broth cultures of K. pneumoniae and P. mirabilis were diluted 1:1000 
in 1 mL of fresh LB broth and incubated by shaking (250 rpm) at 37°C for 3 hours. After the 
incubation period, levofloxacin was added to a final concentration of 100 µg/mL and 
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incubated at 37°C with shaking (250 rpm) for 3 hours to lyse the cells. Cells remaining after 
lysis were pelleted by centrifugation at 10,000 x g for 5 minutes at a temperature of 10°C. 
The pellets were resuspended in 25 mL fresh LB broth and incubated aerobically at 37°C for 
18 – 24 hours. Their CFU/mL was determined in order to test for their ability to resist killing 
by Levofloxacin. The determination of CFU/mL of bacteria has been explained in section 
2.3.3. This assay was repeated 4 times on 4 different days and the results compared.  
2.5.4 Isolation of persister cells from biofilm  
Antibiotic of choice for this assay was levofloxacin. A two–fold dilution of levofloxacin 
(5120 µg/mL) was added to 24–hours old K. pneumoniae and P. mirabilis biofilms in a 96–
well conventional microtitre plate. The plates were further incubated at 37°C for 3 hours. The 
wells were washed with PBS to get rid of planktonic cells in suspension after which the 
biofilms (with embedded persister cells) were disrupted by rigorous shaking and sonication 
for 30 minutes. The sonicated–biofilm–forming cells were washed again and centrifuged at  
10,000 x g for 5 minutes as described by Keren et al. (2004). The pellets were resuspended in 
fresh PBS, diluted and spot–plated for viability count as previously described in section 2.3.3. 
Persister cells were recovered from antibiotic agar plates, resuspended in fresh LB broth and 
inoculated in 96–well plates for crystal violet staining biofilm assay as described above 
(section 2.4.1). Antibiotic susceptibility testing of 5 antibiotics (ampicillin, ceftazidime, 
ciprofloxacin, gentamicin and levofloxacin) of biofilm–derived K. pneumoniae and P. 
mirabilis persister cells was performed and compared to the wild–type using the disc 
diffusion method described in section 2.3.2. 
2.6 Quorum sensing (QS) detection in Gram–negative DFU isolates 
The presence of quorum sensing mechanisms in Gram–negative clinical isolates was tested. 
A representation of all strains, K. pneumoniae and P. mirabilis were investigated for their 
ability to form biofilm using quorum sensing. Three control strains selected for these 3 
analyses were P. aeruginosa PA01 and V. harveyi strains NCIMB 1280 and NCIMB 1872. 
These control strains belong to the same class of Gammaproteobacteria and phylum 
Proteobacteria as the clinical strains under study with similar ancestors and evolutionary 
relationships (Gao et al., 2009; Williams et al., 2010). The AI–1 – mediated las/rhl QS 
systems in P. aeruginosa and three parallel HAI–1, CAI–1 and AI–2 mediated QS circuits in 
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V. harveyi have been well studied (Bassler et al., 1993; Bassler et al., 1994; Domka et al., 
2006; Lopez et al., 2010; Patriquin et al., 2008; Xavier and Bassler, 2005b; Wang et al., 
2015). 
2.6.1 Quorum sensing detection by cross–feeding and cross–stimulation assays 
2.6.1.1 N–acyl–homoserine lactone (AHL) detection using biosensor–reporter system  
Diabetic foot isolates were tested for their ability to produce QS molecules using the lacZ–
fusion reporter gene in an A. tumefaciens (NCIMB 14543) broad–spectrum biosensor reporter 
strain. The production of AHLs by Gram–negative bacteria has previously been reported 
using different biosensor reporter strains hosts to plasmids with different transcriptional 
promoter genes fused to the reporter system/gene of interest (Steindler and Venturi, 2007). 
Table 2.5 provides a summary of some selected reporter systems and the range of AHLs they 
detect. The biosensors can detect and respond to AHLs ranging from C4–AHL to C16: 1–3–
oxo–AHL. AHL detection is normally performed by one of 4 methods; by ‘T’ –  streak 
analysis on solid media, thin layer chromatography (TLC) analysis on developed (stained) 
silicone plate, epifluorescence or by quantification (absorbance reading).  
Table 2 –5 AHL biosensor reporter system 
Host strain Plasmid sensor QS system Reporter system Reference 




β–galactosidase Zhu et al. 
(1998) 
A. tumefaciens pMJ258 HyuC/R  
(A. tumefaciens) 
β–galactosidase Jiwaji (2006) 




McClean et al. 
(1997) 
E. coli pSB401 LuxI/R (V. fischeri) luxCDABE Winson et al. 
(1998a) 
E. coli pSB1075 LasI/R  
(P. aeruginosa) 
luxCDABE Winson et al. 
(1998a) 
P. aeruginosa M71LZ LasI/R  
(P. aeruginosa) 
β–galactosidase Dong et al. 
(2005) 
S. meliloti pJNSinR SinI/R (S. meliloti) β–galactosidase Llamas et al. 
(2004) 





2.6.1.2 AHL production and detection using the Cross–feeding assay 
In this study, a broad host biosensor reporter strain A. tumefaciens NCIMB 14543 (also called 
A. tumefaciens RU–AE01 [pMJ258]) with a divergent promoter region separating the 2 
reporter genes, lacZ and gus was used to detect AHL production in diabetic foot clinical 
isolates. This reporter strain technique which allows the concurrent analyses of promoter 
sequence–directed transcription and β–galactosidase and β–glucuronidase reporter activities 
can be used in a wide range of Gram–negative bacteria (Jiwaji, 2006; Jiwaji et al., 2008; 
Jiwaji and Dorrington, 2009; Matcher et al., 2013). The cross–feeding assay was performed 
as previously described by Stickler et al., (1998) with few modifications. In the cross–feeding 
assay the biosensor reporter strain has a lacZ gene which is fused together with a 
transcriptional promoter gene which responds to autoinducer stimulation (Stickler et al., 
1998). Quorum sensing molecules produced by a test strain streaked parallel to the biosensor 
detector strain (in this case, A. tumefaciens NCIMB 14543) on an agar plate diffuses through 
agar and activates the transcription of the lacZ–promoter fusion gene. This leads to the 
production of β–galactosidase enzyme which metabolises the substrate 5–bromo–4–chloro–
3–indolyl–β–D–galactopyranoside (X–gal) to galactose and an insoluble blue 4–chloro–3–
brom–indigo pigment. Thirty–six clinical strains (n = 36) were tested for their ability to 
produce AHLs. They included 22 P. mirabilis, 9 K. pneumoniae, 1 K. variicola, 1 P. 
aeruginosa, 1 C. koseri, 1 E. coli and 1 P. stuartii strains. Prior to the assay, all 36 clinical 
isolates as well as the A. tumefaciens NCIMB 14543 reporter (control) strain were inoculated 
in LB broths in 96–well microtitre plates and incubated overnight. The wells containing the 
inoculated A. tumefaciens NCIMB 14543 reporter strain were supplemented with 0.05 µg/L 
kanamycin before incubation. This is because the A. tumefaciens NCIMB 14543 reporter 
strain is resistant to kanamycin and hence the addition of 0.05 µg/L kanamycin was selective 
for its growth while preventing the growth of contaminants present in the suspension. 
Biofilms produced after overnight incubation were washed once and then resuspended in 100 
µL of 1X PBS to produce a suspension of biofilm extracts corresponding to 0.5 McFarland 
standard. X–gal stock solution was also prepared by dissolving 200 mg of X–gal powder 
(VWR, UK) in 10 mL of dimethyl–sulfoxide (Sigma–Aldrich, UK). The X–gal stock solution 
was stored at –20°C in a bottle covered with aluminium foil to protect it against light when 
not in use. LB agar plates were then covered with 40 µL of 20 mg/mL X–gal solution. The 
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agar plates were left to dry after which the AHL reporter strain and the biofilm extracts of 
each clinical isolate were streaked across each plate about 1 cm apart and parallel to each 
other. The plates were incubated at 35–37°C overnight. The plates were observed after 24 
hours for evidence of AHL production which was shown by blue colonies for positive results 
and cream colonies for negative results. A. tumefaciens NCIMB 14543 streaked next to itself 
was used as a negative control. Clinical test strains that stimulated A. tumefaciens NCIMB 
14543 to produce blue colonies in a positive assay were classified as AHL producers. Clinical 
test strains that could not stimulate A. tumefaciens NCIMB 14543 to produce blue colonies 
were classified as non–AHL producers.  
2.6.1.3 Nitrosoguanidine mutagenesis of V. harveyi NCIMB 1280 
This assay was performed to determine the ability of diabetic foot isolates to responds to 
exogenous addition of autoinducer molecules (AI–2) before and after induced mutagenesis. 
The V. harveyi strain NCIMB 1280 has been genetically modified to only respond to AI–2 
stimulation through the expression of the luxICDABEG operon (confirmed by PCR in section 
2.8.5). Prior to the cross–stimulation assay, the NCIMB 1280 strain was subjected to site–
directed mutagenesis of the luxQ locus using a chemical mutagen called N–methyl–N'–nitro–
N–nitrosoguanidine (NTG). NTG can induce GC to AT transitions in the DNA of bacteria 
and yeast cells (Müller et al., 1978, Siripong et al., 2014) to produce phenotypic variants of 
the wild–type strains that have either a reduced or increased functionalities. In this study, two 
V. harveyi control strains, NCIMB 1280 luminous strain and NCIMB 1872 aldehyde mutant 
(i.e., the non–luminous mutant of the wild–type V. harveyi strain without the fatty acid 
reductase complex (luxCDE) and could not produce light even after the exogenous addition 
of long chain aldehyde substrate such as n-decanal) strain were used. Stock solution of 2.5 
mg/ml NTG was freshly prepared by dissolving 25 mg of the NTG crystalline powder in 10 
mL of 95% ethanol. The NCIMB 1280 strain was mutagenized according to the modified 
method described by Bassler et al. (1994). The 2 strains (mutagenized and wild–type) were 
cultured in LM broth (Table 2.3) at 30°C overnight to an OD600 of 1.0. Two representative 
clinical strains, K. pneumoniae and P. mirabilis in LB broths were also cultured overnight at 
35–37°C in LB broths. The control strains were subcultured in LM broth by adding 2.5 mL of 
the overnight cultures to 50 mL of fresh LM broth and incubated overnight. Five (5) 
millilitres of each broth culture was pipetted into 10 separate 15 mL centrifuge tubes and 10 
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µL of 2.5 mg/mL NTG was added. The resultant cultures were incubated for 10 mins at room 
temperature, pelleted by centrifugation at 12,000 x g for 10 mins and then resuspended again 
in fresh LM broth. The cultures were then incubated at 30°C overnight with agitation. After 
overnight incubation, the NCIMB 1280 cells were then screened for mutations by plating out 
1:10 dilutions of the broth cultures on LM agar to look for dark and dim mutants in a dark 
room. Putative dark and dim mutant strains were subsequently designated as V. harveyi 
NCIMB 1280d. 
2.6.1.4 Cross–stimulation assay 
In this assay both wild–type and putative dim and dark mutants of V. harveyi NCIMB 1280 
as well as the aldehyde mutant NCIMB 1872 strains were tested for their ability to produce 
and respond to exogenously added autoinducer (AI–2) molecules using the method described 
by Bassler et al. (1994) with some modifications. The cross–stimulation assay involved the 
induction of bioluminescence in a V. harveyi reporter strain through the production and 
diffusion of an exogenous AI–2 from a test strain streaked in close proximity to the V. 
harveyi reporter strain (Bassler et al., 1994). A positive test resulted in the observation of 
luminescence at the edges of the reporter strain close to the AI–2 donor. Expression of 
luminescence was by exposure of the agar plate to X–ray film or in a dark film development 
room. Biofilm extracts (as described above) of both control strains (wild–type V. harveyi 
NCIMB 1280, V. harveyi NCIMB 1280d and aldehyde mutant V. harveyi NCIMB 1872 
strains) and K. pneumoniae and P. mirabilis clinical isolates were prepared in sea–water 
broth and LB broth respectively with final suspensions in 1X PBS adjusted to 0.5 McFarland 
standard. Control cells were applied onto the centre of sea–water agar (SWA) and L–marine 
agar plates using sterile cotton swabs to make a 2–cm diameter inoculum. The plates were 
incubated at 30°C for 4 hours to dry after which the clinical strains were radially streaked 
from the edges of the petri dishes to the edges of the control strains in the middle of the agar 
plates. A second set of LB assay was set up using A. tumefaciens 14543 as a negative control 
and K. pneumoniae and P. mirabilis as AI–2 donors. In this assay, biofilm extracts were 
inoculated and streaked on LB agar supplemented with 0.05 µg/mL of kanamycin. The plates 
were incubated between 8 and 16 hours and then observed for luminescence expression. 
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2.6.2 Bioluminescence assay  
The ability of diabetic foot isolates to induce luminescence in V. harveyi strain in a co–
culture was tested using the bioluminescence assay previously described by Bassler et al. 
(1994). Cell–free culture supernatants were initially prepared from all strains. Both control 
and clinical strains were grown in AB medium (Table A2, Appendix A) overnight at 30°C in 
a shaking incubator. Control strains for this assay included V. harveyi strains NCIMB 1280, 
NCIMB 1280d and NCIMB 1872. The AB medium used in this assay was the ATCC 2746 
autoinducer bioassay (AB) medium. Overnight cultures of the V. harveyi strains were diluted 
1:5000 into fresh AB medium and incubated again. When the bacteria achieved growth of 
about 1.0 at OD600, they were placed on ice and centrifuged at 5000 x g for 10 minutes. Their 
supernatants were filtered with a 0.22 µm filters and stored at –20°C. Fresh stocks were 
prepared every two weeks.  
Cell–free culture supernatants from K. pneumoniae and P. mirabilis overnight cultures were 
prepared using the method described by Han et al. (2010) with some modifications. Ten 
millilitres (10 mL) of overnight cultures of the clinical strains were centrifuged at 5000 x g 
for 10 minutes to collect cells and resuspended in 10 mL of fresh AB medium. One–in–one–
hundred (1:100) dilutions of broth cultures were prepared by inoculating 500 µL of the 
resuspended cells into 50 mL of fresh AB medium, which were incubated overnight at 30°C. 
The growth of the cultures was monitored using a spectrophotometer until it reached 1.0 at 
OD6oo. The cultures were then centrifuged at 5000 x g for 10 minutes to settle the cells at the 
bottom of the tubes. The supernatants were then filtered using 0.22 µm filter and the cell–free 
supernatant stored at –20°C for further analysis.  
The bioluminescence plates were set up in 96–well plates at 10% (v/v) by adding 10 µL of 
cell–free supernatant of clinical strains to 90 µL of V. harveyi controls. Positive control wells 
were made of cell–free supernatants of Vibrio harveyi NCIMB 1280 strain and cell–free 
supernatants of 2 known AI–2 producers; 028b K. pneumoniae and 005a P. mirabilis. 
Negative control wells were made up of 90 µL of fresh AB medium and 10 µL cell–free V. 
harveyi NCIMB 1280 or V. harveyi NCIMB 1872 (as the reference strains were sensors but 
not AI–2 producers). Similar to the bioluminescence batch culture mentioned above in this 
section, a second batch culture assay was set up to determine fold induction of 
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bioluminescence of V. harveyi NCIMB 1280. In this assay, cell–free culture supernatants of 
028b K. pneumoniae and 005 P. mirabilis were used as sources of exogenous AI–2 for light 
production in V. harveyi. To one set of the assay, a commercially prepared AI–1; N–(3–
hydroxybutanoyl) homoserine lactone was also added at 1 µg/mL in the presence of AI–2 to 
determine their combined effect on fold induction of bioluminescence. Luminescence was 
measured for the first 5 hours and then at 18 and 24 hours using the GloMax®–Multi 
Detection system (Promega, UK). The luminescence plate was incubated inside the 
luminometre plate reader throughout the reading period. The results of bioluminescence were 
expressed as relative light units (RLU) and fold induction of bioluminescence was given as 
the ratio of the relative luminescence (in RLU) of the reporter strain (V. harveyi NCIMB 
1280) cultured in a conditioned AB medium (in the presence of the donor autoinducer) to the 
that of V. harveyi NCIMB 1280 grown in sterile AB medium. 
The ability of exogenous AI–2 donated by 028b K. pneumoniae and 005 P. mirabilis to 
stimulate biofilm formation in V. harveyi NCIMB 1280 and its mutagenized counterpart 
NCIMB 1280d was also assessed. Biofilms were set up according to the MBEC™ HTP assay 
outlined in section 2.4.3 in the presence of exogenous AI–2 from 028b K. pneumoniae and 
005 P. mirabilis cell–free culture supernatants. BGC was determined and presented as 
CFU/mL.  
2.6.3 Quorum sensing inhibitors and antibiotic synergy assays 
In these assays, the synergy (i.e., when the effects of an antibiotic and an antimicrobial agent 
in a combination assay were greater than the sum of their individual effects) between quorum 
sensing inhibitors such as baicalin hydrate (BH), cinnamaldehyde (CIN) and (5Z)–4–bromo–
5–(bromomethylene)–3–butyl–2(5H)–furanone (2(5H)–furanone) listed in Table 2.3 and two 
antibiotics (ceftazidime and levofloxacin) was evaluated in an attempt to develop a strategy 
for biofilm inhibition and disruption using the high–throughput Physiology and Genetics 
(P&G) MBEC™ assay (Ceri et al., 1999; Conlan et al., 2013; Harrison et al., 2004; Harrison 
et al., 2005). Klebsiella pneumoniae and Proteus mirabilis biofilms of initial broth 
suspensions of 108 colony forming units (CFU)/mL, cultivated on the pegs of the MBEC™ 
device were challenged with 5120 µg/ml of ceftazidime (CAZ) and levofloxacin (LEV) in a 
double dilution assay in the presence of 1000 µM of CIN. The assays were also performed in 
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the presence of BH (2500 µg/mL) and 2(5H)–furanone (250 µg/mL). The MICs and MBCs 
of baicalin hydrate, cinnamaldehyde and 2(5H)–furanone were determined prior to each 
combination assay. Working solutions of 25 mg/mL, 10000 µM, and 500 µg/ml for BH, CIN 
and 2(5H)–furanone respectively were diluted in a two–fold dilution for the determination of 
MIC and MBC. Sub–inhibitory concentrations for BH, CIN and 2(5H)–furanone were then 
selected for synergy assays with ceftazidime and levofloxacin. The rest of the assay was 
carried out as outlined from sections 2.4.2 to 2.4.3.3. The presence and extent of synergy 
between the antimicrobials, quorum sensing inhibitors and the antibiotics (CAZ and LEV) 
was determined by calculating the fractional inhibitory concentration (FIC) index (Ghosh et 
al., 2013; Ruden et al., 2009). FIC index was defined as combined antimicrobial effect of 
agents’ A and B and calculated as follows: 
FIC index = MIC (A in combination with B)/ MIC (A alone) + MIC (B in combination with   
A)/MIC (B alone) 
Where A is BH, CIN or 2(5H)–furanone and CAZ or LEV 
FIC index values were interpreted using the definitions provided by Ruden et al. (2009) as 
guidelines. Synergy was defined as ≤ 0.5; FIC index > 0.5 < 2.0 was indicative of “additive 
effect, and FIC index above 2.0 was indicative of antagonistic effect.  
At least 3 replicates of each assay were performed and their mean standard deviations used 
for statistical analysis. OD650 values computed for mean standard deviations were ≤ 10% 
coefficient of variation. 
2.7 Glycan–lectin interactions among DFU isolates 
During biofilm formation, the attachment of bacteria to each other using their cell–surface 
appendages is an important step in the perpetuation of the biofilm and subsequent reinfection. 
This is because it provides structural integrity for the biofilm embedded in the EPS (Lopez et 
al., 2010). Participating bacteria in a developing biofilm use their cell–surface carbohydrate–
binding proteins (lectins) to specifically bind to corresponding proteoglycans, glycolipids or 
glycoproteins of other members of the biofilm consortium. This cell–cell or cell–matrix 
attachment can provide a useful diagnostic tool for the identification of bacterial species in 
biofilms using a panel of lectin that specifically bind to receptor carbohydrate monomers or 
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oligosaccharides. This attachment has also enabled the characterisation of the different 
carbohydrates and proteins involved in biofilm development. Panel of plant lectins (Table 
2.6) have been employed to target and identify some bacterial cell–surface carbohydrates 
(Afrough et al., 2007; Munoz et al., 1999; Munoz et al., 2003; Slifkin and Doyle, 1990).  
Table 2 –6 Panel of commonly used biotinylated plant lectins. Sources and glycan specificity 
adapted from (Afrough et al., 2007; Lis and Sharon, 1998). 
Lectins  Source Sugar Specificity  
Peanut Agglutinin (PNA) Peanuts Galactose 
Jacalin (JAC) Jackfruit seed Galactose/GalNAca 
Erythrina cristagalli (ECA) Erythrina 
cristagali seeds  
Galactose/GlcNAcb 
Sophora japonica (SJA) Japanese pagoda 
seeds 
GalNAc/Galactose 
Ricinus communis Agglutinin I (RCA–I) Castor bean GalNAc/Galactose 
Griffonia simplicifolia Lectin I (GSL–I) Griffonia seeds GalNAc/Galactose 
Soybean Agglutinin (SBA) Soybean GalNAc 
Dolichos biflorus (DBA) Horse gram seeds GalNAc 
Vicia villosa Lectin (VVA) Hairy vetch seed GalNAc 
Griffonia simplicifolia Lectin II (GSL–II) Grifonia seeds GlcNAc 
Wheat Germ Agglutinin (WGA) Wheat gem GlcNAc/NANAc 
Succinylated Wheat Germ Agglutinin (SWGA) Wheat gem GlcNAc 
Lycopersicon esculentum (LEA) Tomato fruit GlcNAc 
Solanum tuberosum (STA) Tomato fruit GlcNAc/Sialic acid 
Lens culinaris Agglutinin (LCA) Lentil seeds Glucose/Mannose 
Concanavalin A (Con A) Jack bean Glucose/Mannose 
Pisum sativum Agglutinin (PSA) Garden pea Glucose/Mannose 
Phaseolus vulgaris Leucoagglutinin (PHA–L) Red kidney beans Complex Sugar 
Phaseolus vulgaris Erythreoglubulin (PHA–E) Red kidney beans Complex Sugar 
Datura stramonium (DSA) Thorn apple LacNAcd 
Ulex europaeus Agglutinin I (UEA–I) Furze seed Fucose 
Sambucus nigra (SN) Elder bark α –2,6 sialic acid 
gal 
a – GalNAc – N–acetyl D–galactosamine 
b – GlcNAc – N–acetyl D–glucosamine; 
c – NANA –   N–Acetylneuraminic acid 
d – LacNAc – N–acetyllactosamine 
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2.7.1 Glycan–lectin analysis of whole cells using the enzyme–linked 
lectinsorbent assay (ELLA) 
Lipopolysaccharides (LPS) are the main components of the outer membranes of Gram–
negative bacteria that are responsible for maintaining their structural integrity.  In biofilms, 
LPS embedded in the EPS increases the overall negative charge of the matrix and contributes 
to the stability and protection of biofilms. The negatively charged LPS neutralises any 
positively charged chemical attack on the developing biofilm. Gygi et al. (1995) 
demonstrated by gas–liquid chromatography that capsular LPS are rich in galacturonic acid 
and galactosamine monomers. This study employed the optimised method developed by 
Dharod (2010) with some modifications. This method helps to detect glycans immobilised in 
the EPS of Gram–negative biofilms by the use of lectins that specifically detect and bind to 
corresponding sugar monomers. Representative clinical strains used in this assay were K. 
pneumoniae and P. mirabilis. A panel of 6 lectins (PNA, JAC, PHA–L, SJA, RCA–I and Con 
A) in a kit purchased from Vector Laboratories (UK) were selected for this assay as they have 
high specificity for affinity binding to galactose and galacturonic acid containing–
carbohydrates.  
Biofilm extracts of the control and clinical strains were prepared as previously mentioned. 
The final suspension in PBS of OD600 0.3 – 0.5 was used to inoculate wells of 96–well 
microtitre plates and incubated overnight at 35–37ºC. To prepare the enzyme extracts, 
overnight broth cultures of all strains in 15 mL centrifuge tubes were pelleted and the 
supernatant discarded. The pellets were resuspended in 1.5 mL PE–LB and vortexed for some 
few seconds. The tubes were incubated for 30 minutes at room temperature and centrifuged 
for 5 minutes at 10,000 rpm. The supernatants were then pipetted into clean 1.5 mL 
Eppendorf tubes and labelled as enzyme extracts. 
Wells of 96–well plates were inoculated with 100 µL of biofilm PBS suspensions of biofilm 
extracts. Two controls, negative and positive were set up for each strain. For the negative 
control, 100 µL of PE–LB was used instead. A known S. aureus strain which specifically 
binds to Con A was used as a positive control (Slifkin and Doyle, 1990). The plates were left 
in the fridge overnight at 4ºC. Unbound cells were removed by carefully pipetting them out. 
The wells were further washed with 200 µL of PBS to remove other contaminants on a 
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shaker for 10 minutes. The bound cells were then blocked with 200 µL of 5% (w/v) albumin 
and incubated at room temperature for 1 hour. The blocking agent (5% (w/v) albumin) was 
discarded after which 100 µL of the appropriate diluted biotinylated lectins of concentration 
0.6 µg/mL were added. The plates were them incubated at room temperature and in the dark 
for 1 hour. The contents were discarded and the plates washed twice with PBS for 5 minutes 
to remove unbound lectins. A 1:1000 dilution of streptavidin–alkaline phosphatase was made 
and 100 µL added to the wells and incubated at room temperature for an hour. The contents 
of the plates were discarded, washed twice with PBS and 100 µL of 1 mg/mL of 
paranitrophenol–phosphate (PNP) added. PNP was prepared by diluting 10 mg of the 
crystalline powder in 10 mL of 100 mM Tris–HCl at pH of 8.0–8.5. The plates were then 
incubated at room temperature in the dark for an hour. Fifty microlitres of 3 M NaOH was 
then added to stop the reaction. The absorbance of the reaction was read using a microtiter 
plate reader at 405 nm.  
2.7.2 EPS staining of in vitro biofilms with Calcofluor white and ethidium 
bromide 
In this study, epifluorescence microscopy was used to target and visualise the major 
components of biofilms such as polysaccharides and DNA in the EPS to qualitatively 
estimate the production of EPS and confirm biofilm formation. Representative strains K. 
pneumoniae and P. mirabilis were grown on coverslips in a 24–well plate to produce biofilms 
as described in section 2.4.4.2. To demonstrate the presence of the EPS in a mature biofilm, 
the coverslips were stained with ethidium bromide (Sigma, UK) and Calcofluor white 
(Sigma, UK) using the method described by Davis et al. (2007). Ethidium bromide is a 
nucleic acid stain which inserts itself between double stranded DNA stains bacterial cells red 
under fluorescent light (Davies et al., 2007). Calcofluor white on the other hand specifically 
helps in the identification of polysaccharides by staining 1,4–linked polymers (Davies et al., 
2007). After overnight incubation, the planktonic cells were discarded and the coverslips with 
biofilms fixed with 2.5% formalin for 45 minutes. The biofilms were then stained with 0.5 
mg/L of ethidium bromide for 15 minutes, rinsed with 1X PBS and then stained with 0.1% 
Calcofluor white for 15 minutes. The stained biofilms were visualised by a Leica 
epifluorescence microscope (Leica Microsystems, UK) with an attached image viewer. The 
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EPS was stained blue by Calcofluor white and the nucleic acids were stained red by ethidium 
bromide.  
2.7.3 EPS staining of in vitro biofilms with Congo red and Ziehl carbol–fuchsin 
A second EPS staining method described by Serralta et al. (2001) was used to stain 
polysaccharides in the EPS. In this assay, the quaternary salt, cetylpyridinium chloride first 
precipitates the polysaccharides in the EPS which is then stained orange/pink by Congo red. 
The second stain, Ziehl carbol–fuchsin then stains the bacterial cells purple/red. K 
pneumoniae and P. mirabilis biofilms were grown on coverslips in a 24–well plate as 
previously described. After discarding the planktonic cells from the overnight cultures, the 
developed biofilms on the coverslips were first covered with 10 mM cetylpyridinium chloride 
solution and air–dried for 20 minutes. The coverslips were further fixed by gentle heating by 
passing them over a flame of a Bunsen burner and allowed to cool down. Coverslips with the 
fixed biofilms were then stained with a 2:1 mixture of Congo red solution and 10% (v/v) 
Tween 80 for 15 minutes, rinsed with distilled water and then stained with 10% (v/v) Ziehl 
carbol–fuchsin for 6 minutes. Coverslips were rinsed with distilled water, dried at 37°C and 
then visualised with the Leica epifluorescence microscope. The polysaccharides in the EPS 
stained orange with Conge red and the bacterial cells stained purple by Ziehl carbol–fuchsin. 
2.8 Molecular biology and in silico studies of DFU isolates 
2.8.1 DNA extraction  
DNA of all 50 clinical isolates was extracted using a method described by Millar et al. 
(2000). In this method, 0.5 mL of overnight broth culture was pipetted into 1.5 mL Eppendorf 
tubes and centrifuged at 13,000 X g for 5 minutes. The pellet was resuspended in TE buffer 
and incubated at 95–100°C in a heat block for 15 minutes. The suspension was then 
centrifuged at 13,000 X g for 15 minutes to pellet the thermally denatured bacteria and the 
resultant supernatant containing the extracted DNA transferred into a sterile 1.5 mL 
Eppendorf tube and stored at –20°C for future use. 
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2.8.2 Primer design, PCR and agarose gel electrophoresis 
All primers used in this study were designed using Primer3 software (Koressaar and Remm, 
2007; Untergrasser et al., 2012). All primers used in this study were synthesised by Eurofins 
MWG Operon, Germany. Unless otherwise stated, all PCR amplifications were performed 
with the Peltier thermal cycler, DNA Engine®, BIO–RAD using the Taq PCR Master Mix kit 
(Qiagen, Crawley, UK). 
All PCR amplified products were resolved on 1% (w/v) agarose gel in 1X TAE buffer. 
Agarose gels were prepared from agarose crystalline powder purchased from Fisher 
Scientific Ltd (Loughborough, UK). PCR amplicons resolved on agarose gels were stained 
with ethidium bromide and subsequently visualised under ultra violet (UV) light using a 
transilluminator. 
2.8.3 PCR/gel purification and DNA sequencing 
All PCR amplicons that showed single clear bands upon agarose gel electrophoresis were 
purified following PCR amplification. Gel extraction/clean–up was performed when more 
than one band was present following agarose gel electrophoresis. All PCR products were 
purified using QIAquick PCR purification or Gel Extraction kits (Qiagen, Crawley, UK) 
following the manufacturer’s instructions. In this assay, the initial buffer, PB or QC 
(solubilising and binding buffer) was added to the PCR amplicons to provide the optimal salt 
concentration and low pH and enhance the negatively charged DNA to adsorb to the 
positively charged silica–gel membrane in the QIAquick spin column. Contaminants in 
solution were then eluted by high speed centrifugation (13,000 rpm) through the column. 
Buffer PE was then used to thoroughly wash DNA–bound membrane to remove remaining 
contaminants through centrifugation. The final step of this assay was the elution of DNA 
using a low concentration Tris buffer (EB). In order to obtain maximum DNA recovery, 40 
µL of buffer EB was added to the centre of the membrane and the column centrifuged after 1 
minute of incubation.  
Purified DNA samples were then sequenced by Source Bioscience Ltd (Cambridge, UK) and 
by GATC Biotech (Germany). DNA sequencing by GATC Biotech (Germany) was 
performed by the LIGHTRUN™ sequencing technique. In this method, 5 µL of purified 
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DNA and 5 µL appropriate primer of concentration 5µM were premixed before being sent for 
sequencing. DNA sequences were analysed using bioinformatics tools like BLASTS and 
MUSCLE to determine their similarities with speciated strains in the databases. 
2.8.4 16S rRNA PCR  
16S rRNA PCR was performed to confirm the identification of all reference strains. Clinical 
strains initially identified using the API RapiD 20E were also confirmed by 16S rRNA PCR 
and DNA sequencing. Three sets of primers (Table 2.7) targeting regions including the V3 
and V6 hypervariable regions of the 16S rRNA gene were used for PCR amplification. These 
primers previously described by Chakravortya et al. (2007) are very specific for the 
conserved 16S rRNA gene sequences in bacteria for identification purposes. 
Table 2 –7 Primers and reaction programme for 16S rRNA PCR 
Primer name Sequence  Programme 
V3F 5’–CCA gꝉAC TCC TAC GGG AGG CAG – 3’ Initial denaturation –
94°C for 5 minutes, 
followed by 35 cycles 
each of 94°C for 30 
seconds, annealing at 
55°C for 30 seconds and 
elongation at 72°C for 1 
minute then finished 
with 10 minutes’ 
elongation at 72°C 
(Chakravortya et al., 
2007) 
V3R 5’–CGT ATT ACC GCG GCT GCTG– 3′  
V6F 5′ –TCG AtG CAA CGC GAA GAA– 3′ 
V6R 5′–ACA TtT CAC aAC ACG AGC TGA CGA– 3′ 
339F 5’– ACT CCT ACG GGA GGC AGCAGT–3’ 
907R 5 –CCG TCA ATT CMT TTG AGT–3’ 
ꝉ – lowercase base pairs (g, t, and t and a) in primer sequences V3F, V6F and V6R 
respectively indicating masked effects which did not affect the performance of the primers. 
2.8.5 Genotypic characterisation of persister cells and ‘wild–type’ strains 
Attempt was made to determine whether persister cells were genotypic variants of the ‘wild–
type’ (hereafter referred to as controls) strains. PCR was performed by amplifying the gyrase 
B (gyrB) genes of both persister cells and control cells of K. pneumoniae and P. mirabilis. 
Persister cells used for gyrB PCR amplification were isolated from biofilms in section 2.5.4. 
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Primers (Table 2.8) were designed to target the gyrB genes of both K. pneumoniae and P. 
mirabilis.  
Table 2 –8 Primers for gyrB PCR amplification 
Primer name Sequence Programme 
PGyrB–F 5’–CAG TGA ACA TGC CCC TGC TA–3’ Initial denaturation at 95°C 
for 5.00 minutes, followed 
by 30 cycles each of 95°C 
for 30 seconds, annealing at 
55°C for 30 seconds and 
elongation at 72°C for 1 
minute, then finished with 10 
minutes elongation at 72°C.  
PGyrB–R 5’–TCA CCA AGC CAC TCA TCC AC–3’ 
KGyrB–F 
5’–GAG GTG AAA TCA GCG GTG GA–
3’ 
KGyrB–R 
5’–AAG GTC AAC AGC AGG GTA CG–
3’ 
 
2.8.6 In silico studies of quorum sensing activities in DFU isolates 
Bioinformatics tools were selected to study the genomes, pathways and other precursors that 
are responsible for the biosynthesis of quorum sensing molecules and their expressions in 
diabetic foot isolates. The in silico studies were conducted along with molecular biology 
techniques such as PCR amplification and DNA sequencing to study the expression of 
quorum sensing genes and the biosynthetic pathways involved in the production of quorum 
sensing molecules in K. pneumoniae and P. mirabilis. QS gene expression and QS molecule 
biosynthesis in K. pneumoniae and P. mirabilis were compared with previously studied QS 
systems in E. coli, Salmonella enterica serovar typhimurium and V. harveyi to determine 
similarities and differences between them (Schauder et al., 2001; Winzer et al., 2002; Xavier 
and Bassler, 2005b). Bioinformatics tools used included the BioCyc database collection 
(http://biocyc.org), National Center for Biotechnology Information (NCBI) databases 
(www.ncbi.nlm.nih.gov), Universal Protein (UniProt) Resource (www.uniprot.org). These 
databases are highly credible sources for accessing high–quality and fully annotated genes, 
protein sequences and their biosynthetic pathways. The databases also provide tools and other 
information for studying the functions of these genes, proteins and pathways. 
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BioCyc database collection is made of a family of databases of 5711 pathways/genome 
databases (PGDBs) and divided into 3 tiers based on their manual curation. For the purpose 
of this study, MetaCyc database, which has tools for the illustration of metabolic pathways, 
chromosomal location of pathway genes, regulation of pathway genes and enzymes from 
over 2063 organisms (Caspi et al., 2014) was used to study K. pneumoniae and P. mirabilis 
QS genes and quorum sensing molecules biosynthesis. This database uses tools that convert 
text to tables and diagrams for the comprehensive analysis of pathways/genomes data.   
NCBI is a division of the United States National Library of Medicine–National Institutes of 
Health that houses major collections of biomedical databases. It provides extensive 
information on genomic and proteomic data on several thousands of organisms relevant to 
biomedicine and biotechnology. NCBI uses bioinformatics tools to access literature and data 
to analyse structure and function of biologically relevant molecules 
(http://www.ncbi.nlm.nih.gov/home/about/mission.shtml). NCBI Nucleotide, GenBank DNA 
sequence and BLAST and PubMed databases and other resources were used for the search of 
QS genes in K. pneumoniae and P. mirabilis relevant to this study.  
UniProt is a comprehensive database that contains high quality and easily accessible literature 
and data for the analysis of protein sequences and functions. In this study UniProt (Swiss–
Prot) was used in searching and confirming annotated protein sequences of QS genes. These 
protein sequences were further reverse–translated to generate nucleotide sequences that were 
input into BioCyc and NCBI for further analysis.  
Table 2.9 provides a summary of the keywords used in searching for QS and associated genes 








Table 2 –9 Summary of search for QS and related genes in 3 databases 
Search Keywords Target genes Database 
“Autoinducer–1 in Pseudomonas 
aeruginosa” 
lasI/rhlR NCBI, UniProt 
“Autoinducer–2 in Vibrio harveyi” luxS, luxA, luxLMN NCBI, UniProt 
“Autoinducer–2 in Klebsiella pneumoniae” luxS NCBI, UniProt 
“Autoinducer–2 binding–protein in 
Klebsiella pneumoniae” 
lsrB NCBI, UniProt 
“Autoinducer–2 in Proteus mirabilis” luxS NCBI, UniProt 
“Biofilm regulator protein in Proteus 
mirabilis” 
bssS/bssR NCBI, UniProt 
 
BioCyc was used to illustrate the biosynthetic pathway responsible for the AI–2 biosynthesis 
in both test strains. Similar searches were carried out for the control strains. All major 
enzymes identified in the pathways were selected for PCR amplification.  
2.8.7 Determination of QS genes by PCR and DNA sequencing 
Primers were designed to target and amplify specific quorum sensing genes in P. aeruginosa 
which are involved in biofilm formation (Table 2.10). They included the autoinducer 1 (AI–
1) synthase gene, lasI, and the transcriptional regulator gene, rhlR, responsible for the 
expression and regulation of the las/rhl QS system in P. aeruginosa (Lopez et al., 2010). 
Primers were also designed for the amplification of QS genes responsible for AI–2 
biosynthesis in K. pneumoniae and P. mirabilis DFU strains as well as in V. harveyi NCIMB 
1280 and NCIMB 1872 control strains. Other PCR amplifications targeted the biofilm 








Table 2 –10 Primers for QS PCR and their respective PCR programmes 
Primer name Sequence Programme 
lasI–F 5’– CAT CTG GGA ACT CAG CCG TT–3’ Initial denaturation at 94°C 
for 4:50 minutes, followed 
by 27 cycles each of 94°C 
for 50 seconds, annealing at 
57°C for 30 seconds and 
elongation at 72°C for 1 
minute, then finished with 10 
minutes elongation at 72°C 
(Patriquin et al., 2008). 
lasI–R 5– AGC GTC TGG ATG TCG TTC TG–3’ 
rhlR–F 5’– GAA ATG GTG GTC TGG AGC GA–3’ 
rhlR–R 5’– TCA CCG TGC TCT CGG AAA TG–3’ 
PluxS–F 5’– TTT GCG GGT TTC ATG CGT AA–3’ Initial denaturation at 95°C 
for 30 seconds, followed by 
30 cycles each of 95°C for 
30 seconds, annealing at the 
temperatures* stated below 
(footnote of table) and 
elongation at 72°C for 1 
minute, then finished with 10 
minutes elongation at 72°C. 
 
PluxS–R 5’–TCT TCC ATA GCT GCC TTC CA–3’ 
PbssS–F 5’–ACA CAT CCT GTT GTA GGC TGG–3’ 
PbssS–R 5’–GCA TTG TCT GGA TGG TGT TCG–3’ 
KluxS–F 5’–GTA TCC ACA CCC TGG AGC AC–3’ 
KluxS–R 5’–TTC GTC GTT GCT GTT GAT GC–3’ 
KlrsB–F 5’–GTG AAA GTC CTG ACC TGG GA–3’ 
KlrsB–R 5’–CTT TGG CTT CCT TCA CCC AC–3’ 
VluxA–F 5’–TGT TAT GTC GTC GCG GAG–3’ 
VluxA–R 5’–ACG GAG GTG ATG TAA GCC AA–3’ 
VluxLMN–F 5’–GGC GAC AAG AAA ACA CCA GT–3’ 
VluxLMN–R 5’–ATC AAA CAC CAA CAC CGA GC–3’ 
VluxS–F 5’–ACC TAC GTT TCA CTG CTC CA–3’ 
VluxS–R 5’–TAG TAC GTC TTC CAT CGC GG–3’ 
*Ta (°C) – annealing temperatures for all PCRs (except lasI and rhlR) in their respective 
order:  52.3°C, 54.8°C, 56.4°C, 55°C, 55°C, 52.3°C and 55°C. 
2.9 Effects of wound dressings on biofilms formed by diabetic foot isolates  
The aim of this study was to determine the antimicrobial effects of wound dressings in 
inhibiting biofilm formation or eradicating them. Two sets of assays were performed. First, a 
selection of wound dressings was tested against the representative strains K. pneumoniae and 
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P. mirabilis in their planktonic and biofilm states. The second set of assays evaluated the 
combined effects of wound dressings and antibiotics on K. pneumoniae and P. mirabilis 
biofilms. 
2.9.1 Inhibition of biofilms by wound dressings (6–well plate assay)  
In this assay, 3 wound dressings with antimicrobial properties namely; Acticoat® (ACT) and 
Silvercel® (SIL, silver–impregnated), and Medihoney™ Apinate (MDA, honey–
impregnated) were tested for their ability to inhibit biofilm formation. According to the 
manufacturers, the antimicrobial efficacy of silver in ACT and SIL is between 20 – 40 ppm 
while Medihoney™ is made of 100% Manuka honey. A 4th dressing called Atrauman (ATR) 
with no antimicrobial properties was used as a control. The assay was performed according to 
the methods described by Percival et al. (2007) and Wright et al. (1998). Wound dressings 
were aseptically cut (in a UV irradiated chamber) into circular shapes (2 cm in diameter). 
Clinical strains, K. pneumoniae and P. mirabilis, were inoculated in Mueller–Hinton broth 
and incubated overnight. Bacterial cell suspension of 108 CFU/mL of each strain was 
prepared and inoculated on each dressing in excess (1 mL) MH broth in a 6–well plate and 
incubated over 3 time periods; 30 and 60 minutes and 24 hours (Wright et al., (1998). 
Bacteria were recovered in sodium thioglycolate solution (STS) after their respective 
incubations times. STS was prepared by adding 0.85% w/v NaCl, 1% v/v Tween 20, and 
0.1% w/v sodium thioglycolate to distilled water to make 1 litre solution. The STS bacterial 
mixture was then vortexed and their OD600 determined using a spectrophotometer (Jenway, 
Bibby Scientific Ltd, UK). At least 3 replicates of the assay were performed and the results 
for OD600 readings were presented as means (±SEM) at 95% confidence interval. The OD600 
readings were plotted in a graph and percentage inhibition of K. pneumoniae and P. mirabilis 
biofilm phenotypes determined at the selected assayed times. 
2.9.2 Inhibition of biofilm by wound dressings – standard agar method 
This assay was performed to determine the effect of wound dressings on quasi–biofilms using 
a standard agar technique. Quasi–biofilms are semi-sessile state biofilms that express 
phenotypes different from clinically relevant biofilm phenotypes and may not express outer 
membrane proteins when grown on standard nutrient agar (Gilbert et al., 1998). Biofilm 
extracts of K. pneumoniae and P. mirabilis were resuspended in 1X PBS to a final 
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concentration of 108 CFU/mL. Mueller–Hinton agar (MHA) plates were pre–inoculated with 
1 mL of each biofilm extract and incubated at 35–37°C for 30 minutes. Circular shaped 
dressings which were pre–moistened with sterile PBS were placed in the middle of the plates 
and incubated overnight at 37°C. After 24 hours, zones of inhibition (ZOIs) developed 
around each dressing after overnight incubation was measured by means of a pair of callipers 
or measuring rule. At least 3 replicates of the assay were performed and the results for ZOI 
measurements were presented as means (±SEM) at 95% confidence interval. A graph of ZO1 
was plotted to determine the extent of inhibition in the presence of each wound dressing 
against K. pneumoniae and P. mirabilis biofilm phenotypes. 
2.9.3 Combined effects of antimicrobial wound dressings and antibiotics on 
biofilms 
In this assay, the combined effects of wound dressings (Acticoat®, Silvercel® and 
Medihoney™ Apinate) and antibiotics (ceftazidime and levofloxacin) in the inhibition of K. 
pneumoniae and P. mirabilis biofilms were evaluated using the standard agar method. In 
addition to MHA plates, Kolliphor® P 407 (a type of poloxamer hydrogel) gels were used to 
grow biofilms in the presence of wound dressings and antibiotics. Poloxamer hydrogels and 
its derivatives such as Kolliphor® P 407 gel (used in this study), are made up of a di–block 
co–polymer of polyoxyethylene and polyoxypropylene (Wirtanen et al., 1998). In aqueous 
state, they show thermo–reversible gelation and remain liquid at temperatures below 15°C 
and become robust gels at temperature above 15°C (Gilbert et al., 1998; Wirtanen et al., 
1998). The ability of poloxamer gels to support biofilm growth has been explained in section 
6.1. This assay was performed according to the method described by Percival et al. (2007) 
with some modifications.  
Stock solutions of ceftazidime (CAZ) and levofloxacin (LEV) were prepared and added to 
biofilm extracts (previously prepared with final broth suspension of 108 CFU/mL) of K. 
pneumoniae and P. mirabilis to final concentrations of 256, 512, 1024 and 5120 µg/mL. One 
microliter volumes of the bacteria–antibiotic suspensions were pre–inoculated on MHA 
plates and 30% (w/v) Kolliphor® P 407 gel plates and incubated at 37°C for 30 minutes to 
dry. Wound dressings aseptically cut into circular shapes (2 cm–diameters) were placed on 
the agar and poloxamer gel plates and incubated at 37°C for 24 hours. ZOIs produced by the 
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3 antibacterial dressings after 24 hours were measured and compared with a control dressing 
(Atrauman (ATR); with no antibacterial activity). At least 3 replicates of the assay were 
performed and the results for ZOI measurements were presented as means (±SEM) at 95% 
confidence interval. A graph of ZO1 was plotted to determine the combined inhibitory effect 
of each wound dressing/antibiotic pair against K. pneumoniae and P. mirabilis biofilm 
phenotypes on  
2.10 Data analysis 
All assays were repeated up to 3 times and their averages determined where necessary. All 
data for assays performed in this study were statistically analysed using GraphPad Prism 
(version 5) to determine P values and establish correlation between data sets. All graphs were 
plotted using GraphPad Prism. For biofilm and persister cell isolation assays, linear 
regression and two–way ANOVA were mostly performed with test of significance limit set at 
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Diabetes mellitus (DM) is one of the major global health concerns with an estimated 415 
million people worldwide living with the disease (both types 1 and 2) by the end of 2015 
(International Diabetes Federation, 2015). The World Health Organisation (WHO) has 
predicted an increase in the global trend of the disease with cases estimated to double in the 
coming years. It has been predicted that about 642 million people would be suffering from 
DM by the year 2040 (International Diabetes Federation, 2015). The International Diabetes 
Federation (IDF) has also projected that the number of DM cases in Sub–Saharan Africa is 
expected to increase from 14.2 million (in 2015) to 34.2 million (in 2040) in line with global 
predictions (International Diabetes Federation, 2015). However, the major burden of diabetes, 
about 80% of cases, is borne by DM patients in developing countries (Chen et al., 2012). 
Also, the incidence/prevalence of the disease among different age groups differ with the 
number of cases among middle–aged diabetics in developing countries being more than in 
developed countries (Shaw et al., 2010).  
Current data (for the year 2014) on DM in Ghana held by the International Diabetes 
Federation are based on comparative estimations from data presented by neighbouring 
countries (Agoudavi et al., 2012; Assah et al., 2011; Ministry of Health Botswana and World 
Health Organization, 2007; Van Der Sande et al., 1997). These comparative estimations 
assume that every country and region have the same age profile (Figure 3.1). The 
comparative and national prevalence estimates were recorded as 3.3 and 3.8% respectively 
(International Diabetes Federation, 2014). This is because data on DM cases in Ghana have 
been very scanty since 2002 when the last ‘crude’ prevalence rate (6.3%) was established 
(Amoah et al., 2002). A recent study by Danquah et al, (2012) characterised type 2 DM 
among Ghanaians with respect to their socioeconomic status and other complications such as 
hypertension and albuminuria and suggested hypertension as a complication in most DM 
cases. It has been estimated that more than two–thirds of people living with diabetes in sub–
Saharan Africa are undiagnosed (International Diabetes Federation, 2015). Ghana like other 
African countries has a higher number of undiagnosed diabetics who are only found at 
screenings (Evaristo–Neto et al., 2010). The current study presented here is the first to 
investigate the prevalence of the disease and one of its major complications, diabetic foot 




Figure 3 .1 Comparison of DM prevalence in Ghana to Africa and rest of world. (Image 
Source: International Federation of Diabetes (IDF), IDF Diabetes Atlas 6th edition, 2014. 
Available from: http://www.idf.org/membership/afr/ghana. Data used with permission). 
The risk of developing foot ulcer increases in people living with advanced diabetes, 
accompanying complications include peripheral neuropathy, vascular disease, history of 
ulceration with foot deformities, limited movement of the joint, trauma to the foot and 
abnormal plantar foot pressure (Boulton, 2004). The development of Charcot foot (also 
known as neuropathic osteoarthropathy) is a progressive condition accompanied by 
pathologic fractures with severe destruction to the architecture of the foot and joint 
dislocation which may result in amputation (Frykberg et al., 2015; Jude and Boulton, 1999). 
The presentation of DFUs has been well characterised and elaborated in previous studies 
(Barshes et al., 2013; Boulton, 2015; Gardner et al., 2013; Frykberg et al., 2015; Rathur and 
Boulton, 2007). The risk of developing DFU among people living with diabetes has been 
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established as 15–25% (Frykberg et al., 2015). The current global and regional trend of DM 
suggests an increase in the prevalence of DFU in developing countries. However, the risk of 
developing a foot ulcer has also been found to be associated with ethnicity (Lavery et al., 
1998; Toledano et al., 1993; van Schie et al., 2011).  For example some studies carried out in 
the UK suggest that people of Asian subcontinent origin are less likely to develop foot ulcers 
and/or undergo amputation than Caucasians (Abbott et al., 2002; Boulton, 2015). With 
respect to the regional differences in the manifestation of DM and DFU, it is therefore 
important that prevalence of DM and DFU is established in every country and region in line, 
hence the Ghanaian study. 
It has been estimated that about half of DFU cases are clinically infected at presentation often 
with complex pathophysiology (Lavery et al., 2006). Asumanu et al. (2010) and Lavery et al, 
(2006) have suggested in separate works that DFU accounts for most diabetes–associated 
hospital admissions. The definition of the microbiome or the microbial bioburden colonising 
DFUs is very important in establishing the role of these bacteria in impaired wound healing. 
Microbial bioburden of chronic wounds is an interplay of 3 factors namely; microbial load, 
microbial diversity and presence of potential pathogens (Spichler et al., 2015). Traditionally, 
the first step in estimating the microbial burden of chronic wounds is by culture methods 
which normally support the growth of non–fastidious bacteria rather than slow–growing ones 
such as anaerobes (Bowler et al., 2001; Gardner et al., 2013). Some studies have suggested 
that critical colonisation usually defined as >105 colony forming units (CFU) per gram of 
host tissue is indicative of wound infection that impairs healing (Cutting and White, 2005; 
Gardner et al., 2009; Richard et al., 2011). However, culture–based assays underestimate the 
bioburden of DFUs (Bowler et al., 2001; Gardner et al., 2013). It has been established that 
there is no association between critical colonisation (determined by standard bacterial culture 
assays), quantitative bacteriology and impaired wound healing and the presence of an 
infection (Gardner et al., 2013; Spichler et al., 2015). It has rather been suggested that 
clinical infection is as a result of the presence and interactions of some specific bacteria and 
their acquisition of virulence factors (Richard et al., 2011).  
The use of molecular techniques has revealed that chronic wounds are polymicrobial, with 
more genetically distinct bacterial population than previously thought to be (Dowd et al., 
2008b; Spichler et al., 2015). Genetically distinct bacteria in diabetic foot infections (DFI) 
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have been found to produce a synergistic community of pathogenic bacteria called a 
functional equivalent pathogroup (FEP) that maintain the chronicity of wounds (Dowd et al. 
(2008b). The use of molecular biology based methods that incorporate analysis of the 16S 
rRNA gene has allowed the taxonomic classifications of these pathogroups. The methods 
include denaturing gradient gel electrophoresis (DGGE), temperature gradient gel 
electrophoresis (TGGE), PCR, pyrosequencing, and multitarget PCR (Lavigne et al., 2015; 
Salipante et al., 2013). These methods are superior to culture based assays as they allow the 
determination of the microbial population and their biodiversity. They also allow the 
phylogenetic identification of all bacteria present in the microbiome. In one such study, 
Gardner et al. (2013) identified several bacterial species belonging to 13 different phyla 
including Firmicutes (Gram–positives), Actinobacteria (Gram–positives), Proteobacteria 
(Gram–negatives), Bacteroidetes (Gram–negative aerobes and anaerobes) and Fusobacteria 
(Gram–negative anaerobes). However, the bacterial ecology of DFIs has been found to be 
affected by the interplay of environmental, hygienic and cultural concerns pertaining to a 
geographical region (Spichler et al., 2015). It is therefore important for healthcare providers 
to be familiar with the microbial population in their geographical settings with respect to 












3.2 Aims and Objectives 
Diabetes mellitus is a global health issue with significant public health interest. The disease 
and its associated complications, especially the diabetic foot ulcer, have been well studied. 
Extensive studies have also been performed to characterise the microbial flora and population 
in diabetic foot ulcers (Dowd et al., 2008b; Gardner et al., 2013; Lavigne et al., 2015; 
Salipante et al., 2013; Spichler et al., 2015). However, there is growing need for further 
studies on DM and DFU among patients in developing countries as they bear the greater 
burden of the disease in terms of its global distribution. The aim of this chapter is to study the 
epidemiological pattern of the disease as well as the microbial burden of diabetic foot ulcer 
among diabetics attending the Diabetes Centre at the Komfo Anokye Teaching Hospital, 
Kumasi, Ghana. In order to address the epidemiological concerns of DM and DFU in Ghana, 
the following objectives were considered; 
 Determination of the prevalence rates and the demographic distribution of DM and 
DFU at KATH, Kumasi, Ghana. 
 Wound sampling and classification of DFUs among DM patients attending the 
Diabetes Centre, KATH, Kumasi, Ghana. 
 Isolation and identification of the microbiome of DFUs using culture–based and 
molecular biology techniques such as PCR and DNA sequencing. 
 Determination of antibiotic susceptibility patterns of all identified isolates.  








3.3 Wound sampling and classification of diabetic foot ulcers 
All participants recruited for this study were sampled once. In all, 356 foot ulcers were 
sampled among 49166 diabetic patients who attended the Diabetes centre at KATH from 
January 2011 to December 2014. All samples were characterised (Table 3.1) with respect to 
the point of collection; whether at the out–patient department (OPD) or in the ward (in–
patient). Participants whose samples were collected at the OPD and later admitted into the 
clinical wards were exempt from subsequent sampling. 
Table 3 –1 Number of DFU samples and point of collection 
Year Out-patient cases In–patient cases Total 
2011 33 21 54 
2012 55 32 87 
2013 39 74 113 
2014 55 47 102 
Total 182 174 356 
 
3.3.1 Prevalence of diabetes and foot ulcers at KATH, Kumasi, Ghana 
During the period of the current study, a four–year data on the attendance of diabetic patients 
to the Diabetes centre, KATH was collated with the help of the Statistics Unit, KATH. The 
corresponding data on diabetic foot ulcers among the diabetic cases were also collated from 
the Clinical Microbiology Department. The distribution of DM and DFU cases recorded 
during this period was further categorised in terms of sex to determine the frequency of the 
cases among male and female subjects (Table 3.2). 
The results show that DM was more prevalent in women than in men (72% and 28% 
respectively). There were at least 42% more women each year who presented with DM than 
men. Throughout the 4–year period of this study, there were 43% more women who were 
diagnosed and/or were receiving treatment for DM at the centre than men. With respect to 
DFU 61% of women were diagnosed compared to 39% of men. With the exception of the 
year 2014, (when there were 5.8% more women with DFU than men) there were at least 27% 
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more women with foot ulcers than men from 2011 to 2013. In all, there was 22% more 
women diagnosed and/or were receiving treatment for foot ulcer than men. It was also 
observed that the number of DM cases among male subjects decreased steadily over the 4–
year period with an average of 2.23% per year and a total of 6.7% at the end of the study 
period. A similar downward trend was observed among female subjects with an average of 
1.74% per year and a total of 5.2% decrease by the end of 2014 (Table 3.1). On the other 
hand, the number of DFU cases increased steadily over the 4–year period with a total of 21% 
and 8.8% among male and female subjects respectively. However, the number of DFU cases 
among female subjects decreased by 14.3% (72 to 54) from 2013 to 2014 (Table 3.2). In all, 
there was 13.5% increase in the number of DFU cases (both male and female subjects) by the 
end of the study period.   
The difference between the numbers of male and female subjects diagnosed and/or receiving 
treatment for DM and DFU at KATH was statistically significant (p < 0.01, at α = 0.05) using 
two–way ANOVA. 
Table 3 –2 DM and DFU cases among male and female subjects, KATH from 2011 to 2014 
 
Year 
DM Cases  
Total 
DFU cases  
Total Male Female Male Female 
2011 4002 9784 13786 19 35 54 
2012 3551 9248 12799 31 56 87 
2013 3273 8294 11567 41 72 113 
2014 3070 7944 11014 48 54 102 
Total 13896 35270 49166 139 217 356 
  
According to the 2010 Population and housing Census (Ghana Statistical Services, 2013) the 
Ashanti region has an estimated population of 4.8 million people representing 19.4% of the 
total population (24.6 million) of Ghana. Records at the KATH show that an average of 
54,000 patients per year attends the hospital. This is about 9000 greater than those in 2006 
recorded by the Statistics unit, KATH. From Table 3.3, the average number of DM cases for 
the four–year period of this study can be calculated as 12292. Therefore, the prevalence rate 
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of DM among patients who attended KATH from 2011 to 2014 was 22.8%. Adult prevalence 
rate (excluding the ≤ 24 age group) was estimated as 22.1%. Assuming all DM patients who 
attended the diabetes centre are residents of the Ashanti region, the estimated prevalence rate 
of DM cases in the region can be calculated as. 0.3%. Though this might not be a true 
reflection of the exact prevalence rate in the region, it is important to mention that, data from 
KATH covers a wider catchment area of Ghana. The prevalence rate of DFU among the DM 
cases seen at KATH, Kumasi, Ghana for the four–year period can be estimated as 0.7%.  
The number of DM and DFU cases were also considered in terms of the age groups 
associated with the disease (Tables 3.3 and 3.4). The median age group for both DM and 
DFU cases was 35–44 years. The mean ages for DM and DFU patients were estimated as 
56.3 and 50.3 years respectively. Most of the diabetic patients in Table 3.3 (41.3% of cases) 
were within the 45–59 age group followed by the ≥ 60s age group (35.6%) and 35–44 years 
(14.5%).  Diabetics belonging to the ≤ 24 age group contributed the least number of DM 
cases (1399) representing 2.8% of cases. 
Table 3 –3 Age and sex distribution of DM cases 
Age Groups 
 ≤ 24 25 – 34 35 – 44 45 – 59 ≥ 60  
Year/Sex M F M F M F M F M F Total 
2011 181 285 217 630 575 1423 1619 4065 1410 3381 13786 
2012 176 253 254 631 527 1351 1375 3906 1219 3107 12799 
2013 129 165 164 462 474 1272 1347 3601 1160 2793 11567 
2014 80 129 115 389 379 1108 1148 3228 1348 3090 11014 
Total 566 832 750 2112 1955 5154 5489 14800 5137 12371 49166 
 
Table 3.4 illustrates that, there were more DFU cases in diabetics of 60 years and above 
representing 39.9% of cases followed by those between 45–59 years (32.8% of cases). 
Diabetics likely to have least number of ulcers were those belonging to the ≤ 24 age group 
(2.2% of cases). Interestingly, the number of DFU cases among the ≥ 60 male subjects 
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increased steadily from 7 in 2011 to 9 in 2013. There was however a sharp increase from 9 in 
2013 to 24 in 2014. There were however inconsistent trends in the number of DFU cases 
recorded in the other age groups over the 4–year period of the study.  
Table 3 –4 Age and sex distribution of DFU cases 
 
There was no statistically significant difference between the number of in–patient and out–
patient cases (Table 3.1) receiving treatment for DM at KATH (p = 0.76). However it is clear 
that the number of OPD to in–patient cases has varied over the last 4 years from a ratio of 
approximately 2:1 to 1:2 in 2012 and 2013 respectively. In 2011 and 2014, the number of 
OPD cases was 22.2 and 7.8% (respectively) more than in–patient cases. It is clear that there 
was no consistent trend in the number cases (OPD and in–patient) sampled each year 
throughout the 4 year–period of the study. A similar situation was observed when the number 
of bacterial isolates identified from ODP and in–patient samples was compared (Figure 3.2). 
There were more isolates (9 and 32) from OPD cases in 2011 and 2012 respectively than 
from in–patient cases. However, more isolates (39 and 9) were recovered from in–patient 
cases in 2013 and 2014 respectively than from OPD cases. There was no significant 
difference (p = 0.82) between the number in–patient and OPD cases. Though there were 8 
more OPD cases in total than in–patient cases, 7 more bacterial isolates were recovered from 
in–patient cases than OPD cases. 
Age Groups 
 ≤ 24 25 – 34 35 – 44 45 – 59 ≥ 60  
Year/Sex M F M F M F M F M F Total 
2011 0 1 2 2 3 4 7 9 7 19 54 
2012 0 1 1 2 8 15 14 18 8 20 87 
2013 1 4 3 0 3 10 25 27 9 31 113 
2014 0 1 6 8 6 16 12 5 24 24 102 
Total 1 7 12 12 20 45 58 59 48 94 356 
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Figure 3 .2 Number of isolates from OPD and In–patients DFU samples. There was no 
significant difference between the number of in–patients DFU and OPD cases (p = 0.82, 
column factor two–way ANOVA). 
Out of the 356 DFUs sampled throughout the period of the current study, only 38 of them 
collected between February and April 2013 were further classified according to Wagner’s 
ulcer classification grade system (Tables 3.5) which is based on the depth of penetration, the 
presence/absence of gangrene and the degree of tissue necrosis (Wagner, 1987).  
Table 3 –5 Distribution of ulcer types and bacterial isolates in 38 DFU 
Ulcer grade Frequency No. of isolates 
Superficial 7 9 
Deep 21 29 
Abscess osteitis 4 5 
Gangrenous foot 5 6 




3.4 Identification of clinical isolates and control strains 
The presence of bacteria in wound samples was confirmed by microbiological, biochemical 
and molecular biology techniques as described in section 2.2, chapter 2. Fifty bacterial 
species (members of the Proteobacteria group) isolated from 38 wound samples collected as 
part of the current study in Ghana were used as representative strains for further 
investigations. The speciation of these 50 bacterial strains was confirmed by 16S rRNA PCR 
and DNA sequencing (Figure 3.3 and Table 3.6). The resultant sequences were aligned with 
speciated strains in the NCBI databases using BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Bacteria identified included P. mirabilis (23) 
representing 46% was the most isolated strain followed by E. coli 12 (24%), Klebsiella 
species 6 (12%), K. pneumoniae 4 (8%), P. stuartii 2 (4%), P. aeruginosa 2 (4%) and C. 
koseri 1 (2%). The initial classification of some Klebsiella isolates was denoted as Klebsiella 
species as biochemical and 16S rRNA sequencing identified different species. API® 
identification denoted them as K. oxytoca as they were the nearest likely identification (based 
on classification hierarchy). 16S rRNA DNA sequencing identified them as K. variicola and 
K. pneumoniae respectively (as highlighted in Table 3.6) after BLAST analysis. Culture–
based assays such as the API® identification strip tests have been reported to have limitations 
in the accurate taxonomic identification for Klebsiella species (Alves et al., 2006). The API® 
identification system is based on the scoring of a panel of biochemical assays using a 
numerical system that identifies organisms from among 700 bacterial and fungal species 
deposited in the API®/ID32 databases (http://www.biomerieux–diagnostics.com/apir–id–
strip–range). The scoring of the API® test strip, which is based on positive and negative 
results of a panel of biochemical tests on the strip, generate a hierarchy of bacterial profiles 
from “through calculation of identification percentage and typicity index” 
(http://www.biomerieux–diagnostics.com/apir–id–strip–range). One of the limitations of 
bacterial identification using biochemical assays such as the API® system is the fact that 
several bacteria share similar biochemical profile which lead to taxonomic complexities 
(Alves et al., 2006; Westbrook et al., 2000). Culture–based methods were able to detect more 
than one species of bacteria in 63 (17.7% of cases) wound samples. The maximum number of 
isolates recovered from a single wound sample in this study was 2. The remaining samples 
produced single species of bacteria each.   
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Figure 3 .3 PCR amplification of the 16S rRNA V3 – V6 hypervariable regions. Lane M – 
100 bp DNA ladder; lanes 1 to 26 with the exception of lane 13 (negative control) represent 
amplified 586 base pairs partial 16S rRNA sequence of clinical isolates from 017 to 031 in 













Table 3 –6 Wagner’s ulcer classification of DFUs and identification of clinical isolates 
  DFI ID Description of ulcer Grade API® ID 16S rRNA ID 
001 Deep 2 P. mirabilis P. mirabilis 
002 Gangrenous forefoot 4 P. mirabilis P. mirabilis 
003a Deep  2 C. koseri C. koseri 
003b Deep 2 P. mirabilis P. mirabilis 
004 Superficial 1 P. mirabilis P. mirabilis 
005 Deep 2 P. mirabilis P. mirabilis 
006 Gangrenous forefoot 4 P. mirabilis P. mirabilis 
007 Abscess osteitis 3 P. mirabilis P. mirabilis 
008 Deep 2 P. mirabilis P. mirabilis 
009 Superficial 1 P. mirabilis P. mirabilis 
010a Deep  2 E. coli E. coli 
010b Deep 2 P. mirabilis P. mirabilis 
011 Superficial 1 P. mirabilis P. mirabilis 
012 Deep 2 E. coli E. coli 
013 Deep 2 E. coli E. coli 
014 Superficial  1 P. mirabilis P. mirabilis 
015 Superficial  1 E. coli E. coli 
016 Superficial  1 P. mirabilis P. mirabilis 
017 Deep 2 E. coli E. coli 
018a Gangrenous forefoot 4 P. mirabilis P. mirabilis 
018b Gangrenous forefoot 4 K. oxytoca K. variicola 
019a Gangrenous forefoot 4 E. coli E. coli 
019b Gangrenous forefoot 4 P. mirabilis P. mirabilis 
020 Deep 2 P. mirabilis P. mirabilis 
021a Deep 2 P. mirabilis P. mirabilis 




Table –3 6 Wagner’s ulcer classification of DFUs and identification of clinical 
isolates. Continued. 
  DFI ID Description of ulcer Grade API® ID 16S rRNA ID 
022a Superficial 1 E. coli E. coli 
022b Superficial 1 K. oxytoca K. pneumoniae 
023a Deep 2 K. oxytoca K. pneumoniae 
023b Deep 2 P. aeruginosa P. aeruginosa 
024 Deep 2 E. coli E.coli 
025a Deep 2 P. stuartii P. stuartii 
025b Deep 2 P. mirabilis P. mirabilis 
026 Deep (toe amputation) 2 P. mirabilis P. mirabilis 
027 Deep (foot amputation) 2 K. oxytoca K. pneumoniae 
028a Abscess osteitis 3 E. coli E. coli 
028b Abscess osteitis 3 K. pneumoniae K. pneumoniae 
029 Abscess osteitis 3 K. pneumoniae K. pneumoniae 
030 Abscess osteitis 3 E. coli E. coli 
031 Gangrenous forefoot 4 E. coli E. coli 
032a Deep 2 P. mirabilis P. mirabilis 
032b Deep 2 K. oxytoca K. pneumoniae 
033 Deep 2 P. mirabilis P. mirabilis 
034a Deep 2 K. pneumoniae K. pneumoniae 
034b Deep 2 P. mirabilis P. mirabilis 
035 Deep 2 K. pneumoniae K. pneumoniae 
036a Whole foot (both) 5 E. coli E. coli 
036b Whole foot (both) 5 P. stuartii P. stuartii 
037 Deep 2 P. mirabilis P. mirabilis 





In all 407 bacterial strains (Table 3.7) were isolated from 356 DFU samples from January 
2011 to December 2014. Bacteria isolated in Ghana were identified using the API® ID strip 
range of testing in the Clinical Microbiology department, KATH, Kumasi and the 
microbiology/molecular biology laboratory, University of Westminster, London. 
Uncultivable or slow growing bacteria if present in some of the DFU samples collected might 
have been undetectable by culture–based assay.  
Table 3 –7 Distribution of the number of different bacterial species in all 356 DFU samples 
Isolate 2011 2012 2013 2014 Total Freq. (%) 
Pseudomonas species 15 32 26 36 109 27 
Proteus species. 11 15 40 21 87 21 
Escherichia species 9 18 32 26 85 21 
Klebsiella species 7 12 21 21 61 15 
Staphylococcus species 8 5 10 8 31 8 
Others* 7 6 8 13 34 8 
Total 57 88 137 125 407 100 
* Others – Other microbes (8.0%) isolated included Enterobacter species, Citrobacter 
freundii, Bacillus species, Citrobacter koseri, Moraxella catarrhalis, Alcaligenes species, 
Bacillus species, coliforms, yeast cells and Providencia stuartii. 
3.4.1 Antibiotic susceptibility determination of DFU isolates 
The disc diffusion test interpreted using the British Society for Antimicrobial Chemotherapy 
(BSAC, 2015) and European Committee on Antimicrobial Susceptibility Testing (EUCAST, 
2014) methods for antimicrobial susceptibility testing indicates that co–trimoxazole (COT) 
was the least effective antibiotic as 86% (350) isolates were resistant followed by 
ampicillin/sulbactam 77% (312) and tetracycline 70% (286) respectively (Figure 3.4). 
Levofloxacin (LEV) was the most effective quinolone as it was effective against 65% (264) 
of clinical isolates followed by the tazobactam/piperacillin 64% (263) ciprofloxacin 62% 
(253) respectively. Table 3.8 provides more details on the antibiotic susceptibility testing of 




Table 3 –8 Antibiotic susceptibility pattern of all clinical isolates 
 
Antibiotics 
Susceptibility patterns of DFU isolates 
Sensitive Intermediate Resistant 
Ampicillin/sulbactam, 20 µg a 20 (5%) 75 (18%) 312 (77%) 
Cotrimoxazole 25 µg 10 (2%) 47 (12%) 350 (86%) 
Cefotaxime, 30 µg 60 (15%) 68 (16%) 279 (69%) 
Tazobactam/Piperacillin, 100/10 µg 263 (64%) 36 (9%) 108 (27%) 
Chloramphenicol, 30 µg 65 (16%) 85 (21%) 257 (63%) 
Ciprofloxacin, 5 µg 253 (62%) 33 (8%) 121 (30%) 
Tetracycline, 30 µg 23 (6%) 98 (24%) 286 (70%) 
Ceftazidime, 30 µg 181 (44%) 89 (22%) 137 (34%) 
Ofloxacin, 5 µg 199 (49%) 70 (17%) 138 (34%) 
Gentamicin, 10 µg 81 (20%) 139 (34%) 187 (46%) 
Amikacin, 30 µg 124 (30%) 162 (40%) 121 (30%) 
Levofloxacin, 5 µg 264 (65%) 30 (7%) 113 (28%) 
a – antibiotic disc concentration.  
The antibiotic susceptibility pattern in Figure 3.4 shows that there were 17.7% more resistant 
cases than there were sensitive cases. However, the increase number of resistance cases was 
not statistically significant (p = 0.25) when compared to the number of sensitive cases. 
According to British Society for Antimicrobial Chemotherapy, an antibiotic is clinically 
intermediate when its therapeutic effect is uncertain, can effectively treat an infection by an 
isolate at body sites where the antibiotic is highly concentrated or can create a buffer zone 
when administered by preventing small, uncontrolled or other bacterial antibiotic invasive 







































Figure 3 .4 Antibiotic susceptibility patterns of all DFU isolates. According to Wilcoxon 
Signed Rank test (α =0.05), the relationship between the antibiotic susceptibility patterns of 
DFU isolates was statistically insignificant (p = 0.25). 
Figure 3.5 (below) illustrates the relationship between the susceptibility patterns of two 
antibiotics against OPD and in–patient strains of K. pneumoniae and P. mirabilis. In all there 
were 175 ODP and in–patient K. pneumoniae and P. mirabilis strains that were sensitive to 
CAZ and LEV compared to 119 strains that were resistant to CAZ and LEV. There were 7 
(5.9%) more OPD strains that were resistant to CAZ and LEV than in–patient strains and the 
difference was found to be statistically significant (p < 0.0001). Similarly, there were 9 
(5.1%) more OPD strains of K. pneumoniae and P. mirabilis that were sensitive to CAZ and 
LEV than in–patient strains and the difference was found to be statistically significant (p < 
0.05). From the analysis of the susceptibility patterns of K. pneumoniae and P. mirabilis test 
strains to CAZ and LEV, 2 strains namely 028b K. pneumoniae and 005 P. mirabilis were 
subsequently selected as representative strains for further investigations in the course of this 
study. K. pneumoniae and P. mirabilis were chosen for further studies in order to establish 
whether their dominance in DFUs samples in the Ghanaian study cohort and relative 
susceptibility to ceftazidime (an extended beta-lactamase inhibitor) and levofloxacin (a 
fluoroquinolone with good tissue permeability and DNA topoisomerase and gyrase B 
inhibitor) make them suitable models to study and understand biofilm formation and quorum 
































































































Figure 3 .5 Comparison of the susceptibility patterns of OPD K. pneumoniae and P. mirabilis 
strains and in–patient K. pneumoniae and P. mirabilis strains. The difference between the 
number of OPD K. pneumoniae and P. mirabilis strains sensitive to ceftazidime and 
levofloxacin and in–patient K. pneumoniae and P. mirabilis strains sensitive to ceftazidime 
and levofloxacin was statistically significant (*p < 0.05). The difference between the number 
of OPD K. pneumoniae and P. mirabilis strains resistant to ceftazidime and levofloxacin and 
in–patient K. pneumoniae and P. mirabilis strains resistant to ceftazidime and levofloxacin 
was statistically significant (**p < 0.0001). 
3.5 Phylogenetic studies of clinical isolates from DFUs 
Before the construction of a tree of relatedness (phylogram), the chromatograms of all 
sequenced DNA were carefully observed for high quality reads and misreads using the 
GATCViewer 1.00 software (errors) (Figure 3.6). All sequences were retrieved from the 
chromatograms and saved as ‘FASTA’ (fas) files which can be used to submit sequences to 
either NCBI BLAST or MEGA6 for further analysis. Sequences with misreads (errors) were 
trimmed by removing all the misread base pairs prior to use. The construction of dendogram 
was preceded by multiple sequences alignments. All 16S rRNA DNA sequences were 
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collected in a FASTA text format and analysed with MUSCLE alignment tool in MEGA6 to 
generate a multiple sequence alignment (Appendix C1).   
 
Figure 3 .6 Chromatogram showing partial genome sequence of a 16S rRNA gene with base 
pairs. Arrowed peaks and base pairs (represented as – NNNNNNNN) indicate error readings 
(misread) of the first 15 base pairs of the sequence. 
The tree of relatedness was constructed using the Neighbor–Joining method (Saitou and Nei, 
1987). Phylogenetic analysis was subsequently carried out to study the ancestral relatedness 
of all 50 strains belonging to the Proteobacteria group. MEGA6 bioinformatics software was 
used to construct a Neighbor–Joining phylogenetic tree using 16S rRNA DNA gene 
sequences of all identified strains (Figure 3.7). The branches of the phylogenetic tree were 
divided into six regions namely; A (1 and 2), B, C, and D (1 and 2), based on either 





Figure 3 .7 Phylogenetic tree of 16S rRNA relatedness of clinical isolates using the 
Neighbor–Joining method (Saitou and Nei, 1987). The optimal tree with the sum of branch 
length = 6.53474913 is shown. The tree is drawn to scale, with branch lengths in the same 
units as those of the evolutionary distances used to infer the phylogenetic tree. The 
evolutionary distances were computed using the Maximum Composite Likelihood method 
(Tamura et al., 2000) and are in the units of the number of base substitutions per site. The 
analysis involved 50 nucleotide sequences. All positions containing gaps and missing data 
were eliminated. There was a total of 34 positions in the final dataset. Evolutionary analyses 










The aim of this chapter was to study the epidemiology of diabetes and foot ulcers among 
patients attending the Diabetes Centre at the Komfo Anokye Teaching Hospital, Kumasi, 
Ghana. However due to scanty data retrieved from recruited participants, this chapter was 
dedicated to study the prevalence of DM and DFU among patients that attended KATH 
during the period of samples collection.  
KATH is the second largest teaching hospital in Ghana with a current total bed capacity of 
1200. Currently the average yearly OPD attendance at KATH has been estimated to be 
54,000 including 20,239 children. The hospital is centrally located and caters for about half 
of the population of Ghana with its catchment area including the Ashanti, Brong Ahafo, 
Northern, Upper East and Upper West, Central, Eastern, Volta and some sections of the 
Western regions. This makes it ideal for such an important study. This is the first time the 
epidemiology of diabetes and DFU have been studied in this part of Ghana. The statistical 
data and demographics provided by the Ghana Statistics Services (GSS) make the Ashanti 
region a perfect location for studies that can make projections for national recommendations. 
Data on the epidemiology of the disease in Ghana and Africa are scanty. This study will 
therefore provide data and recommendations for future work in line with global forecast of 
the disease.   
One of the aims for this study was to collate enough data to establish the current prevalence 
of DM and DFU among patients attending KATH, Kumasi, Ghana. The current prevalence 
rate established by the IDF was calculated based on comparative studies with other 
neighbouring developing countries due to lack of data in Ghana (Agoudavi et al., 2012; Baldé 
et al., 2007; Ministry of Health and Benin, 2007; Ministry of Health Botswana, 2007; Van 
Der Sande et al., 1997). The diabetes prevalence rate of 22.8% among 54000 patients, 
estimated in the current study is the first to be established at KATH, the second largest 
teaching hospital in Ghana. However, a number of factors affected the high prevalence rate 
established by this study. One such factor is the population from which the participants were 
drawn. Unlike Amoah et al. (2002), who conducted a cross–sectional study based on random 
selection and recruitment of study participants from some communities based on 
recommendation by the Ghana Statistics Service, the participants for the current study, were 
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made up of a hospital–based controlled population whose diabetes statuses were already 
known. They included both old and newly diagnosed cases who regularly attended the 
diabetes centre at KATH. Another factor was the age range for enlisting participants onto 
both studies. Amoah et al. (2002) recruited participants who were ≥ 25 years whilst the 
current study recruited participants who were ≤ 24 to 60 years and over. This is because the 
current study was intended to establish a prevalence rate not only for the adult population but 
also for juveniles living with the disease. A third factor that might have contributed to the 
increased current prevalence rate was the fact that some of the DM participants recruited for 
the current study might have been referral cases from other part of the country including, 
Brong Ahafo, Eastern and Northern regions. Finally, participants’ information collated for the 
current study was inconclusive which could have provided a more precise exclusion – 
inclusion criterion for eliminating biases in sampling. Some of these factors can be 
considered in the future to increase precision and provide a more accurate analysis of data.  
DM was found to be about 2.5 times more prevalent in Ghanaian women than in men (72% 
and 28% respectively). Similar trends have been found in previous DM studies in Ghana 
(Amoah et al., 2002; Darkwa, 2011; Owiredu et al., 2008). In other studies, in Mauritius, 
India and China, DM was also found to be more prevalent in women than in men (Agrawal 
and Ebrahim, 2012; Magliano et al., 2010; Yang et al., 2010). However, the prevalence of the 
disease among men and women in developed countries like the UK and the USA are slightly 
higher in men than in women (Centers for Disease Control and Prevention, 2014; Centers for 
Disease Control and Prevention, 2015; Diabetes in the UK, 2012). It has also been found that 
a complex combination of genetic and environmental factors as well as social deprivation 
make DM about six times more common among people of South Asia descent and about 
three times more common in people of African and African–Caribbean lineage than 
Caucasians (Chen et al., 2012; Diabetes in the UK, 2012). In the case of Ghana, it can be 
suggested that, the risk of developing DM is about 2.5 times higher in women than in men. 
The higher number of DM cases among Ghanaian women may be due to physical inactivity, 
obesity, unemployment, illiteracy and probably genetic predisposition (Chen et al., 2012; 
Danquah et al., 2012; Wild et al., 2004). According to Danquah et al. (2012), illiteracy and 
other independently associated factors such as unemployment, crowded living conditions and 
living on the outskirts of town/cities or in villages with little or no access to information on 
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healthy living or adequate healthcare have been found to contribute to the increase in DM 
cases among Ghanaians.  
Age–standardised prevalence of DM was found to be highest among the 45 – 59 age group 
representing 41.3% of cases (Table 3.4). Similarly, observations have previously been 
reported in Ghana (Amoah et al., 2002; Darkwa, 2011; Owiredu et al., 2008) and elsewhere 
in Africa (Evaristo–Neto et al., 2010; Evaristo–Neto et al., 2012; Kyari et al., 2014; Nyenwe 
et al., 2003; van der Sande et al., 1997). The above–mentioned findings correlate with the 
global trend of the disease in developing countries as predicted by the WHO (King et al., 
1998; Zimmet et al., 2001; International Diabetes Federation, 2013). Urbanisation, 
acculturation, obesity, aging and physical inactivity have been linked to increase in DM 
prevalence among this age group (Wild et al., 2004). However, the age group associated with 
the highest prevalence in developed countries like the UK and USA is the 60 – 79 years’ 
group (Centers for Disease Control and Prevention, 2014; Centers for Disease Control and 
Prevention, 2015; Diabetes in the UK, 2012). This is possibly due to difference in life 
expectancy between the developing and the developed countries. In Ghana, the estimated life 
expectancies at birth for males and females are from 60.2 – 62 and 63.4 – 64 respectively 
(Ghana Statistical Service, 2013; World Health Organisation, 2013). In developed countries, 
however, life expectancies for males and females are 79 and 81 respectively (Ediev, 2011; 
World Health Organisation, 2013).  
On the other hand, DFU was more prevalent among diabetics who were 60 years and above 
(Table 3.5). In Ghana, most people belonging to this age group are peasant farmers or 
pensioners who live alone. They normally do not get help with the proper management of 
their diabetes hence the increase in DFU among them. Some of them also live in the country 
and have no access to health care or attend regular diabetes reviews at their designated health 
centres (Danquah et al., 2012, Ministry of Health Ghana, 2013). Lack of properly managed 
community healthcare or wound nursing has also aggravated the situation (Ministry of Health 
Ghana, 2013). 
The low prevalence (0.7%) of DFU established among diabetics recruited for this study is a 
significant achievement as far as global prevalence and predicted increases are concerned 
(Singh et al., 2005; International Diabetes Federation, 2015). The current global prevalence 
ranges from 4 – 27% (Abbott et al., 2002; Bakri et al., 2012; Nathan et al., 2008; Richard and 
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Schuldiner, 2008; Yazdanpanah et al., 2015). It has been found that foot ulcers are less 
common in Asians and Afro–Carribeans living with DM (Abbott et al., 2005) hence the low 
prevalence in Ghanaian patients. Credit must also be given to the Nurse–in–charge and other 
staff at the Diabetes Centre, KATH who have embarked on a DFU sensitisation and 
awareness programme for the past 5 years called ‘I want my leg back.’ The programme has 
also contributed to the low DFU prevalence recorded especially in 2011 and 2012 among 
patients accessing the centre (Table 3.4). Like DM, DFU was more prevalent in diabetic 
women (61%) than in men (39%) unlike in developed countries where it is more common in 
men than in women (Boulton, 2015).  
It has previously been mentioned in section 1.1.3 that DFU contributes to most hospital 
admissions among DM patients in Ghana with concomitant amputations and even death 
(Asumanu et al., 2010).  In this study, however, the number of OPD DFU cases was slightly 
higher (2.2%) than in–patient cases. Though the ratio of total OPD DFU cases to in–patient 
DFU cases over the 4 year–period of the study was approximately 1:1 (51.1%: 48.9%), their 
combined prevalence (0.7%) was significantly low with respect to global predictions and 
trend of the disease. There is a consensus that the more OPD DFU cases there are, the better 
the management and prognosis of the ulcers. On the other hand, the higher the number of in–
patient DFU cases the higher the risks of amputation and/or death (Asumanu et al., 2010; 
Setacci et al., 2009). High risks of amputation and death among DFU patients in the 
nosocomial setting are mainly due to colonisation and infection of these chronic wounds by 
multidrug resistant bacteria that resist treatment and subsequently impair wound healing 
(World Health organisation, 2002; World Union of Wound Healing Societies, 2008).  
It was also observed that, the number of in–patient and out–patient DFU samples with 
multispecies bacteria (maximum of 2 bacterial species per sample) were 37 and 26 pairs 
respectively. The recovery of more clinical isolates from in–patient DFU samples in the work 
presented here could be due to a number of factors including acquisition from other infected 
wounds in the ward (World Health Organisation, 2002). Others include from the infected 
hands of healthcare staff providing wound care, use of infected wound dressing equipment 
and from the microflora of surrounding skin or the healthcare environment (Cruse and Foord, 
1980; Orrett et al., 1998; World Health Organisation, 2002). Bacterial colonisation of DFUs 
in wound care units poses a threat to other patients with open wounds as they may also be 
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colonised and become reservoir hosts for the transmission of multidrug resistant pathogens 
(Dzidic and Bedeković, 2003; Mayon–White et al., 1998). Lack of infection control measures 
can lead to widespread nosocomial infection and the dissemination of hospital–acquired 
antibiotic resistant bacteria into the community on the discharge of in–patients into the 
communities (Dzidic and Bedeković, 2003; Popovich et al., 2008; Setacci et al., 2009). The 
conglomeration of nosocomial and community–acquired resistant pathogens in the same 
ecological niche could provide the environment for the transfer of multidrug resistance genes 
and the widespread of multidrug resistant infections. 
The work present here observed that the Proteobacteria group was the dominant bacteria 
(Table 3.6) constituting more than 90% of all clinical isolates identified. The Proteobacteria 
group has previously been found as major constituents of the microbiome of DFIs and are 
among the dominant bacteria in deep wounds (Gardner et al., 2013; Malik et al., 2013). For 
example, Gardner et al. (2013) were able to establish that the presence of Proteobacteria in 
deep wounds was associated with the increased duration of ulceration and the presence of a 
dominant species. They also established Staphylococcus species as the predominant species 
in superficial wounds because they have more oxygen to support their existence than in deep 
wounds which support the growth of mostly Proteobacteria and anaerobes. Out of the 38 
DFUs categorised in Table 3.2, 31 (82%) were deep wounds (including gangrenous forefoot 
and abscess osteitis). Although all 38 wounds yielded 50 bacterial isolates belonging to the 
Proteobacteria group (Table 3.7), the relationship between wound depth, duration and their 
microbial diversity could not be established in the current work presented. This is due to the 
fact that no data was collated on the duration of ulcers. It can therefore be assumed that most 
of the remaining 318 DFU samples which were analysed by the staff at the Clinical 
Microbiology Department, KATH, Kumasi, Ghana were probably from deep wounds as they 
produced more than 90% bacterial species belonging to the Proteobacteria group. However, 
this assumption cannot be proven as there is no data evidence to support it.  
The recovery of bacteria from the wounds sampled in the current study yielded growth 
corresponding to ≥ 105 CFU/mL. However, there was not enough evidence such as the 
characterisation of clinical factors like neuropathy, ulcer duration and glycaemic control to 
effectively establish the microbial bioburden of infected foot ulcers. The microbial burden, 
which is a function of microbial load, diversity and presence of functional equivalent 
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pathogroups, has been associated with impaired wound healing and amputation (Dowd et al., 
2008b; Gardner et al., 2014; Spichler et al., 2015). However, culture–based methods that 
mostly support the growth of non–fastidious bacteria have underestimated the microbial 
burden of DFIs (Bansal et al., 2008; Gardner et al., 2013; Lipsky et al., 2013). As a result, 
molecular–based techniques such as 16S rRNA–based assays like DGGE, TGGE and 
pyrosequencing have been widely employed to establish the microbial bioburden of DFIs 
(Gardner et al., 2013; Lavigne et al., 2015; Salipante et al., 2013). 16S rRNA–based assays 
such as 16S rRNA PCR amplification (Figure 3.3) and DNA sequencing (Figure 3.6) have 
also enabled the species–specific identification of the whole microbial diversity of DFIs using 
bioinformatics tools such as Neighbor–Joining, Fitch–Margoliash, Maximum–Parsimony, 
Maximum–Likelihood and Minimum–Evolution methods that allow the study of the 
evolutionary relationships between the microbiome of DFUs (Saitou and Imanishi, 1989). 
DFUs with high microbial burden lead to increased amputation, morbidity and mortality. 
Though this study did not fully investigate microbial burden of DFUs, it is probably 
sufficient to suggest that there was a relationship between microbes colonising DFUs and the 
presentation of clinical factors among DFU patients sampled in this study.  
The distribution of bacteria in infected DFUs in a population, geographical location or 
treatment centres depends on a number of factors including the presence of dominant 
bacterial species in that region, the ecology of the wounds, host immune response and 
antibiotic selective pressure (Bansal et al., 2008; Spichler et al., 2015). The microbiological 
profiles of DFUs sampled in this study have been summarised in Tables 3.6 and 3.7. The 
microbiological profile identified included Gram–negative and Gram–positive strains 
belonging to two main phyla; Firmicutes (Bacillus and Staphylococcus species.) and 
Proteobacteria (all the Gram–negative strains). Similar findings were also observed in 
separate works carried out in Kuwait, Southwestern Nigeria and North and South India 
(Abdulrazak et al., 2005; Ako–Nai et al., 2006; Shankar et al., 2005; Zubair et al., 2011). 
Unlike the studies conducted in Ghana and other developing countries, a similar study 
conducted in Lisbon, Portugal, identified less than 30 % of Proteobacteria from DFUs 
(Mendes et al., 2012). Candida albicans was the only eukaryotic organism identified in the 
Ghanaian study. The presence of yeast cells in DFIs has been associated with Wagner’s 
grades 3, 4 and 5 DFUs with attendant osteomyelitis (Enderle et al., 1999; Levin, 1998; 
Spichler et al., 2015). Although most of the wounds sampled in the present study were 
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categorised as Wagner’s wound grades 3, 4 and 5 wounds, Candida species was not 
determined in any of them. 
The results from the current study suggest that the relative abundance of bacterial species like 
P. aeruginosa, P. mirabilis, E. coli and K. pneumoniae in the wounds of Ghanaian DFU 
patients can be attributed to the fact that they are ubiquitous and mostly found in 
environmental habitats, on the skin as normal flora, on solid surfaces and as nosocomial 
bacteria and their ability to perpetuate opportunistic infections (Grice and Segre, 2012; Misic 
et al., 2014; Persson, 2010). The preponderance of members of the Enterobacteriaceae in the 
microbial ecology in Ghanaian DFU cases may be due to factors such as the indiscriminate 
use of antibiotics, which leads to selection of antibiotic resistance, as well as lack of proper 
maintenance of environmental and personal hygienic conditions. Similar conditions have 
been found to account for the high prevalence of Gram–negative pathogens in infections in 
developing countries like India (Malik et al., 2013; Rawat et al., 2012). In other studies, the 
dominant bacterial species isolated from DFIs were Gram–positive aerobes especially 
MRSA, coagulate negative Staphylococcus and other Streptococcus species (Citron et al., 
2007; Lipsky et al., 2004). Their presence in DFUs either as single species or in a consortium 
(called FEPs) with other species has been associated with clinical factors such as 
microvascular disease, peripheral vascular disease neuropathy and hyperglycaemia, impaired 
wound healing and amputation (Gardner et al., 2013; Malik et al., 2013; Spichler et al., 
2015).  
In this study, the susceptibility patterns of clinical isolates to some of the commonly used 
antibiotics for treating DFIs at KATH were evaluated (Table 3.8). Antibiotic resistance 
ranged from 27–77% (108 to 312 isolates) while sensitivity was from 2–65% (10 to 264 
isolates). Though the difference between the number of antibiotic sensitive and resistant 
bacteria (Figure 3.4) was not statically significant (p = 0.25) by Wilcoxon Signed Rank test, 
it is clinically a worrying scenario. The current study also compared the antibiotic 
susceptibility patterns of OPD and in–patient strains of K. pneumoniae and P. mirabilis 
(Figure 3.5) to 2 third generation   cephalosporin and fluoroquinolone antibiotics (ceftazidime 
and levofloxacin respectively) commonly used in Ghana. Though antibiotic resistance among 
OPD K. pneumoniae and P. mirabilis strains was 5.9% more than in–patient strains (for both 
antibiotics tested), the difference between the total number of antibiotic sensitive and 
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resistant K. pneumoniae and P. mirabilis strains for both OPD and in–patient cases was 
statistically significant by two–way ANOVA; p < 0.0001. Also, there were more sensitive 
OPD and in–patient strains of K. pneumoniae and P. mirabilis (60%) than there were resistant 
strains (40%); a development which is good for the prognosis of DFUs infected with either K. 
pneumoniae or P. mirabilis or both. 
The recovery of wound pathogens with increased antibiotic resistance to first line antibiotics 
such as ampicillin, gentamicin and ciprofloxacin has been widely reported (Papasian and 
Kragel, 1997; Spichler et al., 2015). Ideally, the start of antibiotic regimen for the treatment 
of chronic infected wounds like DFIs should be empirically chosen, as microbiological 
analyses of clinically significant isolates and their antibiogram are important in confirming 
diagnosis and advising clinicians on the appropriate choice of antibiotic regimen (Bowler et 
al., 2001). Though the in vitro antibiotic susceptibility of clinical isolates may not directly 
relate to the prevailing clinical conditions in vivo, it contributes to the successful management 
of chronic wounds (Bowler et al., 2001). 
In Ghana and some other developing countries, the treatment of DFIs is mostly by the use of 
broad–spectrum antibiotics and wound dressings before microbiological tests are requested or 
reports released. This practice of prolonged antibiotic treatment leads to selective pressure on 
the microbial flora of the wound and the subsequent acquisition of resistance by some strains 
(Boulton, 2015). The failure of antibiotic treatment in some wounds may be compounded by 
the route of delivery such as systemic administration, which may be impaired by ischaemia 
and distal sensory neuropathy (Jeffcoate and Harding, 2003). The presence of biofilms 
colonising DFUs have also been found to impair wound healing and have increased 
resistance to antibiotics and other antimicrobials and sustained host defence mechanisms than 
planktonic cells (James et al., 2008; Lopez et al., 2010; Wolcott et al., 2008). A biofilm is a 
community of multicellular aggregates of bacteria or fungi (such as Candida species) 
enclosed in a self–produced extracellular matrix (James et al., 2008). Bacteria in biofilms 
have been reported to acquire resistance for various antibiotics through the horizontal transfer 
of genetic elements such as plasmids and transposons (Martinez and Silley, 2010; Murray, 
1991). The extracellular matrix also called extracellular polymeric substance has been 
described as a physical barrier that inhibits the penetration of antibiotics and large 
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antimicrobial proteins such a lysozyme and complement from the host immune system 
(Bjarnsholt et al., 2005; Lewis, 2001). 
The classification of the microbial diversity in the microbiome of infected DFUs is an 
important process in determining the microbiological profile of a given population or 
geographical area. The taxonomical relationships between members of the 
Gammaproteobacteria class of the phylum Proteobacteria have been well classified based on 
their 16S rRNA gene (also known as the small subunit (SSU) ribosomal RNA) and protein 
sequences (Chun et al., 2007; Williams et al., 2010). Other phylogenetic studies of this class 
of bacteria have reported that deep tree branches make it difficult to construct a large and 
well organised phylogenetic tree with good resolution using the 16S SSU ribosomal RNA 
(Gao et al., 2009; Wu and Eisen, 2008). Additionally, the validity of the tree interpretation of 
some SSU rRNA–based phylogenies has been challenged by the idea of horizontal gene 
transfer which is thought to take place during bacterial biofilm formation (Bapteste et al., 
2005). However, in the event where multiple bacterial protein families are shared by bacterial 
consortia in a biofilm, phylogenetic signals that represent trends of vertical inheritance have 
been detected (Puigbo et al., 2009). A phylogenetic signal has been defined as the tendency 
for microbial species that are related to resemble each other, more than they resemble species 
randomly drawn from a phylogenetic tree (Kamilar and Cooper, 2013). Though horizontal 
gene transfer is common among members of the Gammaproteobacteria class, the acquisition 
of a gene and its retention in the genome of the recipient depends on a strong positive 
selection for its functionality (Lerat et al., 2003; Ochman et al., 2000). However, the presence 
of a gene in the genome of the recipient homologous to the acquired gene makes the acquired 
gene an unlikely selection or redundant for its functions (Ochman et al., 2000). Despite the 
above–mentioned limitations in the use of 16S rRNA as a phylogenetic marker, it is still a 
useful tool to study the ecological diversity of microbial populations (Wu and Eisen, 2008).  
In the present study, sequence data from amplicons of the 16S rRNA of 50 clinical isolates 
were used to reconstruct a gammaproteobacterial phylogeny using the Neighbor–Joining 
method (Figure 3.7). To increase concordance and tree resolution, the tree of relatedness was 
focused on the genera of two major families; Enterobacteriaceae and Pseudomonadaceae of 
the Gammaproteobacteria class. The purpose of the SSU 16S rRNA reconstruction of the 
gammaproteobacterial phylogeny in this study was to demonstrate the microbial diversity of 
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the Ghanaian DFU ecology. The phylogeny of the 50 isolates demonstrates high degrees of 
convergent and divergent evolution among the strains. The P. aeruginosa strains labelled A1 
and A2 in Figure 3.7 have divergently evolved with low phylogenetic signal between them. 
The possible interpretation to these divergently related P. aeruginosa strains maybe due to 
the lateral acquisition of genes selected for their functions during the evolutionary process 
leading to high degree of differences between them (Kamilar and Cooper, 2013; Ochman et 
al., 2000). The 2 P. stuartii strains (labelled B) isolated from 2 different DFUs and from 2 
different subjects, a male and a female were 100% related. The observation of an apparent 
absolute convergent evolution with high phylogenetic signal between the 2 P. stuartii strains 
may be interpreted as phylogenetic conservatism characterised by low levels of evolutionary 
activities, pleiotropy (the influence of two or more phenotypic traits by a single gene) low 
rates of biotic interactions such as competition with other microbes for new niches and 
survival, high levels of gene flow (Bradshaw, 1991; Losos, 2008; Wiens, 2004; Wiens and 
Graham, 2005; Wiens et al., 2010). The tree region labelled C was made up of isolates with 
different degrees of convergent evolution from a common root (ancestor). This probably 
means they share similar traits such as pleiotropic genes that encodes for proteins responsible 
for moderate to high levels of antibiotic resistance or virulence (Losos, 2008). Also, the 
relative convergent relatedness between branches of the tree region labelled C (also members 
of the family Enterobacteriaceae) suggests that they can coexist in the same ecological niche 
with little or no competition (Wiens and Graham, 2005; Wiens et al., 2010). The branches of 
the tree labelled D1 show gradual divergence to the root of the tree. Though they are all P. 
mirabilis strains, they might have acquired other genetic elements from the environment but 
have retained a few of their ancestral genes over the years (Kamilar and Cooper, 2013). The 3 
different isolates in group D2; 012 E. coli, 018a P. mirabilis and 003a C. koseri demonstrate 
100% divergent evolution (leading to instability of the root) but are linked to ancestors of the 
C and A1 subgroups. Though these 3 species are divergently related members of the 
Enterobacteriaceae family, their ancestors may probably be related with some common traits 
shared between them (Kamilar and Cooper, 2013).  
The Gammaproteobacteria has been reported as one of the oldest bacterial taxonomic groups 
with one of the most ecologically diverse bacterial population including free–living species 
like Azotobacter, human pathogens like E. coli, P. aeruginosa, Vibrio and Salmonella 
species. as well as plant pathogens, such as Xanthomonas species (Lerat et al., 2003). Recent 
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development in molecular biology and bioinformatics has made it possible to sequence and 
publish the genomic DNA of many prokaryotes to enable large scale construction of 
evolutionary events using whole genome sequences (Chun et al., 2007; Gao et al., 2009; 
Lerat et al., 2003). The availability of large numbers of published genomic sequences and 
their taxonomic coverage will enable better examination of evolutionary relationships by 
pulling conserved sequences of large protein families together (Lerat et al., 2003; Wu and 
Eisen, 2008). Multiprotein approach of phylogenetic analysis has been found to provide more 
robust trees with better resolutions and details of phylogenetic signals that may suggest 
obvious vertical or lateral gene inheritance among the different isolates (Williams et al., 
2010). 
The presence of anaerobes such as Clostridium perfringens, Finegoldia magna, 
Peptostreptococcus anaerobius, Prevotella bivia, Propionibacterium acnes and 
Fusobacterium nucleatum has been found as one of the major contributors to impaired wound 
healing in DFU patients (Dharod, 2010; Dowd et al., 2008a; Dowd et al., 2008b; Gardner et 
al., 2013; Jauhangeer, 2006). Dharod (2010) and Jauhangeer (2006) in their separate works 
established P. bivia, P. acnes and F. magna as important pathogens in DFUs in an Indian and 
Mauritian cohort studies respectively. Due to lack of a dedicated anaerobic culture system at 
the site of sample collection in Ghana, anaerobes were not isolated and analysed in the 
current study. The presence of and relative abundance of facultative anaerobes such K. 
pneumoniae and P. mirabilis in non–healing chronic wounds such as DFUs has been well 
documented (Bowler and Davies, 1999; Bowler et al., 2001; Gardner et al., 2014; Grice and 
Segre, 2012; Martin et al., 2010). However, their contribution to the chronicity of wounds at 
the molecular level has not been well explored compared to other predominant Gram–
negative wound pathogens such as E. coli and P. aeruginosa (Costerton et al., 1999; Dowd et 
al., 2008a; Kokare et al., 2009; Lembre et al., 2012; Ling et al., 2015; Lopez et al., 2010). In 
the current study, the relative abundance of the combined total of Klebsiella and Proteus 
species. was 36% representing more than one–third of all bacteria isolated in this study. 
Against the backdrop of the relative abundance of Klebsiella and Proteus species and their 
antibiotic susceptibility to CAZ and LEV (Table 3.7 and Figure 3.3) 2 in–patient strains, 
028b K. pneumoniae and 005 P. mirabilis were subsequently selected as the main test strains 
for further investigations throughout the current study. In addition to their sensitivity to 
amikacin, ofloxacin, ciprofloxacin and tazobactam/piperacillin, 028b K. pneumoniae was also 
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completely sensitive to levofloxacin. On the other hand, 005 P. mirabilis was completely 
resistant to ceftazidime and intermediate resistant to levofloxacin in addition to being 
resistant to ofloxacin, ciprofloxacin and amikacin. It can therefore be suggested that, in line 
with the characteristics of K. pneumoniae and P. mirabilis mentioned in this chapter, such as 
their dominance in DFUs in the Ghanaian setting and their antibiotic resistance profiles, they 
can be employed as model strains just like previously used model strains, E. coli and P. 
aeruginosa (Lopez et al., 2010), to study biofilm formation in DFUs and the mechanisms 














Chapter 4  
The in vitro study and the effect of antimicrobial 











Diabetes–associated amputations have been found to be preceded by impaired wound 
healing, which is as a result of ischaemia, Charcot neuroarthropathy and foot ulcer with 
infection (Dowd et al., 2008a; Boulton, 2015). Loss of protective covering of skin means 
that, all open wounds are susceptible to bacterial contamination and subsequent colonisation 
from both endogenous and exogenous sources (Percival et al., 2015). Bacteria colonising 
chronic wounds like diabetic foot ulcers (DFUs) replicate and adhere to the wound beds 
without causing tissue damage (Dow et al., 1999; Edwards and Harding, 2004). Therefore, 
colonisation alone does not necessarily lead to impaired wound healing (Edwards and 
Harding, 2004). However, critical colonisation, which is the transition between colonisation 
and invasive wound infection and characterised by lack of progress towards healing, may 
progress to critical infection or invasive wound infection. Invasive wound infection normally 
stimulates host immune response and host (Edwards and Harding, 2004). The inability of the 
host to sustain effective immune response against the replicating bacteria leads to critical 
infection which is characterised by more than 105 colony forming units (CFU) of bacteria per 
gram of host tissue with accompanied virulence and pathogenicity (Wysocki, 2002).  Bacteria 
involved in critical colonisation of DFUs have been found to exist as polymicrobial 
communities called biofilms (James et al., 2008; Wolcott et al., 2008). Bacterial 
autoaggregation or coaggregation with other wound bacteria has been suggested as an 
important step that precedes biofilm formation (Hill et al., 2010; Rickard et al., 2003). 
Biofilm formation is a common trait by which bacteria and fungi adhere to solid surfaces 
(inert or living) and form structurally complex communities of multicellular aggregates 
enclosed in a self–produced extracellular matrix called extracellular polymeric substance 
(EPS). Percival et al. (2015) further noted that, in addition the virulence and pathogenicity of 
individual bacteria colonising DFUs, the presence of pathogenic biofilms plays a major role 
in impairing wound healing.  
It has been estimated that biofilms account for about 80% of all infections (Centers for 
Disease Control and Prevention, 2001; Davies, 2003; Percival and Cutting, 2009) and 85% of 
lower–limb amputations in biofilm–infected wounds among diabetics (Adler et al., 1999; 
Palumbo and Melton, 1985; Pecoraro et al., 1991). Evidence of biofilm in wounds has been 
well documented through in vitro studies over the past 2 decades. Animal studies using 
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mouse models have demonstrated Staphylococcus epidermidis and Staphylococcus aureus 
biofilms in wounds from biopsies taken 3 – 60 hours after wound inoculation (Gallimore et 
al., 1991; Akiyama et al., 1996). Similar studies confirmed the presence of biofilms in 
experimental murine and porcine acute wounds (Rashid et al., 2000; Serralta et al., 2001). 
Serralta et al. (2001) made partial wounds on the back of experimental pigs which were 
inoculated with Pseudomonas aeruginosa and covered them with coverslips for 72 hours. 
Congo red stained coverslips of the 72–hours biofilms observed under the microscope 
revealed EPS matrix with embedded biofilms. In another study, Davies et al. (2008) observed 
S. aureus biofilms using light, scanning electron and epifluorescence microscopy from an in 
vitro porcine wound model. Laboratory mice and rats with induced diabetes have been 
employed to study impair wound healing when challenged with P. aeruginosa (PA01) (Zhao 
et al., 2010). In human clinical studies, James et al. (2008) was able to demonstrate the 
presence of biofilms from tissue biopsies in chronic wounds using scanning electron 
microscopy.  
Other in vitro methods used to study biofilms include the microtitre plate (MTP) assay and its 
derivatives to quantitatively estimate biofilm biomass formed by isolates recovered from 
wounds or infections (Merritt et al., 2011; O’Toole et al., 1999; O’Toole, 2011; Stepanovic et 
al., 2001; Ceri et al., 1999; Sepandj et al., 2003; Bardouniotis et al., 2003; Harrison et al., 
2006; Tomlin et al., 2005). MTP–based assays enable the study of physiology and metabolic 
activities of biofilms as well as their quantitative analysis. For instance, the MTP–based 
assays have been used to study the effects of changes in environmental conditions such as 
nutrient concentration, temperature and pH on a growing biofilm (Cotton et al., 2009; Moller 
et al., 2008; Stapper et al., 2004; Cochran et al., 2000; Harjai et al., 2005). A derivative of 
the MTP–based assay called the Minimum Biofilm Eradication Concentration (MBEC™) 
assay, a high–throughput technique, enables the study of antimicrobial efficacy on biofilms 
formed on pegs of a standardised density (Ceri et al., 1999; Harrison et al., 2006; Tomlin et 
al., 2005).  
In addition to MTP–based assays, agar–based methods that incorporate staining with dyes 
such as Congo red, ethidium bromide, Calcofluor white and Ziehl carbol–fuchsin have also 
been used to demonstrate components within a developed biofilm such as 
exopolysaccharides, EPS and bacterial cells (Davies et al., 2008; Serralta et al., 2001). The 
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study of the effects of environmental conditions on a growing or developed biofilm has 
enabled the determination of optimum conditions for the identification of bacterial strains 
responsible for biofilm–associated infections (Uhlich et al., 2014). Jones et al. (2015) further 
suggested that pH determination of wounds could help in the identification and 
characterisation of non–healing wounds for effective treatment. This is because, a healthy 
skin has slightly acidic pH (4–6) whiles the presence of a wound disrupts the acidic 
environment of the skin resulting in a more neutral pH of about 7.4 (Schneider et al., 2007). 
Two separate studies have suggested that the treatment of wounds with nonpermeable 
dressings and solutions that induce acidic pH lead to quicker healing time than when treated 
at pH of 7.4 (Schneider et al., 2007; Wilson et al., 1978). Therefore, the regular 
determination of wound pH can distinguish between healing and non–healing wounds.   
In Ghana, the treatment for diabetic foot infections involves the administration of broad–
spectrum antibiotics such as the quinolones (ciprofloxacin and levofloxacin), and third 
generation cephalosporins such as cefotaxime and ceftazidime. Other antibiotics used are 
metronidazole, clindamycin and aminoglycosides such as gentamicin and tobramycin 
(Bonham, 2001; Nelson et al., 2006; O’Meara et al., 2000). Other treatment options include 
topical applications of biocides such as povidone iodine 0.25–0.5 % hydrogen peroxide 
(H2O2) which has been reported to kill bacteria in wounds, induce connective tissue 
formation and promote wound closure (Goldenheim, 1993; Loo et al., 2012).  Honey has also 
been a traditional salve for wounds for centuries (Ankra–Badu, 1992; Molan, 2006; Zumla 
and Lulat, 1989). However, biofilm–infected wounds have been found to have increased 
resistance to antimicrobials and sustained host defence mechanisms than planktonic cells 
(Lopez et al., 2010). For instance, the EPS acts as a diffusion barrier that inhibits the entry of 
antibiotics and other antimicrobials that target the bacterial cells embedded in the biofilm 
(Bjarnsholt et al., 2005; Lewis, 2001; Mah and O’Toole, 2001). In addition to the structural 
protection provided by the EPS to the biofilm community, other mechanisms have been 
found to be responsible for the antimicrobial resistance in the biofilm community. Brown et 
al. (1988) and Walters et al. (2003) in their separate works found that growth rate and 
nutrient deprivation in a growing biofilm were regulatory modulators fundamental to 
antibiotic activity which affect the susceptibility of bacterial cells to antimicrobial agents. 
Biofilm communities respond to environmental stresses such as low oxygen and nutrient 
levels which lead to reduced metabolic activities and low growth rates. The resultant 
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physiological changes lead to changes in bacterial cell envelope composition such as fatty 
acids, extracellular proteins, polysaccharides and envelope proteins (Brown and Williams, 
1985; Gilbert and Brown, 1978; Sutherland, 1982). Also, phenotypic changes of bacterial 
cells during biofilm formation leading to persister cell formation have been suggested to lead 
to antimicrobial resistance (Costerton et al., 1999). Other resistance mechanisms include 
quorum sensing (Gilbert et al., 2002; Haas et al., 2002), efflux pump expression (Brooun et 
al., 2000) and persister cells production (Keren et al., 2004; Lewis, 2007).  
The presence of resistant bacterial strains and persister cells in biofilms have been found to 
increase their susceptibility to antibiotics to about 100–1000 fold their minimum inhibitory 
concentrations (MICs) (Gilbert et al., 2002; Lewis, 2001; Lewis, 2007). The inhibition and 
eradication of biofilms and persister cells are topics which have engaged debates in the 
microbiology community over the past decade (Conlon et al., 2013; Gerdes and Ingmer, 
2013; Hurst et al., 2005; Keren et al., 2004; Keren et al., 2012; Lewis, 2001; Lewis, 2005; 
Lewis, 2007; Mah and O’Toole, 2001; Maisonneuve and Gerdes, 2014; Stewart, 2015; van 
Acker et al., 2014). Throughout these debates, suggestions have been put forward for 
consideration in terms of finding a mechanism for biofilm disruption. Some of the approaches 
include the study of persister genes, bacterial metabolism and growth rate, bacterial response 
to changes in micro–environmental condition and effect of antimicrobial challenge on the 
growing biofilm (Lewis, 2010; van Acker et al., 2014). With respect to persister eradication, 
Lewis (2010) suggested that the combination of a regular antibiotic with a compound capable 
of disabling the maintenance of persister cells could lead to the total disruption of biofilms. In 
line with the latter idea, Conlon et al. (2013) noted in their work that the combination of a 
cyclic peptide called acyldepsipeptide antibiotic (ADEP4) with a conventional antibiotic, 
rifampicin, completely eradicated Staphylococcus aureus biofilms in vitro. In their work, they 
introduced ADEP4 into the cytoplasm of S. aureus that activated and dysregulated the 
ubiquitous ClpP protease after binding to it. The ADEP4 – ClpP complex recognised and 
eliminated misfolded proteins in the growing biofilm thereby causing autolysis of the cells. 






4.2 Aims and objectives 
The role of biofilms in infections and especially in chronic wounds has been well 
documented as stated in section 4.1. The presence of biofilms in chronic wounds is of great 
concern when considering treatment strategies for implementation. Methods for estimation of 
biofilm formation and development in vitro of different clinical and environmental bacterial 
strains have also been well studied. However, two main issues are still outstanding as far as 
diagnosis of biofilm–infected wounds such a diabetic foot ulcers are concerned: the accurate 
quantitative estimation of biofilm in infections, and the presence of persister cells in biofilms 
(Hurst, 2005; Lewis, 2005; Lewis, 2007; Keren et al., 2012). The aim of this chapter is to 
investigate biofilm formation among diabetic foot isolates using three different in vitro 
methods namely; the conventional 96–well microtitre plate assay, the MBEC™ assay and the 
Quasi–Vivo® system (Kirkstall, UK). This study will also consider the effect of antibiotics 
on Klebsiella pneumoniae and Proteus mirabilis biofilms which are the main representative 
test strains used in all assays (see Chapter 3, section 3.4 for more details). The following 
objectives will be considered in order to achieve the above aims;  
 To determine the growth characteristics of diabetic foot isolates and their ability to 
coaggregate. 
 To demonstrate in vitro biofilms formation and development and the production of the 
EPS. 
 To study the effect of biofilm formation under different environmental conditions 
 Isolation and characterisation of persister cells from planktonic and biofilm cultures 
of diabetic foot isolates. 
 Determination of MIC, MBC and MBEC using both conventional MTP and MBEC™ 
high–throughput. 
 Perform time–dependent killing assay on DFU isolates with some selected 




4.3 Growth curve of clinical strains K. pneumoniae and P. mirabilis 
The growth dynamics of test strains, K. pneumoniae and P. mirabilis together with E. coli 
NCTC 10418 reference strain, were monitored during the initial lag and log phases (0–5 and 
5–12 hours respectively) and then the stationary and decline phases (12–18 and 18–24 hours 
respectively). Though the growth phases were only monitored for some selected time period, 
which were 1, 2, 3, 4, 5, 12, 18 and 24 hours, of the 24–hour period, it was observed that the 
test strains and the reference strain, E. coli NCTC 10418, have similar growth pattern (Figure 
4.1). The estimation of bacterial biomass at the selected time points showed increases in 
biomass from 5.7 x 107 to 15.0 x 108 CFU/mL for E. coli NCTC 10418; 6.7 x 107 to 23.81 x 
108 CFU/mL for K. pneumoniae; and from 5.8 x107 to 22.41 x 108 CFU/mL for P. mirabilis 
with corresponding increases in OD600.  The growth curve analysis of the test strains was 
helpful in the dilution of cultures and estimation of inoculum sizes for subsequent assays in 
this study.   



















Figure 4 .1 Growth curve for biofilm–producing test strains K. pneumoniae and P. mirabilis 
and reference strain E. coli NCTC 10418.
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4.4 Coaggregation assay 
All 8 DFU isolates demonstrated their ability to form both intra– and inter–species 
aggregates. Using the visual scoring system based on visual examination of coaggregation 
with the eye, the degree of coaggregation was from 1+ to 3+. No isolate recorded a 0 or 4+ 
score either in autoaggregation or pairwise coaggregation assay after 2 hours of incubation. 
All isolates except C. koseri, recorded 3+ score at some point, either in an autoaggregation or 
with a coaggregation pair (Table 4.1). Selective coaggregation was not evident but 001 P. 
mirabilis and 015 E. coli formed more definite visible (2+) and large (3+) intra– and 
interspecies aggregates 2 hours post–incubation (Table 4.1).  The autoaggregation and 
coaggregation score (intra– and interspecies respectively) for the remaining 6 isolate was 
from 1+ to 3+.   



















1 003a C. koseri 1+a 2+ 2+ 2+ 1+ 1+ 2+ 1+ 
2 001 P. mirabilis  2+ 2+ 2+ 2+ 2+ 3+ 2+ 
3 015 E. coli   2+ 2+ 2+ 3+ 2+ 2+ 
4 038 P. aeruginosa    2+ 3+ 3+ 1+ 1+ 
5 025a P. stuartii     3+ 3+ 2+ 1+ 
6 021b K. pneumoniae      3+ 1+ 3+ 
7 005 P. mirabilis       3+ 2+ 
8 028b K pneumoniae        2+ 
* − Coaggregation score (scale from 0 – 4) according to the visual scale described by Cisar et 
al. (1979) reported as; 0 – no visible aggregates; 1+ − small uniform aggregates; 2+ − 
definite visible aggregates without settling in suspension; 3+ − large aggregates settling 
easily leaving a turbid supernatant fluid; 4+ – large aggregates with clear supernatant which 
settles immediately after vortex.  
a – autoaggregation controls (emboldened) made up of equal volumes of bacterial suspension 
and coaggregation buffer. 
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Coaggregation scores were also recorded 24 hours after incubation (Table 4.2) to determine 
whether initial scores recorded 2 hours post–incubation had increased or reduced with time. 
The visual score for 3 pairs of coaggregation pair 003a C. koseri/005 P. mirabilis, 001 P. 
mirabilis/015 E. coli and 025a P. stuartii/021b K. pneumoniae decreased from 2+ to 1+ and 
3+ to 2+ respectively. Also, the 3 visual score for autoaggregation for 3 isolates, 025a P. 
stuartii; 021b K. pneumoniae; and 005 P. mirabilis decreased from 3+ to 2+. On the other 
hand, the visual score for 3 pairs of coaggregation pair 003a C. koseri/001 P. mirabilis, 001 
P. mirabilis/038 P. aeruginosa and 015 E. coli/038 P. aeruginosa increased from 2+ to 3+ 
respectively. 003a C. koseri/025a P. stuartii coaggregation pair also recorded an increase 
from 1+ to 2+ (Table 4.2).  
Quantitative coaggregation results are shown in the lower left half of Table 4.2 below the 
diagonal column. Quantitative autoaggregation/coaggregation results were calculated using 
the formula in section 2.3.4 in chapter 2 and expressed as a percentage. The percentage 
coaggregation estimated for the pairwise combination assays ranged from 8.3% to 53.4%. 
Autoaggregation/coaggregation percentages above 5% were regarded as positive (Shen et al., 
2005). In this study, none of the combination reactions was below 5%. The strongest 
combination reactions were between 038 P. aeruginosa–001 P. mirabilis (47.0%), 028b K. 
pneumoniae–021b K. pneumoniae (52.1%) and 038 P. aeruginosa–015 E. coli (53.4%). 
However, the corresponding visual score for the 3 strongest percentage coaggregation 










Table 4 –2 Coaggregation visual score* (after 24 hours) and percentage (%) coaggregation 
score (measured by a microtitre plate reader) described by Shen et al., (2005) for pairs of 
diabetic foot isolates. 
Isolate  003a   001  015  038  025a 021b  005 028b 
003a C. koseri 1+a 3+ 2+ 2+ 2+ 1+ 1+ 1+ 
001 P. mirabilis 32.7 2+ 1+ 3+ 2+ 2+ 3+ 2+ 
015 E. coli 23.6 15.0 2+ 3+ 2+ 3+ 2+ 2+ 
038 P. aeruginosa 21.6 47.0 53.4 2+ 3+ 3+ 1+ 1+ 
025a P. stuartii 15.9 23.8 21.4 31.3 2+ 2+ 2+ 1+ 
021b K. pneumoniae 28.2 32.3 23.5 38.4 19.2 2+ 1+ 3+ 
005 P. mirabilis 12.4 42.1 23.4 11.8 24.5 8.3 2+ 2+ 
028b K pneumoniae 19.2 26.3 30.4 15.1 9.2 52.1 19.6 2+ 
* – Coaggregation score scale description given in the footnote of Table 4.1. Highlighted 
scores show the difference between 2 and 24 hours readings. The scores in the diagonal grille 
indicate the autoaggregation visual score. The figures in the lower left half of the table (below 
the diagonal grille) represent the percentage coaggregation measured using a microtitre plate 
reader. The corresponding percentage (%) autoaggregation figures for the scores in the 
diagonal grille are as follows: 003a – 11%, 001 – 21%, 015 – 30%, 038 – 48.5%, 025a – 
24.8%, 021b – 44.8%, 005 – 48.0% and 028b – 22.0%.  
a – autoaggregation controls described in Table 4.1. 
4.5 Biofilm formation using the conventional microtitre plate assay (MTP) 
Normal conditions for growth and development of biofilm was overnight incubation (18 – 24 
hours) at a pH of 7.0 – 7.5, temperature of 37ºC and under aerobic condition. All the 3 media 
(LB, TSB/TSB + 0.25% glucose and BHI) used to grow the representative clinical and 
control strains supported their growth with little or no difference in their optical densities and 
growth curve analysis (results not presented). As a result, LB agar and broth were selected for 
subsequent assays. Selection of clinical strains for the biofilm assays was based on their 
coaggregation profiles and their presence in polymicrobial wounds. All clinical strains were 
found to be biofilm producers (Table 4.3). The quantification of biofilm biomass was carried 
out according to the classification described by Pye et al. (2013). In this study, however, the 
classification of bacterial isolates as biofilm producers was slightly adjusted to take into 
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account changes made in the technique used; which included growth media, number of 
washing steps, type of solubiliser and concentration used. Clinical isolates and control strains 
were classified as either, weak, moderate or strong biofilm producers based on the definitions 
outlined in section 2.4.1 in chapter 2. Out of the 11 selected strains, 9 produced biofilms > 
0.13 at OD570 (Table 4.3). 









0.05 ≤ OD < 0.13 
Moderate 
Producers (M) 




OD ≥ 0.25 
003a C. koseri 0.103 W*   
015 E. coli 0.102 W   
018b K. variicola 0.199  M  
021a P. mirabilis 0.179  M  
021b K. pneumoniae 0.179  M  
025a P. stuartii 0.25   S 
028b K. pneumoniae 0.286   S 
005 P. mirabilis 0.312   S 
038 P. aeruginosa 0.187  M  
NCTC E. coli  0.13  M  
NCTC S. aureus  0.140   S 
* − Definition of biofilm producers; W – Weak producers; M – Moderate producers; and S – 
Strong producers 
4.5.1 EPS production during biofilm formation 
The production of EPS by DFU isolates during biofilm formation was demonstrated and 
confirmed by 2 staining techniques. The stained slides were then visualised by 
epifluorescence microscopy that uses 2 filters to differentiate between stained 
polysaccharides and bacterial cells in the biofilm. In the first staining assay, the primary stain, 
Calcofluor White stained the polysaccharide matrix of the biofilm blue when viewed under 
the DAPI (4’,6–diamino–2–phenyindole) light filter (Figure 4.3A (i)). The secondary stain, 
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ethidium bromide which inserts between the double strands of nucleic acids stains the 
bacterial cells which appear red under fluorescent light filters (Figure 4.3A (ii)).  
The second confirmatory staining technique, Congo red and Ziehl carbol fuchsin dyes were 
used to stain the EPS. Under the DAPI filters, Congo red stains the polysaccharide matrix of 
the biofilm orange (Figure 4.3B (i)). The counterstain, Ziehl carbol fuchsin stained the 
































Figure 4 .2 Epifluorescence biofilm images of: (A) (i) P. mirabilis EPS stained blue by 
Calcofluor white and (ii) nucleic acids stained red by ethidium bromide; and (B) (i) K. 
pneumoniae polysaccharide stained orange by Congo red and (ii) bacterial cells stained 






4.6 Effects of environmental conditions on biofilm formation 
4.6.1 MTP assay for nutrient concentration, temperature and pH changes  
The ability of selected clinical strains to form biofilms was determined under both normal 
conditions and other environmental conditions such as changes in temperature, pH and 
nutrient concentrations. To determine the statistical significance of the environmental 
changes made with respect to pH, temperature and nutrient concentration of the growth media 
and growth conditions, the set changes were compared to normal conditions (i.e., at pH 7, 
37°C and full nutrient concentration). With the exception of 021a P. mirabilis, 028b K 
pneumoniae, 005 P. mirabilis and 038 P. aeruginosa which showed significant growth (p = 
0.0008) at pH 4 or 10 (pH 4 and 10 for 038 P. aeruginosa), all other isolates showed 
reduction in biofilm formation when the pH was either 4 or 10 (Figure 4.4A). Biofilm 
reduction at both pH 4 and 10 was statistically significant for 018b Klebsiella variicola and 
025a P. stuartii (p < 0.05). At pH 4, biofilm reduction for 021a P. mirabilis was statistically 
significant (p < 0.05).  
The incubation temperature of 26°C did not affect biofilm formation in 6 out of the 11 strains 
tested (Figure 4.4 C). They included 003a C. koseri, 021a P. mirabilis, 021b K. pneumonia, 
025a P. stuartii, 028b K. pneumoniae and 038 P. aeruginosa. The difference between biofilm 
growth among these 6 strains at 26ºC and 37ºC was not significant (p > 0.05). Biofilm 
formation in the remaining 4 isolates (015 E. coli, 018b K. pneumoniae, E. coli NCTC 10418 
and S. aureus NCTC 6571) at 26°C was decreased by about half compared to normal growth 
temperature at 37ºC (p < 0.05). When incubation temperature was set at 42ºC, biofilm 
formation by all 11 isolates was significantly decreased by half or less (p = 0.0001) (Figure 
4.4 C). 
When nutrient concentrations in growth media were reduced by two–fold dilution, there was 
minimal effect on biofilm development in the case of 003a C. koseri and 015 E. coli (Figure 
4.4 A). Biofilm development by 025a P. stuartii was decreased by one–third when nutrient 
concentrations were halved. In the cases of 028b K. pneumoniae and 005 P. mirabilis, the 
difference between biofilm biomass recovered at ½ and ¼ concentrations compared to the 












































































































































































































































































































































































Figure 4 .3 Changes in the microenvironment during biofilm formation: (A) Effect of changes 
in pH; (B) Effect of reducing nutrient concentrations; and (C) Effect of changes in incubation 
temperature on biofilm. Differences between the range of environmental conditions for 
example, high and low pH, high and low temperature and normal and reduced nutrient 
concentration in growth media were determined using two–way ANOVA (*p < 0.05; **p = 






4.7 Biofilm inhibition and eradication assays  
4.7.1 Determination of MIC, MBC and MBEC using the conventional MTP 
assay 
The efficacy of some selected antibiotics to inhibit and/or eradicate biofilm was tested on the 
K. pneumoniae (Figure 4.4A and B) and P. mirabilis (Figure 4.5A and B) respectively. 
Antibiotic selected for this assay included ampicillin (AMP), ceftazidime (CAZ), 
ciprofloxacin (CIP), gentamicin (GEN) and levofloxacin (LEV). A working concentration of 
5120 µg/mL for all antibiotics used was diluted in a two–fold dilution for the determination 
of MIC, MBC and MBEC (i.e., 5120, 2560, 1280, 640, 320, 160, 80, 40, 20 and 10 µg/mL). 
EUCAST antibiotic susceptibility testing breakpoints were used as guidelines for the 
interpretation of MIC data. For the purpose of this study, MIC and MBEC determinations 
using the conventional MTP biofilm assay were defined by percentage inhibition and 
eradication (respectively) of bacteria with OD570 ≤ 0.05 representing complete inhibition or 
eradication of biofilm.   
The efficacy of antibiotics in inhibiting K. pneumoniae and P. mirabilis biofilms ranged from 
44% to 75%; and from 59% to 71% respectively. Levofloxacin was the most effective 
antibiotic (75%) in significantly inhibiting K. pneumoniae biofilm formation (p = 0.0001) at 
an MIC ≥ 640 µg/mL (Figure 4.4 A, Table 4.4). Ceftazidime and ciprofloxacin also recorded 
efficacies of 70% at MIC ≥ 5120 and ≥ 1280 µg/mL respectively (Table 4.4). Ampicillin and 
gentamicin were the least effective with MIC > 5120 µg/mL against both K. pneumoniae and 
P. mirabilis (Tables 4.4 and 4.5). 
There was no observable growth on LB agar plates inoculated with samples from the selected 
wells that showed efficacy ≥ 70%. With the exception of LEV, the MBC values for all the 
other antibiotics against K. pneumoniae and P. mirabilis were > 5120 µg/mL. The MBC 
values for LEV against K. pneumoniae and P. mirabilis were 640 and 1280 µg/mL 
respectively. The MBEC values determined for all 5 antibiotics against both test strains were 
> 5120 µg/mL (Table 4.5).  However, the efficacy of LEV in eradicating 71% of K. 
pneumoniae and 70% of P. mirabilis biofilms was found to be statistically significant (p < 
0.0001) as shown in Figures 4.4B and 4.5B.  
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Figure 4 .4 Determination of MIC and MBEC of 5 selected antibiotics (ampicillin, 
ceftazidime, ciprofloxacin, gentamicin and levofloxacin) against; (A) K. pneumoniae 
planktonic cells (p = 0.0001) and (B) K. pneumoniae biofilms (p < 0.0001). P values were 




























Figure 4 .5 Determination of MIC and MBEC of 5 selected antibiotics (ampicillin, 
ceftazidime, ciprofloxacin, gentamicin and levofloxacin) against (A) P. mirabilis planktonic 
cells (p = 0.0002) and (B) P. mirabilis biofilms (p < 0.0001). P values were determined by 
two – way ANOVA. 
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Table 4 –4 Antibiotic efficacy of 5 antibiotics in inhibiting K. pneumoniae and P. mirabilis 
biofilms 
 Antibiotic (µg/mL) / Percentage inhibition (PI) (%) 
Bacterial strain AMP*/PI CAZ/PI CIP/PI GEN/PI LEV/PI 
K. pneumoniae > 5120 (44) ≥ 5120 (70) ≥ 1280 (70) > 5120 (58) ≥ 640 (75) 
 
P. mirabilis > 5120 (60) > 640 (65) > 1280 (65) > 5120 (59) ≥ 1280 (71) 
 
* − Antibiotic: AMP – Ampicillin; CAZ – Ceftazidime; CIP – Ciprofloxacin; GEN – 
Gentamicin; LEV – Levofloxacin. Percentage inhibition/reduction (PI/PR) values were 
calculated as outlined in section 2.4.3.7 in chapter 2. 
Table 4 –5 Antibiotic efficacy of 5 antibiotics in eradicating K. pneumoniae and P. mirabilis 
biofilms  
 Antibiotic (µg/mL) / Percentage reduction (PR) (%) 
Bacterial strain AMP*/PR CAZ/PR CIP/PR GEN/PR LEV/PR 
K. pneumoniae > 5120 (42) > 5120 (67) > 5120 (39) > 5120 (41) ≥ 5120 (71) 
     
P. mirabilis > 5120 (46) > 5120 (47) > 5120 (63) > 5120 (46) ≥ 5120 (70) 
 
* − Antibiotic: See footnote of Table 4.4 for details. 
The individual antibiotic efficacy of CAZ and LEV were tested against mixed biofilm of K. 
pneumoniae and P. mirabilis to determine their MIC and MBEC values as illustrated in 
Tables 4.6 and 4.7 respectively. The MIC and MBC of CAZ against mixed K. pneumoniae 
and P. mirabilis biofilm was > 320 µg/mL. However, the MIC and MBC of levofloxacin was 
estimated as ≥160 µg/mL and inhibited K. pneumoniae and P. mirabilis mixed biofilm by 
83%. The MIC assay plates were incubated up to 72 hours. There was however no significant 
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difference between the readings recorded over the 3 days’ period. This means that both 
antibiotics have sustained inhibitory effects on biofilm formation up to 72 hours. 
Table 4 –6 Antibiotic efficacy of CAZ and LEV in the inhibition of K. pneumoniae and P. 










Ceftazidime (320) 0.198 56 44 
Levofloxacin (160) 0.077 83 17 
Control (33% acetic acid) * 0 0 0 
* − Acetic acid (33%) was used as a control to blank the microtitre plate reader during all 
readings. OD570 of positive mixed biofilm was 0.452. Mean antibiotic activity and mean 
residual biofilm biomass were determined using the formulae given in section 2.4.3.7 in 
chapter 2.  
The individual antibiotic efficacy of CAZ and LEV to eradicate half or more of the mixed K. 
pneumoniae and P. mirabilis biofilm was found to be 320 and 160 µg/mL respectively (Table 
4.7). It was however observed that CAZ (320 µg/mL) had almost the same effect in inhibiting 
and eradicating K. pneumoniae and P. mirabilis mixed biofilm. In the case of LEV, it was 
found to be about 24% less active in the eradication of K. pneumoniae and P. mirabilis mixed 
biofilm but at half the efficacy of CAZ. 









biofilm biomass (%) 
Ceftazidime (320) 0.146 57 43 
Levofloxacin (160) 0.139 59 41 
Control (33% acetic acid) 0 0 0 
* − Acetic acid (33%): OD570 of positive mixed biofilm was 0.341. See footnote of Table 4.6 
for further details. 
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The combined antibiotic efficacy of CAZ and LEV were also tested against mixed K. 
pneumoniae and P. mirabilis biofilm in 2 separate assays to determine their combined 
inhibitory and eradication concentrations respectively (Tables 4.8. and 4.9). It was observed 
that the combined effect of CAZ and LEV at 160 µg/mL inhibited mixed K. pneumoniae and 
P. mirabilis biofilm by 76% (Table 4.8). The combined MIC and MBC were found to be > 
160 µg/mL. 
Table 4 –8 Combined effects of CAZ and LEV in inhibiting mixed biofilm of K. pneumoniae 











Levofloxacin (160) 0.098 76 24 
Control (33% acetic acid) 0 0 0 
OD570 of mixed biofilm was 0.409. There was no significant difference between assays 
incubated for 24 hours and 72 hours. See footnote of Table 4.6 for further details. 
It was also observed that the combined efficacy of CAZ and LEV at 640 µg/mL, tested 
against K. pneumoniae and P. mirabilis mixed biofilm eradicated only 39% of biofilm 
formed (Table 4.9). The combined MIC and MBC were found to be > 1280 µg/mL. 
Interestingly, it was observed that the individual antibiotic efficacy of CAZ (320 µg/mL) and 
LEV (160 µg/mL) were more effective (Table 4.7) in eradicating K. pneumoniae and P. 
mirabilis mixed biofilm than their combined efficacy (640 µg/mL) (Table 4.9). Similarly, 
LEV (160 µg/mL) was more effective in inhibiting K. pneumoniae and P. mirabilis mixed 







Table 4 –9 Combined effects of CAZ and LEV in eradicating mixed biofilm of K. 








biofilm biomass (%) 
Ceftazidime and 
Levofloxacin (640) 0.239 39 61 
Control (33% acetic acid) 0 0 0 
OD570 of mixed biofilm was 0.394. There was no significant difference between assays 
incubated for 24 hours and 72 hours. See footnote of Table 4.6 for further details. 
When the individual efficacy of CAZ and LEV were assessed on K. pneumoniae and P. 
mirabilis mixed biofilms, LEV at 160 µg/mL, significantly inhibited K. pneumoniae and P. 
mirabilis mixed biofilms 20% more than as individual strains (Table 4.6). On the other hand, 
there was no significant difference between the inhibition of K. pneumoniae and P. mirabilis 
individual biofilms (53 and 63% respectively) and K. pneumoniae and P. mirabilis mixed 
biofilm (56%) by CAZ at 320 µg/mL. Again, the MBEC of CAZ (320 µg/mL) needed to 
eradicate more than 50% of K. pneumoniae and P. mirabilis mixed biofilm (Table 4.7) was 8 
and 16 times (respectively) less than that needed by CAZ to eradicate 50% or more of K. 
pneumoniae and P. mirabilis individual biofilms. In the case of LEV, the MBEC (160 
µg/mL) needed to eradicate 50% or more of K. pneumoniae and P. mirabilis mixed biofilm 
was 2 and 4 times less than that needed by LEV to eradicate 50% or more of K. pneumoniae 
and P. mirabilis individual biofilms. 
Interestingly, the combined efficacy of CAZ and LEV at 160 µg/mL each (Table 4.8), 
inhibited K. pneumoniae and P. mirabilis mixed biofilm by 76%. LEV at the same 
concentration was 7% more effective whiles CAZ was less effective even at twice (320 
µg/mL) the concentration of LEV (Table 4.6). Also, the combined effects of CAZ and LEV 
(640 µg/mL each) could only eradicate 39% of the mixed biofilm (Table 4.9). The individual 
efficacies of CAZ (320 µg/mL) and LEV (160 µg/mL) were 18 and 20% more effective at 
MBEC 2 and 4 times lower respectively. 
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4.7.2 Determination of MIC, MBC and MBEC using the MBEC™ HTP assay 
In the MBEC™ assay, 2 of the 5 antibiotics (ceftazidime and levofloxacin) previously used 
in the conventional MTP assay (section 4.5.1) above were selected and used to challenge K. 
pneumoniae and P. mirabilis in a series of assays to determine their MIC, MBC and MBEC 
values (Table 4.11). CAZ and LEV were selected because they were more effective against 
K. pneumoniae and P. mirabilis biofilms than AMP, CIP and GEN. The results obtained in 
MBEC™ assay together with that obtained using the conventional 96–well MTP assay were 
compared. For the MBEC™ assay, MIC and MBEC determinations were defined as 
percentage inhibition and eradication/removal (respectively) of biofilm with OD650 < 0.1 
representing complete inhibition or eradication of biofilm after appropriate incubation period 
(Allan et al., 2011). The definition of MBC (i.e., the lowest concentration of antibiotic that 
can prevent the growth of bacteria after subculture onto media free from antibiotic) was 
maintained as described in section 2.4.2.2 (Andrews, 2001). However, MIC, MBC and 
MBEC values of at least 3 replicate assays were determined following the reading of 
absorbance at OD650 using a microtitre plate reader. 
















K. pneumoniae 7.78 7.0 7.0 7.90 
P. mirabilis 8.15 7.60 8.08 8.48 
 
Table 4.10 represents biofilm growth (positive) control estimated from 3 replicates (1 peg per 
plate). The average CFU/peg was calculated as 7.94 x 107 CFU/peg for K. pneumoniae and 
3.02 x 108 CFU/peg for P. mirabilis. The difference between biofilm growths on replicate 
pegs for both K. pneumoniae and P. mirabilis was found to be statistically insignificant (two–
way ANOVA; p = 0.224). This also means that, the pegs challenged during the MIC, MBC 
and MBEC assays formed equivalent biofilms across the rows.  
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The MIC, MBC and MBEC values of CAZ in inhibiting and/or eradicating K. pneumoniae 
and P. mirabilis biofilms were ≥ 5120 µg/mL (Table 4.11). However, the MIC of CAZ in 
inhibiting P. mirabilis biofilm was 640 µg/mL, 8 times lower than that against K. 
pneumoniae. Levofloxacin at MIC 40 µg/mL completely inhibited K. pneumoniae and P. 
mirabilis biofilm formation (Table 4.11). However, the MBC of LEV (2560 µg/mL) needed 
to completely prevent the growth of P. mirabilis was 8 times more than that (320 µg/mL) 
needed for K. pneumoniae.   
Table 4 –11 Residual K. pneumoniae and P. mirabilis biofilm (Log10 reduction) estimation 
after antibiotic challenge. MIC, MBC and MBEC values were expressed as percentage (%) of 














K. pneumoniae Ceftazidime ≥ 5120 (88) ≥ 5120 (83) > 5120 (37) 
Levofloxacin 40 (95) 320 (96) ≥ 5120 (84) 
P. mirabilis Ceftazidime 640 (80) 5120 (91) > 5120 (60) 
Levofloxacin 40 (90) 2560 (84) > 5120 (77) 
a – Definition of percentage Log10 reduction: PI – percentage inhibition; PC – percentage 
clearance; and PE – percentage eradication. Percentage Log10 reduction values were 
calculated as outlined in section 2.4.3.3 in chapter 2. 
It should be mentioned that the concentrations of antibiotics used to achieve the MIC, MBC 
or MBEC in the inhibition and/or eradication of K. pneumoniae and P. mirabilis biofilms 
using the MBEC™ assay were above the required therapeutic range for treatment of clinical 
conditions. The antibiotic therapeutic range for treatment of K. pneumoniae and P. mirabilis 
using CAZ and LEV are given as 0.125–4.0 mg/L and 0.25–4.0 mg/L respectively 
(EUCAST, 2014). 
In the MBEC™ assay, Log10 reduction (residual biofilm) estimations (Table 4.11) were made 
after the MIC, MBC and MBEC determinations of CAZ and LEV. The Log10 reduction 
estimates provide data on the extent of inhibition and/or eradication of K. pneumoniae and P. 
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mirabilis biofilms after antibiotic treatment. The MIC of LEV that completely inhibited 
individual K. pneumoniae and P. mirabilis biofilms was found to be 40 µg/mL; 10 times 
more than the reference MIC. However, neither CAZ nor LEV could completely eradicate 
biofilm at concentrations > 5120 µg/mL. The MBCs of LEV and CAZ that completely 
prevented the growth of K. pneumoniae and P. mirabilis determined at OD650 and by viable 
cell count on agar plate were 320 and 5120 µg/mL respectively.   
















K. pneumoniae CAZ ≥ 5120 70 > 5120 67 
 LEV ≥ 640 75 ≥ 5120 71 
P. mirabilis CAZ > 640 65 > 5120 47 
 LEV ≥ 1280 71 ≥ 5120 70 
 MBEC™ assay 
K. pneumoniae CAZ ≥ 5120 88 > 5120 37 
 LEV 40 95 ≥ 5120 84 
P. mirabilis CAZ 640 80 > 5120 60 
 LEV 40 90 > 5120 77 
* – Definition of percentage Log10 reduction: PI (%) – percentage inhibition; PR (%) – 
percentage reduction. Percentage Log10 reduction values were calculated as outlined in 
section 2.4.3.3 in chapter 2. 
In Table 4.12, it was observed that the MIC values of LEV for K. pneumoniae and P. 
mirabilis using the MBEC™ assay recorded higher percentage inhibition values with 
concentrations 16 – 32 times lower than with the MTP assay. Though the MBEC of CAZ and 
LEV were ≥ 5120 µg/mL for both MTP and MBEC™ assays, percentage eradication of K. 
pneumoniae and P. mirabilis biofilms obtained from the MBEC assay were higher than that 
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from the MTP assay. The exception to this was in the case of MBEC of CAZ for K. 
pneumoniae which was lower in the MBEC™ assay. 
4.8 Isolation of persister cells in Gram–negative DFU isolates after 
antibiotic challenge 
The ability of test strains, K. pneumoniae and P. mirabilis to produce persister cells was 
assessed using 3 methods described by Keren et al. (2004). Two phases of the bacterial 
growth cycle, logarithmic and stationary, were challenged with ceftazidime and levofloxacin 
respectively (Spoering and Lewis, 2001). In a 4th method persister cells were isolated from 
K. pneumoniae and P. mirabilis biofilm in a two–fold dilution assay with levofloxacin of 
working concentration of 5120 µg/mL. LEV also targets non–growing cells and biofilm 
cultures (Brooun et al., 2000). To determine whether persister cells are genetic variants of 
‘wild–type’ or ‘parent cells’, two tests were performed. The susceptibility of persister cells 
and their planktonic (parent) cells were tested against ampicillin, ceftazidime, ciprofloxacin, 
gentamicin and levofloxacin. The second test was the use of PCR amplification to determine 
differences in gyrase B gene of biofilm–extracted persister cells and parent cells.  
4.8.1 Time–dependent isolation of persister cells from DFU isolates 
K. pneumoniae and P. mirabilis, clinical (test) strains used in this study have been found to 
be strong biofilm producers (Table 4.3) and are partially tolerant to CAZ and LEV. The 
antibiotic concentration used for the time–dependent assay was 25 times the MIC for K. 
pneumoniae and P. mirabilis (EUCAST, 2014). At designated time points (1, 2, 3, 4, 5 and 
24 hours) cell numbers were estimated as CFUs and graphs of Log10 CFU/mL against time 
were plotted. The time – kill graph in Figure 4.6A shows an initial killing of exponential 
phase K. pneumoniae cells when challenged with CAZ and LEV. A fraction of the population 
of K. pneumoniae cells was not killed after 4 hours of incubation. However, a killing plateau, 
which was indicated by either slow killing of cells or the presence of subpopulation 
dormant/antibiotic tolerant cells called persister cells, was observed from early stationary 
phase to the decline phase. The killing pattern was however similar to that previously 
observed for other bacteria that showed typical killing patterns characteristic of the presence 
of persister cell subpopulation, a fraction of the population that tolerated killing by 
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ampicillin, gentamicin and ofloxacin (Keren et al., 2004; Keren et al., 2012; Kint et al., 2012; 
Lewis, 2007; Spoering and Lewis, 2001). Unlike LEV, P. mirabilis persister cells produced 
after challenge with CAZ were undetectable when spot–plated on agar after 3 hours of 
incubation (Figure 4.6B). However, when exponential phase P. mirabilis was challenged with 
LEV, a gradual killing pattern was observed that stabilised from early stationary phase to the 
decline phase.   
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Figure 4 .6 Time–dependent isolation of persister cells using ceftazidime and levofloxacin 
(100 µg/mL). (A) K. pneumoniae and (B) P. mirabilis planktonic cells were challenged with 
ceftazidime and levofloxacin and the amount of persister cells produced were monitored 
every hour for 4 hours.  
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4.8.2 Growth–stage dependent production of persister cells from DFU isolates 
It has been suggested that, the persister cell subpopulation of a bacterial culture are generated 
during growth phase before any antibiotic treatment (Balaban et al., 2004; Balaban et al., 
2013; Keren et al., 2004). However, the number of persister cells produced during the 
stationary phase is dependent on growth conditions such as age of inoculum/culture, types of 
bacterial strain (either slow–growing or rapid–growing), type of culture media and the types 
of antibiotics used for the challenge assays (Luidalepp et al., 2011). For example, Luidalepp 
et al. (2011) observed that, the levels of persister cells produced by both 18–hour stationary 
phase E. coli hipA7 and its wild–type challenged with ampicillin and incubated for extended 
period of time decreased. On the other hand, all cells were killed when challenged with 
amikacin during growth resumption experiments with fresh LB broth (Luidalepp et al., 
2011). In the current study, the difference between persister cell production during 
exponential and stationary phases of growth were challenged with CAZ and LEV and 
assessed. In the growth–stage dependent assays for persister cell isolation from K. 
pneumoniae and P. mirabilis, the concentration of CAZ and LEV was doubled (200 µg/mL) 
due to high levels of non–dividing cells produced during the stationary phase of bacterial 
growth. The method was slightly modified to incorporate 2 time points; antibiotic challenge 
at (a). 1 hour after incubation and (b). 3 hours after incubation to determine if extended 
incubation periods affect the levels of persister cell production. The number of persister cells 
produced was then estimated as CFU/mL and plotted against time. 
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Figure 4 .7 Growth–state dependent isolation of persister cells. K. pneumoniae and P. 
mirabilis were challenged with 200 µg/mL of CAZ and LEV at (A) and (C) 1 hour and; (B) 
and (D) 3 hours post–incubation with CAZ and LEV and samples removed at designated time 
points (hourly) and CFU determined. Control was made up of unchallenged K. pneumoniae 
or P. mirabilis sampled at the same time as the test strains. 
Aliquots of growing K. pneumoniae cells were removed every hour and challenged with CAZ 
and LEV. It was observed that K. pneumoniae cells were quickly killed by CAZ and LEV and 
persister cells were undetected for 2 hours (Figure 4.7A). After the two–hour dormancy, K. 
pneumoniae cells were detected again and stabilised afterwards. When samples were 
removed, and challenged after every 3 hours, persister cells produced by LEV–challenged K. 
pneumoniae cells were undetectable at 2 time points whereas persister cells produced by 
CAZ–challenged K. pneumoniae cells were undetectable at only one–time point (Figure 
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4.7B). Similarly, in Figure 4.7C), persister cells produced by CAZ and LEV–challenged P. 
mirabilis cells were undetectable at 2 time points. On the other hand, persister cells produced 
by LEV–challenged P. mirabilis following 3 hours of initial incubation were undetectable at 
only one–time point after which the levels reached a plateau. The patterns of growth of K. 
pneumoniae and P. mirabilis persister cells illustrated in Figure 4.7A, B, C and D are slightly 
different from that observed with E. coli by Keren et al. (2004). This can be explained as 
probably increase in the number of uncultivable cells in broth due to the length of the 
stationary phase which resulted in late onset of growth after being plated–out on agar. In 
future, growth – dependent persister cell isolation assays could incorporate biosensor 
reporters such as the green fluorescent protein or its derivatives which could bind to non–
dividing or uncultivatable cells and determined by fluorescent microscopy (Luidalepp et al., 
2011; Yuste, 2005). 
4.8.3 Isolation of persister cells from biofilms produced by DFU isolates 
In this assay, the production of persister cells from biofilm cultures was determined by 
estimating the survival (as CFU/mL) of K. pneumoniae and P. mirabilis cells after challenge 
of biofilm cultures with antibiotic. In order to confirm that persister cells were produced after 
antibiotic challenge of K. pneumoniae and P. mirabilis biofilms with LEV, persister cells 
were harvested from biofilm cultures using the method outlined in section 2.5.4. K. 
pneumoniae and P. mirabilis wild–type or planktonic parent cells and their biofilm – derived 
persister cells counterparts were tested for their antibiotic susceptibility against a selection of 
antibiotics in order to confirm the hypothesis that, the biofilm–derived persister cells are not 
genetic variants of the wild – type; results of which are shown in section 4.7.4.1.  
In Figure 4.8, it was observed that, LEV at high concentration (5120 µg/mL, which is 1280 
times the MIC) was unable to completely eradicate K. pneumoniae and P. mirabilis biofilms 
and/or persister cells after 3 hours of incubation. At 5120 µg/mL, LEV eradicated 71 and 
70% of K. pneumoniae and P. mirabilis biofilms respectively which was found to be 
statistically significant by two–way ANOVA (p = 0.0031). It can be observed in Figure 4.8 
that biofilm cultures of K. pneumoniae and P. mirabilis showed significant tolerance to 
killing by LEV with Log10 CFU/mL survival of 8.63 and 8.55 compared to planktonic cells in 
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the exponential (5.2 and 5.4) and stationary phases (4.8 and 5.8) of K. pneumoniae and P. 
mirabilis growth respectively in Figures 4.6 and 4.7.   
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Figure 4 .8 Isolation of persister cells from biofilms challenged with different concentrations 
of levofloxacin (160–5120 µg/mL). Total viable cell count recovered from levofloxacin agar 
plates ranged from 1.2X108 to 2.6X108 CFU/mL. 
4.8.4 Persister cells are not genetic mutants of wild–type cells 
To confirm that persister cells are not genetic mutants of the wild–type, a series of assays 
were performed. Biofilm–derived persister cells were tested for their antibiotic susceptibility 
patterns against 5 antibiotics and compared with the wild–type. Persister cells produced after 
K. pneumoniae and P. mirabilis planktonic cells were challenged with LEV were tested in a 
time–dependent assay to determine whether the mechanisms that lead to persister cell 
formation were inherited from parent cells. In another assay, biofilm–derived persister cells 
were grown in a conventional 96–well MTP, stained with 0.1% crystal violet and the OD570 
values compared to that obtained in Table 4.3 (results not included). Lastly, PCR 
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amplifications were performed to compare the gyrase B (gyrB) genes in biofilm–derived K. 
pneumoniae and P. mirabilis persister cells with the wild–type. 
4.8.4.1 Antibiotic susceptibility testing of planktonic and biofilm–derived persister cells 
The antibiotic susceptibility testing of K. pneumoniae and P. mirabilis planktonic and 
biofilm–derived persister cells were performed using 5 selected antibiotics (ampicillin, 
ceftazidime, ciprofloxacin, gentamicin and levofloxacin). The susceptibility patterns of K. 
pneumoniae and P. mirabilis planktonic and biofilm–derived persister cells were compared 
using the BSAC and EUCAST breakpoints as reference. EUCAST breakpoints were used for 
some specific strains in the Enterobacteriaceae family where BSAC had no established 
breakpoints for the interpretation of their zones of inhibitions for some antibiotics. The 
susceptibility profiles in Table 4.13 show that biofilm–derived K. pneumoniae and P. 
mirabilis persister cells retained the same susceptibility profiles as the wild–type following 
antibiotic challenge and regrowth in fresh medium. 
Table 4 –13 Antibiotic susceptibility profile of K. pneumoniae and P. mirabilis and their 














R ≤ I ≥ S 
Antibiotic Planktonic Persister Planktonic Persister Enterobacteriaceae 
Ampicillin, 10 
µg 
10 10 10 11 14 ≤ − ≥ 15 
Ceftazidime, 
30 µg 
5 5 12 15 19 < 20–21 ≥ 22a 
Ciprofloxacin, 
5µg 
22 22 3 3 19 < 20–21 ≥ 22b 
Gentamicin, 10 
µg 
11 11 12 13 16 ≤ 17–19 ≥ 20 
Levofloxacin, 
5 µg 
22 22 22 21 19 <20–21 ≥ 22c 




4.8.4.2 Persister heritability assay 
This assay was performed to determine whether persister cells are genetically different from 
the wild–type and their increased survival was transferrable to their progeny (Wolfson et al., 
1989). The time–dependent assay (Figure 4.9) following 4 hours of incubation after antibiotic 
challenge showed a similar killing pattern observed for the wild–type demonstrated in Figure 
4.6 above. The similar pattern of killing in both independent assays shown in this study is 
suggestive that mechanisms underlying persister cell formation are not heritable. A similar 
observation was made by Keren et al. (2004) using ampicillin for the time–dependent killing 















































Figure 4 .9 Persister heritability assay showing exponentially grown (A) K. pneumoniae and 
(B) P. mirabilis cells challenged with LEV. Time–dependent killing of the bacterial cells 
over the 4 day–period was found to be statistically significant (p < 0.0001 by two–way 
ANOVA). 
4.8.4.3 Genotypic characterisation of biofilm–derived persister cells and wild–type 
strains 
The amplification of the gyrB gene in both K. pneumoniae and P. mirabilis planktonic and 
biofilm–derived persister cells showed no differences in the amplified gene products. Primers 
designed to target the gyrB gene in both the persister cell DNA and wilt–type DNA amplified 
partial sequences of the gene of the same size as resolved by gel electrophoresis (Figure 
4.10). The results were also confirmed by PCR purification and DNA sequencing. The 
sequenced partial gene products were aligned with speciated strains deposited in the 
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databases to look for similarity between the sequenced. There was 100% alignment between 
the genes which also suggests that, there was no genotypic difference between the gyrB genes 
of K. pneumoniae and P. mirabilis biofilm – derived persister cells and their wild –type 





Figure 4 .10 PCR amplification of gyrB partial gene of both wild–type and persister cells of; 
(A) P. mirabilis (200 bp) and (B) K. pneumoniae (509 bp) and. Lanes: M – DNA marker (100 
bp); 1 and 2 represent of wild–type K. pneumoniae strains; 3 and 4 represent K. pneumoniae 
persister; 5 represents wild–type P. mirabilis and 6 represents P. mirabilis persister; N1 and 
N2 are negative controls. 
4.9 Quasi–Vivo® QV500 chamber assay – time–dependent biofilm 
eradication 
This is the first time the Quasi–Vivo® system, a continuously flow system, has been used for 
a bacterial assay. In this study, the Quasi–Vivo® system was used to assess the effect of 
antibiotic treatment of biofilm on coverslips in a continuous flow system in a time–dependent 
killing assay. In this assay, biofilm eradication was monitored as a function of the measure of 
the direct effect of antibiotic challenge on dispersed bacteria in suspension on biofilms 
seeded on coverslips by spectrophotometry and viable cell count (CFU/mL). Residual biofilm 
on the coverslips in the QV500 chambers were qualitatively determined after antimicrobial 
challenge by epifluorescence microscopy after staining with LIVE/DEAD® BacLight 
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Bacterial Viability kit (Molecular Probes, USA). It was observed that, the amount of K. 
pneumoniae and P. mirabilis cells dispersed from the biofilm decreased steadily over time 
after the antibiotic challenge (Figures 4.11A and B). A direct relationship was observed 
















































Figure 4 .11 Time–dependent eradication of; (A) K. pneumoniae and (B) P. mirabilis 
biofilms using the QV500 chamber assay. Amount of dispersed bacterial cells in solution 
(OD600) decreased steadily over the time-period (two–way ANOVA, p = 0.0017 and p 
=0.0011 respectively). Control was made up of a cover slip of K. pneumoniae or P. mirabilis 
biofilm passed through the chamber and sampled at the selected time points without 




Epifluorescence microscopy of the LIVE/DEAD® stained biofilm coverslips showed the 
extent of biofilm eradication which was indicated by dead bacterial cells (shown as red cells) 
and the voids between the microcolonies (Figure 4.12B).  
A  B  
Figure 4 .12 Epifluorescence images of BacLight LIVE/DEAD® stained coverslips of 
biofilms images of; (A). 24–hours old P. mirabilis biofilm without antibiotic challenge and; 












K. pneumoniae and P. mirabilis strains have been well studied as members of the 
Enterobacteriaceae family with medical importance. K. pneumoniae and P. mirabilis are 
environmental organisms and part of the normal flora of the skin and intestines which have 
been associated with both community– and hospital–acquired conditions such as pneumonia, 
urinary tract infections (UTIs) and septicaemia (Chong et al., 2013; Podschun and Ullmann, 
1998). Their presence in opportunistic infections such as wounds and burns has also been 
well studied (Gardner et al., 2013; Gjødsbøl et al., 2006; James et al., 2008; Malik et al., 
2013; Oates et al., 2012; Rhoads et al., 2012). This work presented here established that, the 
growth cycles of K. pneumoniae and P. mirabilis (designated as strains 028b and 005 
respectively) were similar to that of the reference E. coli NCTC 10418 strain. The estimations 
of bacterial biomass at each stage of the growth cycle of the 3 strains were comparable 
(Figures 4.1 and 4.2). The growth cycles of K. pneumoniae and P. mirabilis suggested that 
they could be used as model strains in the studies of bacterial physiology and metabolism and 
their response to external stresses.  
In the coaggregation assay, K. pneumoniae and P. mirabilis showed their ability to 
autoaggregate and coaggregate with other DFU isolates (Table 4.1 and 4.2). Their ability to 
autoaggregate and/or coaggregate after 2 hours of incubation with little or no changes in 
coaggregation score up to 24 hours of incubation suggests that they have the ability to form 
and sustain biofilm formation (Hill et al., 2010). The formation of coaggregation phenotypes 
by wound isolates is an important step in biofilm formation in vivo (Rickard et al., 2003; 
Rickard et al., 2004). Coaggregation reaction was stronger among some coaggregation pairs 
than others with both higher visual and percentage (quantitative) scores. These higher scores 
are consistent with specificity between cell surface appendages that mediate bacterial 
adhesion to one another as evident in dental plaques (Kolenbrander, 2000; Stinson et al., 
1991). Low coaggregation scores among some wound isolates do not rule out bacterial 
interactions within these wounds (Hill et al., 2010). This is because, bacteria colonising 
wounds are not exposed to high shear forces as evident in the oral cavity where bacteria 




In this study, K. pneumoniae and P. mirabilis were classified as strong biofilm producers 
using the method described by Merritt et al. (2011) and Pye et al. (2013). Biofilm formation 
by K. pneumoniae and P. mirabilis was also confirmed by the production of the extracellular 
polymeric substance (EPS) which was demonstrated by 2 staining techniques and visualised 
by epifluorescence microscopy (Figure 4.3). However, biofilm production by K. pneumoniae 
and P. mirabilis and other wound isolates was found to be affected by changes external to the 
bacterial microenvironment such as the incubation temperature, pH and nutrient 
concentration of the growth media.  
It was observed that biofilm production among some isolates notably, 021a P. mirabilis, 038 
P. aeruginosa and test strains 028b K. pneumoniae, and 005 P. mirabilis, was inconsistent 
with changes in pH as they did not relate to growth optima. However, the clinical test isolates 
used in this study, 028b K. pneumoniae and 005 P. mirabilis showed significant growth at pH 
4 and 10 respectively (Figure 4.4A). K. pneumoniae has been previously found to grow 
optimally at pH 5.5 – 7.0 (Jones et al., 2015). A similar observation was made in the 
temperature assay (Figure 4.4B and C). P. aeruginosa for example has previously been found 
to produce more biofilm at high pH which was also observed in this study (Harjai et al., 
2005).  Two major regulatory genes, rpoS and algT responsible for initiating stress response 
during biofilm formation have been found in P. aeruginosa and E. coli (Cochran et al., 2000). 
These genes mediate physiological changes that protect the biofilm structure from 
environmental stresses such as cold shock, heat shock, oxidative stress as well as other 
chemical agents. The ability of P. aeruginosa to form biofilm under such extreme 
environmental conditions is due to the production of the extracellular polysaccharide called 
alginate (Cotton et al., 2009; Moller et al., 2008; Stapper et al., 2004).  Alginate in itself is 
not required for biofilm formation but has a role in providing structural protection for the 
biofilm to resist environmental stress as well as antibiotic killing (Cotton et al., 2009; Stapper 
et al., 2004). Algt and RpoS are also known to coordinate responses that make biofilms less 
susceptible to treatment with oxidative agents such as hydrogen peroxide (Cochran et al., 
2000). The structural integrity of E. coli biofilm is also maintained by the RpoS sigma factor 
through the regulation of genes such as nlpl and osmB that are involved in membrane 
resealing after exposure to external stresses (Charoenwong et al., 2011; Cochran et al., 2000). 
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Jones et al. (2015) mentioned in their recent review that the effect of pH on wound isolate on 
growth and biofilm formation has not been specifically considered by any study. This current 
study however, is one of the few that has considered the in vitro effects of pH and 
environmental conditions on wound isolates other than the usual pathogens such as E. coli, P. 
aeruginosa and S. aureus. Against the backdrop that P. aeruginosa and E. coli possess 
regulatory genes which can be upregulated to protect them against changes in environmental 
conditions, it can be suggested that, K. pneumoniae and P. mirabilis, may possess similar 
regulatory factors hence their ability to produce significant biofilm at pH of 4 and 10 
respectively. However, little is known about any intrinsic regulatory systems that enable K. 
pneumoniae and P. mirabilis to withstand such degrees of environmental stress. In this study, 
the determination of such regulatory factors in K. pneumoniae and P. mirabilis was not 
further investigated as it was beyond the budget of this project. It can also be suggested that 
their ability to form strong coaggregation phenotypes (Tables 4.1 and 4.2) and synthesise 
polysaccharides and EPS (Figure 4.3) during biofilm formation may play a part in their 
ability to withstand some external stresses. There was a positive correlation between the 
production of biofilm and nutrient concentration. This is very significant as bacterial growth 
media especially LB contain both tryptone and yeast extract and other nutrients such as 
amino acids, vitamins, nitrogen and carbon sources with carbon–nitrogen ratio of 0.26:1 
which are essential requirements for bacterial growth (O’Kennedy et al., 2000; Ramli et al., 
2012). 
Although biofilm production was markedly reduced in some isolates during the pH, 
temperature and nutrient concentration assays, they were not completely inhibited. However, 
the regulation of biofilm formation and development in chronic wounds is a complex process 
that is species–specific and influenced by both the genetic make–up of the bacterial species 
involved, the environmental conditions and host immune responses prevailing at the site of 
infection (Lopez et al., 2010; Ramli et al., 2012). It has been noted that, the slow rate of 
healing of chronic wounds is due to the alkaline nature of the wounds (Schneider et al., 
2007). However, as a wound progress towards healing, the pH also shifts towards acidity 
(Shukla et al., 2007). This suggests that, pH plays a role in wound healing and can serve as a 
tool for monitoring non–healing wounds. In the future, treatment strategies targeting non–
healing wounds could consider the use of biocides or antimicrobials that can reduce the pH of 
the wound environment in order to facilitate healing. 
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The antibiotic susceptibility patterns (using the disc diffusion method) of planktonic cells of 
all DFU isolates including test strains K. pneumoniae and P. mirabilis have previously been 
determined (section 3.3 in Chapter 3). In this chapter, the ability of 5 antibiotics including 
ceftazidime and levofloxacin, to inhibit and/or eradicate biofilms was assessed using two 
microtitre plate based assays. Ceftazidime and levofloxacin were selected for subsequent 
assays and for the analyses of MIC, MBC and MBEC results obtained from both 
conventional MTP and MBEC™ assays. Their modes of action also make them suitable 
choices for investigation bacterial biofilm and isolation of persisters (Brooun et al., 2000; 
Keren et al., 2004, Keren et al., 2012 Spoering and Lewis, 2001). Ceftazidime (CAZ), a 
third–generation cephalosporin with a beta–lactam mode of action is less susceptible to the 
action of beta–lactamases (Lagacé–Wiens et al, 2014). Levofloxacin, like all other 
quinolones has good tissue penetration and is effective against slow–growing bacterial cells. 
The high antibiotic efficacy of levofloxacin against slow–growing cells has been attributed to 
its good pharmacokinetics, i.e., rapid and complete absorption and high bactericidal activity. 
It is also thought that, like ciprofloxacin, efflux pumps do not export levofloxacin hence its 
increased bactericidal activity (Brooun et al., 2000). In the bacterial cell, Levofloxacin 
inhibits the 2 type II topoisomerases; DNA gyrase and topoisomerase IV, leading to DNA 
separation after replication (Drlica and Zhao, 1997). 
In the MTP assay, levofloxacin at ≥ 160 µg/mL (40 times the MIC) was the most effective 
antibiotic to inhibit 63% of K. pneumoniae biofilm (Table 4.4). However, ≥ 640 times the 
MIC (≥ 2560 µg/mL) was needed by ceftazidime to inhibit 62% of K. pneumoniae biofilm. 
The concentration of CAZ and LEV (≥ 640 µg/mL) that inhibited P. mirabilis biofilm by 
65% each was 160 times the MIC. The MBEC of CAZ and LEV needed for complete 
eradication of K. pneumoniae and P. mirabilis biofilms was ≥ 5120 and 2560 µg/mL (> 640 
times their MICs) (Table 4.5).  It can be suggested that both CAZ and LEV have increased 
efficacy against both K. pneumoniae and P. mirabilis cells during the lag and logarithmic 
phases of their growth cycles (Desai et al., 1998). However, their respective efficacies reduce 
during the stationary growth phase where there is decreased metabolic rate, slow growth and 
formation of biofilm hence the increase in their MICs. Also, the synthesis of the EPS during 
biofilm formation serves as a barrier that prevents the entry of antibiotics into the embedded 
biofilm (Lopez et al., 2010; Mah and O’Toole, 2001). The increased MIC of CAZ and LEV 
in inhibiting K. pneumoniae and P. mirabilis biofilms may also be due to the presence of 
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multiple antibiotic resistance genes (Mah and O’Toole, 2001; Singla et al., 2013). In the work 
presented here, planktonic cells of both K. pneumoniae and P. mirabilis were susceptible to 
LEV but resistant to CAZ.  
Mixed biofilms have been found to be more prevalent in the oral cavity where their 
interactions benefit one or all partners (Kolenbrander et al., 2010; Stacy et al., 2014). In this 
study, however, the coaggregation phenotypes and corresponding scores suggest that DFU 
isolates are capable of forming mixed biofilms through bacterial cell–to–cell interactions. It 
has been established that bacteria involved in biofilm formation engage in active 
communication, coordination and collective behaviour in mature biofilm communities (Dow 
et al., 2003; Dunne, 2002; Hammer and Bassler, 2003; Stoodley et al., 2002). However, these 
biofilm communities are more complex and diverse than they were thought to be. Complex 
adherence kinetics and dynamics in the physiological environment of polymicrobial biofilms 
have been found to affect the development of microcolonies and spatial biofilm structures 
(Ibusquiza et al., 2012; Xavier and Bassler, 2005a; Xavier and Bassler, 2005b). Fight–and–
flight responses and competitive effects have also been found to affect specific and non–
specific adherence between 2 strains during mixed biofilm formation leading to differential 
responses to environmental stresses like antibiotic treatment and antimicrobial production 
(Burmølle et al., 2006; Mellefont et al., 2008; Stacy et al., 2014). For instance, Stacy et al. 
(2014) demonstrated an in vitro bacterial fight–and–flight response in dental plaque and 
suggested that such fight–and–flight responses enhance the virulence of pathogenic bacteria 
in a polymicrobial infections. In their study, Stacy et al. (2014) observed that, Streptococci 
gordonii promoted the growth and virulence of the oral pathogen Aggregatibacter 
actinomycetemcomitans by producing L–lactate as a carbon source and in effect produced 
hydrogen peroxide (H2O2). They observed that A. actinomycetemcomitans responded to the 
high levels of the antimicrobial H2O2 either by a catalase – mediated enzymatic detoxification 
(i.e., fight response) of H2O2 or by spatial dispersion (i.e., flight response) of the A. 
actinomycetemcomitans biofilm through the action of an enzyme called dispersin B. 
Mellefont et al. (2008) also noted that, competitive effects otherwise known as the ‘Jameson 
Effect’ among bacterial pairs in a mixed culture, may lead to the production of growth 
inhibitors by one strain against the other. In addition to the Jameson Effect, other more 
complex interactions in a mixed culture lead to competition for nutrients, pH reduction or 
increase and differential use of available substrate. The above variations and some other 
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factors may account for the complex responses of mixed biofilms to antibiotic/antimicrobial 
treatment compared to monospecies biofilms.  
Biofilm estimation results following MIC and MBEC determinations (as shown in Table 
4.12) either by the conventional MTP or MBEC™ assay may be due to the sensitivity of each 
assay. Due to its many modifications, the conventional MTP assay may be less sensitive with 
a wider margin of error compared to the calibrated MBEC™ assay. Hence the results 
obtained using the in vitro MBEC™ assay may provide more accurate analysis comparable to 
in vivo situations. 
The differences between the methodologies used in the conventional MTP and MBEC™ 
assays pose a challenge in the quantitative comparisons of the independent results obtained 
by the 2 assays. Some of the differences include the volume and the inoculum size of the 
starting inoculum suspension for both assays. In the MTP assay, the volume of starting 
inoculum suspension range from 100 to 200 µL whiles that of the MBEC is fixed at 150 µL. 
In the MTP assay, biofilm estimation is performed on biofilms formed in the bottom and 
walls of the wells whereas in the MBEC™ assay biofilms formed on pegs suspended from 
the lid of the MBEC™ plate are estimated and that formed in the bottom of the wells are 
discarded. The starting inoculum suspension for the MBEC™ assay is always 3.0 x 108 
CFU/mL whiles that of the MTP assay is usually 0.5 McFarland (i.e., approximately 1.5 x 108 
CFU/mL) with occasional references to the optical densities (Ceri et al., 1999; Harrison et al., 
2005; Merritt et al., 2011; O’Toole et al., 1999; O’Toole, 2011; Stepanovic et al., 2001). 
Against the backdrop of differences in initial inoculum suspension volumes and cell 
concentrations, the MTP assay may result in the formation of more biofilms than in the 
MBEC™ assay hence requires antibiotics with higher concentrations to inhibit and/or 
eradicate biofilm formation (Table 4.12). Therefore, the use of different starting inoculum 
suspension volumes and inoculum sizes prevents comparison of biofilm estimations between 
the MTP and MBEC™ assay. The incubation step of the MBEC™ involves either rotation at 
5 rocks per minute (for the trough–base assay) on a rotor or 110 rpm (for the 96–well base 
assay) in a shaking incubator. The incubation step of the conventional MTP assay is 
undefined and subject to modifications based on the growth requirements of the bacteria 
under investigation; whether slow– or fast– growing. Also, the washing step in the MTP 
assay involves a rigorous and careful washing of the 96–well plate submerged in a bowl of 
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water (Merritt et al., 2011). Discrepancies in the final absorbance readings of the crystal 
violet stained biofilm can be attributed to other factors such as the washing steps as some 
biofilms are likely to be washed off during the washing of unbound cells after overnight 
incubation of the MTP plate (Merritt et al., 2011; Pye et al., 2013). This implies that bacterial 
isolates classified either as weak, moderate or strong biofilm producers using MTP assay may 
be classified otherwise using the MBEC™ assay. The above–mentioned variations of the 
MTP assay suggest that the MTP assay may be an unreliable assay for biofilm estimations 
and subsequent classification of bacterial isolates as biofilm producers.  
In this study, some of the modifications made to the MTP assay outlined in section 2.4.1 
included, fixation of the biofilm after the appropriate incubation period with 4% 
formaldehyde before the initial washing step. Also, in place of the rigorous washing step in a 
bowl, a careful aspiration of the unbound cells in suspension by means of a pipette can be 
done. The last modification of this assay is the choice of a solubilising agent (30 – 33% acetic 
acid, 95% ethanol, 80% ethanol/20% acetone, 100% dimethyl sulfoxide) which depends on 
the type of biofilm producing strain (Merritt et al., 2011). The MBEC™ assay is calibrated 
by the manufacturer with no external modifications allowed during the assay. The 
classification of bacterial strains as biofilm producers is based on the determination of their 
CFU/mL. Biofilm estimation in the MTP assay involves the absorbance reading at OD570 (in 
nanometres) of crystal violet–stained biofilm in the bottom and on the walls of the 96–well 
plate. In the MBEC™ assay, biofilm growth estimation on each peg was removed by 
sonication of the formed biofilm into a recovery medium followed by spot–plating of diluted 
cells on agar to determine their CFU/mL. For the purpose of this study, the definitions for 
MIC and MBEC are given as complete inhibition or eradication of biofilm at OD570 < 0.05 
and OD650 < 0.1 for the MTP and MBEC™ assays respectively. Where there were no 
complete inhibition or eradication of biofilm, percentage inhibition or eradication were 
provided to define the extent of biofilm inhibition or eradication at the concentrations of the 
antibiotics/antimicrobials used. 
In this study, the disc diffusion assay results of antibiotic susceptibility testing (Figure 3.5, 
section 3.3.1) suggest that, both ceftazidime and levofloxacin were more effective against K. 
pneumoniae and P. mirabilis planktonic cells than the other antibiotics used. However, 
neither ceftazidime nor levofloxacin could completely inhibit or eradicate biofilms. Biofilm 
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eradication has been a major dilemma (Lewis, 2007). Though the development of resistance 
by biofilms is not fully understood, a number of factors that contribute to this phenomenon 
depend on the type of bacterium and the type of antibiotic treatment (Hall–Stoodley and 
Stoodley, 2009). The development of gradients within biofilm clusters has been found to 
create anoxic, acidic and nutrient–depleted zones which can activate a dormancy state 
responsible for generalised resistance of biofilms to antibiotics (Stoodley et al., 2008; Walters 
et al., 2003). The inability of potent antibiotics even at high concentrations to completely 
inhibit or eradicate biofilms is possibly partly due to the presence of persister cells (Lewis, 
2007). 
Persister cells are the sub-population of bacteria that are found to be produced during 
stationary growth phase or become tolerant to antimicrobial killing and survive. They are 
responsible for repopulating and continuing biofilm infections through dispersal and 
colonisation of new niches (Lewis, 2001; Lewis, 2007; Keren et al., 2004; Keren et al., 
2012). Persister cells account for approximately 1% of the total biofilm population (Anderson 
and O’Toole, 2008; Hall–Stoodley and Stoodley, 2009; Lewis, 2001; Lewis, 2007). Though 
the mechanisms underlying the formation of persister cells remain a puzzle, it is known that 
the highest rate of persister formation is at stationary phase of growth and independent of 
quorum sensing as spent growth media and early exponential cultures of E. coli or P. 
aeruginosa added together did not show appreciable increase in the number of persister cells 
isolated (Lewis, 2007). In this study, the ability of K. pneumoniae and P. mirabilis to produce 
persister cells from planktonic and biofilm cultures after exposure to antibiotics such as 
ceftazidime and levofloxacin was assessed. The production of persister cells by the two 
clinical strains (K. pneumoniae and P. mirabilis) was compared with the dynamics of 
persister cell production by 3 well studied strains namely; E. coli, P. aeruginosa and S. 
aureus (Keren et al., 2004; Keren et al., 2012; Lewis, 2000; Spoering and Lewis, 2001). In 
the present study, persister cells produced by DFU isolates were tested to determine their 
survival after exposure to increased concentrations of CAZ and LEV. CAZ, like any other β–
lactam antibiotic disrupts peptidoglycan layer synthesis by inhibiting transpeptidases 
responsible for the crosslinking of the peptidoglycan layer during the exponential growth 
phase. LEV like any other fluoroquinolone can kill slow growing cells during the stationary 
growth phase (Keren et al., 2004). It was observed that, K. pneumoniae and P. mirabilis 
persister cells were tolerant to killing even after 4 hours of exposure to antibiotics 
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concentrations 25 times the MIC (Figures 4.6). However, CAZ–induced P. mirabilis persister 
cells were undetectable during lag and early exponential phases. This scenario presents with 
one of two possible outcomes. The first is the possibility of complete eradication of P. 
mirabilis persister cells by CAZ at a concentration high enough to even kill strains with 
resistance gene determinants (Geller et al., 2011; Keren et al., 2012). The second possibility 
is the complete shutdown of all metabolic processes and the presence of undetectable levels 
of persister cells that would resume after the return of favourable growth conditions. 
The pattern of K. pneumoniae and P. mirabilis persister cell production in the growth–state 
dependent assay was intriguing when antibiotic concentration was doubled (200 µg/mL). 
Persister cell production at the lag and early exponential phases (Figure 4.7A and C) was 
similar to the time–dependent killing assay by CAZ in Figure 4.6B. However, persister cells 
which were undetectable during the lag and early exponential phases were detectable again 
from the mid–exponential phase, reached high levels at early stationary phase and stabilised 
throughout the decline phase (Figure 4.7A and C). A similar pattern of K. pneumoniae 
persister cells production was observed when the cells were challenged 3 hours post–
incubation (Figure 4.7C) except in Figure 4.7D where the level of CAZ–induced P. mirabilis 
persister cells were detectable and stabilised throughout the growth phase. Again, it can be 
suggested that the concentrations of CAZ and LEV against the actively dividing K. 
pneumoniae and P. mirabilis cells were too high hence the switch from exponential growth to 
dormancy. In a similar assay, Keren et al. (2004) challenged P. aeruginosa and S. aureus 
with ciprofloxacin and ofloxacin respectively to monitor the levels of persister cells 
production in a growing culture. In their work, persister cell production showed a sharp 
decline during the lag and early exponential phases which was followed by increases in the 
early to mid–exponential phases and finally stabilised in early stationary phase. In the present 
study, the dynamics of persister cells formation from K. pneumoniae and P. mirabilis 
planktonic cells were different from that reported by Keren et al, (2004) and Spoering and 
Lewis, 2001). The levels of persister cells produced by K. pneumoniae and P. mirabilis 
reached high levels at mid–exponential phase and then stabilised through late–exponential, 
stationary to the decline phases.  
Spoering and Lewis (2001) and Keren et al, (2004b) have proposed that, the idea that 
biofilms are resistant to antibiotics than planktonic cells is a misconception and that; persister 
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cells are fundamentally responsible for biofilm resistance to killing by antibiotics and not by 
the presence of biofilm specific resistance mechanisms. Although biofilms are largely 
protected by the EPS barrier from disruption, majority of the embedded cells are susceptible 
to killing by antibiotics (Spoering et al., 2001). They also reported that, biofilm and 
stationary–phase cultures of P. aeruginosa were tolerant to tobramycin and noted that at low 
antibiotic concentrations, persister cells were revived to repopulate the biofilm. In the present 
study, the killing pattern of K. pneumoniae and P. mirabilis biofilms by LEV was found to be 
similar to that of their planktonic counterparts (Figure 4.6). Unlike what was reported by 
Spoering and Lewis (2001), the levels of persister cells produced from biofilms in the present 
study were rather higher than their counterparts produced from planktonic cells (Figures 4.6 
and 4.8). The present study also confirms that persister cells productions are growth–phase 
dependent with high levels detectable in late–exponential and early stationary phases.  
Attempts were made to find differences between K. pneumoniae and P. mirabilis persister 
cells and the wild–type. Three assays were performed to consider the fact that, persister cells 
are not genetic mutants of the wild–type. Biofilm–derived persister cells and the planktonic 
counterparts were found to have the same antibiotic susceptibility profiles when tested 
against ampicillin, ceftazidime, ciprofloxacin, gentamicin and levofloxacin. A time–
dependent assay showing the production of K. pneumoniae and P. mirabilis persister cells 
after challenged with LEV showed the same killing pattern observed with the wild–type. A 
similar observation was made by Keren et al. (2004). It has been argued that the blocking of 
the DNA replication fork by the DNA gyrase–fluoroquinolone complex during bacterial 
replication is a temporary process that cannot induce defects in bacterial cells leading to 
persister cell formation (Keren et al., 2004). This idea was revisited in the present work to 
determine whether levofloxacin, whose primary target is DNA gyrase (Hooper, 2000), is 
likely to induce any defect that results in persister cell formation. However, gel 
electrophoresis and DNA sequencing following PCR amplification of the gyrase B gene in 
both K. pneumoniae and P. mirabilis persister cells and the wild–type showed no differences 
between them. These findings suggest that K. pneumoniae and P. mirabilis persister cells are 
not genetic variants and hence identical to their wild–type counterparts. Currently, the only 
bacterial model that has been found to genetically regulate persistence is in E. coli through 
the toxin–antitoxin (TA) system (Moyed and Bertrand, 1983).  
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The Quasi–Vivo® assay is a continuous flow system adapted in the present work to mimic in 
vivo settings to study the effect of antibiotics (CAZ and LEV) on established biofilm. The 
degree of biofilm eradication was monitored in a time–dependent assay that illustrated a 
direct relationship between biofilm eradication and time for the first few hours of the assay. 
Interestingly, the concentrations (512 and 5120 µg/mL) of CAZ and LEV used in this assay 
showed little or no difference in the degree of biofilm eradication showing a similar pattern 
of killing previously observed (Figure 4.9). The results presented here also indicate that 
persister cells production is not only an antibiotic–specific phenomenon but also specialised 
cells that are produced at low levels in stationary phase or biofilm cultures and regulated by 
the bacterial population throughout its growth cycle (Keren et al., 2004). 
In summary, it can be said that the colonisation of diabetic foot ulcers by K. pneumoniae and 
P. mirabilis may result in the establishment of biofilm infections in DFUs that may be 
difficult to treat by antibiotics. Non-healing DFUs with accompanying biofilm infections 
which do not respond to antimicrobial treatment may increase the risk of amputations in DFU 
patients. The risk of amputation among DFU patients with established biofilm infections may 
also be aggravated by the presence of persister cells which are have been found to be tolerant 
to antimicrobial killing. Although high concentrations of antibiotics (i.e., above 
recommended therapeutic levels) have been found (including this study) to significantly 
inhibit and/or eradicate biofilms, their administration would induce tissue damage or 
cytotoxicity. In order to decrease these high antibiotic concentrations to achieve therapeutic 
levels, this study further proposes that the formulation of a topical treatment option that will 
combine the efficacies of two or more antimicrobial agents at either sub–inhibitory or 
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Quorum sensing (QS), also called bacterial communication, is a process where bacteria in a 
community produce, release, detect and respond to small chemical signalling molecules 
called autoinducers that correspond to a threshold of cell population density (Davies et al., 
1998; Miller and Bassler, 2001; Ng and Bassler, 2009; Parsek and Greenberg, 2005; 
Schauder and Bassler, 2001; Waters and Bassler, 2005; Whitehead et al., 2001). Through 
quorum sensing bacteria can simultaneously regulate gene expression in response to changes 
in cell density and species variation (Ng and Bassler, 2009). This synchronised behaviour has 
been linked to regulation of cellular processes such as bioluminescence, antibiotic 
production, antibiotic resistance, biofilm formation and virulence expression (Davies et al., 
1998; Engebrecht and Silverman, 1984; Haas et al., 2002; Ng and Bassler, 2009). The two 
most commonly described QS systems are the acyl–homoserine lactone (acyl–HSL) 
signalling system in Gram–negative species and the autoinducing peptide signalling system 
in Gram–positive species (Bassler, 2002; Sturme et al., 2002). A third system called the 
autoinducer–2 QS system, which was first described in Vibrio harveyi and implicated in 
interspecies communication has been found to be produced by a large number of Gram–
negative and Gram–positive species (DeKeersmaecker and Vanderleyden, 2003; Surrette and 
Bassler, 1998). The signalling molecule for the AI–2 QS systems is a furanosyl borate diester 
(Chen et al., 2002).  
Bacterial communication in Gram–negative species was first discovered in the marine 
bioluminescent bacterium Vibrio fischeri (Hastings and Nealson 1977). The typical Gram–
negative QS system is made of the LuxI/LuxR (HSL/transcriptional activator) signalling 
circuits (Fuqua et al., 1995; Miller and Bassler, 2001). However, QS in V. harveyi, another 
bioluminescent bacterium, does not use the typical LuxI/LuxR signalling system but rather an 
evolved QS system with characteristics that resemble both Gram–negative and Gram–
positive QS systems (Schauder and Bassler, 2001). V. harveyi makes and responds to 3 
autoinducers (V. harveyi autoinducer 1 (HAI–1), V. cholerae autoinducer 1 (CAI–1) and AI–
2) in three parallel QS systems that eventually controls the production of the master regulator 
LuxR (Henke and Bassler, 2004a; Henke and Bassler 2004b; Waters and Bassler, 2006). The 
production of LuxR has been found to directly or indirectly control the expression of genes 
required for bioluminescence, biofilm formation, type III secretion and protease production 
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(Waters and Bassler, 2006). It has been suggested that AI–2 and CAI–1 maybe associated 
with V. harveyi biofilms as mixed Vibrio consortium would contain significant levels of both 
AI–2 and CAI–1 (Waters and Bassler, 2006). It was observed that AI–2 consumptions in 
mixed V. harveyi – E. coli cultures significantly altered QS regulation in V. harveyi (Xavier 
and Bassler, 2005a; Xavier and Bassler, 2005b). Xavier and Bassler (2005b) therefore 
suggested that other bacteria with AI–2 QS systems could coexist with V. harveyi in in vivo 
settings such as in the gastrointestinal tracts of marine animals. In P. aeruginosa, there is a 
hierarchical QS system; two LuxI/LuxR pairs (LasI/LasR and RhlI/RhlR) that function 
together to control virulence expression and biofilm formation (Brint and Ohman, 1995; 
Parsek and Greenberg, 1999). A specific Pseudomonas quinolone signal (PQS) whose 
biosynthesis and function is mediated by the las and rhl QS systems is responsible for the 
control of lasB gene which encodes for the LasB elastase virulence factor (Calfee et al., 
2001). A third regulator, called the quorum–sensing–controlled regulator encoded by the 
qscR gene and homologous to the LasR and RhlR signal receptors has also been found to 
repress lasI which regulates acyl–HSL production (Chugani et al., 2000). Agrobacterium 
tumefaciens, like V. fischeri, also has the Ti plasmid TraI/TraR QS signalling circuit that 
activates and regulates the expression of genes responsible for mating between bacterial 
strains and the mobilisation of virulence factors in the Ti plasmid (Fuqua et al., 1995; Zhang 
et al., 1993). Reference A. tumefaciens strains KYC6, A136 and NTL4 have widely been 
used as biosensor reporter strains for the production and detection of the different AHL 
molecules produced by Gram–negative bacteria in bacterial cultures (Rickard et al., 2010; 
Stickler et al., 1998; Yin et al., 2012). A. tumefaciens biosensor strains carry the traI–lacZ 
reporter fusion gene which is activated by a transcriptional activator protein in the presence 
of AHL molecules (Stickler et al., 1998). The transcription of the fusion gene results in the 
production of β–galactosidase which cleaves X–gal (5–bromo–4–chloro–3–indolyl–β–D–
galactopyranoside), a β–galactosidase substrate, in a reaction that results in a distinctive blue 
pigmentation of colonies on agar plates (Stickler et al., 1998; Yin et al., 2012). 
In bacterial ecological units, the ability to rapidly colonise a surface and form biofilm is 
central to their survival in the midst of other competitors (Verstraeten et al., 2008). Costerton 
et al. (1987) and Brown and Williams (1985) have suggested that the adherence of bacteria to 
both biological (such as tissues) and non–biological (environmental) surfaces and to each 
other during biofilm formation and colonisation of niches may be promoted by the synthesis 
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of cell–surface associated polysaccharides called capsular polysaccharides (CPS). As a result, 
Jenkinson (1994) suggested that the interaction of bacterial (mono–species or multispecies) 
consortia within a biofilm may partly be mediated through glycan–lectin interactions that 
involve capsular polysaccharides and other ligands. In addition, capsular polysaccharides 
have been found to protect the growing biofilm from host–immune defence mechanisms such 
as lactoferrin, macrophages and complement 3 (Kamiya et al., 2012). The CPS acts as a thick 
matrix that prevents host immune attack (Schembri et al., 2005). Bacterial cell–surface 
appendages such as fimbriae have also been found to be expressed and associated with 
biofilm formation during initial adhesion (Schembri et al., 2005). Gram–negative fimbrial 
adhesins such as types 1 and 3 found at the tip of most fimbriae have been demonstrated to 
have specificity in binding to carbohydrate–containing receptors on the surfaces of others 
cells during cellular adhesion (Gygi et al., 1995; Schembri et al., 2005; Schroll et al., 2010). 
Though the long fimbrial structures allow them to penetrate the CPS, the CPS can interfere 
with their adhesive properties (Goncalves et al., 2014; Schembri et al., 2005).  
It has been demonstrated that, the expression and functions of the CPS and fimbriae may be 
regulated by quorum sensing (Chemani et al., 2009; Schembri et al., 2005; Tuson, and 
Weibel, 2013). For example, the role of LecA and LecB lectins (carbohydrate–binding 
proteins) which specifically bind to D–galactose and D–fucose in P. aeruginosa pathogenesis 
and biofilm formation in lung infection has been found to be regulated by quorum sensing 
(Chemani et al., 2009; Diggle et al., 2006; Tielker et al., 2005; Winzer et al., 2000). A third 
group of polysaccharides associated with biofilm formation is synthesised as part of the EPS 
by bacteria in a biofilm consortium. These polysaccharides which primarily make up the bulk 
of the EPS, together with other synthesised biopolymers such as extracellular DNA, proteins 
and lipids, make up the intercellular space of biofilm aggregates facilitating the 
differentiation of the growing biofilm (Vu et al., 2009). The main function of the EPS is to 
provide structural support to the mature biofilm (Branda et al., 2005; Latasa et al., 2006; 
Lopez et al., 2010; Rice et al., 2007). Extracellular polysaccharides, also called 
exopolysaccharides produced by some biofilm–forming bacterial strains include alginate, 
glucose–rich PEL and mannose–rich PSL by P. aeruginosa; polysaccharide intercellular 
adhesin (PIA) and poly–N–acetylglucosamine (PNAG) by S. aureus; and poly–δ–glutamate 
(PGA) and the polysaccharide EPS by Bacillus subtilis (Branda et al., 2006). EPS production 
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by biofilm–forming bacteria has been found to be regulated by quorum sensing (Davies et al., 
1998; Donlan, 2002; Ruiz et al., 2008; Waters and Bassler, 2005). 
The characterisation of the carbohydrate contents of the capsular polysaccharide, 
exopolysaccharides and other cell–surface glycans involved in adhesion and biofilm 
formation has been made possible through assays such as gas chromatography–mass 
spectrometry (GC–MS), high performance liquid chromatography–mass spectrometry 
(HPLC–MS), high pressure anion exchange chromatography (HPAEC) and electron 
microscopy (Al–Halbouni et al., 2009; Goncalves et al., 2014; Pierre et al., 2012; Wozniak et 
al., 2003). The carbohydrate contents of some strains of P. aeruginosa include mannose, 
glucose, galactose, mannuronic acid, rhamnose, N–acetyl fucosamine, N–acetyl 
galactosamine and N–acetyl glucosamine (Wozniak et al., 2003). Cell–free extracts of K. 
pneumoniae containing CPS and analysed by HPAEC were found to be composed of 
monosaccharides such as galactose, glucose, rhamnose, glucuronic acid and glucosamine 
(Goncalves et al., 2014). Gygi et al.  (1995) also demonstrated through GC–MS that P. 
mirabilis cell–surface polysaccharides were composed of galacturonic acid and 
galactosamine. However, characterisation of the carbohydrate contents of bacterial cell–
surface polysaccharides using the above–mentioned methods is expensive and is mostly 
beneficial for research purposes. The characterisation of the carbohydrate contents of 
biofilm–associated exopolysaccharides and bacterial cell–surface polysaccharides may prove 
to be new targets in the strategic development and design of effective anti–biofilm 
therapeutic agents (Bales et al., 2013; Vu et al., 2009). 
The individual use of biocides, antibiotics, antimicrobial peptides (such as polymyxin B and 
dermicidin) and antimicrobial wound dressings in the treatment of biofilm–infected chronic 
wounds as single treatment regimen has proven futile (Cowan, 2011; Hill et al., 2010; 
Percival et al., 2007). The biofilm EPS in addition to its role as a structural support for the 
biofilm also acts as a diffusion barrier that prevents the entry of large antimicrobial 
peptides/proteins such as lactoferrin, lysozyme and complement from the host immune 
system as well as antibiotics, thereby conferring resistance to the biofilm (Bjarnsholt et al., 
2005; Kimaya et al., 2012; Lewis, 2001). In Gram–negative bacteria such as P. aeruginosa, 
the anionic properties of neutral or polyanionic polysaccharides in the EPS such as cyclic and 
periplasmic glucans are enhanced by the presence of uronic acids and ketal–linked pyruvate 
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(Vu et al., 2009). Cyclic and periplasmic glucans bind to divalent cations such as calcium and 
magnesium to increase the binding force of the mature biofilm (Vu et al., 2009). In addition, 
the anionic properties of cyclic and periplasmic glucans enable them to bind and sequester 
aminoglycosides such as gentamicin, kanamycin and tobramycin on the cell surfaces or in the 
periplasm (Bagge et al., 2004; Brodgen, 2005; Colvin et al., 2011; Mah et al., 2003; 
Sadovskaya et al., 2010; Shigeta et al., 1997). Mah et al. (2003) further suggested that, 
bacteria embedded within biofilms also employ diverse mechanisms to resist antimicrobial 
actions. Bacterial resistance mechanisms that are evident during biofilm formation include; 
target modification by mutation; enzymatic changes leading to target modification; 
substitution of target (expression of alternative target); modification or destruction of 
antibiotic; antibiotic efflux, restricted entry of antibiotics and persister cell formation (Lewis, 
2007; Mah et al., 2003; Soto, 2013). The role of persister cells in biofilm resistance to 
antibiotics has been discussed in section 4.8 in Chapter 4. Also, poor efficacy of oral 
administration of antibiotics against wound biofilms even at high concentrations may 
probably be due to oxygen limitation (ischaemia), poor tissue perfusion and low metabolic 
activity rather than poor antibiotic penetration (Lipsky, 2004; Walters et al., 2003). The 
penetration of antibiotics or antimicrobial peptides such as polymyxin B and its derivatives 
may further be exacerbated in diabetic foot ulcer patients with peripheral vascular disease, 
neuropathy and/or Charcot disease (Hill et al., 2010; Kropec and Daschner, 1991; Martin et 
al., 2015).  Hill et al. (2010) further noted that biocides such as iodine impregnated in wound 
dressings with a gel base did not only have prolonged efficacy against wound biofilms, but 
also helped to degrade the biofilm EPS. Wound dressings impregnated with silver 
nanoparticles, Manuka honey, triglycerides, metals such as copper, zinc, gold and iron salts 
with different concentrations and drug delivery systems such as hydrogels, microemulsions, 
liposomes and metal nanoparticles have been tested on chronic wounds to determine their 
efficacies on both growing and mature biofilms (Hill et al., 2010; Martin et al., 2015; 
Percival et al., 2007). Though these antibiotics/antimicrobial agents, through their delivery 
systems can be delivered to biofilm–forming bacteria or biofilms, and interfere with 
mechanisms underlying biofilm formation such as quorum sensing and persister cell 




5.2 Aims and objectives 
The regulation of cellular processes underlying biofilm formation by QS resulting in 
resistance to clinically relevant antimicrobials and antibiotics is one of the biggest dilemmas 
as far as treatment of biofilm–related infections are concerned (Beceiro et al., 2013; Drenkard 
and Ausubel, 2002; Yao et al., 2006; Yi and Tian, 2012). The inhibition of quorum sensing 
has been considered as an alternative strategy to antibiotic treatment that can be useful in the 
treatment of chronic infections through the prevention and disruption of biofilm formation. 
Quorum sensing inhibitors (QSI) such as cinnamaldehyde (CIN), baicalin hydrate (BH) 
hamamelitannin and furanone derivatives have been found to influence EPS production and 
biofilm formation a fundamental step in the development of anti–biofilm strategies 
(Brackman et al., 2011; Estephane et al., 2008; Ponnusamy et al., 2010; Ren et al., 2001). 
However, the influence of QS in the formation of biofilms in K. pneumoniae and P. mirabilis 
is less known compared to other Gram–negative species such as E. coli and P. aeruginosa 
which are widely used as model strains for biofilms and QS studies (Lopez et al., 2010).   
The aim of this chapter is to investigate molecular mechanisms such as quorum sensing and 
bacterial cell–surface interactions in biofilm formation by K. pneumoniae and P. mirabilis. In 
silico techniques, such as bioinformatics database analysis using BioCyc, National Center for 
Biotechnology Information (NCBI) and Universal Protein Resource (UniProt), as well as in 
vitro assays were employed to study the biosynthetic pathways of QS genes in Klebsiella 
pneumoniae, Proteus mirabilis and P. aeruginosa clinical strains for autoinducer (AI–1 and 
AI–2) production. The 3 autoinducers produced by V. harveyi have been found to act 
synergistically to produce light in V. harveyi (Henke and Bassler, 2004b). The deletion of any 
of V. harveyi autoinducer synthases (CqsAvh for CAI–1; LuxM for HAI–1; and LuxS for AI–
2) has been found to significantly reduce light production by 83, 99.9 and 96% respectively 
in mutant strains (Henke and Bassler, 2004b). However, the addition of exogenous HA–1 and 
AI–2 signalling molecules restored light production in luxM and luxS mutants (Bassler et al., 
1993; Bassler et al., 1994).  
Against the backdrop of light production in V. harveyi, the current study investigated the 
bioluminescence of reference V. harveyi mutant strains through the exogenous addition of 
AI–2 signalling molecules produced from cell–free culture fluids of K. pneumoniae and P. 
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mirabilis clinical strains. The ability of exogenous AI–2 to induce biofilm formation in the 
reference V. harveyi strains was also accessed. Bacterial cell–cell adhesion and synthesis of 
polysaccharides in the EPS during biofilm formation were also investigated using a panel of 
plant lectins to determine the carbohydrate components of these polysaccharides. The role of 
AI–2 in K. pneumoniae and P. mirabilis biofilm formation was investigated through the 
inhibition of QS using a selection of QS inhibitors. The final part of this chapter considered 
the synergistic effects of antibiotics and antimicrobial agents such as QS inhibitors, cell 
membrane permeabilisers (PMB and PMBN) and wound dressings on biofilms in an attempt 
to identify and recommend a topical formulation for biofilm treatment. The following 
objectives were considered in an attempt to achieve the above aims;  
 Determination of quorum sensing (QS) genes in DFU isolates using in silico and in 
vitro methods such as bioinformatics tools and PCR amplification respectively. 
 To study the evolutionary relationship between DFU isolates and other speciated 
strains using QS genes. 
 Perform QS inhibition assays using MBEC™ Physiology & Genetics assay.  
 Perform bioluminescence assay according to the method described by Bassler et al, 
(1994). 
 Perform glycan–lectin assay using the enzyme–linked lectin–sorbent assay (ELLA) to 
confirm bacterial cell surface interactions during biofilm formation 
 To determine the synergistic effects of antibiotics and anti–biofilm agents on biofilms. 
 To determine the effects of wound dressings on DFU isolates and their synergy with 







5.3 Genomic studies of QS activities in Ghanaian DFU isolates 
Three strains namely; Klebsiella pneumoniae 028b, Proteus mirabilis 005 and P. aeruginosa 
038, (subsequently referred to as Klebsiella pneumoniae, Proteus mirabilis and P. 
aeruginosa) previously identified (Table 3.7, Chapter 3) were selected as diabetic foot 
representative strains for these studies. Two reference strains; P. aeruginosa PAO1 with 
las/rhl QS systems and V. harveyi NCIMB 1280 luminous strain (also known as ATCC 
14126 were used as control strains (Pearson et al., 1997; Pesci et al., 1997; Urbanczyk et al., 
2008).  
5.3.1 las/rhl regulated biofilm formation in P. aeruginosa 
Quorum sensing in P. aeruginosa is regulated by 2 hierarchical QS systems designated as las 
and rhl (Davies et al., 1998; Juhas et al., 2005; Schuster and Greenberg, 2006; Venturi, 
2006).  The correspondent increase in the signalling molecule 3–oxo–dodecanoyl (3–O–C12) 
homoserine lactone in response to increase cell density, leads to the formation of signalling 
molecule–LasR (a transcriptional regulator) complex (Sakuragi and Kolter, 2007). In addition 
to 315 other QS–activated genes, the 3–oxo–dodecanoyl HSL–LasR complex also directly 
activates lasI (autoinducer–1 synthase promoter gene) and rhlR (subordinate transcriptional 
regulator gene) leading to the regulation of several cellular processes such as virulence and 
biofilm formation (Gilbert et al., 2009; Sakuragi and Kolter, 2007). It has been found that, P. 
aeruginosa mutants with a defective Las QS system produced amorphous and weak biofilms 
(Davies et al., 1998). This suggests that Las QS system may be indirectly responsible for the 
synthesis of exopolysaccharides such as PEL that provide structural support to the growing 
biofilm (Davies et al., 1998; Friedman and Kolter, 2004; Sakuragi and Kolter, 2007; Vasseur 
et al., 2005). Since the sequential recognition of LasR and RhlR regulated processes leading 
to biofilm formation in P. aeruginosa is not fully defined, the predictions of such sequential 
process is difficult (Sakuragi and Kolter, 2007). In the current study, the presence of the 
las/rhl QS system in a DFU P. aeruginosa strain was determined by PCR (Figure 5.1A) and 
the sequenced DNA was compared with other published QS related genes that regulate 
biofilm formation in K. pneumoniae and P. mirabilis. BLAST and Genome Browser analyses 
of NCBI and BioCyc databases respectively failed to detect any QS gene in K. pneumoniae 
and P. mirabilis homologous to the las/rhl autoinducer–1 QS system in P. aeruginosa.  
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5.3.2 Light production in V. harveyi 
Light production by luminous bacteria (also called bioluminescence) has been previously 
described by Bassler et al. (1993) and Bassler et al. (1994). Bioluminescence in V. harveyi is 
synergistically controlled by HAI–1 and AI–2 QS systems (Bassler et al., 1993; Bassler et al., 
1994). In the HAI–1 – QS system, HAI–1 (N–(3–hydroxybutanoyl) HSL) produced by the 
autoinducer–1 synthase, LuxM is detected by a sensor kinase, LuxN at high cell density 
(Bassler et al., 1993). At high cell density, autoinducer–2 synthase, LuxS produces AI–2 
which is detected by the AI–2 sensors LuxP and LuxQ (Chen et al., 2002; Surrette et al., 
1999). At high cell density LuxN and LuxQ switch from being kinases to phosphatases and 
unphosphorylate and inactivate the response regulator, LuxO leading to the expression of 
luxR which encodes the activator protein LuxR (Freeman et al., 2000; Lenz et al., 2004). 
LuxR subsequently binds to promoter region and activates the expression of the luxCDABE 
operon encoding the luciferase and fatty acid reductase complex needed for light production 
(Bassler et al., 1993). For the purpose of the current study, a luminous reference strain V. 
harveyi NCIMB 1280 (also designated as V. harveyi ATCC 14126 strain) which is a luxM 
and luxS mutant (HAI–1¯ AI–2¯), and an aldehyde (luxCDE) (HAI–1¯ AI–2¯) mutant 
reference strain V. harveyi NCIMB 1872 (an aldehyde mutant of V. harveyi ATCC 33843 
(392 [MAV]) were employed for bioluminescence studies (Jensen et al., 1980; Johnson and 
Shunk, 1936; Nealson and Markovitz, 1970; Wang et al., 2015). The presence of the 














Figure 5 .1 PCR amplification of partial DNA sequences of; (A) lasI (126 bp, in lanes 2 and 
4), and rhlR (364 bp, in lanes 3 and 5) QS genes in P. aeruginosa and P. aeruginosa 
PAO1respectively. Lanes M – 100 bp DNA ladder, 1 – 203 bp 16S rRNA V3 hypervariable 
gene in P. aeruginosa (positive PCR control) and lane 6 is negative control (B). 190 bp luxA 
(lanes 1 and 2) QS genes in V. harveyi reference strains 1280 and 1872. Lanes 3 and 4 – 
negative controls and, lanes 5 and 6 – 125 bp 16S rRNA V6 hypervariable genes in V. 
harveyi as positive PCR controls. 
5.3.3 AI–2 biosynthesis in V. harveyi, K. pneumoniae and P. mirabilis 
Two biosynthetic pathways have been found to be responsible for the production of AI–2 in 
V. harveyi (and other members of the bacterial order Vibrionales) and other Gram–negative 
bacteria (Bassler et al., 1994; Miller et al., 2004; Rezzonico and Duffy, 2008). In both AI–2 
biosynthetic pathways, the precursor compound S–adenosyl–L–methionine donates a methyl 
group to become S–adenosyl–L–homocysteine in a reaction catalysed by S–
ribosylhomocysteine lyase (LuxS) with S–ribosyl–L–homocysteine and L–homocysteine as 
the major end–products (Schauder et al., 2001: Surrette et al., 1999; Zhu and Mekalanos, 
2003; Zhu et al., 2003; Zhu et al., 2004). The production of the final AI–2 molecule from L–
homocysteine which is detected by members of the order Vibrionales and other Gram–
negative bacteria such as Salmonella enterica serovar typhimurium creates the difference 
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between the 2 biosynthetic pathways. The precise nature and cascade of reactions that result 
in the ultimate AI–2 production is species specific and involves spontaneous transformations 
that include cyclisation and isomerisation processes leading to (2R,4S)–2–methyl–2,3,3,4–
tetrahydroxytetrahydrofuran synthesis in S. enterica serovar typhimurium (as shown in Figure 
5.2) and (2S,4S)–2–methyl–2,3,3,4–tetrahydroxytetrahydrofuran–borate in Vibrionales 
(Bassler et al., 1994; Chen et al., 2002; Miller et al., 2004; Rezzonico and Duffy, 2008). The 
recognition of AI–2 in Vibrionales is by dedicated AI–2 receptors encoded by the luxP and 
luxQ genes (Bassler et al., 1994; Reading and Sperandino, 2006). The AI–2 in S. 
typhimurium and other Gram–negative bacteria is recognised by AI–2 receptors belonging to 
the ABC transporter–periplasmic binding protein family (Miller et al., 2004). 
Unlike K. pneumoniae and P. mirabilis, the presence and processes underlying QS–regulated 
activities in V. harveyi such as virulence and biofilm formation have been well studied 
(Bassler, 1993; Bassler and Silverman, 1994; DeKeersmaecker and Vanderleyden, 2003; 
Henke and Bassler, 2004a; Henke and Bassler 2004b; Surrette and Bassler, 1998; Waters and 
Bassler, 2006; Surrette and Bassler, 1998; Xavier and Bassler, 2005a; Xavier and Bassler, 
2005b). In the current study, BioCyc database was employed in the analysis of biosynthetic 
pathways leading to the production of AI–2 in V. harveyi, K. pneumoniae and P. mirabilis. 
The database model strains used in these analyses were Klebsiella pneumoniae 342, Proteus 
mirabilis HI4320 and Vibrio harveyi CAIM 1792 (Espinoza–Valles et al., 2012; Fouts et al., 
2008; Pearson et al., 2008). Biosynthetic pathways leading to AI–2 productions in K. 
pneumoniae and P. mirabilis was found to be similar to that previously described in S. 
typhimurium (above) resulting in the production of (2R,4S)–2–methyl–2,3,3,4–
tetrahydroxytetrahydrofuran as shown in Figure 5.2 (Miller et al., 2004; Xavier and Bassler, 
2005b). In addition, AI–2 mediated QS in K. pneumoniae leads to the expression of the 
lsrACDBFGE operon, cytoplasmic kinase lsrK gene and the transcriptional repressor lsrR 
gene (De Araujo et al., 2010; Taga et al., 2003; Xavier and Bassler, 2005b). In this study, 
primers were designed to amplify the luxS gene that encodes the synthesis of LuxS, the main 
enzyme that catalyses the hydrolysis of S–ribosylhomocysteine to L–homocysteine and 
autoinducer–2 in K. pneumoniae and P. mirabilis (Figures 5.3A and B). The luxS PCR 
amplicons of K. pneumoniae and P. mirabilis were sequenced and the DNA sequences 




Figure 5 .2 Summary of the AI–2 biosynthetic pathways in K. pneumoniae 342 and P. 
mirabilis H14320. In reaction 1 (R1), S–adenosyl–L–methionine donates a methyl group to 
become S–adenosyl–L–homocysteine in a reaction catalysed by a methyltransferase. In 
reaction 2 (R2) 5'–methylthioadenosine/S–adenosylhomocysteine nucleosidase catalyses the 
hydration of S–adenosyl–L–homocysteine to release an adenine and form S–ribosyl–L–











Figure 5 .3 PCR amplification of partial DNA sequence of; (A) 320 bp of the luxS QS gene in 
9 K. pneumoniae (lanes 1 – 10) and 1 K. variicola strains (lane 11). Lane 10 – negative 
control. (B) 152 bp luxS QS gene in 22 P. mirabilis strains (except in lane 8). Lane 24 – 
negative control.  
5.3.4 Biosynthesis of lrsB and bssS in K. pneumoniae and P. mirabilis  
At high cell density, the synthesised AI–2 signalling molecules in the extracellular milieu are 
internalised, phosphorylated, sequestered and destroyed (Taga et al., 2001; Taga et al., 2003; 
Xavier et al., 2007). The sequestering and destruction of modified AI–2 by some bacteria 
such as S. enterica serovar typhimurium has been found to interfere with intercellular 
communication in a bacterial consortium (Xavier et al., 2007). In the present study, BioCyc 
Genome Browser analysis tool was used to locate the position of the lsrACDBFG operon in 
the chromosome of K. pneumoniae 342 database strain (Appendix A). The presence of the 
LuxS regulated (Lsr) ABC transporter gene in 10 Klebsiella species (9 K. pneumoniae and 1 
K. variicola) was determined by PCR amplification of the lsrB gene (Figure 5.5A) which 
encodes the LsrB ABC transporter – periplasmic AI–2 binding protein responsible for the 
internalisation of bound AI–2 molecules (Xavier et al., 2007). The PCR amplicons were then 
sequenced and compared to other lsrB genes published in the databases (Figure 5.8). 
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Two biofilm formation regulatory genes known as bssR and bssS have been found to be 
induced during biofilm formation in E. coli and other Gram–negative bacteria such as K. 
pneumoniae, P. mirabilis, Citrobacter freundii, Yersinia pestis, Shigela flexneri, Salmonella 
enterica subspecies enterica serovar typhimurium and Enterobacter aerogenes (Beloin et al., 
2004; Domka et al., 2006; Jayaraman and Wood, 2008; Ren et al., 2004; Schembri et al., 
2003). The expressions of bssR and bssS were found to regulate biofilm formation (Figure 
5.4) through the uptake and the processing of extracellular AI–2, and the differential 
expressions of other genes responsible for biofilm formation (Domka et al., 2006). 
 
Figure 5 .4 Proposed regulation (positive (+), negative (–)) of biofilm in E. coli by biofilm 
formation regulatory genes, bssR and bssS (Domka et al., 2006).  
In the current study, the presence of the bssS gene in P. mirabilis was determined using 
Genome Browser and Nucleotide/Gene BLAST search tools of BioCyc and NCBI databases 
respectively and confirmed by PCR amplification of the gene (Figures 5.5B). The bssS gene 
was found to be centrally located (from position 1793752 to 1794006) in the chromosome of 
P. mirabilis HI4320 (Appendix B). Unlike E. coli, K. pneumoniae and S. typhimurium which 
have both bssR and bssS genes in the same chromosome, P. mirabilis has been found to have 
only bssS. The chromosomal position of the 255 base pairs (bp) bssS gene is species–specific. 
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In the E. coli K–12 sub–strain MG1655 chromosome (4,609,408 bp) where bssR and bssS 
were first found, bssS is located upstream with an intergenic distance of 242070 bp between 
them. BioCyc Genome Browser analysis further revealed that, while none of the genes is part 
of an operon, they are also transcribed in opposite directions; with bssR towards the right 
(forward) and bssS in the reverse direction. In this study, the partial bssS gene sequence 
amplified by PCR was sequenced and compared with other sequenced bssS and bssR (384 bp) 





Figure 5 .5 PCR amplification of partial DNA sequences of; (A) 199 bp lrsB QS gene in 8 K. 
pneumoniae and 1 K. variicola strains (lanes 2 – 9 and lane 10) and lane 11 – negative 
control, (B) 104 bp bssS QS gene in 23 P. mirabilis strains. Lane 24 – negative control.  
The evolutionary relationships inferred using the cladograms in Figures 5.6, 5.7, 5.8 and 5.9 
were based on protein–coding nucleotide sequences for the purpose of homology 
comparisons. The computer–generated evolutionary distances were for references only and 
not used for analyses of the trees. Figure 5.6 shows a high degree of homology between the 
luxS genes in 018b K. variicola and 028b K. pneumoniae as well as between V. harveyi 
(GenBank Accession number AF120098) and P. mirabilis HI4320. The P. mirabilis strain 
identified in this study (005 P. mirabilis) however showed lower degree of homology to the 
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others. The multiple sequence alignment in Appendix C used for the construction of the tree 
provides more details on the homology of all the 5 sequences. 
Two Klebsiella species identified in this study, 018b K. variicola and 028b K. pneumoniae 
showed a high degree of homology between their lsrB genes (Figure 5.7). Also, sequence 
homology between S. enterica subspecies enterica serovar typhimurium CDC 2011K–0870 
and K. pneumoniae 342 lsrB genes was higher than with the lsrB gene of E. coli RS76 
(Figure 5.7, Figure C4 in Appendix C). As expected the bssS genes in 005 P. mirabilis and P. 
mirabilis HI4320 showed a high degree of homology when aligned together (Figure 5.8). The 
bssS genes in K. pneumoniae 342 and K. variicola At–22 also showed high degree of 
homology (Figure 5.8). However, bssS gene homology between E. coli RS76, K. pneumoniae 
342 and K. variicola At–22 was found to be higher than that between P. mirabilis HI4320 
and test strain 005 P. mirabilis (Figure 5.8). In Figure 5.9, gene sequence homology was 
found to be higher in the bssS clade (005 P. mirabilis and P. mirabilis HI4320 branches) and 












 018b K. variicola luxS
 028b K. pneumoniae luxS
 V. harveyi luxS AF120098
 P. mirabilis HI4320 luxS gi172046403










Figure 5 .6 A Cladogram showing the evolutionary relationship between 3 DFU isolates and 
2 published speciated strains using the protein–coding nucleotide sequence of the luxS gene. 
Partial DNA sequences for 018b K. variicola, 028b K. pneumoniae and 005 P. mirabilis were 
used for the analysis. The optimal tree was reconstructed using the Neigbor–Joining (N–J) 
method (Saitou and Nei, 1987). The tree is drawn to scale, with branch lengths (next to the 
branches) in the same units as those of the evolutionary distances used to infer the 
phylogenetic tree. The evolutionary distances were computed using the Maximum Composite 
Likelihood method and are in the units of the number of base substitutions per site (Tamura et 
al., 2004). All positions containing gaps and missing data were eliminated. There was a total 
of 124 positions in the final dataset. Evolutionary analyses were conducted in MEGA6 
(Tamura et al., 2013). 
 018b K. variicola lsrB
 028b K. pneumoniae lsrB
 E. coli RS76 lsrB gi959839705
 K. pneumoniae 342 lsrB gi206564770










Figure 5 .7 Cladogram based on lsrB gene sequence reconstructed using the N–J method. 
Five protein–coding nucleotide sequences (partial sequences of 018b K. variicola and 028b 
K. pneumoniae from this study; and complete sequences of K. pneumoniae 342 lsrB 
gi206564770, E. coli RS76 lsrB gi959839705 and S. enterica subsp. enterica serovar CDC 




 K. pneumoniae 342 bssS gi206575712
 K. variicola At-22 bssS gi288932888
 E. coli RS76 gi959839705 bssS
 005 P. mirabilis bssS













Figure 5 .8 Cladogram based on the bssS gene sequence reconstructed using the N–J method. 
Five protein–coding nucleotide sequences (partial sequences of 005 P. mirabilis bssS gene 
from this study; and complete sequences of K. pneumoniae 342 bssS gi206575712, K. 
variicola At–22 bssS gi288932888 and E. coli RS76 bssS gi959839705 from NCBI 
GenBank) were used to predict their evolutionary relationship. 
 005 P. mirabilis bssS
 P. mirabilis HI4320 bssS gi197283915
 E. coli str. K-12 substr. MC4100 bssR gi557270520
 K. pneumoniae 342 bssR gi206575712










Figure 5 .9 Cladogram based on the bssS and bssR gene sequences reconstructed using the N–
J method. Five protein–coding nucleotide sequences (partial sequences of 005 P. mirabilis 
bssS gene from this study; and complete sequences of K. pneumoniae 342 bssR gi206575712, 
P. mirabilis HI4320 bssS gi197283915, S. enterica subsp. enterica serovar typhimurium P–
stx–12 gi374352002 and E. coli str. K–12 substr. MC4100 bssR gi557270520 from NCBI 
GenBank) were used to predict their evolutionary relationship.  
Multiple sequence alignments from which the cladograms were constructed can be referred to 
from Appendices C2 to C6. Appendix C1 also provides details on the 16S rRNA gene 




5.4 Quorum sensing detection assays 
Three QS assays were employed to study QS activities in a selection of DFU isolates. In the 
biosensor–reporter assay, an A. tumefaciens reference strain, NCIMB 14543 with a lacZ–
fusion reporter gene was used to detect the production of AHL by 37 DFU isolates. The 
ability of exogenously produced AI–2 from DFU isolates to stimulate the wild–type and 
mutagenized V. harveyi reference strains on sea–water or Luria–marine agar to produce light 
was also determined. Finally, the ability of the V. harveyi reference strains to detect 
exogenous AI–2 in solution and produce light was quantitatively determined using the 
bioluminescence assay. 
5.4.1 Detection of AHL production by DFU isolates  
In this study, the A. tumefaciens control used in the cross–feeding assay A. tumefaciens 
NCIMB 14543 was a non–AHL producer and a broad–spectrum host that carries a hyuC–
lacZ fusion gene activated by a LuxR family transcriptional regulator in the presence of 
exogenously produced AHL molecules (Jiwaji, 2006; Jiwaji and Dorrington, 2009; Jiwaji et 
al., 2008). The production of AHL molecules by the DFU isolates used in this study was 
detected by the presence of blue pigmentation of the control strain streaked next to the test 
strain (Figure 5.10A and B). A. tumefaciens streaked next to itself (cream colonies) was used 
as a negative control (Figure 5.10D). Out of the 37 clinical strains tested, 29 (78%) of them 
were positive for AHL production. Fifteen (65%) out of the 23 P. mirabilis strains tested 
were AHL producers. All 9 K. pneumoniae strains as well as the only K. variicola strain were 
found to be AHL producers. The remaining 4 isolates; C. koseri, E. coli, P. aeruginosa, and 
P. stuartii were also positive for AHL production. However, out of the 23 P. mirabilis strains 
5 of them; 004, 009, 010b, 020 and 037, were slightly positive with a hint of blue 
pigmentation of the colonies that could just be seen on the agar plates. The remaining 3 P. 
mirabilis strains (014, 032a and 033) were completely negative for AHL production (Table 











Figure 5 .10 Cross–feeding assay for AHL detection production in DFU isolates using A. 
tumefaciens NCIMB 14543 biosensor reporter strain.  A. tumefaciens NCIMB 14543 reported 
AHL production in; (A) 005 – P. mirabilis; and (B) 028b K. pneumoniae. (C) 033a – P. 
mirabilis showing a negative result and; (D) A. tumefaciens NCIMB 14543 against itself as a 
negative control. 
5.4.2 Detection of AI–2 molecules by DFU isolates  
In the cross–stimulation assay, K. pneumoniae and P. mirabilis were used as AI–2 donors to 
induce bioluminescence in V. harveyi references strains. Three V. harveyi strains; wild–type 
V. harveyi NCIMB 1280, mutagenized (dim and dark) V. harveyi NCIMB 1280 (designated 
as V. harveyi NCIMB 1280d) and an aldehyde mutant V. harveyi NCIMB 1872 strain were 
stimulated by exogenous AI–2 and the intensity of their light production compared (Bolton, 
2012). The detection of bioluminescence of the V. harveyi strains was done by image 
capturing in a dedicated darkroom (Figure 5.11A, B, C and D). Bioluminescence was 
observed at the edges of centrally placed AI–2 recipient V. harveyi strains in close proximity 
to the 028b and 005 (K. pneumoniae and P. mirabilis respectively) AI–2 donors. The wild–
type NCIMB 1280 strain produced the brightest glow on exposure to darkness (Figure 
5.11A). The mutagenized NCIMB 1280dd also produced a dim glow at the proximal edges 
indicating reduced functionalities to produce and sustain luminescence (Figure 5.11B). The 
absence of a functional fatty acid reductase complex in the NCIMB 1872 strain resulted in 
the absence of aldehyde; one of the substrates oxidised by luciferase to produce fatty acids 
that leads to light production (Hastings et al., 1985). Reduced functionality of the luciferase 
enzyme as a result of a defective aldehyde synthesis leads to the formation of aldehyde 
mutant (dim and dark) strains that produce little or no light even after stimulation by 
exogenous AI–2 (Hastings et al., 1989; Shimomura et al., 1974). In the present study, 
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mutagenesis of the wild–type V. harveyi NCIMB 1280 strain produced a dim mutant whereas 










Figure 5 .11 AI–2 cross–stimulation assay for light production in V. harveyi. On exposure to 
darkness; (A) wild–type NCIMB 1280 strain produced the brightest glow followed by, (B) 
mutagenized NCIMB 1280d with dim glow. (C) Aldehyde mutant NCIMB 1872 appeared 
dark even after 20 mins of exposure to darkness. (D) A. tumefaciens NCIMB 14543 was used 
as the negative control (no light production). 
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5.4.3 Induction of bioluminescence by AI–2 – producing DFU isolates  
The AI–2 activity in cell–free supernatants extracted from batch cultures of 23 P. mirabilis, 9 
K. pneumoniae and 1 K. variicola strains was determined using a 96–well plate assay. In a 
separate assay, the synergy between commercially prepared HAI–1, (N–(3–hydroxybutanoyl) 
homoserine lactone) and AI–2 in the bioluminescence of V. harveyi was also determined. The 
GloMax®–Multi Detection system (Promega, UK) was used to quantitatively determine 
bioluminescence, presented as relative light units (RLU) and fold induction of 
bioluminescence over a period of time. In this study, fold induction of bioluminescence was 
defined as the ratio of the relative luminescence (in RLU) of the reporter strain (V. harveyi 
NCIMB 1280) cultured in a conditioned AB medium to the that of V. harveyi NCIMB 1280 
grown in sterile AB medium. A conditioned AB medium (as described in chapter 2, section 
2.6.2) is defined as a filter–sterilised cell–free culture supernatant of an organism prepared 
from an overnight broth culture in AB medium to a predetermined optical density (Schneider 
et al., 2002) The positive controls were 005 P. mirabilis and 028b K. pneumoniae (known 
AI–2 producers) and the negative control was made of AB medium and V. harveyi NCIMB 
1280 (non–AI–2 producer).  
Fold induction of bioluminescence in V. harveyi NCIMB 1280 was determined per the 
method described by Blehert et al. (2003) and Rickard et al. (2010) with few modifications 
(Table 5.1). Fold induction of ≥ 10 representing 19.3% bioluminescence of V. harveyi–P. 
mirabilis positive control were considered positive results as no supplements such as borate 
was added to increase AI–2 signal strength and increase background signal (Rickard et al., 
2010). It is evident in Table 5.1 that all 33 K. pneumoniae and P. mirabilis DFU strains 
induced bioluminescence in the V. harveyi NCIMB 1280 reporter strain with fold induction > 
10. The 3 highest fold induction values were recorded in 005 P. mirabilis (100%), 032a P. 
mirabilis (104%) and 035 K. pneumoniae (440%). Although 034a K. pneumoniae was 
negative for luxS PCR (Figure 5.3A), it was able induce light production in the V. harveyi 
reporter strain by 35.6%. The concentration of AI–2 produced and detected during batch 
culture has been found to vary at different time points and differ among chronic wound 




Table 5 –1 AHL detection by reporter strain A. tumefaciens NCIMB 14543 and induction of 
bioluminescence in reporter strain V. harveyi NCIMB 1280 by cell–free culture supernatants 









Fold induction of 
bioluminescence in V. 
harveyi NCIMB 1280 
V. harveyi NCIMB 1872ꝉ   ND ND ND 
001 P. mirabilis + 40 49.4 
002 P. mirabilis + 38 46.9 
003b P. mirabilis + 30 37.0 
004 P. mirabilis ̶ 30 37.0 
005 P. mirabilis* + 42 51.9 
006 P. mirabilis + 27 33.3 
007 P. mirabilis + 24 29.6 
008 P. mirabilis + 22 27.2 
009 P. mirabilis ̶ 26 32.1 
010b P. mirabilis ̶ 30 37.0 
011 P. mirabilis + 34 42.0 
014 P. mirabilis ̶ 23 28.4 
016 P. mirabilis + 38 46.9 
018a P. mirabilis + 24 29.6 
019b P. mirabilis + 20 24.7 
020 P. mirabilis Slightly + 22 27.2 
021a P. mirabilis + 26 32.1 
025b P. mirabilis + 15 18.5 
026 P. mirabilis + 17 21.0 
032a P. mirabilis ̶ 44 54.3 
033 P. mirabilis ̶ 32 39.5 
034b P. mirabilis + 34 42.0 
037 P. mirabilis Slightly + 29 35.8 
018b K. variicola + 21 25.9 
021b K. pneumoniae + 30 37.0 
022b K. pneumoniae + 18 22.2 
023a K. pneumoniae + 24 29.6 
027 K. pneumoniae + 25 30.9 
028b K pneumoniae* + 34 42.0 
029 K. pneumoniae + 38 46.9 
032b K. pneumoniae + 39 48.1 
034a K. pneumoniae + 15 18.5 
035 K. pneumoniae + 185 228.4 
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Key for Table 5.1 (above) 
(+) and (–) indicate positive and negative results respectively. 
ꝉ – V. harveyi NCIMB 1872 – negative control; ND – Not determined.   
* – Positive controls (005 P. mirabilis and 028b K. pneumoniae). The value for V. harveyi 
NCIMB 1280/AB medium used for fold induction calculations was 8100 RLU.  
It has also been observed that exogenous AI–2 signal detected by bioluminescence reporter 
strains like the wild–type V. harveyi BB170, which produces and detects its own AI–2, 
decreases between 5 and 5 ½ hours after inoculation (DeKeersmaecker and Vanderleyden, 
2003; Ren et al., 2001; Surrette and Bassler, 1998). The reduction of exogenous AI–2 has 
been associated with interference from endogenous AI–2 of the reporter strain which 
contributes to < 1% of total bioluminescence signal detected (DeKeersmaecker and 
Vanderleyden, 2003). DeKeersmaecker and Vanderleyden (2003) therefore recommended 
that in investigating the effects of exogenous AI–2 on the fold induction of bioluminescence 
in V. harveyi over a time–period, AI–2 production must be assayed at selected time points. 
This will allow the observation of peak and decline in AI – 2 production and their effect on 
bioluminescence. In the work presented here, fold induction of bioluminescence in V. harveyi 
NCIMB 1280 by exogenous AI–2 donated by 2 DFU isolates, 028b K. pneumoniae and 005 
P. mirabilis was monitored at selected time points (Figure 5.12A). It was observed that 
expression and detection of AI–2 peaked at time–point 3 (Figure 5.12AB). Addition of 
commercially prepared N–(3–hydroxybutanoyl) HSL to exogenous AI–2 to increase 
bioluminescence in V. harveyi NCIMB 1280 showed similar pattern in the luminescence of 
the biosensor reference strain without necessarily increasing fold induction. However, the 
values obtained for the AI–2 + HAI–1 assay in Figure 5.13B were inconsistent but generally 
lower than (except 110.5 for FIKp (AI–2+HAI–1) and 46.1 for FIPm (AI–2+HAI–1)) those 
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Figure 5 .12 Fold induction of luminescence of V. harveyi NCIMB 1280 reporter strain over a 
period of 24 hours; (A). Expression and detection of AI–2 only and; (B) combined effect of 
AI–2 and HAI–1 (N–(3–hydroxybutanoyl) HSL on the induction of luminescence in 
biosensor reporter strain. Combined AI–2 and HAI–1 activity was monitored at 7 time–points 
using the GloMax®–Multi Detection system luminescence plate assay.  
The difference between the fold induction of bioluminescence in the V. harveyi NCIMB 1280 
biosensor reporter strain by AI–2 only and AI–2 + HAI–1 in Figure 5.13AB was statistically 
insignificant (p > 0.28). The typical domed–shaped pattern of AI–2 induction of 
bioluminescence in V. harveyi reporter strains has been observed in previous works (Rickard 
et al., 2010; Schneider et al., 2002). 
5.4.4 Effect of exogenous AI–2 in biofilm formation by V. harveyi reference 
strains    
The addition of exogenous AI–2 extracted from DFU isolates on V. harveyi in a biofilm co–
culture was performed to assess the effect of quorum sensing on biofilm formation. Biofilm 
formation by V. harveyi strains NCIMB 1280 and NCIMB 1280d in the presence or absence 
of exogenous AI–2 was estimated using the biofilm growth check (BGC) step of the 
MBEC™ assay as outlined in section 2.4.3.1. BGC was expressed as CFU/mL and a graph of 
Log10 (CFU/mL) plotted both the wild–type and mutant V. harveyi strains (Figure 5.13). It 
was observed that, addition of exogenous AI–2 increased biofilm formation by 17.0% in the 
wild–type (NCIMB 1280) and 8.8% in the mutant (NCIMB 1280d) strain. Despite the 
addition of exogenous AI–2 to the NCIMB 1280d mutant strain, biofilm formation by the 
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wild–type strain was 9.5% more than that produced by the mutant strain in the presence of 
AI–2. The difference between biofilm biomass formed by the wild–type NCIMB 1280 in the 
presence of exogenous AI–2 (1280+AI–2) and that produced by the wild–type only (1280) 
was found to be statically significant by One Sample (two–tailed) t test (p = 0.0014).  





















Figure 5 .13 Biofilm formation by V. harveyi NCIMB 1280 reference strain before and after 
mutagenesis and addition of exogenous AI–2. The wild–type V. harveyi NCIMB 1280 and 
dim mutant V. harveyi NCIMB 1280 strains have been denoted as 1280 and 1280d 
respectively. One Sample t test between 1280 and 1280+AI–2 was statistically significant (*p 
= 0.0014). 
5.5 Bacterial cell–cell interaction in biofilm formation 
The expression and types of cell–surface polysaccharides during biofilm formation can 
provide important information in the characterisation of the biofilm for diagnostic and 
treatment purposes (Bales et al., 2013; Tielker et al., 2005; Winzer et al., 2000). In the 
present study, an attempt was made to characterise the polysaccharides that are expressed by 
K. pneumoniae and P. mirabilis during biofilm formation using an ELISA–based technique 
called enzyme–linked lectinsorbent assay (ELLA). The presence of K. pneumoniae and P. 
mirabilis cell–surface polysaccharides which contain galactose and galacturonic acid 
monomers was determined by a panel of seven biotinylated lectins with specificity for those 
carbohydrates (Figure 5.14). From Figure 5.14, it can be seen that the lectin with high affinity 
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binding to corresponding glycans on the cells surfaces of K. pneumoniae and P. mirabilis 
biofilm extracts as well as the S. aureus (positive control) strain was Ricinus communis 
Agglutinin I (RCA–I) followed by Concanavalin A (CON A) and Jacalin (JAC). This implies 
that the exopolysaccharides, capsular polysaccharides and other protein–binding 
polysaccharides produced by K. pneumoniae and P. mirabilis DFU isolates contain glucose, 
mannose, N–acetyl D–galactosamine and galactose sugar monomers. Phaseolus vulgaris 
Leucoagglutinin (PHA–L) which binds to complex sugars also showed positive results which 
indicated the presence of sugars other than those detected by RCA–I, CON or JAC. In Table 
5.2 it can be seen that, Peanut Agglutinin (PNA) could only detect galactose on the cell–
membrane of P. mirabilis but not on K. pneumoniae or S. aureus. There was no detectable 
binding between Sophora japonica (SJA) and any of the bacterial cells.  






















Figure 5 .14 Specificity of carbohydrate–binding lectin to polysaccharides on whole cells of 
K. pneumoniae (ODKp), P. mirabilis (ODPm) and S. aureus (ODSa). S. aureus was used as a 












PNA JAC SJA RCA PHA–L CON A 
K. pneumoniae – +++ – +++ + +++ 
P. mirabilis + +++ – +++ + +++ 
S. aureus – +++ – +++ + +++ 
*– A positive ELLA result was scored as (+) and a negative result as (–). Scoring of the assay 
was done using the following range as a guide as described by Dharod (2010): 0 – 0.05) 
represents (–); 0.06 – 0.14 represents (+); 0.15– 0.22 represents (++); and 0.23 and above 
represent (+++). 
5.6 Effects of antimicrobial agents and quorum sensing inhibitors on 
biofilms 
In the present study, the effect of 3 quorum sensing inhibitors (QSI); cinnamaldehyde (CIN), 
baicalin hydrate (BH) and (Z–)–4–Bromo–5–(bromomethylene)–2(5H)–furanone (2(5H)–
furanone) were assessed on their ability to inhibit K. pneumoniae and P. mirabilis biofilms.  
CIN, BH and 2(5H)–furanone are cyclic organic compounds which are derivatives of natural 
compounds that have widely been used as anti–quorum sensing agents (Brackman and 
Coenye, 2015; Brackman et al., 2009; Christensen et al., 2012; Romano et al., 2013; Ren et 
al., 2001). The MICs of baicalin hydrate, cinnamaldehyde and 2(5H)–furanone were 
determined in two–fold dilution assays using the MBEC™ assay as outlined in section 
2.4.3.5. Sub–inhibitory concentrations of BH, CIN and 2(5H)–furanone selected for synergy 
assays were 2500 µg/mL, 1000 µM (132.06 µg/mL) and 250 µg/mL respectively. The 
combined effects of BH, CIN and 2(5H)–furanone (at sub–inhibitory concentrations) and 
ceftazidime and levofloxacin (at minimum inhibitory concentrations) were assessed on K. 
pneumoniae and P. mirabilis biofilms (Tables 5.3, 5.4 and 5.5). In two–fold dilution assays, 
the synergy between the antibiotics (ceftazidime and levofloxacin), and the QSIs (BH, CIN 
and 2(5H)–furanone), and the antimicrobial peptides (polymyxin B and polymyxin B 
nonapeptide) was also assessed (Tables 5.6 and 5.7).  
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5.6.1 Synergistic effects of anti–biofilm agents and antibiotics on DFU biofilms  
The synergy between anti–biofilm agents such as baicalin hydrate, cinnamaldehyde, 
hamamelitannin and 2(5H)–furanone have been evaluated as alternate strategies to eradicate 
biofilms (Brackman et al., 2011; Ghosh et al., 2013; Janssens et al., 2008). The current study 
evaluated the combinatorial effects of 3 QSIs, baicalin hydrate, cinnamaldehyde and 2(5H)–
furanone and 2 antibiotics, ceftazidime and levofloxacin on 2 DFU biofilm–forming isolates, 
K. pneumoniae and P. mirabilis. In 2 separate assays, the synergy between 2 antimicrobial 
peptides (AMP); polymyxin B (PMB) and its derivative polymyxin B nonapeptide (PMBN) 
and CAZ/LEV in the inhibition of K. pneumoniae and P. mirabilis biofilms was also 
assessed.  















K. pneumoniae Ceftazidime  640 2560 5120 
Levofloxacin 40 1280 2560 
P. mirabilis Ceftazidime 2560 5120 5120 
Levofloxacin 40 640 1280 
* – Sub–inhibitory of centration of BH was maintained at 2500 µg/mL while concentrations 
of CAZ and LEV at 5120 µg/mL, were diluted in a two–fold dilution across the rows (from 1 
to 10) of the 96–well base of the MBEC™ P&G plate. Columns 11 and 12 were used as 
positive controls for biofilm growth check. 
a – Log10 reduction assay at which ≥ 50% bacterial cells were killed or eradicated. 
Table 5.3 shows the MIC values for CAZ and LEV in the presence of BH (2500 µg/mL) 
which resulted in complete inhibition of K. pneumoniae and P. mirabilis biofilms. Log10 
reduction assays also showed the MBC and MBEC at which 50% or more K. pneumoniae and 
P. mirabilis biofilm cells were prevented from growing on agar plates or eradicated by the 
combined activity of BH and CAZ/LEV. The MBC and MBEC values were 2 – 16 times 
more than their respective MICs. 
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The MIC values in Table 5.4 were the concentrations of CAZ and LEV in the presence of 
CIN (132.06 µg/mL) which resulted in complete inhibition of K. pneumoniae and P. 
mirabilis biofilms from forming on the pegs of the MBEC™ lid. However, the concentrations 
of CAZ and LEV needed to prevent ≥ 50% biofilm cells from growing on agar plate or 
eradicated were between 2 to 8 times more than their respective MICs. 















K. pneumoniae Ceftazidime 640 1280 2560 
Levofloxacin 40 640 2560 
P. mirabilis Ceftazidime 640 1280 5120 
Levofloxacin 20 640 2560 
* – Sub–inhibitory of centration of CIN was maintained at 1000 µM (132.06 µg/mL) while 
concentrations of CAZ and LEV at 5120 µg/mL, were diluted in a two–fold dilution across 
the rows (from 1 to 10) of the 96–well base of the MBEC™ P&G plate. Columns 11 and 12 
were used as positive controls for biofilm growth check. 


























K. pneumoniae Ceftazidime 10 40 40 
Levofloxacin 10 640 640 
P. mirabilis Ceftazidime 20 320 5120 
Levofloxacin 10 640 2560 
* – Concentration of 2(5H)–furanone was maintained at 500 µg/mL whereas concentrations 
of CAZ and LEV at 5120 µg/mL were diluted in two–fold across the rows (from 1 to 10) of 
the 96–well base of the MBEC™ P&G plate. Columns 11 and 12 were used as positive 
controls for biofilm growth check. 
a – see footnote of Table 5.3 for details on Log10 reduction. 
In Table 5.5, the MBC and MBEC of CAZ and LEV in the presence of 2(5H)–furanone 
needed to prevent K. pneumoniae and P. mirabilis growth on agar or eradicate their biofilm 
were 4 – 256 times more than their individual MICs. The MICs of CAZ and LEV in the 
presence of 2(5H)–furanone were also found to be 2 – 128 times lower than those obtained 
when combined with BH or CIN. 
Similarly, the MBECs of CAZ and LEV needed to eradicate K. pneumoniae and P. mirabilis 
biofilms by 50% or more in the presence of sub–inhibitory concentrations of PMB and PMB 
were 16 – 64 times higher than their individual MICs (Appendix B3 and 4). 
5.6.1.1 Evaluation of synergy between QSI/AMP and antibiotics 
In order to establish synergism between the QSI/AMP and the antibiotics in inhibiting K. 
pneumoniae and P. mirabilis biofilms, fractional inhibitory concentration (FIC) index for 
each synergy pair was calculated according to the formula described by Ruden et al., (2009) 
as mentioned in Chapter 2, section 2.6.3. Tables 5.6 and 5.7 show the summary of FIC 




Table 5 –6 Determination of the effects of antimicrobial combinations on biofilm–forming 




















K. pneumoniae BH 12500 5120 2500 640 0.325 
CIN 660.8 5120 132.06 640 0.325 
2(5H)–furanone 500 5120 250 10 0.593 
PMB 500 5120 100 40 0.21 
PMBN 500 5120 100 40 0.21 
P. mirabilis BH 12500 640 2500 640 1.2 
CIN 660.8 640 132.06 640 1.2 
2(5H)–furanone 500 640 250 20 0.813 
PMB 500 640 100 10 0.7 
PMBN 500 640 100 10 0.7 
ꝉ – FICCAZ index determined for each combination assay between CAZ and sub–inhibitory 
concentrations of QSI/AMP. Interpretation of FIC index: Synergy was defined as ≤ 0.5; FIC 
index > 0.5 < 2.0 was indicative of “additive effect”, and FIC index above 2.0 was indicative 
of “antagonistic effect.” 
a – MIC pair: individually determined MICs for each QSI/AMP and antibiotic (CAZ). 




























K. pneumoniae BH 12500 40 2500 40 1.2 
CIN 660.8 40 132.06 40 1.2 
2(5H)–furanone 500 40 250 10 0.75 
PMB 500 40 100 40 1.2 
PMBN 500 40 100 40 1.2 
P. mirabilis BH 12500 40 2500 40 1.2 
CIN 660.8 40 132.06 20 0.7 
2(5H)–furanone 500 40 250 10 0.75 
PMB 500 40 100 10 1.2 
PMBN 500 40 100 10 1.2 
ꝉ – FIC index determined for synergy between LEV and sub–inhibitory concentrations of 
QSI/AMP. Refer to footnote * for interpretation of FIC index reference values. 
a – MIC pair: individually determined MICs for each QSI/AMP and antibiotic (LEV). 
Synergy pair: MIC of each QSI/AMP and antibiotic (LEV) determined in a synergy assay. 
FIC index values obtained for the antimicrobial combination assays between CAZ/LEV and 
all quorum sensing inhibitors, BH, CIN, 2(5H)–furanone and antimicrobial peptides (PMB 
and PMBN) showed synergistic or additive effects (Tables 5.6 and 5.7). For the purpose of 
this study, the definitions of synergism, additive and antagonistic effects of antimicrobial 
combinations adapted from the definitions provided by Thellin et al. (2015). Synergy or 
synergistic effect was indicative when the effects of an antibiotic and an antimicrobial agent 
in a combination assay were greater than the sum of their individual effects. Additive effect 
on the other hand was indicative when the combined effect of an antibiotic and an 
antimicrobial agent in a combination assay was not greater than the sum of their individual 
effects but still greater than the effect of each individual antimicrobial agent. Finally, an 
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antagonistic effect was indicated when the effects of an antibiotic and an antimicrobial agent 
in a combination assay were lower than their individual effects (Bassolé and Juliani, 2012).  
In the current study, it was observed that the antibacterial effects of the synergy pair in some 
combination assays resulted in the reductions of the MIC values of antibiotics compared to 
when they were individually used. For example, in the case of CAZ, the MIC in the 
combination assays against K. pneumoniae biofilms was 8 – 512 times lower than when it 
was used alone (Table 5.6). When tested against P. mirabilis, the MIC of CAZ in 
combination assays involving 2(5H)–furanone, PMB and PMBN, was 32 – 64 times lower 
than when used alone (Table 5.6). The MIC of CAZ in combination assays with BH and CIN 
against P. mirabilis biofilms remained unchanged (640 µg/mL). With the exception of the 
combination assay with 2(5H)–furanone against K. pneumoniae (which was near–synergy), 
CAZ combinations assays with BH, CIN, PMB and PMBN resulted in synergy effects with 
FIC indices ≤ 0.5 (Table 5.6). On the other hand, CAZ combination assays with BH, CIN, 
2(5H)–furanone, PMB and PMB resulted in additive effects.  
When tested against K. pneumoniae, the MIC of LEV in the presence of 2(5H)–furanone was 
4 times lower than when used on its own (Table 5.7). However, the MIC of LEV remained 
unchanged (the same as when used alone) when tested against K. pneumoniae in 
combinations with BH, CIN, PMB and PMBN. When tested against P. mirabilis however, the 
MIC of LEV was 1 – 4 times lower than when used alone (Table 5.7). All the combination 
assays involving LEV resulted in additive effects with the exception of combinations with 
2(5H)–furanone against K. pneumoniae and P. mirabilis respectively which resulted in near–
synergy effect. 
5.6.2 Antimicrobial effects of wound dressings on diabetic foot isolates 
The antibacterial effects of 3 wound dressings namely; Acticoat® (ACT), Silvercel® (SIL, 
silver–impregnated), and Medihoney™ Apinate (MDA, honey–impregnated) were assessed 
on 2 biofilm–forming DFU isolates, K. pneumoniae and P. mirabilis. In order to compare 
their antibacterial effects, a 4th wound dressing called Atrauman (ATR), with no antibacterial 
activity was used as a growth control check. The inhibition of K. pneumoniae and P. 
mirabilis biofilm formation was evaluated by a 6–well plate assay and a standard agar 
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method. In both assays, the antimicrobial effects of individual wound dressings and in 
combination with antibiotics (CAZ and LEV) were assessed. 
5.6.2.1 6–well plate assay 
In Figure 5.15, the inhibitory effects of ACT, MDA and SIL at 3 selected time points (30 
minutes, 1 hour and 24 hours after incubation) were compared to that of ATR which showed 
no inhibition at any of the selected time points. The selection of the 3 time points was based 
on manufacturers’ recommendations. The antimicrobial efficacy of ACT has been suggested 
to attain peak levels within 1 hour of application (Keene, 2002; Smith & Nephew Data on file 
report 0810018; Smith & Nephew report reference DS/08/062/R2; Wright et al., 1998). On 
the other hand, MDA has been found to have sustained antimicrobial effect up to 7 days 
following initial application (Bateman and Graham, 2007; George and Cutting, 2007; Gethin 
and Cowan, 2005). The non–adherent SIL has also been found to sustain its efficacy up to 7 
days after initial application (Clark and Bradbury, 2010). Interestingly, all 3 wound dressings 
were most effective 1-hour post–incubation with K. pneumoniae and P. mirabilis. ACT was 
the most effective by inhibiting K. pneumoniae and P. mirabilis biofilm formation by 60% or 
more at 1-hour post–incubation. Percentage inhibition by Acticoat® against K. pneumoniae 
(ACTKp) and Acticoat® against P. mirabilis (ACTPm) at 1 hour was found to be statistically 
significant (p = 0.0105) compared to that of SIL and MDA. Although inhibition of biofilm 
after 24 hours was inconsistent among the 3 wound dressings, Medihoney™ Apinate against 
K. pneumoniae (MDAKp) and Medihoney™ Apinate against P. mirabilis (MDAPm) showed 
sustained antimicrobial effect. However, the sustained antimicrobial effect of MDA was 
inadequate to significantly or completely inhibit K. pneumoniae and P. mirabilis biofilms 
after a 24–hour incubation period (p = 0.0921).  
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Figure 5 .15 Effect of wound dressings on biofilm formation by K. pneumoniae and P. 
mirabilis. Percentage inhibition by SILKp and SILPm was statistically significant (p = 0.0071, 
two–way ANOVA).  
In Figure 5.16, the combined effect of wound dressings and the two antibiotics, CAZ and 
LEV at 512 and 5120 µg/mL were evaluated in the inhibition of K. pneumoniae and P. 
mirabilis biofilms after a period of 24 hours of incubation. It was observed that the combined 
effect of the 3 wound dressings, ACT, MDA and SIL in the presence of 5120 µg/mL of CAZ 
or LEV completely inhibited K. pneumoniae and P. mirabilis biofilms. In the case of 
Acticoat® against P. mirabilis (ACTPm), which recorded the least inhibition, 78.8%, for CAZ 
among the 3wound dressing – antibiotic combination assays, a further test on agar to detect 
bacterial growth was negative. It was also observed that, the combination of ACTKp and 
LEV512, and SILKp and CAZ512 inhibited K. pneumoniae biofilms by more than 60% (Figure 
5.16A). Similarly, the combined effect of ACTPm and LEV512, and SILPm and LEV512 
inhibited P. mirabilis biofilm by more than 60% (Figure 5.16B). The combined effect of 
LEV512 and ACT, MDA or SIL (in Figure 5.16A) in the inhibition of K. pneumoniae biofilms 
was found to be statistically significant (p = 0.0049) while that of CAZ512 and ACT, MDA 
was not (p = 0.4013) when compared with the individual effects of ACT, MDA and SIL (in 
Figure 5.15) 24-hour post–incubation. On the other hand, the combined effects of CAZ512 and 
ACT, MDA or SIL, and that of LEV512 and ACT, MDA or SIL (in Figure 5.16B) were also 
found to be statistically significant (p = 0.0432 and p = 0.0046 respectively) when compared 
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with the individual effects of ACT, MDA and SIL (in Figure 5.15) in the inhibition of P. 
mirabilis biofilms 24 hours post–incubation. 






















































Figure 5 .16 Combined effects of wound dressings and antibiotics in inhibiting; (A). K. 
pneumoniae biofilm, *p = 0.4013 and **p = 0.0049 represent combined effects of CAZ512 
and ACT, MDA and SIL, and LEV512 and ACT, MDA or SIL respectively in the inhibition of 
K. pneumoniae biofilms. (B). P. mirabilis biofilm, ap = 0.0432 and aap = 0.0046 represent 
combined effects of CAZ512 and ACT, MDA and SIL, and LEV512 and ACT, MDA or SIL 




In order to determine synergism between the combined inhibitory effects of the 3 wound 
dressings used in this study, Acticoat®, Medihoney™ Apinate and Silvercel®, and the 2 
antibiotics, ceftazidime and levofloxacin, the FIC index for each synergy assay was 
calculated as described earlier (Chapter 2, section 2.6.3). Details of each combination assay 
can be found in Tables 5.8 and 5.9 
Table 5 –8 Antimicrobial effect of combinations wound dressings and antibiotics on biofilm–




















K. pneumoniae ACT–512 48.6 70 53.4 55 1.66 
ACT–5120 48.6 70 92.4 70 2.01 
MDA–512 58.0 70 50.0 55 1.74 
MDA–5120 58.0 70 84.3 70 2.03 
SIL–512 57.2 70 62.7 55 1.96 
SIL–5120 57.2 70 88.5 70 2.08 
P. mirabilis ACT–512 43.1 65 43.5 65 1.33 
ACT–5120 43.1 65 78.8 70 1.79 
MDA–512– 47.0 65 57.2 65 1.6 
MDA–5120 47.0 65 85.1 70 1.94 
SIL–512 49.3 65 42.0 65 1.41 
SIL–5120 49.3 65 85.4 70 1.98 
ꝉ – FIC index determined for the interpretation of synergism between CAZ and wound 
dressings. Interpretation of FIC index: Synergy was defined as ≤ 0.5; FIC index > 0.5 < 2.0 
was indicative of “additive effect”, and FIC index above 2.0 was indicative of “antagonistic 
effect.” 
a – Individual pair: individually determined MICs and inhibitory concentrations for the 
antibiotic (CAZ at 5120 µg/mL for K. pneumoniae and 640 µg/mL for P. mirabilis) and each 
wound dressing respectively. Synergy pair: pre–determined concentrations of the antibiotic 
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(CAZ at 512 and 5120 µg/mL) and the MIC of each wound dressing in a synergy assay. All 
MICs and inhibitory concentrations were expressed as percentage inhibitions. 
In Table 5.8, the FIC index values obtained for combination assays between the wound 
dressings and CAZ at 5120 µg/mL (70% inhibition) resulted in antagonistic effects against K. 
pneumoniae but not P. mirabilis. This implies that, the effect of the concentration of CAZ at 
5120 µg/mL was not complementary to that of the wound dressings. However, a different 
scenario was observed in the combination assays involving LEV and the wound dressings in 
Table 5.9. All combination assays resulted in additive effects suggesting LEV as antibiotic of 


















Table 5 –9 Antimicrobial effect of combinations of wound dressings and antibiotics on 




















K. pneumoniae ACT–512 48.6 75 68.5 75 1.56 
ACT–5120 48.6 75 90.4 80 1.78 
MDA–512 58.0 75 59.7 75 1.57 
MDA–5120 58.0 75 91.0 80 1.91 
SIL–512 57.2 75 53.1 75 1.47 
SIL–5120 57.2 75 88.6 80 1.87 
P. mirabilis ACT–512 43.1 71 65.0 65 1.61 
ACT–5120 43.1 71 88.9 83.2 1.68 
MDA–512 47.0 71 56.3 65 1.53 
MDA–5120 47.0 71 90.1 83.2 1.74 
SIL–512 49.3 71 61.6 65 1.64 
SIL–5120 49.3 71 89.4 83.2 1.76 
ꝉ – FIC index determined for the interpretation of synergism between LEV and wound 
dressings. Interpretation of FIC index: Synergy was defined as ≤ 0.5; FIC index > 0.5 < 2.0 
was indicative of “additive effect”, and FIC index above 2.0 was indicative of “antagonistic 
effect.” 
a – Individual pair: individually determined MICs and inhibitory concentrations for the 
antibiotic (LEV at 640 µg/mL for K. pneumoniae and 1280 µg/mL for P. mirabilis) and each 
wound dressing respectively. Synergy pair: pre–determined concentrations of the antibiotic 
(LEV at 512 and 5120 µg/mL) and the MIC of each wound dressing in a synergy assay. All 
MICs and inhibitory concentrations were expressed as percentage inhibitions. 
5.6.2.2 Standard agar assay 
In the standard agar assay, the individual and combined effects of ACT, MDA and SIL and 
with CAZ and LEV were studied on K. pneumoniae and P. mirabilis quasi–biofilms on 
Mueller–Hinton agar (MHA) and Kolliphor® P 407 (KP 407) gel, a derivative of poloxamer 
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hydrogel. Unlike the 6–well plate assay in Figure 5.16, the individual effects of ACT, MDA 
and SIL showed no zone of inhibition (ZOI) on either MHA or KP 407 gels. Bacterial growth 
on KP 407 gels were less susceptible to ACT, MDA and SIL with smaller ZOIs than those 
grown on MHA. This is because poloxamer gels support the growth of biofilm than 









Figure 5 .17 Biofilm phenotypes of P. mirabilis in the presence of: (A) ACT with 1024 
µg/mL of LEV on MHA; (B) Medihoney with 512 µg/mL of LEV on Kolliphor® P 407 gel 
(C) Atrauman showing no ZOI after 24 hours of growth on MHA; (D) Medihoney with 5120 
µg/mL of LEV on Kolliphor® P 407 gel;  
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Figure 5 .18 Combined effects of wound dressings and antibiotics on (A) K. pneumoniae and 
(B) P mirabilis biofilm. K. pneumoniae and P mirabilis biofilm formation on MHA was 
significantly inhibited by LEV at 5120 µg/mL (*p < 0.05).   
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The combined effects of CAZ/LEV and wound dressings that showed significant ZOI on 
MHA and KP 407 gels were measured and compared (Figures 5.18 and 5.19). Wound 
dressings in the presence of CAZ and LEV from 512 to 5120µg/mL showed significant (p = 
0.0329 and p = 0.0029 respectively) inhibitory effect against K. pneumoniae and P. mirabilis 
with ZOIs between 5.0 and 35 mm on MHA (Figure 5.18A and B).  Similarly, significant (p 
= 0.0153 and p = 0.0028) ZOIs on KP 407 gels against K. pneumoniae and P. mirabilis 
quasi–biofilms were between 4.5 and 30 mm at the concentrations of CAZ and LEV 
mentioned earlier (Figure 5.19A and B).  
It was also observed that K. pneumoniae and P. mirabilis on MHA or KP 407 gels were more 
susceptible to LEV than CAZ (Figures 5.18 and 5.19). K. pneumoniae and P. mirabilis 
biofilm forming cells were found to be susceptible to three concentrations of LEV (512, 1024 
and 5120 µg/mL) and only one concentration of CAZ (5120 µg/mL) in the combination 
assays. A similar scenario was observed in the 6–well plate assay (Figure 5. 16) except that 
K. pneumoniae and P. mirabilis were susceptible to CAZ (512 µg/mL) in all combination 
assays. In Figure 5.19B, none of the CAZ–MDA combination assays was effective against P. 
mirabilis. 
It was not possible to calculate the FIC index for the combination assay using the standard 
agar technique as K. pneumoniae and P. mirabilis were completely resistant to all 3 wound 
dressings hence showed no ZOI. However, a reference range for interpretation of ZOI was 
deduced from the results of a similar work by Percival et al. (2007). In their work, Percival et 
al. (2007) compared the ZOIs of known antibiotic susceptible and resistant reference NCIMB 
strains which included E. coli NCIMB 8545, P. aeruginosa NCIMB 8626 and P. aeruginosa 
NCIMB 8506 respectively with clinical isolates. The range of ZOI associated with the 
antibiotic susceptible reference strains was between 1.9 and 17.5 mm. By this definition, all 
combination assays that resulted in ZOIs > 1.9 mm were synergistic and those < 1.9 were 




















































































































































































































Figure 5 .19 Combined effects of wound dressings and antibiotics on; (A) K. pneumoniae and 
(B) P. mirabilis biofilms. K. pneumoniae and P mirabilis biofilm formation on Kolliphor® P 
407 gel was significantly inhibited by LEV at 5120 µg/mL (*p < 0.05). 
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5.7 Discussion  
The evidence that the existence of cell–to–cell signalling processes that allow bacteria to 
regulate gene expression by producing, secreting, detecting and responding to extracellular 
signalling molecules has increased knowledge and enhanced the use of molecular techniques 
in the study cellular and molecular processes such as virulence gene expression, swarming 
and motility, biofilm formation, antibiotic resistance, horizontal gene transfer and evasion of 
host defence mechanisms (Antonova and Hammer, 2011; Bassler, 1999; Davies et al., 1998; 
De Kievit et al., 2000; De Kievit et al., 2001;  Hammer and Bassler, 2003; Tseng et al., 2016; 
Waters and Bassler, 2005). For examples Davies et al. (1998) demonstrated that quorum 
sensing was required for P. aeruginosa cells to differentiate into complex structures called 
biofilms and mutation in the wild–type P. aeruginosa that resulted in lasI mutant strains 
could not differentiate resulting in abnormal biofilm production. In another study, Daniels et 
al. (2004) demonstrated that swrI/swrR quorum sensing system was responsible for the 
control of at least 28 genes in Serratia liquefaciens that leads to the production of serrawettin, 
a lipodepsipentapeptide biosurfactant responsible for producing swarming colonies. Induction 
of mutation in wild–type S. liquefaciens resulted in the loss of swarming ability which was 
restored after the exogenous addition of AHLs.  
The idea that AI–2 – mediated QS is widely distributed among bacteria and hence involved in 
interspecies communication, have led to the discovery that, the biosynthetic pathway leading 
to the production of the precursors of AI–2 in V. harveyi are identical in E. coli, S. enterica 
serovar typhimurium, V. harveyi, V. cholerae, Enterococcus faecalis, Neisseria meningitidis, 
Porphyromonas gingivalis, and even in Gram–positive bacteria such as S. aureus (Schauder 
et al., 2001; Winzer et al., 2002; Xavier and Bassler, 2005b). In the current work presented 
here, BioCyc biosynthetic pathway tools (as outlined in section 2.8.6) revealed that, the 
pathway leading to AI–2 biosynthesis has already been found in K. pneumoniae and P 
mirabilis and is identical to that of V. harveyi except in the final product (Bassler et al., 1994; 
Chen et al., 2002; Miller et al., 2004). Upon PCR, the luxS synthase gene was found to be 
expressed by both K. pneumoniae and P mirabilis. In order to determine the relatedness of 
the luxS genes expressed by K. pneumoniae, P mirabilis and other speciated strains in the 
databases, partial DNA sequences of K. pneumoniae and P mirabilis were used to perform a 
multiple sequence alignment and construct a cladogram (Figures 5.6 and C3 (in Appendix C). 
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The multiple sequence alignments in Figures C3, C4, C5 and C6 in Appendix C, showed 
some differences (in base pairs) in the variable and conserved regions of the 5 luxS, lsrB and 
bssS/bssR genes.  
Differences (in DNA base pairs) in the variable regions of the above–mentioned quorum 
sensing regulated genes suggest that they are highly conserved in Gram–negative bacteria 
(Inoue and Takikawa, 2006). Highly conserved genes are useful in the grouping and typing of 
bacterial species and strains (Inoue and Takikawa, 2006). Similarly, differences in variable 
regions of the same gene may also indicate diverse functional roles in different bacterial 
species (Birkenmeier et al., 1993). For examples, the variable regions of the luxS gene in K. 
pneumoniae may direct the transcription of quorum sensing genes for the synthesis of cell 
surface proteins for bacterial cell–cell attachment during biofilm formation and that of P 
mirabilis may lead to the expression of genes that support nitrogen fixation. It can therefore 
be suggested that DNA sequence variations in the variable regions of the luxS gene confirm 
their specificity in binding to their respective receptor proteins during quorum sensing 
(Xavier and Bassler, 2005b). For example, V. harveyi AI–2 specifically binds to the 
periplasmic protein LuxP during QS regulation in V. harveyi while AI–2 produced by S. 
enterica serovar typhimurium binds to the ABC transporter protein, LsrB which internalises 
AI–2 in the cytoplasm for QS signal transduction (Xavier et al., 2007).  
In this study, the effect of exogenously produced quorum sensing molecules, AHL and AI–2, 
in the regulation of cellular activities in other bacteria was investigated. In the cross–feeding 
assay (as outlined in section 2.6.1.2), the biosensor reporter strain, A. tumefaciens NCIMB 
14543 could detect exogenous acylated homoserine lactone produced by DFU isolates which 
resulted in blue pigmentation of A. tumefaciens NCIMB 14543 colonies on agar (Figure 5.10 
A and B). In another assay (i.e., the cross–stimulation assay, outlined in section 2.6.1.4), AI–
2 produced by DFU isolates, K. pneumoniae and P mirabilis were detected by V. harveyi 
NCIMB 1280 reference strain which resulted in bioluminescence as a result of the activation 
of the luxCDABE operon (Bassler et al., 1993). Bioluminescence in V. harveyi is QS–
regulated as mentioned in section 5.3.2. The production, secretion, detection and response to 
QS molecules, AHL and AI–2 in bacteria confirm that quorum sensing as one of the 
mechanisms that regulate cellular activities in bacteria such as bioluminescence and biofilm 
formation (Figures 5.11 and 5.12). 
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The current study also investigated bacterial cell–cell interactions during in vitro biofilm 
formation using a panel of biotinylated lectins to identify corresponding protein–binding 
polysaccharides on the surfaces bacteria involved in biofilm formation. The results obtained 
for the glycan–lectin assay suggest that the detected protein–binding carbohydrates on the 
cell–surfaces of K. pneumoniae and P mirabilis can be expressed in vivo during colonisation 
and biofilm formation in diabetic foot ulcers. 
Attempts were made to develop antimicrobial formulations that effectively combine the 
efficacies of antibiotics such as ceftazidime and levofloxacin; antimicrobials such as 
polymyxin B and polymyxin B nonapeptide; and quorum sensing inhibitors such as baicalin 
hydrate, cinnamaldehyde and 2(5H)–furanone (Tables 5.6 and 5.7). In other assays, the 
combined effects of wound dressings and antibiotics were also assessed on diabetic foot 
isolates, K. pneumoniae and P mirabilis, in inhibiting their growth either as planktonic cells 
or biofilm phenotypes (Figures 5.16 and 5.18). The combination of antibiotics and the other 
antibiofilm agents in the combination assays outlined in section 2.6.3 generated fractional 
inhibitory concentration indices (defined in section 2.6.3) that have been reported as 
benchmarks for the development of antimicrobial formulations that may provide alternative 
treatment for infections which otherwise cannot be treated using a single antimicrobial 
regimen (Ghosh et al., 2013; Ruden et al., 2009). This study therefore proposes that 
development of further combination assays based on the FIC indices obtained, using 
antibiotics such as ceftazidime and levofloxacin in combinations with other anti–quorum 
sensing and antibiofilm agents may provide alternate treatment with acceptable therapeutic 































6.1 General Discussion 
Diabetes mellitus (DM) is one of the major global health concerns which results in severe 
life–changing complications such as neuropathy, nephropathy, cardiovascular and peripheral 
vascular diseases and diabetic foot ulcers (International Diabetes Federation, 2015). It has 
been predicted that current global prevalence of 1 in 11 adults with the disease will change to 
1 in 10 by the year 2040 with 75% of the disease among people living in developing 
countries (King et al., 1998; International Diabetes Federation, 2015; Zimmet et al., 2001). 
Lack of understanding and awareness of the disease have been identified as the major barriers 
to the effective prevention and management of the disease (International Diabetes Federation, 
2015). A complex combination of genetic and environmental factors in addition to social 
deprivation makes diabetes more common in people of African, African–Caribbean and 
South Asian lineages (Chen et al., 2012). Due to social deprivation and economic constraints, 
the major burden of DM and its complications are borne by patients living in developing 
countries (Abbott et al., 2005; Chen et al., 2012; International Diabetes Federation, 2015). 
The work presented here studied diabetic foot ulcers (DFU) among diabetic patients who 
attended the Diabetes Centre, Komfo Anokye Teaching Hospital, KATH, Kumasi, Ghana 
from January 2001 to December 2004. It is also a follow–up on two previous cohort studies 
conducted by Jauhangeer (2006) and Dharod (2010) in Mauritius and Mumbai, India 
respectively. In the Mauritian study, Jauhangeer (2006) conducted a cohort study that 
investigated the clinical and microbiological profile of patients with infected diabetic foot 
ulcers. In line with the aim of the Mauritian study, Jauhangeer (2006) further investigated 
diabetic foot ulcer patients’ resistance to infections by studying single nucleotide 
polymorphisms (SNP) in host defensin genes; which encode broad spectrum host immune 
defence molecules, defensins, responsible for attacking invading microorganisms. Jauhangeer 
(2006) observed that differences in SNP profiles of defensin genes 1 and 2 in diabetics 
correlated with the frequency of amputations between Mauritians of African and Indian 
origins. For example, it was observed that Mauritian diabetic patients of African origin were 
more susceptible to foot infections with 44% amputation rate than those of Indian origin 
(Jauhangeer, 2006). In addition, Jauhangeer (2006) also optimised molecular techniques such 
as random amplified polymorphic DNA (RAPD) and conserved segment PCR amplifications 
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to characterise anaerobes such as Finegoldia magna and other Gram–positive and Gram – 
negative aerobes in diabetic foot samples.  
Dharod (2010) on the other hand studied the microbiological and antibiotic resistance profiles 
as well as the dominant species in infected diabetic foot ulcers in an Indian cohort study in 
comparison with a UK cohort. Dharod (2010) investigated bacterial pathogenic mechanisms 
such as glycan–lectin interactions responsible for cell–cell adherence and biofilm formation 
in establishing infections. Dharod (2010) optimised as in–house biochemical assay, enzyme 
linked lectinsorbent assay (ELLA) to characterise glycans such α–2, 6 sialic acid linked to 
galactose on the cell surface of F. magna using a panel of biotinylated lectins (outlined in 
Table 2.6, section 2.7) and suggested their involvement in cell–cell attachment in biofilm 
formation and in establishing infections (Severi et al., 2007). 
However, the current study presented here also characterised the microbial profiles of 
diabetic foot ulcers among the Ghanaian diabetic cohort recruited for the study, and in 
addition studied the ability of identified bacteria to form biofilm, mechanisms underlying 
their ability to cause persistent infections and attempted the development of in vitro assays as 
strategies to antagonise pathogenic effects of bacteria in wounds through the inhibition of 
quorum sensing and biofilm formation. Previous studies in DM with respect to secondary 
complications such as hypertension and nephropathy and the burden of the disease on the 
socioeconomic status of Ghanaians have also been reported (Asumanu et al., 2010; Danquah 
et al., 2012). The operational prevalence of DM in Ghana, 6.3%, established in 2002 
provided the basis for revisions as well as formulation and implementation of new health 
policies in the management of diabetes in Ghana (Amoah, et al., 2002). The prevalence of 
DM, 22.8% established in the present study, the first to be carried out in a major hospital in 
Ghana, reveal that little has been done in terms of the management of the disease.  The 
present study therefore supports the idea that, there is the need for the formulation and 
implementations of stringent policies on early diagnosis, treatment and follow–up 
programmes in the management of DM in Ghana in line with WHO–predicted insurgence of 
the disease in developing countries. In addition, prevalence of DFU was estimated as 0.7% 
which is 5.7 – 38.6 times lower than the global prevalence (Abbott et al., 2002; Bakri et al., 
2012; Richard and Schuldiner, 2008; Yazdanpanah et al., 2015). The current “I want my leg 
back” campaign against amputation at the Diabetes Centre, KATH must be commended for 
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the decrease in DFU among diabetic patients accessing the centre. The spread of such 
campaigns across the major health centres in Ghana should be encouraged. Other findings 
such as the high prevalence of the disease among women (72%) than men (28%) is in 
conformity with the trend of the disease among people of sub–Saharan African and South 
Asian descent who reportedly are genetically predisposed to the disease (Chen et al., 2012; 
Diabetes in the UK, 2012; Gatineau, 2014).   
In all 407 bacterial isolates were identified from 356 DFU samples collected during the 
period of the study. No (strict) anaerobe was isolated as there was no dedicated anaerobic 
identification system at the site of sample collection and processing. The presence of bacteria 
(both aerobes and anaerobes), dominant species and their ability to cause pathogenic 
infections in wounds including diabetic foot ulcers have been well studied (Dharod, 2010; 
Gardner et al., 2013; Jauhangeer, 2006; Malik et al., 2013; Spichler et al., 2015). As a result, 
the current work also studied the role of two facultative anaerobes, Klebsiella pneumoniae 
and Proteus mirabilis in maintaining the chronicity of diabetic wounds. K. pneumoniae and 
P. mirabilis were selected as the main test strains because they were recovered from 
Wagner’s grade 3 (abscess osteitis) and 2 (deep) in–patients’ wounds respectively. They also 
showed resistance to more than 3 antibiotics including ciprofloxacin, ofloxacin, gentamicin, 
tobramycin and ceftazidime (for P. mirabilis), and gentamicin, cefotaxime, amikacin and 
ceftazidime (for K. pneumoniae) respectively. Out of the 407 DFU isolates, 50 of them 
belonging to the Proteobacteria group were taxonomically classified using the protein–coding 
nucleotide sequences of their 16S rRNA genes. The phylogenetic analysis of the 50 isolates 
was important in demonstrating their evolutionary relatedness as either divergent or 
convergent as illustrated by the phylogenetic tree and its branches and explained in Figure 3.7 
and section 3.5. Also, information from the phylogenetic data of some bacteria either within 
the same or different species or even strains of the same species with high degree of 16S 
rRNA homology, can provide the basis for the study of virulence genes that are shared by 
these bacteria. For example, two bacterial species, P. mirabilis DFI020 and K. pneumoniae 
DFI034a, and two K. pneumoniae strains DFI032 and DFI035 with 100% 16S rRNA 
homology (located in region C of the phylogenetic tree in Figure 3.7) can be studied to 
determine whether they belong to the same functional equivalent pathogroups using 
bioinformatics techniques such as multivariate hierarchical clustering described by Dowd et 
al., 2008b). Dowd et al., (2008b) demonstrated that polymicrobial infections may comprise 
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of specific mixtures of anaerobes and aerobes that can symbiotically act (through quorum 
sensing) to establish pathogenic biofilm infections (Bowler et al., 2001; Brook, 1987; 
Mayrand and McBride, 1980; Rostein and Kao, 1988). Also, whole genome sequence 
mapping can be performed to identify specific genes that encode virulence factors such as 
toxin production which are common to these bacteria with 100% 16S rRNA homology. The 
phylogenetic data generated for bacteria with high degree of 16S rRNA homology can also 
provide the basis for the study of antibiotic resistance genes; which can be acquired by 
horizontal gene transfer within a bacterial consortium in an environment setting or probably 
through polymicrobial biofilm infections (Antonova and Hammer, 2011; Fux et al., 2005; 
Kamilar and Cooper, 2013; Lerat and Moran, 2004; Ochman et al., 2000). It can therefore be 
suggested that, the characterisation of antibiotic resistance genes, whole-genome sequencing, 
couple with 16S rRNA homology profiling can enhance the typing of diabetic foot isolates 
for diagnosis and treatment of wounds, epidemiological surveillance of infectious diseases 
and the control of the spread of antimicrobial resistance (Köser et al., 2014; Reuter et al., 
2013).  
The presence of K. pneumoniae and P. mirabilis in clinical conditions such as pneumonia, 
urinary tract infections (UTIs) and septicaemia have been studied (Chong et al., 2013; Dowd 
et al., 2008b; Podschun and Ullmann, 1998). Though K. pneumoniae and P. mirabilis have 
also been found in diabetic foot infections their contributions to impaired wound healing have 
not been fully explained (Gardner et al., 2013; George et al., 2015; Gjødsbøl et al., 2006; 
James et al., 2008; Malik et al., 2013; Oates et al., 2012; Rhoads et al., 2012). In Chapter 4 of 
the present work, the role of K. pneumoniae and P. mirabilis biofilms in diabetic foot 
infections was investigated. K. pneumoniae and P. mirabilis were not only found to be strong 
biofilm producers at normal in vitro growth conditions, but also found to produce persister 
cells during stationary phase of growth and when challenged with antibiotics at high 
concentrations. When changes were made in vitro to the environmental conditions that 
support their growth, K. pneumoniae biofilm was found to be inhibited at low pH (4), high 
temperature (42ºC) but grew quite well at pH 10 and at 26ºC. Although high alkaline pH of 
up to 8.9 has been recorded in non–healing wounds, pH of 10 which was set as the upper 
limit for the pH biofilm inhibition experiments was for reference only (Gethin, 2007; 
Romanelli et al., 1997; Tsukada et al., 1992; Wilson et al., 1979). However, it is noteworthy 
that, the development of any antimicrobial intervention in the treatment of wounds should 
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have or attain bioavailability even at pH of 8 or more. This is because certain enzymes such 
as elastase, plasmin and neutrophil elastase that prevent wound healing have been found to 
attain peak activity between pH of 8.0 to 8.3 (Greener et al., 2005). Although P. mirabilis 
biofilm on the other hand formed normally at 26ºC and pH 10, its growth in Luria–Bertani 
broth was significantly inhibited when nutrient concentrations were reduced by 2–fold or 
below. The significant effects of environmental changes in inhibiting K. pneumoniae and P. 
mirabilis biofilms can be considered in the development of treatment strategies in eradicating 
biofilms in infected wounds. For example, low or acidic pH has been found to support 
chronic wound healing (Milne and Connolly, 2014; Percival et al., 2014). Also, the use of 
Manuka honey as an antimicrobial agent has been found to induce low pH which negatively 
affects the growth of bacteria such as P mirabilis (Milne and Connolly, 2014). 
In their biofilm states, K. pneumoniae and P. mirabilis were resistant to ceftazidime and 
levofloxacin 1280 and 10 times, and 64 and 10 times more than their respective therapeutic 
concentrations (EUCAST, 2014). Although the individual antibiotic resistance mechanisms 
K. pneumoniae and P. mirabilis were not evaluated, data from their antibiogram, their ability 
to form biofilms coupled with other unknown combinations of antimicrobial resistance 
mechanisms suggest that they may contribute to the persistence of pathogenic infections. The 
ability of the test strains used in the current study to form persister cells was investigated 
using the method described by Keren et al., (2004).  K. pneumoniae and P. mirabilis were 
found to produce persister cells when challenged by antibiotics and at low levels during 
stationary growth phase. The ability of the multidrug resistant K. pneumoniae and P. 
mirabilis DFU strains to form biofilms and produce persister cells is a worrying scenario 
which has bad prognosis for wound healing. Perhaps the combinatorial effect of two or more 
antibiotics or antimicrobial agents may provide a possible treatment regime.   
In the study presented here, the Quasi–Vivo® assay, a continuous flow cell culture system was 
adapted for the study of time–dependent killing of biofilms grown on cover slip. The purpose 
of this assay was to mimic in vivo conditions in an attempt to develop a strategy for biofilm 
eradication using predetermined antibiotic concentrations. Though eradication of biofilm was 
not achieved at the pre–determined concentrations (512 and 5120 µg/mL) of ceftazidime and 
levofloxacin used, fluorescent–stained biofilms on cover–slips demonstrated the visualisation 
of live and dead bacterial cells using epifluorescence microscopy. The images from 
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epifluorescence microscopy enabled the qualitative assessment of the efficacy of the 
antibiotics used by comparing the number of live and dead stained bacterial cells.  
The concluding part of the present work investigated the role of bacterial communication, 
quorum sensing, in the regulation of biofilm formation by K. pneumoniae and P. mirabilis. 
Genomic studies have demonstrated the presence of interspecies AI–2 quorum sensing 
system in some Gram–negative and Gram–positive bacteria which was confirmed to be 
present in K. pneumoniae and P. mirabilis DFU isolates by PCR amplification of the luxS 
gene. Multiple sequence alignment of the luxS genes in K. pneumoniae, P. mirabilis and in 
Vibrio harveyi, where it was first discovered, showed high degree of homology. The current 
study further demonstrated that exogenously produced AI–2 from K. pneumoniae and P. 
mirabilis cell–free culture fluids could be used to induce biofilm formation in V. harveyi luxS 
mutant strain. Interspecies QS was also confirmed using the bioluminescence assay through 
the induction of light production in the V. harveyi reference strain used in the current study. 
The bioluminescence study presented here and other previous studies suggest that, V. harveyi 
and other luminous Vibrio species such as V. fischeri can be used as biosensor reporter strains 
in the expression of QS–associated genes responsible for interspecies AI–2 bacterial 
communications among Gram–negative bacteria explained in section 5.7 (Bassler, 2002; 
Meighen, 1991; Nealson and Hastings, 1979). Brackman et al. (2011) have demonstrated 
that, the inhibition of quorum sensing using quorum sensing inhibitors such as 
hamamelitannin, baicalin hydrate and cinnamaldehyde can increase the bacterial biofilms 
susceptibility to antibiotic treatment. This observation by Brackman et al. (2011) was 
confirmed in the current study as the effective combination of baicalin hydrate, 
cinnamaldehyde and 2(5H)–furanone and the antibiotics, ceftazidime and levofloxacin, 
significantly inhibited K. pneumoniae and P. mirabilis biofilms compared to antibiotics only 
assays (section 5.7). 
To determine if K. pneumoniae and P. mirabilis produce other QS molecules apart from AI–
2, AHL production and detection using the A. tumefaciens NCIMB 14543 biosensor reporter 
assay (also known as the cross–feeding assay as outlined in section 2.6.1.2, Chapter 2) was 
performed which suggested that both K. pneumoniae and P. mirabilis produced acyl–
homoserine lactones (AHL). The determination of the exact AHLs produced by these 2 DFU 
isolates was beyond the scope of the present study in terms of budget allocation and time. In a 
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similar study conducted by Yin et al., (2012), Agrobacterium tumefaciens NTL4(pZLR4) and 
Escherichia coli [pSB401] biosensor reporter strains together with high resolution mass 
spectrometry was used to determine and confirm the production of short and long chained – 
acylated homoserine lactones, N–octanoyl–homoserine lactone and N–3–dodecanoyl–L–
homoserine lactone by K. pneumoniae. In another study by Ngeow et al. (2013), K. 
pneumoniae was found to produce a short chain acyl–homoserine lactones, N–hexanoyl–
homoserine lactone (C6–HSL) using matrix–assisted laser desorption ionization–time–of–
flight (MALDI–TOF) mass spectrometry. On the other hand, the production of AHL by P. 
mirabilis has not yet been discovered. However, a study conducted by Stankowska et al. 
(2012) demonstrated that exogenous addition of AHL such as N–butanoyl–homoserine 
lactone increased the production of exopolysaccharide during P. mirabilis 018 biofilm 
formation. The possible production of AHL by the DFU P. mirabilis strain used in the 
present study can be reconsidered and confirmed using techniques such as mass spectrometry 
and thin layer chromatography. 
Glycan–lectin assays performed to determine the synthesis of exopolysaccharides and other 
cell–surface glycans suggested the production of polysaccharides during biofilm formation by 
K. pneumoniae and P. mirabilis DFU isolates. A panel of plant biotinylated lectins detected 
the presence of mannose, galactose, glucose and N–acetyl–D–galactosamine monomers in 
cell–surface glycans. The glycan–lectin results imply that the assay can be adapted for 
screening of cell–surface sugars for diagnostic purposes. It has previously been demonstrated 
that certain carbohydrate monomers such as L-rhamnose and D-fucose are strong inhibitors 
of bacterial coaggregation while galactosides such as methyl galactoside, D-galactose, 
lactose, and α–methyl galactoside are weak coaggregation inhibitors (Weiss et al., 1987). In a 
separate study, Ruhl et al. (2014) also investigated the interspecies adhesion between 
coaggregating dental plaque isolates such as type 2 fimbrial adhesin–bearing Actinomyces 
naeslundii and receptor polysaccharide–bearing Streptococcus oralis using an in vitro solid–
phase fluorescence–based assay. Specific fimbrial adhesin–receptor polysaccharide mediated 
interaction was detected between the two coadhesive partners which were also present in 
other adhesin and/ or receptor bearing strains of Neisseria pharyngitis, Rothia dentocariosa, 
and Kingella oralis (Ruhl et al., 2014). Nonetheless, it can be suggested that glycan–lectin 
profiles of bacterial coaggregating partners can provide useful data for the study and 
characterisation of bacterial cell surface appendages involved in mixed species biofilms. Data 
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from glycan–lectin and coaggregation assays can also direct the strategic design of 
antagonists that can inhibit protein–sugar binding to control biofilm formation in Gram–
negative bacteria (Bales et al., 2013; Vu et al., 2009). 
Current wound dressings on the market have been designed to target planktonic bacteria 
rather than biofilms in wounds. In the work presented here, 3 wound dressings Acticoat® 
(ACT), Medihoney™ Apinate (MDA) and Silvercel® (SIL) were able to inhibit K. 
pneumoniae and P. mirabilis biofilms by 22 to 61.7% using a 6–well plate assay. In a second 
method, planktonic or sessile growth of the same bacteria on a standard agar (Mueller–
Hinton) or poloxamer gel were found to be resistant to ACT, MDA and SIL. Poloxamer gel 
biofilm models which were first described by Gilbert et al. (1998) are known to create or 
mimic the characteristic biofilm environment with localised high cell densities, growth rates 
and oxygen gradients from the top to the bottom of the biofilm. Biofilms grown on 
poloxamer gels have also been demonstrated to exhibit more clinically relevant biofilm 
phenotypes that express outer membrane proteins between 78 and 87 kilo Daltons, and show 
enhanced resistance to biocide (Gilbert et al., 1998; Wirtanen et al., 1998). In both assays, 
bacterial cell suspension of 108 CFU/mL was challenged by a 2–cm–diameter wound 
dressing. Two or more methods have been described for the determination of the inhibitory 
effects of wound dressings (Hill et al., 2010; Percival et al., 2007; Wright et al., 1998). The 
disparity in the methods used in the present study, despite at least 3 replicates of the assay 
performed, suggests that differences in techniques used in the assays may affect the results. 
Optimisation of both assays to include similar materials and conditions may help to redress 
this disparity.  
The inhibition of QS in K. pneumoniae and P. mirabilis biofilm formation by 2(5H)–
furanone and CIN in the present study suggests that quorum sensing inhibitors can increase 
the susceptibility of bacteria that colonise diabetic foot ulcers to killing. The subsequent 
combination of the antibiotics, ceftazidime and levofloxacin, with QS inhibitors, BH, CIN 
and 2(5H)–furanone, or with antimicrobial peptides, PMB and PMBN in synergy assays 
significantly inhibited K. pneumoniae and P. mirabilis biofilm formation and in effect 
suggest that, effective combination of antimicrobial and antibiofilm agents may provide 
alternate treatment regime that can significantly inhibit the growth diabetic foot isolates. 
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For the past decade, attempts are being made to combat persister cells through the 
combination of antibiotics, antimicrobials and other molecules such as enzymes (Brötz–
Oesterhelt et al., 2005; Conlon et al., 2013). Brötz–Oesterhelt et al. (2005) have documented 
the successful eradication of Gram–positive bacterial cells with the caseinolytic protease P, 
ClpP; a subunit of protease enzyme Clp. Clp is ubiquitous in all bacteria and can be regulated 
for the breakdown of some specific proteins (Gerdes and Ingmer, 2013). The enzyme consists 
of a proteolytic subunit ClpP which has two heptameric rings with small central pores which 
lead to the central proteolytic chamber where peptide chains are strung and degraded after 
they are unfolded by the Clp ATPase regulatory enzymes (Frees et al., 2007). ClpP was also 
found to be capable of uncontrolled proteolytic degradation when activated by a peptide 
antibiotic called acyldepsipeptide (ADEP) (Conlan et al., 2013). ADEPs are a new class of 
antibiotic peptides isolated through fermentation from broth cultures of Streptococcus 
hawaiiensis NRRL 15010 (Brötz–Oesterhelt et al., 2005). They are effective against 
multidrug resistant pathogens and act by dysregulating ClpP in a process that leads to 
uncontrolled protein degradation and subsequent cell death.  
A recent study has also confirmed the successful eradication of persister cells in chronic 
biofilm infections using ADEP4–activated ClpP which degraded over 400 proteins 
compelling bacterial cells to eventually undergo autolysis (Conlon et al., 2013). It was shown 
that ADEP4 in the presence of conventional rifampicin completely eradicated persister cells 
in a S. aureus biofilm. On the other hand, less success has been achieved with Gram–negative 
bacteria. This is because in Gram–negative bacteria, an outer membrane permeabilizer such 
as polymyxin B nonapeptide (PMBN) a derivative of polymyxin B (PMB), is required before 
ADEP can activate ClpP in the bacterial cell (Tsubery et al., 2002). PMB binds to the 
negatively charged lipopolysaccharide (LPS) on the outer membrane which increases 
membrane permeability by causing membrane damage (Tran et al., 2005). However, unlike 
ADEP, PMB has been found to be nephrotoxic and neurotoxic and therefore discontinued in 
clinical practice (Falagas et al., 2006). In the current study, almost all the isolates were 
Gram–negative and it will be interesting to study the effect of other ADEP and its derivatives 
and activated ClpP in the presence of other cell membrane permeabilisers.  
In vitro antibiotic assays suggest that high dosage of antibiotics can successfully eradicate 
biofilms. However, the application of this in clinical practice can lead to the development of 
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secondary antibiotic resistance in patients and cause cytotoxicity (Bordi and Bentzmann, 
2011). Diabetic foot ulcers can also be treated by cleaning and sterilising the wound with 
antiseptics such as hydrogen peroxide, 70% ethanol and povidine–iodine. Unfortunately, 
bacteria have developed resistance to these sterilising agents. Low concentrations of H2O2 
(0.25% – 1%) which are recommended for clinical use have been found to increase bacterial 
tolerance and resistance as explained earlier (Cochran et al., 2000; Elkins et al., 1999). Other 
treatment options include surgical debridement and amputation (Fisher et al., 2010; Davis et 
al., 2006; Frykberg, 2000). The different debridement methods include enzymatic, water–jet 
powered and ultrasound techniques. Debridement can be effective when it is considered 
together with antimicrobial chemotherapy. It has been found that surgical debridement 
procedures affect quorum sensing within biofilms leading to reduction in coordinated 
virulence (Davis et al., 2006). 
Diabetic foot ulcers can be prevented in diabetics who adhere to a stringent lifestyle that 
includes avoiding the use of flip–flops, walking bare foot, smoking, and drinking alcohol. 
Tobacco smoke has been found to be toxic to the pancreas and contributes to the 
development of chronic pancreatic cancer (Lynch et al., 2009). Alcohol on the hand 
contributes to the development and aggravation of diabetes in 3 ways namely: reducing the 
body’s sensitivity to insulin leading to increase blood glucose levels, increasing risk of 
pancreatitis which results in diabetes, and increasing the risk of obesity through the addition 
of excess calories to the body (Shah, 1987; NHS Choices websites). Diabetics can also 
develop foot ulcers from injured foot when drunk. Diabetic patients who regularly take their 
medications to control their glucose levels will reduce the risk of having a foot ulcer. In 
Ghana, the development of ulcer among diabetics is largely due to treatment default, 
unhealthy eating and alcoholism (this was established through a personal conversation with 
Prof Benjamin A. Eghan, and staff at the Diabetes Centre, KATH, Kumasi, Ghana). 
This study has demonstrated the varying efficacies of conventional antibiotics in inhibiting 
and disrupting biofilms. From this and other previous studies, it is imperative to mention that 
the future of biofilm eradication probably lies in the effective combination of antibiotics that 
will target all the different stages of biofilm formation. However, due to ischaemic conditions 
in DFUs, active metabolites from orally administered antibiotics most often do not reach their 
target sites in order to effect treatment. Therefore, effective formulation of antimicrobial 
220 
 
treatment should consider topical application to achieve effective treatment. Nevertheless, the 
complete treatment of chronic wounds should consider the treatment of the main underlying 
cause as well as accompanying complications. 
6.2 Future work and recommendation 
The present work investigated the ability of K. pneumoniae and P. mirabilis to produce 
persister cells at different phases of growth and after antibiotic challenge. Further studies are 
needed to investigate the molecular mechanisms by which they form persister cells. Currently 
such studies have been successful with E. coli (Lewis, 2010; Maisonneuve and Gerdes, 2014; 
Moyed and Bertrand, 1983). A confirmation of persister cells formation with a molecular 
genetic basis will increase the understanding of the role of persistence in chronic wounds.   
Some schools of thought have suggested that multiprotein families of conserved proteins 
should be the basis for phylogenetic analysis rather than the use of small–subunit rRNA 
sequences to provide a more robust taxonomical classification and a comprehensive analysis 
of evolutionary relatedness of bacterial families (Gregoretti et al., 2004; Williams et al., 
2010; Wolf et al., 2001). Reconstruction of the phylogenies of all 50 DFU isolates presented 
in the current study will be necessary to fully understand the evolutionary relatedness of some 
members of the Proteobacteria group.   
In this study, K. pneumoniae and P. mirabilis were found to be AHL producers using A. 
tumefaciens NCIMB 14543 as a biosensor reporter in the cross–feeding assay. The 
confirmation of the exact AHLs produced by these DFU isolates may provide further 
understanding in their use of QS systems either for virulence expression, pathogenicity or 
acquisition of antibiotic resistance. The characterisation of AHLs produced by K. 
pneumoniae and P. mirabilis in this study can also provide potential targets for complete 
inhibition of biofilms through QS inhibition. 
The use of gyrase B PCR amplification of both wild–type and persister cells of K. 
pneumoniae and P. mirabilis as a differential test of persister cell formation must be 
supported by a series of tests that will allow the cloning and expression of highly conserved 
protein or a family of proteins whose expressions are directly or indirectly regulated during 
biofilm formation.  
221 
 
A recent study by Carvalhais et al. (2015) characterised 19 intracellular proteins of S. 
epidermidis that were expressed during an induced dormancy in a human–bacteria immune 
interaction. They have suggested that immune–proteomic approaches may provide fresh 
insight into the expression of possible biofilm markers by bacteria that respond to either host 
immune serum or externally administered antimicrobial agents. A similar study by Conlon et 
al. (2013) used an antimicrobial peptide, acyldepsipeptide (ADEP4) to dysregulate 
intracellular proteins, ClpP, leading to the degradation of more than 400 proteins and 
subsequent autolysis.      
The initial plan for this study was to collate demographic data as well as some clinical history 
of participants in order to establish the complete clinical presentation of diabetic patients 
recruited for the study. Though plans were far advanced in this direction, the practicality of 
these plans was not realised as some participants were willing and others were not. The other 
shortcomings were due to the fact that staff recruited at the site of sample collection were 
very busy and could not fit taking participants’ details into their working schedules. A 
follow–up on the present work should consider recruiting dedicated staffs that are not 
necessarily part of the clinical teams at the site of sample collection.     
Though this study has demonstrated the importance of clinical biofilms produced by aerobes 
and facultative anaerobes, the demonstration of biofilm formation by anaerobes isolated from 
the Ghanaian cohort study would have provided basis for comparison and more 
understanding into the role of anaerobes in impaired wound healing. It is recommended that a 
follow–up on the work presented here should consider equipping the site of sample collection 
with a dedicated anaerobic bacterial isolation unit.   
The characterisation of AHLs produced by K. pneumoniae and P. mirabilis in this study can 
provide potential targets for complete inhibition of biofilms through QS inhibition. Future 
work should consider the complete characterisation of these AHL molecules by either gas 
chromatography–mass spectrometry or thin layer chromatography to determine the length of 
their respective acyl chains (either short or long). The determination of the length of the acyl 
chains will provide more information on their functionality (i.e., their ability to bind to a 
transcriptional regulator and elicit quorum sensing response). Finally, data obtained from the 
determination of FIC indices can be experimented on animal models to determine effective 
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additive and synergy effects which can be recommended for the formulation of topical 
treatment for DFU.   
6.3 Conclusions 
The work presented here is the first to establish the prevalence of diabetes mellitus and 
diabetic foot ulcer among patients attending the Diabetes Centre, Komfo Anokye Teaching 
Hospital (KATH), Kumasi, Ghana since 2002 when Amoah et al. (2002) established national 
prevalence. A total of 407 bacterial isolates were recovered from 356 diabetic foot ulcers 
which were sampled from January 2011 to December 2014. This work has also provided the 
taxonomic classification of 50 out of the 407 DFU isolates based on the phylogeny of their 
16S rRNA genes to demonstrate their diversity. Data generated from the taxonomic 
classification together with the antibiotic susceptibility patterns of these isolates can serve a 
guide in the selection of treatment options for diabetic foot management at the KATH. 
This study has provided evidence that, DFU isolate can form biofilms. Two representative 
DFU isolates, Klebsiella pneumoniae and Proteus mirabilis further showed their ability to 
produce persister cells and were resistant and/or tolerant to antibiotic concentrations as high 
as 1280 times their therapeutic MIC. K. pneumoniae and P. mirabilis also showed their 
ability to communicate with other bacterial species (V. harveyi) through AI–2–mediated 
quorum sensing. In addition, K. pneumoniae and P. mirabilis were found to produce AHLs 
which were not characterised in this study. It can therefore be said that in addition to E. coli, 
Staphylococcus aureus and P. aeruginosa, K. pneumoniae and P. mirabilis can now serve as 
model strains for future research into biofilm, QS and persister cell formation.  
A dedicated continuous flow cell culture system called Quasi–Vivo® system produced by 
Kirkstall Ltd, UK was adapted to demonstrate time–dependent killing of biofilms. The 
resultant antibiotic effect was determined through the visualisation of live/dead cells using 
epifluorescence microscopy. This was the first time the equipment had be used to study 
bacterial cells. 
This study also demonstrated through antibiotic–quorum sensing inhibitor combination 
assays that, the synergy between antibiotics and other antimicrobial agents have the potential 
to significantly inhibit DFUs colonised by K. pneumoniae and P. mirabilis. It was also shown 
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that the individual antimicrobial efficacy of some wound dressings currently in use to treat 
DFU may be ineffective against some wound isolates such as K. pneumoniae and P. 
mirabilis. Nonetheless, the combined efficacy of wound dressings and antibiotics 
significantly inhibited both planktonic and quasi–biofilms. 
In summary, this thesis has provided evidence that DFUS provides potential environments 
that support the biofilm growth of pathogenic and opportunistic bacteria and may provide the 
platform for the exchange of multidrug resistance genetic materials. The ability of these DFU 
isolates to resist and/or tolerate antibiotic concentrations more than 1000 times their 
therapeutic range poses a threat to their treatment and public health. However, the 
combinatorial (additive) effect and synergy between antibiotics and other antimicrobial 
agents (derived from natural products) such as cinnamaldehyde, baicalin hydrate, 2(5H)–
furanone, polymyxin B and polymyxin B nonapeptide provide reassurance that they are 






































7.1.1 Appendix A 
Recipes for media and solutions 
Table A 1 V. harveyi growth media and their compositions 
Media Amount Media Amount 
L–marine agar Per 1 Litre Sea–water agar Per 1 Litre 
Tryptone 10 g Sea water 750 mL 
Yeast extract 5 g Agar 20 g 
NaCl 20 g Peptone 10 g 
Agar* 15 g Beef extract 10 g 
Distilled water Add up to 1 litre Distilled water Add up to 1 litre 
 
 
Table A 2 Composition of ATCC 2746 Autoinducer Bioassay (AB) medium 
Component A (Base medium) Component B (Stock solutions) 
NaCl 17.5 g  1 M KH2PO4 10 mL 
MgSO4 12.3 g  0.1 M L–arginine 10 mL 
Casamino acids 2.0 g  Glycerol (50%) 10 mL 
Deionised water 970 mL    
NB – The base medium was prepared and the pH of the solution brought to 7.5 with 3 M 
NaOH and sterilised by autoclaving at 121°C for 15 minutes. The stocks solutions were also 
prepared separately and sterilised by autoclaving. To make 1 litre of the final AB medium 






Table A 3 Composition of BM medium  
Media Amount (g/L) 



























Table A 5 50X TAE buffer (1 Litre of solution in deionised water) 
Compound Amount 
Tris base (Mw – 121g/mol) 
Glacial acetic acid 



















Note: Add deionised water to bring to 1 Litre and autoclave to sterilise. 
 
7.1.2 Appendix B 
Calibration of Quasi–Vivo® QV500 chamber system 

























7.1.3 MBEC™ HTP assay protocol (Harrison et al., 2005) 
PROTOCOL 
High–throughput (HTP) metal susceptibility testing of microbial biofilms using the 
MBEC™–HTP assay        
Last revised by Joe J. Harrison, February 11, 2005 
Disclaimer: Mention of trade names or commercial products in this protocol is solely for the 
purpose of providing specific information and does not imply endorsement by the authors. 
An overview of all steps in this protocol is provided in supplementary Figure S1. 
This protocol has been developed for use with Nunc Brand, flat bottom, 96–well microtiter 
plates. These microplates have a maximum volume of 300 µl per well. The medium and 
buffer volumes listed here may need to be adjusted for different brands of microtiter plates. 
A. Inoculating the MBEC™–HTP assay plate 
1. From the cryogenic stock (at –70ºC), streak out a first sub–culture of the desired bacterial 
strain on an appropriate agar plate. Incubate for up to 24 h at the optimum growth 
temperature of the microorganism. The first sub–culture may be wrapped with Parafilm™ 
and stored at 4ºC for up to 14 days. 
2. Check the first sub–culture for purity (i.e. only single colony morphology should be 
present on the plate). 
3. From the first sub–culture, streak out a second sub–culture on an appropriate agar plate. 
Incubate for up to 24 hours at optimum growth temperature of the microorganism. The 
second sub–culture must be used within 18 to 30 h starting from the time it was first placed in 
the incubator. 
4. Verify the purity of the second sub–culture. 
IMPORTANT: DO NOT GROW THE SUB–CULTURES ON MEDIA CONTAINING A 
SELECTIVE AGENT. ANTIBIOTICS AND OTHER ANTIMICROBIALS MAY 
TRIGGER AN ADAPTIVE STRESS RESPONSE IN BACTERIA. THIS MAY RESULT IN 
AN ABERRANT SUSCEPTIBILITY DETERMINATION. 
The following steps must be carried out in a biological safety cabinet (BSC): 
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5. Obtain a sterile 96–well microtiter plate. For each MBEC™–HTP assay, fill 4 ‘columns’ 
of the microtitre plate from ‘rows’ A to F with 180 µl of a physiological saline solution (ie. 
0.9% saline or phosphate buffered saline). 
6. Put 1.5 ml (plus 1.0 ml for each additional MBEC™ device being inoculated at the same 
time) of the desired broth growth medium into a sterile glass test tube. 
7. Using a sterile cotton swab, collect the bacterial colonies on the surface of the second agar 
subculture. Cover the tip of the cotton swab with a thin layer of bacteria. 
8. Dip the cotton swab into the broth to suspend the bacteria. The goal is to create a 
suspension that matches a 1.0 McFarland standard (i.e. 3.0 x 108 CFU/ml). Be careful not to 
get ‘clumps’ of bacteria in the solution. 
9. Repeat steps 6 and 7 as many times as required to match the optical standard. Page 2 
10. Put 29 ml of the appropriate broth growth medium into a sterile 50 ml polypropylene 
tube. To this, add 1.0 ml of the 1.0 McFarland standard bacterial suspension. This 30–fold 
dilution of the 1.0 McFarland standard (i.e. 1.0 x 107 CFU/ml) serves as the inoculum for the 
MBEC™ device. 
11. Open the sterile package of the MBEC™–HTP assay. Put 22.0 ml of the inoculum into 
the corrugated trough of the MBEC™ device. Place the peg lid onto the trough. Label the 
device appropriately. 
12. Place the device on a rocking table in a humidified incubator at the appropriate 
temperature. The channels in the trough of the MBEC™ device must be positioned parallel to 
the direction of motion. 
IT IS CRITICAL THAT THE ANGLE OF THE ROCKING TABLE BE SET BETWEEN 9º 
AND 16º OF INCLINATION. THIS MOTION MUST BE SYMMETRICAL. 
13. Place a 20 µl aliquot of the inoculum in ‘row’ A of each of 4 ‘columns’ in the microtitre 
plate set up in step 5. Serially dilute the inoculum in 10-fold increments along the length of 
the microtiter plate. 
14. Spot plate the serial 10-fold dilutions of the inoculum from 10–6 to 10–1 on an 
appropriately labelled series of agar plates. Incubate the spot plates for an appropriate period 
of time and score for growth. These plates are controls used to verify the starting cell number 
in the inoculum. 
B. Setting up the ‘challenge’ plate 
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1. Get a brand new, sterile microtitre plate and open in it in the laminar flow hood. DO NOT 
USE RECYCLED MICROTITRE PLATES FOR SETTING UP CHALLENGE PLATES. 
For example, the Anprolene (ethylene dioxide) gas sterilization method used to recycle the 
microtitre plates may discolour the plastic, and this may affect optical density measurements 
obtained using the microtitre plate reader. 
2. Setup a working solution of metal cation or oxyanion in the appropriate growth medium. 
Do not dilute the growth medium by more than 20% (ie. no more than 1 part metal solution 
per 4 parts of growth medium). The working solution of the metal should be made at a 
concentration equal to the highest concentration to be tested in the challenge plate. 
3. Add 200 µl of growth medium to ‘column’ 1 and ‘column’ 12 of the challenge plate. These 
will serve as sterility and growth controls, respectively. 
4. Add 100 µl of growth medium to ‘columns’ 3 to 11 of the microtitre plate. 
5. Add 200 µl of the working solution to ‘column’ 2 of the microtitre plate. 
6. Add 100 µl of the working solution to ‘column’ 3 and ‘column’ 4 of the microtitre plate. 
7. Using the multichannel micropipette, mix the contents of ‘column’ 4 by pipetting up and 
down. After mixing, transfer 100 µl from the wells in ‘column’ 4 to the corresponding wells 
in ‘column’ 5. 
8. Mix and transfer 100 µl from ‘column’ 5 to ‘column’ 6. Serially repeat this mix and 
transfer process down the length of the microtitre plate until reaching ‘column’ 11. 
9. Mix the contents of column 11 up and down. Extract 100 µl from each well in ‘column’ 11 
and discard. 
10. Add 100 µl of growth media to the wells in ‘columns’ 4 through 11. 
11. Replace the lid on the challenge plate. Gently tap the plate to facilitate mixing of the 
metals and media.  
DO NOT PREPARE CHALLENGE PLATES MORE THAN 60 MINUTES PRIOR TO 
USE. METALS CAN 
SPONTANEOUSLY REACT WITH MEDIA TO FORM REDUCTION PRODUCTS WITH 
ALTERED BIOLOGICAL TOXICITY. 
C. Exposing the biofilms 
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1. Setup a sterile microtitre plate with 200 µl of physiological saline solution in every well. 
This plate will be used to rinse the pegs to remove loosely adherent planktonic cells from the 
biofilm (this is termed a ‘rinse plate’). 
2. Setup a sterile microtitre plate with 200 µl of physiological saline solution in 4 ‘columns’ 
of row A for each MBEC™ device inoculated (ie. 1 microtitre plate is required for every 3 
MBEC™ devices). Fill rows B to F with 180 µl of physiological saline solution. In a second 
microtitre plate, fill 4 ‘columns’ from rows A to H with 180 µl of physiological saline 
solution for each MBEC™ device inoculated. The first microtitre plate will be used to do 
serial dilutions of biofilm cultures, the second will be used to check the growth of planktonic 
cells in the trough of the MBEC™ device. 
3. Following the desired period of incubation, remove the MBEC™–HTP device from the 
rocker and into the laminar flow hood. Remove the peg lid from the trough and submerse the 
pegs in the wells of the rinse plate. Let the rinse plate sit for 1 to 2 minutes while performing 
step 4 below. 
4. Use a micropipette to transfer 20 µl of the planktonic colure (in the trough of the MBEC™ 
device) into the 180 µl of saline in row ‘A’ of the latter plate set up in step 2 (immediately 
above). Repeat this three more times for a total of 4 × 20 µl aliquots. 
5. Take the remainder of the planktonic culture and discard it in a solution of dilute 5% 
bleach. Allow a minimum of 25 minutes to completely eradicate the culture. Immediately 
discard the trough in the autoclave garbage. 
6. In the laminar flow hood, dip a pair of pliers into 95% ethanol. Flame the pliers using the 
ethanol lamp in the hood. 
CAUTION: DO NOT LIGHT THE ETHANOL LAMP AND DO NOT FLAME THE 
PLIERS BEFORE YOUR GLOVES HAVE DRIED FOLLOWING DISINFECTION 
USING 70% ETHANOL. 
7. Using the flamed pliers, break off pegs A1, C1, E1 and G1 from the lid of the MBEC™ 
device and immerse them in the 200 µl of saline in row A (and each in a different ‘column’) 
of the first plate setup in step 2. 
8. Using the flamed pliers, break off pegs B1, D1, F1 and H1 and discard. 
9. Insert the peg lid of the MBEC™–HTP device into the challenge plate. Place the challenge 
plate in the same incubator where the biofilms were formed (ie. the incubator that houses the 
rocking table). 
10. Place the microtitre plate containing the broken pegs in the tray of the water table 
sonicator (Aquasonic). Sonicate on the setting ‘high’ for 5 minutes. 
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11. Serially dilute 20 µl aliquots of the planktonic cultures (from step 4) in the wells of the 
corresponding microtitre plate. Once sonication is complete, repeat this serial dilution process 
with the biofilm cultures. 
12. Spot plate the serial 10-fold dilutions of the planktonic and biofilm cultures from 10–8 to 
10–3 and 10–5 to 100 on an appropriately labelled series of agar plates. Incubate the spot 
plates for an appropriate period of time and score for growth.  
D. Neutralization plates, recovery media, MBC and MBEC determinations 
Neutralization is a two–part procedure. First, an inorganic agent or a chelator is used to 
precipitate, coordinate, or reduce the metal to a less biologically toxic species. Second, the 
neutralized cultures are spot plated onto rich agar media. This latter step allows the diffusion 
of metals into the rich agar media (where they may be coordinated or precipitated) whilst 
bacteria remain on top where they may recover. 
Neutralizing agents should be prepared as stock solutions in the range of 0.1 to 0.5 M each. 
The stock solutions should be syringe filtered and stored at –20°C until use. 
1. Add the appropriate neutralizing agent (in a quantity to obtain the desired concentration) to 
25 ml of rich media (ex. Luria–Bertani media, Tryptic Soy Broth, etc.). 20 ml of recovery 
medium will be required for each MBEC™–HTP assay used. Add 200 µl of this recovery 
medium to each well of a brand new, 96–well microtitre plate. This plate is termed the 
‘recovery plate’. 
2. Add the appropriate neutralizing agent (in a quantity to obtain 5 times the desired 
concentration) to 5ml of physiological saline solution. 2.0 ml of 5 × neutralizing solution will 
be required for each MBEC™–HTP assay used. Add 10 µl of this neutralizing solution to 
each well of a (preferably recycled) 96–well microtitre plate. This plate is termed the 
‘neutralizing plate’. 
3. Prepare 2 rinse plates for every MBEC™–HTP assay used (as described in part C, step 1). 
4. Remove the challenge plate from the incubator and into the laminar flow hood. Remove 
the peg lid and immerse in the pegs in the physiological saline of a rinse plate. Cover the 
challenge plate with the sterile lid of the rinse plate. The challenge plate now contains the 
planktonic cultures that will be used for MIC and MBC determinations. Label the planktonic 
cultures appropriately. 
5. After approximately 1 min, transfer the peg lid from the first rinse plate into the second 
rinse plate. While the rinse steps are in progress, proceed with step 6. 
6. Using the multichannel pipette, transfer 40 µl of the planktonic cultures from the wells of 
the challenge plate to the corresponding wells of the neutralizing plate. Allow a minimum of 
15 minutes for the neutralization reaction to occur before spot plating. 
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7. Transfer the peg lid from the second rinse plate into the recovery plate setup in part D, step 
1. 
Transfer the recovery plate (containing the pegs of the MBEC™ device into the tray of the 
water table sonicator. Sonicate on high for 5 min. 
8. After sonication, remove the peg lid from the recovery plate and replace the original lid of 
the microtitre plate. Note any reduction or colour changes to the biofilms on the pegs. The lid 
of the MBEC™ device may now be discarded. 
9. Transfer 40 µl from each well of the recovery plate into the corresponding well of a sterile 
(preferably recycled) 96–well microtitre plate. Place the recovery plate in the same incubator 
used to form the biofilms and incubate a minimum of 48 h. 
10. On an appropriately labelled stack of agar plates, spot 20 µl aliquots of the neutralized 
planktonic and biofilm cultures (use the aliquots of recovery media prepared in step 9 above, 
do not spot plate directly from the recovery plate). Incubate at an optimal growth temperature 
for a minimum of 48 h before scoring qualitatively for growth.  
Log–Killing and Viable Cell Counts 
Instead of preparing neutralization plates as outlined above, transfer planktonic cultures into 
serial dilution microtitre plates that contain 180 µl of physiological saline solution in each 
well of rows B to H, and 10 µl of the 5 × neutralizing solution in row A. Serially dilute 20 µl 
using the multichannel pipette. 
Similarly, for biofilm cultures, add 40 µl of the recovery media (containing the sonicated 
biofilms) from the recovery plate to row A of a serial dilution plate containing 180 µl of 
physiological saline solution in each well of rows B to F. Serially dilute 20 µl using the 
multichannel pipette. 
Spot plate biofilm and planktonic cultures (which have been serially diluted) on appropriately 
labelled agar plates. Incubate for a minimum of 48 h. 
To calculate log–kill, use the following formula:  
Log–kill = log10 (initial cfu/ml) – log10 (remaining cfu/ml after exposure) 
To calculate percent kill, use the following formula: 




1. MIC values are obtained by reading the optical density of the challenge plate at 650 nm 
(OD650) 48 to 72 h after the pegs have been removed from the challenge media. 
2. MBC and MBEC values are determined by +/– scoring of growth on the spot plates after a 
minimum of 48 h incubation. (Note that after this period of time, scoring is not a time 
sensitive operation). 
Alternatively, if viable cell counts are being determined, enumerate the bacteria growing on 
the spot plates. 
3. MBEC values are redundantly determined by reading the OD650 of the recovery plate on 
the microtitre plate reader after 48 h incubation. 
Abbreviations used 
MIC = minimum inhibitory concentration; MBC = minimum bactericidal concentration; 
MBEC = minimum biofilm eradication concentration; HTP = high–throughput; MBEC™ = 
the MBEC™–device. 
Table B 1 Synergistic effects of PMB and CAZ/LEV in the inhibition and eradication of K. 








MIC/PIa MBEC/PRa MIC/PIb MBEC/PRb 
K. pneumoniae Ceftazidime 40 90 640 50 20 90 640 60 
Levofloxacin 40 > 90 640 > 50 10 > 90 640 > 70 
P. mirabilis Ceftazidime 10 70 640 50 20 70 320 60 
Levofloxacin 10 > 90 640 > 50 10 > 95 320 > 60 
a – MIC/PI – minimum inhibitory concentration (in µg/mL) and percentage inhibition (%) of 
biofilm by CAZ and LEV when PMB concentration was 100 µg/mL; MBEC/PRa – minimum 
biofilm eradication concentration (in µg/mL) and percentage reduction (%) of biofilm by 
antibiotics CAZ and LEV when PMB concentration was 100 µg/mL, 
b – MIC/PI – minimum inhibitory concentration (in µg/mL) and percentage inhibition (%) of 
biofilm by CAZ and LEV when PMB concentration was 500 µg/mL; MBEC/PRb – minimum 
biofilm eradication concentration (in µg/mL) and percentage reduction (%) of biofilm by 




Table B 2 Synergistic effects of PMBN and CAZ/LEV in the inhibition and eradication of K. 








MIC/PIa MBEC/PRa MIC/PIb MBEC/PRb 
K. pneumoniae Ceftazidime 40 > 70 640 50 20 > 80 640 > 50 
Levofloxacin 40 60 640 70 10 95 640 > 70 
P. mirabilis Ceftazidime 10 60 640 30 20 > 60 320 > 40 
Levofloxacin 10 > 90 640 50 10 > 95 320 > 60 
a – MIC/PI – minimum inhibitory concentration (in µg/mL) and percentage inhibition (%) of 
biofilm by CAZ and LEV when PMBN concentration was 100 µg/mL; MBEC/PRa – 
minimum biofilm eradication concentration (in µg/mL) and percentage reduction (%) of 
biofilm by antibiotics CAZ and LEV when PMBN concentration was 100 µg/mL, 
b – MIC/PI – minimum inhibitory concentration (in µg/mL) and percentage inhibition (%) of 
biofilm by CAZ and LEV when PMBN concentration was 500 µg/mL; MBEC/PRb – 
minimum biofilm eradication concentration (in µg/mL) and percentage reduction (%) of 














7.1.4 Appendix C 
 
Figure C 1 Multiple Sequence Alignment of 50 16S rRNA protein–coding sequences aligned 




Figure C 2 Multiple Sequence Alignment of gyrB protein–coding sequences for persister 









Figure C 4 LsrB multiple sequence alignment in 5 Gram–negative strains. Variable regions 




Figure C 5 BssS multiple sequence alignment in 5 Gram–negative strains. Conserved regions 





Figure C 6 BssR–BssS multiple sequence alignment in 5 Gram–negative strains. Variable 
regions highlighted in yellow. 
242 
 
7.1.5 Appendix D 
 
Figure D 1 lsrACDBFG operon.  
BioCyc Genome Browser map showing the location of the lsrACDBFG operon (in orange) in the chromosome of K. pneumoniae 342. LsrR 





Figure D 2 bssS Transcriptional unit 
BioCyc Genome Browser map showing the chromosomal location of the bssS transcriptional unit (in purple) in P. mirabilis HI4320 (image 
available from http://biocyc.com/tmp/JB967.gif). 
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7.1.6 Appendix E 




















7.1.7 PARTICIPANT INFORMATION SHEET 
Project Title: Diabetic foot Ulcers in Ghana 
 
You are kindly invited to take part in a research project, designed by the University of 
Westminster (UoW), London, UK in collaboration with the Komfo Anokye Teaching 
Hospital (KATH), Kumasi, Ghana. Mr. George Gyamfi–Brobbey, the project student and the 
study team will provide you with all the information concerning the project and your 
participation. Do not hesitate to contact the study team if there is anything you do not 
understand. You can confirm your participation by signing or thumb–printing the consent 
form below. 
 
What is the purpose of the study? 
Chronicity of diabetic foot ulcers (DFU) with attendant amputations is largely believed to be 
due to mutual attachment and interactions among colonising bacteria. This study therefore 
hypothesises that the pre–treatment of bacteria in a biofilm with sugars and lectins blocking 
host lectins and sugars respectively can inhibit bacterial attachment and interaction and 
subsequent disruption of biofilms in diabetic foot ulcers. To fully understand the 
microbiology and polymicrobial nature of DFUs, this study will investigate the mechanisms 
underlying biofilm formation in diabetic foot infections and consider the possible 
development of strategies to inhibit biofilm development through the use of glycan–lectin 
analogues and quorum quenching. 
The study involves collaboration with the Microbiology departments at the Kwame Nkrumah 
University of Science and Technology and the University of Ghana Medical School, Ghana. 
The study aims to establish the prevalence and incidence rates of diabetic foot infections 
among diabetics in Ghana and provide a data on the microbiology of the infections. Data 
from the study will be used to inform health policies on diabetes management in Ghana; 
provide education and serve as foundation for future researches on diabetes in Ghana and 
Africa as a whole.  
 
What will you be asked to do?  
Participation in this study is voluntary. Wound specimens will be collected from you as part 
of your routine clinic appointment. A sterile cotton swap will be introduced into your wound 
to collect the sample. This will be done by an experienced staff of the clinic/ward in the safest 
and most non–invasive way possible. You have every right to withdraw from the exercise if 
you are not comfortable or unwell. The sample that you provide will be processed 
immediately for the detection of the bacteria that colonise the wound. 
 
Risks and Discomfort 
It is very unlikely that there will be any side effects for taking part in the study.  You may 
experience slight discomfort when wound swaps are being taken. However, this will be done 
in the safest and most non–invasive way as possible. 
 
Why have I been asked to participate? 
You have been asked to participate because of your present condition and history of being 
diabetic with foot ulcer/infection. 
 Do I have to take part? 
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Participation is voluntary. However, if you decide to take part, a copy of this information 
sheet will be given to you to keep. You are free to withdraw at any time without giving 
reasons and can request the removal of your sample from the study. Moreover, your decision 
to withdraw will not affect your eligibility for any future research.  
 
What do I have to do? 
In order to be recruited for the study, you are kindly requested to answer some few simple 
questions below. You can then confirm your participation by signing the consent form below. 
 
Confidentiality 
This is a student research project which may be published.  In the course of the project and in 
the event of subsequent publication, your participation, name and any other personal details 
will be kept highly confidential.  Your sample will be given a specific research number and 
anonymised.  Access to identifiable data will be held in Ghana only by your respective GPs 
who have access to your information. Dr Patrick Kimmitt, Dr Pamela Greenwell and George 
Gyamfi–Brobbey will only handle anonymised samples with no bearing to your identity. 
 
Expenses and Payments 
Participation is entirely voluntary and as such there will be no payments for your 
participation in the study.   
 
Contact for further information  
If you have any problem or query about any aspect of the study at any time, please do not 
hesitate to contact the researchers on their contacts given below:  
 
PhD student:             George Gyamfi–Brobbey 
ggyamfb@gmail.com 
+44 7852 946933/ +233 20 7967849 
 
Director of studies: Dr Patrick Kimmitt   
p.kimmitt@westminster.ac.uk 
+44 20 7911 5000 EXT 3668/ 64135 
 
Second Supervisor: Dr Pamela Greenwell 
greenwp@westminster.ac.uk 
020 7911 5000 EXT 64147 
 
External Collaborator Prof Enoch H. Frimpong 
ehfrimps@yahoo.co.uk 











7.1.8 Participant’s Questionnaire 
Question we need to ask you: 
 
 Which part of Ghana do you come from? …………………………………………. 
 How long have you been diagnosed as being diabetic? ………………………… 
 Have you had an ulcer/wound on your foot before? Yes/ No 
If yes, when did it first appear? ……………  Size/Grade…………………………. 
 Have you been attending the diabetic clinic regularly? Yes/ No 
If yes, for how long? …………………………………………………………     
If no, why? …………………………………………………………………………… 
 Do you smoke? Yes/No 
 Do you live alone? Yes/No 
 Do you often wear, a) flip–flops, b) shoes with socks or c) walk bare foot? 
 Do you have hypoglycaemia (low sugar level) attacks? Yes/ No 
If yes, how often? .................. 
 Do you have hyperglycaemia (high sugar level) attacks? Yes/ No 























7.1.9 PARTICIPANT CONSENT FORM 
Project Title: Diabetic foot ulcers in Ghana 
Statement by subject 
I confirm that I have been provided with sufficient information about this project. 
I understand that I have volunteered to take part and can withdraw at any time, without being 
disadvantaged and without giving my reasons. 
I am satisfied that the results will be stored securely. 
I know that the results will not be linked to me and will be kept confidential.  
I am aware of any possible risks and discomfort. 
I agree to inform the researcher immediately if I feel uncomfortable or experience any 
discomfort. 
I have had the chance to ask questions. 
I know that I will not receive any money for taking part. 




Name: ……………………………………………...            
Age: ……………… 
Sex: Male/Female                               Signature/Thumbprint: ………………………… 
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